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Abstract 
Background: Obesity is not only a major health concern, it is an economic problem. The 
current rates of obesity (defined as body mass index (BMI)  30 kg/m²) are epidemic and severe 
obesity (defined as BMI  35 kg/m²) is increasing more rapidly than obesity. Treatments for 
overweight and obesity include dietary therapy, exercise/behavioural interventions, weight loss 
medications and bariatric surgery. Bariatric surgery is considered the most efficacious 
intervention for severe and resistant obesity.  
This PhD thesis titled ‘The Health Economics of Obesity and Bariatric Surgery’ is an important 
part of a comprehensive, mixed-methods and multi-disciplinary Australian National Health and 
Medical Research Council (NHMRC) partnership project regarding bariatric surgery as a 
treatment option for obesity, within the State of Tasmania (Australia), nationally, and 
internationally. Key health economic evidence gaps were initially identified in the development 
of the successful NHMRC partnership project grant proposal.  
Aims: As a health economist within the NHMRC partnership project team, the principal aims 
of my PhD research were to: provide critical baseline analyses of the key themes and evidence 
gaps regarding the health economic reporting of bariatric surgery, locally, nationally and 
internationally; address key evidence gaps regarding the physical and psychosocial domains of 
health-related quality of life from the time of waitlisting for bariatric surgery; establish the 
multi-attribute utility instrument that preferentially captures the physical and psychosocial 
health-related quality of life of people waiting for, or who have undergone bariatric surgery; 
use qualitative research methods to investigate bariatric surgery patients’ experiences to 
identify and prioritise health economic impacts of bariatric surgery that are typically excluded 
from existing studies, or not provided with sufficient priority; and develop a strategic research 
alliance with our Tasmanian State Government project partner to investigate the resource use 
and costs of obesity and bariatric surgery to the Tasmanian public hospital system. 
Methods: This thesis adopted a mixed-methods approach within real-world policy settings, 
consistent with a call for health economists to implement mixed-methods and policy-relevant 
research that is embedded in, and derived from real-world policy settings.  
First, validated guidelines and methodologies were followed in the systematic selection and 
analyses of the published literature regarding the health economic evaluation of bariatric 
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surgery. The findings of this comprehensive systematic review informed the methods of the 
remainder of the thesis (Chapter 2).  
Second, the vastly different EQ-5D-5L and AQoL-8D multi-attribute utility instruments were 
systematically selected to investigate health state utility valuations (both instruments) and 
individual and super dimension scores (AQoL-8D only) in two cohorts of bariatric surgery 
patients. Patients who had received bariatric surgery many years previously in the private 
healthcare system (cross-sectional - Chapter 3) and patients who were publicly waitlisted for 
their surgery for many years and then operated on as part of a government policy decision to 
reduce waiting lists (longitudinal - Chapters 4 and 5) were studied. 
Third, qualitative research methods were used to investigate bariatric surgery patients’ ‘lived’ 
experiences to identify and prioritise health economic impacts of bariatric surgery that are 
typically excluded from existing studies (Chapters 6 and 7). 
Fourth, a strategic research alliance with the critical health and project partner was adopted to 
construct and analyse a Tasmanian public hospital resource use and cost database about 
publicly-waitlisted patients before and after their primary bariatric surgery and surgical 
sequelae (Chapter 8).  
Thesis outline and summary of key results: 
Chapter 1 presents a general introduction of the health and economic burden of the obesity 
epidemic and bariatric surgery as a treatment option, and health economic concepts pertinent 
to this thesis.  
Chapter 2 provides a published comprehensive systematic review of the health economic 
evaluation of bariatric surgery. Evidence gaps identified in the systematic review informed the 
direction of the subsequent PhD projects of this thesis, part of the work program for the 
NHMRC partnership project, and some of the future directions for research beyond this thesis. 
Among other things, this study found that only 13% of included studies adopted a broader 
societal perspective, the cost of complications and reoperations for bariatric surgery were not 
included in one-third of studies and when they were included conservative estimates were 
generally adopted, out-of-pocket costs were largely ignored, the EQ-5D suite of multi-attribute 
utility instruments was prevalent in the health economic evaluation of bariatric surgery, and 
that only one study investigated publicly waitlisted patients. The study’s quality appraisal 
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against the Consolidated Health Economic Evaluation Reporting Standards checklist found 
heterogeneous approaches, inconsistent quality and key evidence gaps in the health economic 
reporting of bariatric surgery. 
Chapters 3, 4 and 5 present the first integrated published suite of health-related quality of life 
studies for the bariatric surgery study population that systematically selected two markedly 
different multi-attribute utility instruments, namely the EQ-5D-5L (Chapter 2 established the 
EQ-5D-5L was the internationally prevalent instrument in the economic evaluation of bariatric 
surgery) and the AQoL-8D (based on psychometric principles and testing). Importantly, the 
two instruments were used and compared for two different cohorts of bariatric surgery patients. 
Chapter 3 provides the first head-to-head comparison of the EQ-5D-5L and AQoL-8D for a 
cross-sectional cohort of patients who had received bariatric surgery in the private healthcare 
sector many years previously (median (interquartile range) 5 (3-8) years). Chapter 3 found that 
psychosocial health was a key driver for the study population and that the AQoL-8D 
preferentially captured and assessed their psychosocial health. This study also explored the 
international dominance of the EQ-5D in the clinical and economic evaluation literature and 
the paper recommended that the choice of multi-attribute utility instrument should be 
influenced by the innate sensitivities of the instrument to the relevant domains of heath for the 
particular study population. 
Chapters 4 and 5 were the first studies to use the EQ-5D-5L and AQoL-8D for a unique cohort 
of long-term and severely obese publicly waitlisted patients who then received bariatric surgery 
due to a public policy decision to reduce waiting lists. Chapter 2 identified that only one health 
economic study investigated the impact of waiting for bariatric surgery. A key finding of these 
studies was that the preoperative AQoL-8D health state utility valuation for this increasingly 
prevalent subgroup of bariatric surgery patients was less than those of people with cancer or 
heart disease. Even 3 months, and then 1 year after bariatric surgery, long-term publicly 
waitlisted patients recorded significant and clinically meaningful health-related quality of life 
improvements. This result suggested that long-waiting patients should not be ‘written-off’ by 
healthcare decision makers: they can still realise significant improvements in health-related 
quality of life outcomes when ultimately treated, and this should be factored into patient 
prioritisation decisions. Chapters 4 and 5 also investigated the emerging literature regarding 
the predictive capabilities of multi-attribute utility instruments in patient-centred bariatric care. 
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Chapters 6 and 7 present studies that harness the unique advantages of qualitative research 
methods to improve our practice in health economics. The inspiration for the method of these 
studies was partly directed by the systematic review (Chapter 2) that identified the limited 
scope of costs and consequences for most health economic evaluations of bariatric surgery. 
Additionally, there has been a call for health economists to effectively integrate combinations 
of qualitative and quantitative methods into their research toolkit to enrich their research 
methodologies and therefore improve their practice in health economic study design, data 
gathering and analysis, reporting and ultimately research translation. These studies listened to 
patients’ stories and key themes were identified inductively through a dialogue between the 
qualitative focus group data and pre-existing economic theory (perspective; externalities; 
emotional capital; information asymmetry). Published Chapter 6 identified the concept of 
emotional capital as a ‘potentiator’ for human capital where participants described life-
changing desires to be productive and participate in their communities postoperatively. Two-
thirds of the focus group participants accessed private healthcare for bariatric surgery and some 
of these participants experienced substantial economic burden to do so.  
Chapter 7 presents a second health economics study that implemented qualitative research 
methods. The inspiration for this study was that a key market failure in healthcare is 
information asymmetry. However, in the information-age, bariatric surgery patients may be 
more empowered in their negotiated relationship with healthcare providers through demand-
induced supply. This study found a divergence between the pre- and postoperative information 
drivers. Psychosocial or socio-emotional drivers informed the sources and types of information 
that were important to participants preoperatively. The study also found that information 
sources relevant to participants preoperatively (e.g. family and friends, and the Internet) were 
different postoperatively (surgeon, allied-health professionals e.g. psychologist).  
Chapter 8’s quantitative study is the final paper of this mixed-methods PhD thesis. This hospital 
inpatient resource use and costing study is the first study within the Australian public hospital 
setting to report on individual episodes-of-care and costed patient-level pathways for primary 
bariatric surgery, and surgical sequelae including secondary/tertiary surgery informed by 
Australia’s Activity Based Funding model. Chapter 2 guided the study’s investigation of the 
patient-level costs, the costs of waiting for bariatric surgery, subgroup analyses (patients with 
diabetes and cardiovascular disease), and the accurate cost of complications and reoperations 
over a long time horizon. Chapter 8 found that the cost of providing primary laparoscopic 
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adjustable gastric band surgery in Tasmanian public hospitals compared with the sleeve 
gastrectomy procedure is similar. The study also suggested that prevalent laparoscopic 
adjustable gastric band device-related costs could be mitigated with alternative surgical 
methods such as sleeve gastrectomy within the Tasmanian public hospital system. Subgroup 
analyses revealed that for people with diabetes, the average cost for an episode-of-care reduced 
from year 1 after surgery. 
Principal conclusions: Overall, this thesis provided a broader societal perspective regarding 
bariatric surgery as a treatment option for obesity. There is disparate health economic 
evaluation and reporting of bariatric surgery of inconsistent quality. Partial and full health 
economic evaluations of bariatric surgery generally populate their models with a narrow 
spectrum of short-term direct medical cost data regarding the primary surgery only from 
administrative databases. The AQol-8D preferentially captures physical and psychosocial 
health for the study population and this finding has implications for the cost-utility analyses of 
bariatric surgery. Long-term waitlisted patients realise significant health state utility valuation 
improvements (and individual and super dimension scores for the AQoL-8D) even three 
months after bariatric surgery suggesting that these patients should not be ‘written-off’ by 
healthcare planners if significant health benefits can be realised when they are ultimately 
treated. Qualitative research methods revealed the importance of emotional capital and out-of-
pocket costs, and the sources and types of information before and after bariatric surgery. 
Bariatric surgery in the Tasmanian public hospital system may be an attractive value-based 
option in the longer term: bariatric surgery realised health benefits (reduced inpatient episodes-
of-care) and reduced costs at year 3 postoperatively. Laparoscopic adjustable gastric band 
device-related costs could be mitigated if replaced with sleeve gastrectomy bariatric surgery 
where clinically appropriate 
. 
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Chapter 1 - General introduction and outline: 
The health economics of obesity and bariatric surgery. 
1.1 National Health and Medical Research Council partnership project 
Economics is one of several social sciences that attempt to explain and predict human 
behaviour, however, it is unique among the social sciences in establishing a concept of scarcity 
and uncertainty: economics is concerned with the way scarce resources are allocated among 
alternative uses to satisfy unlimited human wants [1]. Health economics, as a highly specialised 
and separate discipline, is both guided by and, more importantly, challenges (both 
philosophically and methodologically) aspects of economic (particularly neoclassical 
economic) orthodoxy. 
My economics undergraduate and honours degrees were based on the neoclassical quantitative 
economist’s toolkit. However, the qualitative component of my mixed-methods health 
economic PhD research and this thesis regarding obesity and bariatric surgery has encouraged 
me to consider the human stories (and therefore the human behaviour) that inform any health 
economic study concerning people with obesity and their experiences before and after their 
bariatric surgery. My previous background as Registered Nurse has also enabled me to reflect 
on these patients’ narratives. 
This PhD research and thesis are part of a comprehensive, mixed-methods and multi-
disciplinary Australian National Health and Medical Research Council (NHMRC) partnership 
project regarding bariatric surgery as a treatment option for obesity, within Tasmania (a state 
of Australia), Australia, and internationally.  
The NHMRC partnership project comprises academic researchers from wide-ranging 
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disciplines, clinicians, government policy decision-makers and allied-health practitioners. My 
PhD research commenced through the collaborative effort between myself and my key 
supervisors and the project team.  
Our Tasmanian State Government project partners stated that ‘the burden of morbid obesity on 
individuals, government and society is unclear and the allocation of public resources to 
bariatric surgery lacks a strong evidence base’. Consequently, my initial health economic 
investigation identified that there were key knowledge gaps in the health economics reporting 
of bariatric surgery in Tasmania, nationally and internationally. The key objective of my PhD 
research was to address these pressing health economic knowledge and policy gaps for people 
with obesity waiting for, and/or who had received bariatric surgery, our project partners, the 
health economics community, the healthcare systems and society. 
My PhD research thesis also aimed to identify the most promising opportunities for future 
research. 
This introductory chapter will provide background regarding the obesity epidemic and bariatric 
surgery as a treatment intervention from an epidemiological and public health perspective. The 
chapter then explores the important health economic concepts that guide this thesis, the health 
economic burden of obesity and key evidence gaps regarding the health economic investigation 
of bariatric surgery. The chapter concludes with a summary of the methods and structure of 
this thesis, the aims of this thesis, and scholarly output as a direct result of this thesis. 
1.2  An introduction to obesity 
Obesity is a not only a public health problem, it is an economic problem [2-9]. 
Overweight and obesity are defined by the World Health Organization (WHO) as ‘abnormal 
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or excessive fat accumulation that may impair health’ [10]. The WHO also notes that body 
mass index (BMI) is a simple index of weight-for-height that is commonly used to classify 
overweight and obesity in adults. BMI is defined as a person’s weight in kilograms (kg) divided 
by the square of his/her height in metres (m), BMI = weight (kg)/height² (m²). For adults, the 
WHO defines overweight and obesity as follows: 
• overweight is a BMI  25 kg/m²; and 
• obesity is a BMI  30 kg/m² [10]. 
Notwithstanding debate in the published literature regarding the accuracy of BMI as a measure 
of obesity, most clinical, epidemiological and health economics research defines obesity using 
BMI as the key measure [11-13]. It has been proposed that social science research would be 
enriched by greater consideration of alternate specifications of weight and height and more 
accurate measures of body fat [12, 13]. For example, a recent study that investigated whether 
or not the association between fat mass and employment status vary by anthropometric 
measures (measured rather than self-report height and weight (BMI) and waist-circumference) 
based on data from 15 rounds (1998-2013) of the Health Survey of England, concluded that 
the consequences of obesity for employment were larger when waist-circumference was used 
as a measure for obesity compared with BMI in the study’s non-instrumental variable models 
[13]. 
For children and adolescents the WHO states that in infants and children under 5 years of age, 
obesity is assessed according to the WHO ‘Child Growth Standards’ (weight-for-length, 
weight-for-height) and the WHO Reference for 5-19 years (BMI-for-age) [10]. However, the 
studies contained in this thesis all concern adult study populations. 
The WHO describes current rates of obesity as an epidemic [5, 14]. Additionally, in a recently 
published (2017) position statement, the World Obesity Federation noted that obesity is a 
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chronic, relapsing, progressive disease process and emphasised the need for immediate action 
for prevention and control of this global epidemic [15, 16]. Against this background of a 
worldwide epidemic, obesity is a profoundly complex global public health, economic and 
strategic policy problem [3, 5, 8, 17, 18]. 
1.2.1 Prevalence of obesity and obesity-related comorbidities 
The prevalence of overweight and obesity has more than doubled since 1980 [19], and the 
WHO has stated that worldwide obesity has nearly tripled since 1975 [10]. The Australian 
Institute of Health and Welfare reported that among mong Australians aged 18 and over, the 
prevalence of obesity alone increased over time from 19% in 1995, to 28% in 2014–15 [20]. 
The Organisation for Economic and Co-operative Development’s (OECD) Obesity Update 
2017 stated that, in 2015, across the OECD’s 35 member countries (mainly high-income 
countries), 19.5% of the adult population was obese [21]. Figure 1.1 highlights the rates of 
obesity in selected OECD countries. It also shows countries that have provided self-reported 
or measured data for rates of obesity. 
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Figure 1.1: Obesity among adults, 2015 or nearest year for selected OECD countries. Source 
OECD Obesity Update 2017. 
 
The World Bank Group that comprises 189 member countries (including many low- and 
middle-income countries) has acknowledged that even while poverty and under- and 
malnutrition continue to affect many low- and middle-income countries, a global nutrition 
transition is underway [22]. The World Bank Group suggests that these changes have 
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stimulated a rapid increase in the burden of overweight/obesity in low- and middle-income 
countries that was previously considered an ailment of wealthy countries. These countries are 
now starting to experience the double burden of overweight among both adults and children, 
and stunting among children [22].  
Obesity-related comorbidities are complex and multifactorial [23]. It is estimated that obesity 
is responsible for 17.3% of coronary heart disease, 61.0% of type 2 diabetes, 24.0% of 
osteoarthritis, 20.8 – 35.4% of colo-rectal cancers, 26.9% of pancreatic cancer, 35.5% of 
gallbladder cancer, and 42.5% of kidney cancer [5, 24, 25]. Obesity has also been found to 
decrease health-related quality of life, particularly psychosocial health-related quality of life 
[26-28]. An exponential increase in the risk of adverse health outcomes is observed with 
increasing severity of obesity [29]. For example, it has been estimated that the risk of 
developing type 2 diabetes is increased 93-fold in women and 42-fold in men who are severely 
obese, relative to their healthy weight counter-parts [30, 31]. 
Notably, severe obesity is now increasing more rapidly than obesity [11]. 
Obesity is categorised into three classes: Class 1 obesity (also labelled as obesity) is defined as 
BMI 30.0 – 34.9 kg/m²; Class 2 obesity (also labelled ‘severe obesity’ [5]) is defined as BMI 
35.0 – 39.9 kg/m²; and Class 3 obesity is defined as BMI  40.0 kg/m² [19, 29]. Recent clinical 
literature also describes a fourth class of obesity that is categorised in the clinical literature as 
‘super-obesity’ defined as a BMI of  50.0 kg/m² [32, 33].  
A recent economic analyses that estimated the prevalence and costs of obesity and severe 
obesity using United States’ data and informed by nonlinear regression methodology, forecast 
a larger increase in prevalence of severe obesity than generated from the linear trends of earlier 
studies [11]. The study concluded that this result is consistent with data revealing that BMI 
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distribution among adults is becoming more right-skewed and subsequently estimated a 33% 
increase in obesity prevalence and a 130% increase in severe obesity prevalence over the next 
2 decades to 2030 [11, 34]. If these forecasts prove accurate, this will further hinder efforts for 
healthcare cost containment [11]. These prevalence trends of obesity and severe obesity are 
also reflected globally [29, 35-37].  
From Australia’s perspective, a birth cohort study by the Australian Institute of Health and 
Welfare shows that the prevalence trends of severe obesity are increasing over time for most 
birth cohorts. At most adult ages (except for ages 26–29, 30–33, and 42–45), the prevalence of 
severe obesity was significantly higher in 2014–15 than in 1995 - those in the birth cohort born 
most recently at each age (measured in 2014–15) were significantly more likely to be severely 
obese than those born 20 years earlier (measured in 1995) [38]. The largest relative difference 
was for age 22–25, where 9.3% of those born in 1990 – 1993 were severely obese, compared 
with 3.1 % of those born in 1970–1973 [38]. 
For 2014 – 15, the Australian Institute of Health and Welfare recently reported that nearly two-
thirds (63%) of Australian adults were overweight or obese, with Tasmania recording the 
highest prevalence of the Australian States and Territories. Figure 1.2 shows the prevalence of 
overweight and obesity in Australia by age and sex in 2014-15.  
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Figure 1.2: Prevalence of overweight and obesity in adults in Australia, by age and sex for 
2014-15. Source: Australian Institute of Health and Welfare (2017). Weight-loss surgery in 
Australia 2014-15. 
 
Variation of overweight and obesity prevalence rates across Australia have been revealed in a 
recent analysis of the 31 Primary Health Networks for 2014-15 [39]. The analysis found there 
are differences in the percentage of adults who were overweight or obese between Primary 
Health Network areas in metropolitan and regional locations. The report stated it is important 
that information regarding the prevalence of overweight and obesity across Australia’s Primary 
Health Networks be interpreted in the local context, taking into account knowledge of the local 
population and its needs [39]. 
Figure 1.3 shows that Tasmania’s estimated adult overweight and obesity rate across its 
Primary Health Network area was 67.5%, with the range of recorded rates across the country 
of 53.4% in Northern Sydney to 73.3% in country South Australia [39].  
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Figure 1.3: Estimated overweight and obesity rates across Australia’s Primary Health Network 
areas 2014-15. Source: Primary Health Networks. Healthy Communities: overweight and 
obesity rates across Australia, 2014-15. 
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A socioeconomic grading in obesity, where greater prevalence of obesity is observed in more 
disadvantaged groups, has been reported in most high-income countries [29, 40]. In Australia 
(and based on measured height and weight), Classes 1, 2 and 3 obesity prevalence increased 
with increasing levels of disadvantage based on both education and an area-level marker of 
socio-economic position [29] (Figures 1.4 and 1.5). 
Figure 1.4 Prevalence of Class 1, 2 and 3 obesity by education level in Australia, 2011–12. 
(did not complete secondary school’: 32.5%, ‘completed secondary school’: 22.7% and 
‘completed degree/diploma’ 19.3%). *p<0.05. Source: Keating et al (2017). Obesity Research 
and Clinical Practice. 
 
 
 
Figure 1.5 Prevalence of Class 1, 2 and 3 obesity by area-level socioeconomic status (IRSD) 
in Australia. 2011-12. *p<0.05. Source: Keating et al (2017). Obesity Research and Clinical 
Practice. 
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As mentioned previously, many databases employed by economists contain only self-reports 
(not measured) of weight and height [5, 9, 41]. A recent study assessed the extent and 
characteristics of reporting error in weight, and examined its impact on regression coefficients 
in models of the healthcare consequences of obesity by analysing data from the United States 
National Health and Nutrition Examination Survey for 2003–2010 (which includes both self-
reports and measurements of weight and height) [41]. The study found that reporting error in 
weight is non-classical: underweight respondents tend to over report, and overweight and obese 
respondents tend to under report their weight, with under reporting increasing in measured 
weight [41]. The error results in approximately one out of seven obese individuals being 
misclassified as non-obese. Interestingly, the study concluded that although it is a common 
misconception that reporting error always causes attenuation bias, comparisons of models that 
use self-reported and measured weight confirm that reporting error can cause upward bias in 
coefficient estimates [41]. 
In parallel with the global obesity epidemic, health spending (locally, nationally and 
internationally) has grown rapidly in absolute and relative terms [42, 43]. This results in the 
complex health economic problem of increased healthcare spending and a worldwide public 
health epidemic that demands even more of the scarce healthcare dollar [8]. The health 
economic burden of obesity is explored in detail in section 1.5 of this thesis. 
Treatments for overweight and obesity include dietary therapy, exercise/behavioural 
interventions, weight loss medications and bariatric (also known as metabolic [44], weight-loss 
or obesity) surgery [45].  
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1.3 Bariatric (metabolic, weight-loss, obesity) surgery 
Bariatric (metabolic [44, 46, 47]) surgery is considered the most efficacious intervention for 
severe obesity [48, 49]. It is generally recommended when non-surgical approaches have failed 
for adults with Class 2 obesity and obesity-related comorbidity (e.g. type 2 diabetes mellitus) 
or Class 3 obesity with or without obesity-related comorbidity [50]. Different surgical options 
are available, and they are continuously evolving, influenced by research results, specific local 
conditions, and the experience of the surgical staff in each location [48]. 
The history of bariatric surgery has been described as a science that has progressed not as a 
single idea by one person, but rather in small collaborative steps that take decades to accept 
[51]. The first recorded case of a bariatric procedure was in 1952 by a Swedish surgeon, Dr 
Victor Henrikson [52, 53]. He noticed that small bowel resections performed for other disease 
processes usually produced no change in the patient’s general status however, in some cases, 
resulted in significant weight loss. Based on his observations, he resected 105 cm of small 
intestine from a 32-year-old obese female who could not complete a weight loss program. 
Interestingly, the patient lost only a small amount of weight but was noted to have an improved 
quality of life. Although this was the first reported operation for obesity, it was not adopted for 
treatment in other patients because of its irreversibility [51-53].  
The past six decades have produced a remarkable series of new techniques and procedures for 
the surgical treatment of obesity and its co-morbidities [48, 49, 51, 54]. Bariatric medicine has 
developed as a clinical subspecialty in some countries, and others are calling for this level of 
subspecialisation as a treatment option for obesity [55]. 
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1.3.1 Types of bariatric surgery, and complications and reoperations 
The types of metabolic/bariatric operations are in continuous flux with different surgical 
options influenced by literature results, specific local conditions and the experience of surgical 
staff [48, 56-60]. As a rapidly evolving subspecialty of gastrointestinal surgery, bariatric 
surgical procedures involve gastric restriction (to augment early satiety and limit meal portions, 
or intestinal diversion (designed to reduce caloric absorption). Some bariatric procedures 
contain elements of restriction and diversion [51, 61]. Figure 1.6 provides a diagrammatic 
overview of the surgical procedures currently in use and others for historical context.  
Figure 1.6 Overview of bariatric surgical operations. Diagrammatic representations of (A) 
Jejunal-ileal bypass: end-to-end jejunoileostomy with ileosigmoidostomy. (B) Biliopancreatic 
diversion with a duodenal switch. (C) Vertical banded gastroplasty. (D) Roux-en-Y gastric 
bypass. (E) Adjustable gastric band. (F) Sleeve gastrectomy. Source: Celio L., and Pories WJ 
(2016). A history of bariatric surgery: the maturation of a medical discipline. 
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Figure 1.7 provides a diagrammatic representation of the most common procedure in Australia 
(sleeve gastrectomy) and the most common procedure in Tasmania (adjustable gastric band) 
[62]. Prevalence of bariatric surgery is detailed in section 1.4.4. 
Figure 1.7 Diagrammatic representations of (A) sleeve gastrectomy (source: 
http://www.portlapsurgery.com.au/the-emotional-journey-to-a-sleeve-gastrectomy/) and (B) 
adjustable gastric band (source http://www.lapgastricband.com.au/gastric_band.html). 
 
Sleeve gastrectomy was originally described as a staging procedure for people with super 
obesity to bridge them to a more definitive operation [51]. The standalone laparoscopic sleeve 
gastrectomy has increased in prevalence in the past decade and has many advantages over the 
other current operations [48, 51] Sleeve gastrectomy is: less technically demanding than the 
gastric bypass or biliopancreatic diversion with duodenal switch; has minimal morbidity; no 
implanted device; and is without marginal ulcers, dumping syndrome, internal hernias, or 
nutritional deficiencies [51]. Complications are mainly staple line leaks and strictures, however, 
the leak rate has decreased with improved surgical techniques [51]. The laparoscopic sleeve 
gastrectomy’s favourable weight loss results, significant remission of comorbidities, and very 
low rates of postoperative mortality and morbidity have contributed to its rise in popularity [48, 
51].  
A B 
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The goal of the adjustable gastric band was to develop a reversible gastric band that could be 
adjusted to the individual needs of the patient. A liquid-filled silastic cuff that is placed around 
the stomach adjacent to the cardia was used and the cuff diameter was adjusted by filling or 
draining fluid from a subcutaneous valve accessed by percutaneous needle puncture [51]. In 
1993 the laparoscopic adjustable silicone band placement was initially described and became 
the most common bariatric operation in Europe and later the United States [51]. The procedure 
provided a less invasive and more reversible operation than a gastric bypass with similar short-
term weight loss, but with long term potential risks of band slippage, erosion, and foreign body 
infection [51]. 
Some published studies have called for a reconsideration of the use and role of adjustable 
gastric band surgery (compared to other procedures such as sleeve gastrectomy), particularly 
for Medicare beneficiaries in the United States [63-65]. A recent key epidemiological study 
that investigated reoperation and Medicare (United States) expenditures after laparoscopic 
adjustable gastric band surgery found that device-related reoperation was common, costly 
(from a Medicare re-imbursement perspective) and varied widely across hospital referral 
regions. On the other hand, the invited commentary to this study suggested that no single 
bariatric procedure is appropriate for all patients, and that the regional variation in outcomes 
observed is important [64].  
Complications and reoperations for each bariatric surgical procedure vary [61, 66]. A recent 
Cochrane systematic review concluded that assessing the risks of different bariatric procedures 
is still hampered by a lack of consistency and quality of evidence in the reporting of adverse 
outcomes and reoperation rates, and that most studies followed participants for only 1 to 2 
years, therefore the long term effects of surgery remain unclear. Recently released standardised 
outcomes reporting guidelines for bariatric surgery [46, 47, 58] (see section 1.3.3) partially 
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address these issues from a clinical perspective. 
Accurate recording of the patient pathway will enable a true reflection of reoperations and 
complications (and provide relevant patient pathways for health economic analyses). Chapter 
2 of this thesis finds under reporting of complications and reoperations in the health economic 
evaluation of bariatric surgery and this result particularly informed Chapter 8 of this thesis. 
1.3.2 Eligibility for bariatric surgery: clinical guidelines 
Bariatric surgery is generally recommended when non-surgical approaches have failed for 
adults with Class 2 obesity and obesity-related comorbidity or Class 3 obesity with or without 
obesity-related comorbidity [50, 67]. 
In Australia, the NHMRC’s 2013 clinical practice guidelines for the management of 
overweight and obesity in adults, adolescents and children, recommend that “for adults with 
BMI > 40 kg/m² or adults with BMI  35 kg/m² and comorbidities that may improve with 
weight loss, bariatric surgery may be considered, taking into account the individual situation”. 
The NHMRC also noted that weight loss surgery is “currently the most effective intervention 
for severe obesity” [62, 68]. 
A co-authored study external to this thesis (and a component of the NHMRC partnership 
project) found that within Australia, policies and guidelines on publicly-funded bariatric 
surgery are highly variable across Australia and at times inconsistent with national guidelines. 
Additionally, the study found that insufficient guidance exists regarding the prioritisation of 
eligible patients for bariatric surgery [69].  
1.3.3 Standardised outcomes reporting guidelines for bariatric surgery 
The American Society for Metabolic and Bariatric Surgeons released standardised outcomes 
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reporting guidelines for bariatric and metabolic surgery in 2013 [46, 47]. Notably, the 
guidelines made no specific recommendation regarding the most appropriate health-related 
quality of life instrument, the recommendation being only to use a ‘validated instrument(s)’ 
[28]. 
1.3.4 Prevalence of bariatric surgery: international, national and local 
The International Federation for the Surgery of Obesity and Related Diseases most recent 
global survey (surveys conducted in 1997, 2003, 2008, 2011 and 2013) found that the total 
number of bariatric procedures performed in 2013 was 468,609; 95.7% of which were carried 
out laparoscopically [48]. Forty-nine of the 54 bariatric surgery registered countries responded 
to the survey, of which 37 provided data from their national registries. USA/Canada was the 
region with the highest number of bariatric procedures (n=154,276). Other nations or national 
grouping that reported 10,000 or more bariatric procedures were Brazil (n=86,840), France 
(n=37,300), Argentina (n=30,378), Saudi Arabia (n=13,194), Belgium (n=12,000), Israel 
(n=11,452), Australia-New Zealand (n=10,467), and India (n=10,002) [48]. 
The most commonly performed procedure in the world was Roux-en-Y gastric bypass, 
followed by sleeve gastrectomy, and adjustable gastric banding. Figure 1.8 shows the trends in 
the number of bariatric surgical procedures from these global surveys over the past decade. 
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Figure 1.8: Trends in number of bariatric surgical procedures worldwide from 2003 to 2013. 
Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), adjustable gastric banding  
(AGB), and biliopancreatic diversion with a duodenal switch (BPD/DS). Source: Angrissani, 
L (2015), Bariatric surgery worldwide 2013. 
 
Within the total number of procedures performed, there have been marked shifts in the relative 
percentages of the specific bariatric procedures being done. Figure 1.9 reveals that over the 
past 10 years sleeve gastrectomy has increased in prevalence from 0 to 37% [48]. 
Figure 1.9: Trends in the percentage of procedures worldwide from 2003 to 2013. Roux-en-Y 
gastric bypass (RYGB), sleeve gastrectomy (SG), adjustable gastric banding (AGB), and 
biliopancreatic diversion with a duodenal switch (BPD/DS). Source: Angrissani, L (2015), 
Bariatric surgery worldwide 2013. 
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The Australian Institute of Health and Welfare reported that there were 22,713 bariatric surgery 
separations in Australia in 2014-15. Furthermore, most of these involved a primary procedure 
defined as “procedures that are typically primary or initial procedures for weight loss surgery” 
(not procedures that are described as adjustments, revisions, removals and other procedures) 
(18,036 procedures 79.4%) [62]. Laparoscopic procedures were the most common surgical 
technique for both separations including a primary procedure (95.0%) and those with 
adjustments, revisions, removals and other procedures (60.1%). The majority (88.0%, or 
20,000 separations) of bariatric surgery occurred in private hospitals [62]. Notably, the most 
common bariatric surgical procedure is laparoscopic sleeve gastrectomy, while in Tasmania 
the most common procedure is laparoscopic adjustable gastric band [62]. Chapter 8 of this 
thesis investigated (n=105) primary bariatric surgical procedures that were conducted in 
Tasmanian public hospitals over an 8 year time horizon. 
In Australia, recent evidence determined that the potential demand for publicly- and privately-
funded bariatric surgery in Australia was 882, 441 adults aged between 18-65 years [70]. Even 
if only 5% of Australian adults estimated to be eligible for bariatric surgery (informed by the 
NHMRC eligibility criteria [50]) sought this intervention, the demand, particularly in the public 
health system and outside major cities, would far outstrip current capacity. Importantly, 45.8% 
(CI: 37.7, 54.4) of these potential bariatric surgery candidates had no private health insurance 
[70]. As mentioned previously, in Australia, Classes 1, 2 and 3 obesity prevalence increased 
with increasing levels of disadvantage [29] 
Constrained public sector budgets contribute to the incapacity of the Australian public health 
system to address the problems of severe obesity increasing more rapidly than overall obesity 
[71]. This problem is reflected internationally [35, 36, 72]. 
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1.4 Introduction to Health Economics 
1.4.1  Neoclassical economic theory and some departures from the ‘parent discipline’ 
Whilst a full exploration of economic and health economic concepts is beyond the scope of this 
chapter, a brief discussion of key concepts provides background to the conceptual and 
methodological approaches employed in this thesis. Key neoclassical economic concepts are 
outlined, followed by health economics adoption of these concepts from the ‘parent discipline’ 
[73] and departures from these fundamental concepts enabling the emergence of the highly 
specialised discipline of health economics. 
Economics is a discipline concerned with scarcity and choice - the existence of limited 
resources and unlimited human wants. We are forced to make choices among competing 
objectives – an inescapable result of scarcity [1]. Within this framework of unlimited wants 
and finite resources, positive economics is concerned with ‘what is’, whereas normative 
economics embodies subjective feelings about ‘what ought to be’ [74]. 
Neoclassic economic theory states that a resource is scarce whenever it has a non-zero 
opportunity cost [42]. Opportunity cost recognises that everything and everyone has 
alternatives – the cost of any decision or action is measured in terms of the value placed on the 
opportunity foregone [1, 42]. Neoclassical economic theory also assumes that human behaviour 
reflects ‘rational self-interest’: individuals look for and pursue opportunities to increase their 
utility (their satisfaction and happiness) [74]. A perfectly competitive market exists if all the 
following conditions can be satisfied: many buyers and many sellers, perfect information, free 
entry and exit, and a homogenous product [42]. Neoclassical theory states that perfectly 
competitive markets will achieve both allocative and productive efficiency; the most desired 
products are produced in the least costly way [42, 74].  
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The concept of efficiency measures how well resources are being used to promote social 
welfare [1]. The ‘welfarist’ view is that Pareto efficiency is an allocation of resources such that 
it is not possible to reallocate any of them without imposing uncompensated losses of utility 
on some individual [75]. Potential Pareto efficiency is another important concept of efficiency 
and the idea is that if gainers from a change could compensate losers and still gain then there 
is an increase in social welfare (even if the compensation is not actually paid) [76]. 
Additionally, if potential losers can offer gainers an equivalent gain sufficient for them to forgo 
the proposed change and still be better off than with the change, then the change will not 
enhance welfare (even if the equivalent is not actually paid) [76]. Importantly, it has been 
proposed that “these ‘contortions’ are gone through in order to avoid having to face up to the 
reality that a dollar of gain may not be of the same value to each person or, even if it were, that 
it should be so treated in the social welfare function” [76]. Compensation tests are a way of 
trying to identify Pareto improvements or potential Pareto improvements [76]. 
Extra-welfarism is a different idea of efficiency developed within the separate discipline of 
health economics [75, 77]. With extra-welfarism (rather than general utility or welfare) as the 
framework, the maximand may be whatever the analyst or policy maker selects as appropriate, 
and in health policy, health or health gain are common objectives [75, 76, 78]. Recent literature 
has suggested that the definition of extra-welfarism has been unclear and confused over the 
years [73]. Extra-welfarism has been more clearly defined recently in the following terms: ‘(i) 
it permits the use of outcomes other than utility; (ii) it permits the use of sources of valuation 
other than the affected individuals; (iii) it permits the weighting of outcomes (whether utility 
or other) according to principles that need not be preference-based and (iv) it permits 
interpersonal comparisons of well-being in a variety of dimensions, thus enabling movement 
beyond Paretian economics [73, 78]. 
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A recent study contended that whilst professing to have increased the evaluative space from a 
concern with utility alone, in practice extra-welfarism appeared to have altered the evaluative 
space from utility to a much narrower domain: that of the health of patients [73]. Additionally, 
extra-welfarism cannot draw on the equity and efficiency divide - instead it has been suggested 
that it draws much more on classical utilitarianism and that is a specific ethical position that 
health economists need to be more aware that they are supporting [73]. 
While efficiency is one ethical imperative in the design and operation of health services and 
other determinants of health, equity is another [76]. It has been suggested that equity is not 
necessarily to be identified with equality or egalitarianism, but relates in general to ethical 
judgments about the fairness of income and wealth distributions, cost and benefit distributions, 
access to health services, exposure to health- threatening hazards and so on [76]. Although not 
the same as ‘equality’, equity frequently involves considering the equality of something (such 
as opportunity, health, access). Horizontal equity refers to the fairness (or equality) in the 
treatment of apparent equals (such as persons with the same income). Vertical equity refers to 
fairness in the treatment of apparent unequals (such as persons with different incomes) and, by 
contrast, concerns fair inequalities [76].  
The World Health Organization proposes that ‘health equity’ implies that ideally everyone 
should have a fair opportunity to attain their full health potential and that no one should be 
disadvantaged from achieving this potential’. Furthermore the World Health Organization’s 
Director-General (Dr Tedros) says that ‘I envision a world in which everyone can live healthy, 
productive lives, regardless of who they are or where they live’ [79] 
Healthcare markets exhibit special features that are departures from the purely competitive 
market and these departures include: ethical and equity considerations (ethical questions 
inevitably intervene in markets where decisions involve quality of life, and literally life and 
Chapter 1: General introduction and outline 
 
23 | P a g e  
death); asymmetry of information where healthcare buyers typically have less information than 
physicians; positive externalities where the medical care market often generates positive 
spillovers; and third-party payments (insurance) [42, 74]. The next section provides further 
detail regarding some of the differentiating characteristics of health economics as a separate 
discipline from its ‘parent discipline’ of economics. 
1.4.2  The emergence of health economics as a specialist discipline 
Health economics has been described as the application of economic theory (generally 
neoclassical microeconomic theory) to phenomena and problems associated with health and 
healthcare [76]. On the other hand, health economics and the work of health economists have 
been described as much broader than adopting the Paretian approach [75]. It has been suggested 
that although most health economists use the familiar theoretical tools of neoclassical 
economics, that they are by no means (and possibly not even a majority) committed to the 
welfarist (specifically Paretian) approach usually adopted by mainstream economists when 
addressing normative issues [75]. This departure from mainstream neoclassical theory by 
health economists turns out to have been the territory in which some of the most innovative 
ideas of health economics have been generated [75]. 
Kenneth Arrow is recognised as the father of the highly specialised discipline of health 
economics. In his ground-breaking seminal paper titled Uncertainty and Welfare Economics of 
Medical Care Arrow stressed the prevalence of uncertainty in healthcare, both on the demand 
side and the supply side [42]. Healthcare markets display a number of significant and special 
characteristics that differentiate them from a perfectly competitive market, including pervasive 
uncertainty, unavoidable information asymmetries and the need for principal-agent 
relationships [80].  
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For example, the patient-physician relationship is a classic example of the principal-agent 
relationship in health economics [81]. Arrow’s seminal paper explored and described the 
concept of product uncertainty and consumer information in the ‘medical-care market’ [82]. 
Notably, he outlined the concept of asymmetry of information by introducing the following 
concepts:  
“Because medical knowledge is so complicated, the information possessed by the physician 
as to the consequences and possibilities of treatment is necessarily very much greater than 
that of the patient, or at least so it is believed by both parties. Further, both parties are 
aware of this informational inequality, and their relation is coloured by this knowledge.” 
As suggested above, the highly specialised discipline of health economics has developed and 
expanded in scope since Arrow’s (1963) seminal paper, especially since the rise of health 
economic evaluation in the 1990s [82, 83]. For example, behavioural economics [80, 84], 
capability and sufficient capability approaches [85], extra-welfarism versus welfarism [77, 78], 
economics of risky health behaviours (including obesity, time-inconsistent preferences and 
bounded rationality [86]) and neuroeconomics [86-88] are examples of the expansion and 
rapidly evolving discipline of health economics. 
Nevertheless, the concepts and tools of health economic evaluation are fundamental to many 
key health economic resource allocation decisions worldwide [83]. Over the past 20 years two 
factors have led to an increased prominence of economic evaluation within health care 
decision-making nationally and internationally [83]. First, increasing pressures on health care 
budgets have led to a shift in focus from merely assessing clinical effectiveness, to one on 
assessing both clinical effectiveness and cost-effectiveness [83]. Secondly, decision-making 
processes have emerged in several jurisdictions that enable the results of economic evaluations 
to be used as an integral part of funding, reimbursement, or coverage, decisions [83]. 
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1.4.3  Health economic evaluation 
Economic evaluation is defined as ‘the comparative analysis of alternative courses of action 
in terms of both their costs and consequences’ [83]. Economic evaluation of health 
technologies seeks to promote the efficient allocation of health care [89]. Economic evaluation 
can be classified as partial (e.g. a cost-outcome study or cost analyses) or full economic 
evaluation (e.g. cost-benefit analysis, cost-effectiveness analysis, or cost-utility analysis) [83].  
The basic tasks of any economic evaluation are to identify, measure, value and compare the 
costs and consequences of the alternatives being considered [83, 90]. Costs should be estimated 
with the theoretical price of the resource used as its opportunity cost that is the value of its 
foregone benefits because the resource is not available for the resource’s next best alternative 
use) [83, 90]. However, there are pragmatic approaches for adjusting prices that are beyond the 
scope of discussion in this section [83, 90]. Costing plays a vital role in Australia’s Activity 
Based Funding model (section 1.4.5 and Chapter 8 of this thesis).  
In regard to full economic evaluation, cost-benefit analysis adopts a ‘welfarist’ philosophy and 
consequences are measured in monetary units [83, 91]. Cost-benefit analysis rests on the 
premise that a project, policy or intervention will improve social welfare if the benefits 
associated with it exceed its costs [42]. Cost benefit analysis usually requires the calculation of 
present values using a social discount rate and the usual decision rule in cost-benefit analysis 
is for the benefit-cost ratio (B / C) to exceed unity or for (B – C) > 0 [75]. 
Cost-effectiveness analysis adopts an ‘extra-welfarist’ philosophy [78] and measures 
consequences in natural units, such as life-years gained, disability days avoided, or cases 
detected. In regard to bariatric surgery the measured consequences could also include type 2 
diabetic free year or additional case of T2DM remitted, or BMI unit decrements and so on. In 
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a variant of cost-effectiveness analysis, called cost-utility analysis, consequences are measured 
in terms of preference-based measures of health namely quality-adjusted life years (QALYs) 
or disability-adjusted life years (DALYs) [83, 91]. Further detail regarding QALYs is outlined 
in section 1.4.4. 
Figure 1.10 describes the distinguishing characteristics of partial and full healthcare economic 
evaluations [83].  
 
Figure 1.10 Distinguishing characteristics of healthcare economic evaluations. Source: 
Drummond et al (2005 and 2015), Methods for the Economic Evaluation of Health Care 
Programs. 
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The incremental cost-effectiveness ratio (or the incremental cost-utility ratio for cost-utilty 
analysis) is defined as the differences between the costs of two alternatives and the difference 
between their effectiveness or outcomes. The algorithm for the incremental cost-effectiveness 
ratio is the cost of the intervention minus the cost of the comparator divided by the effectiveness 
of the intervention minus the effectiveness of the comparator. The incremental cost-
effectiveness ratio can then be mapped onto the cost effectiveness plane (a diagrammatic way 
of comparing two technologies - see Figure 1.11 [76]) to compare the technologies.  
Figure 1.11: The cost-effectiveness plane is a diagrammatic way of comparing two 
technologies. A four quadrant diagram of cost difference plotted against effect difference yields 
quadrant I (intervention is more effective and more costly than the comparator), quadrant II 
(intervention is more effective and less costly than the comparator), quadrant III (intervention 
is less effective and less costly than the comparator), and quadrant IV  (comparator dominates 
the intervention). Quadrants I and III represents cases where the cost-effectiveness of the 
alternatives depends on the size of the incremental cost-effectiveness ratio and on whether the 
∆E is positive or negative. The dashed red line ʎ represents the willingness-to-pay threshold. 
All points below the willingness to pay threshold are in the region of acceptability. Source: 
Adopted from Culyer (2010), Dictionary of Health Economics. 
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The choice of cost-effectiveness threshold (or the willingness-to-pay threshold) is crucial in 
determining the value of healthcare interventions – international willingness to pay thresholds 
vary [61, 92]. For example, in Australia, the Pharmaceutical Benefits Advisory Committee was 
unlikely to recommend a drug for listing if the incremental cost-effectiveness ratio exceeded 
$76,000 (Australian dollars) [26, 93]. Similarly, the National Institute for Health and Care 
Excellence (United Kingdom) has never identified an incremental cost-effectiveness ratio 
above which interventions should not be recommended and below which they should. However 
interventions with an incremental cost-effectiveness ratio of less than ₤20,000 per QALY 
gained are considered to be cost-effective. As the incremental cost-effectiveness ratio of an 
intervention increases in the ₤20,000 to ₤30,000 range, an advisory bodies judgment about its 
acceptability as an effective use of National Health Service resources should make reference 
to relevant factors outlined by the Institute [61, 94]. There is an ongoing debate in health 
economics about setting thresholds (e.g. using the World Health Organization-recommended 
cost-effectiveness thresholds of 1 to 3 times GDP per capita versus cost-effectiveness 
thresholds reflecting opportunity costs) [95]. A recent study has suggested that rather than 
settling on a single threshold, it would be preferable to use multiple thresholds, ideally ones 
based on the available resources for the relevant decision maker and possible alternative uses 
of those resources. For example, decision makers in resource-poor settings would have a lower 
willingness to pay threshold [61, 95]. 
The perspective (or viewpoint) of the economic evaluation is important because a program or 
intervention that looks unattractive from one perspective may look significantly better when 
other perspectives are considered [83]. The perspective of a health economic evaluation will 
reflect the perspective of the individual, the payer or society [83].  
Although economic evaluation can be applied to all health technologies, including drugs, 
Chapter 1: General introduction and outline 
 
29 | P a g e  
devices, procedures, and systems of organisation of health care, in the main the formal 
requirement for assessment of cost-effectiveness has been applied to pharmaceuticals. This 
formal requirement was first introduced in Australia in 1993 and the policy has been adopted 
in numerous countries (e.g. half the countries of the EU, Canada, NZ, and several payers of the 
United States and some countries in Latin America and Africa) [83]. Government policy in the 
United States is that cost/QALY thresholds have been legislated against [95]. 
Some jurisdictions have requested economic evaluations for technologies other than drugs, 
including the United Kingdom, where the National Institute for Health and Care Excellence 
assesses the clinical and cost-effectiveness of a wide range of technologies, including public 
health interventions, before issuing guidance for their use in the National Health Service. 
Economic evaluations have been much more prominent in jurisdictions with single-payer 
systems, most notably Australasia, Canada, the Scandinavian countries, and the United 
Kingdom [83]. 
There is tension between the academic rigour of health economics and the realities of policy 
making [75, 96]. Recent literature discussed the policy use of economic evaluation in 
healthcare: evidence from economic evaluation in healthcare decision making is used if the 
evidence is accessible and acceptable [96]. Interestingly, there has also been a call to adopt the 
capability and sufficient capability approaches in economic evaluation [73].  
Furthermore, there has also been a call for the use of qualitative research methods to improve 
practice in health economic evaluation - Chapters 6 and 7 of this thesis make a novel 
contribution to the literature regarding qualitative research. The broader discipline of health 
economics is repeatedly scrutinised for its relevance and translation into healthcare policy 
making [97]. As a professional community that strives to convince the decision maker about 
the optimal allocation of the scarce healthcare dollar at the margin, our research will only be 
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relevant if decision makers trust that we have considered all of the costs and benefits that are 
in fact relevant (and a priority) to the recipients of the healthcare dollar.  
1.4.4 Health-related quality of life 
The International Society for Quality of Life Research states that a number of definitions of 
health-related quality of life exist and that there is broad agreement that health-related quality 
of life is a functional effect of a medical condition and/or its consequent therapy upon a patient 
[98]. Health-related quality of life is thus subjective and multidimensional, encompassing 
physical and occupational function, psychological state, social interaction and somatic 
sensation [98]. 
It is beyond the scope of the thesis to explore the published literature regarding the assumption 
that a person is the best judge of the value of worth of their own lives [99]. Nevertheless, when 
researchers measure a person’s overall quality of life in terms of his or her self-reported 
happiness or satisfaction, they are most likely assuming that people are the best judges of the 
value or worth of their own lives and that as their reported levels of happiness or satisfaction 
increase or decrease, the quality of their lives (its value or worth) is increasing or decreasing 
[99]. 
Measures of happiness and socialising activities are important measures of overall quality of 
life and broader health-related quality of life research suggests that self-perceived good health 
is not equivalent to perceived quality of life: that is ‘good health is not the same as good life’ 
[100]. In turn, psychosocial health status has been increasingly identified as a crucial health-
related quality of life outcome measure for the morbidly obese population who then receive 
bariatric surgery [28]. Additionally, long-term waitlisted bariatric surgery patients realise 
significant psychosocial health-related quality of life gains when ultimately treated [26, 27]. 
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Numerous instruments have been created which produce indices of health-related quality of 
life including generic (e.g. Short Form (SF)-36, EQ-5D-5L and Assessment Quality of Life 
(AQoL)-8D) and non-generic instruments (e.g. BOSS (Bariatric and Obesity Specific Survey), 
or IWQoL-lite) A subset of the generic instruments is multi-attribute utility instruments (e.g. 
EQ-5D-5L and AQoL-8D) that create indices of health state utility valuations [101]. A health 
state utility valuation is an important health economic metric that measures the strength of 
preference for a particular health state and a health state utility valuation is represented as a 
number on a scale where ‘1.0’ represents the best possible health state and ‘0.0’ represents 
death. In principle, values less than 0.0 are possible when a health state is worse than death [27, 
102]. Importantly health state utility valuations are key health economic metrics that are an 
input measure to QALYs in cost-utility analysis [83]. A QALY provides a year of future life 
expectancy adjusted for the expected quality of life during that time: in the formation of the 
QALY multiple effects of health care provision are essentially reduced to a single value and 
this single score is then used to weight years of future life expectancy to give years of quality-
adjusted future life expectancy. QALYs have been aligned with the extra-welfarism 
perspective in the United Kingdom [78]. 
Multi-attribute utility instruments are a health-related quality of life assessment tool designed 
to rapidly and conveniently assess and capture an individual’s health state utility values through 
application of pre-established formulae/weights to the array of self-reported responses obtained 
on the multi-attribute utility instrument’s questionnaire. A multi-attribute utility instrument is 
developed and defined with particular characteristics including: the number of questionnaire 
items, the depth and breadth of the descriptive/classification system, the number of health states 
described, the number of individual and super dimensions (if there are super dimensions) and 
the algorithmic range [27, 103]. 
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The EQ-5D-3L and EQ-5D-5L multi-attribute utility instruments dominate clinical and 
economic evaluation studies, including the obesity and bariatric surgery published studies [61, 
104]. The standard format of the EQ-5D descriptive health classifier system consists of five 
dimensions of health, each with three levels of problems for the EQ-5D-3L (243 health states) 
or the more recently developed 5-level EQ-5D-5L that expands the range of responses to each 
dimension from three to five levels (3,125 health states) [105]. Four out of the five EQ-5D-5L 
domains of health focus on physical health only [106]. 
1.4.5  Australia’s Activity Based Funding model 
In August 2011 the Council of Australian Governments ratified the National Health Reform 
Agreement that informed the establishment of Australia’s Independent Hospital Pricing 
Authority (IHPA). IHPA plays a pivotal role in Activity Based Funding model through key 
functions outlined in section 3B of the National Health Reform Agreement [107]. 
IHPA states that Activity Based Funding is a way of funding hospitals whereby they get paid 
for the number and mix of patients they treat. If a hospital treats more patients, it receives more 
funding. Additionally, because some patients are more complicated to treat than others, 
Activity Based Funding also takes this factor into account [108]. 
Within the ABF funding model our Tasmanian State Government project partner focuses on 
costs at the patient level. The DHHS states that a consistent approach to identifying how 
individual patient costs are constructed can help organisations understand where variations 
arise within a patient pathway, for example, in theatres, wards or diagnostics [109]. The 
DHHS’s development of patient level costs builds costs from the bottom-up, identifying where 
possible the resources used in treating individual patients – for example, prosthetic devices 
(such as laparoscopic adjustable gastric band appliance), the intensity of nursing resources and 
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indirect or overhead costs such as the costs of the payroll or finance team through appropriate 
allocation and apportionment methods [109]. 
Every year within the Tasmanian public healthcare setting, an annual State hospital costing 
study that use bottom-up costings are undertaken that match patient activity and usage data 
from various hospital information systems with costs from the general ledgers [109]. This work 
aims to cost all hospital activity covering all products and this essential work underpins the 
Activity Based Funding model requirements laid out by the National Health Reform 
Agreement signed by the Australian States and Territories and the Commonwealth [109]. 
1.5 The health economic burden of obesity 
1.5.1 The health economic burden of obesity worldwide 
In contrast to the research on the economic causes of obesity that is often characterised by 
conflicting results, the evidence on the economic consequences of obesity is relatively 
consistent: obesity worsens labour market outcomes (such as lower wages and lower 
probability of employment) and raises medical care costs [5]. Moreover, medical care costs do 
not rise significantly with BMI until the severe and morbid obesity range (Class 2 and Class 3 
obesity) [5]. 
The economic burden of the obesity epidemic and its associated comorbidities places undue 
stress on healthcare systems [110]. A recent systematic review regarding the direct costs of 
obesity worldwide found that obese individuals have medical costs that were approximately 
30% greater than their normal weight peers [110]. Nevertheless, this review stated that cost-
of-illness analyses for most diseases are commonplace for most diseases, but the complexities 
for obesity and its constantly expanding list of comorbidities makes obesity’s evaluation 
challenging. For example, in a recent review of decades of Canadian obesity research, only 1% 
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pertained to costs and healthcare utilisation, and Canada does not seem to be unique in this 
phenomenon [110]. 
The economic burden of obesity also extends well beyond the healthcare sector into societal 
domains including work productivity [7, 13, 111-113], and personal and family impacts arising 
from discrimination and stigmatisation of the overweight and obese both individually and 
collectively, poorer relationships and social engagement [6, 114]. 
A recent study that estimated the savings in medical expenditures associated with reductions 
in BMI among United States adults with obesity found that the relationship between medical 
care costs over BMI is J-shaped: costs rise exponentially in the range of Class 2 and Class 3 
obesity (BMI 35 kg/m²) [23]. The study found that the heavier the obese individual, the greater 
the reduction in medical care costs associated with a given percent reduction in BMI and that 
medical care expenditures are higher, and rise more with BMI, among individuals with diabetes 
than among those without diabetes [23]. 
1.5.2 Australia’s healthcare system and the health economic burden of obesity in 
Australia 
The Australian healthcare system is characterised by a complex and fragmented set of 
arrangements between the public (two tiers of government) and private sectors [115]. The 
national government (the Commonwealth) holds the major revenue-raising powers, so the 
States and Territories (six States and two Territories) rely on financial transfers to provide 
services. The States operate public hospitals (which account for about two thirds of all 
hospitalisations and provide emergency department visits without charge), though funding 
them is a joint responsibility of both levels of government. The Commonwealth has 
responsibility for paying benefits through Medicare (for out-of-hospital medical care and in-
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hospital private medical services) and for the Pharmaceutical Benefits Scheme (covering most 
prescribed drugs), however, funding arrangements for other services often involve both levels 
of government [115]. The National Health Reform Agreement was signed by all States and the 
Commonwealth in 2011. It established a new basis for the Commonwealth’s contribution to 
public hospital funding, based on organisations’ case-mix and known as Activity Based 
Funding [104, 105]. 
Total spending on health in Australia was $170.4 billion in 2015-16 [43]. The share of the 
economy (Gross Domestic Product (GDP)) represented by health was 10.3% [43]. Of this total 
government health expenditure was $114.6 billion, or approximately two-thirds (67%) of all 
health expenditure [43]. Government expenditure on public hospital services was $46.9 billion 
(40.9% of total government expenditure) in 2015-16 [43]. State and Territory expenditure 
accounted for 52.2% of all sources of expenditure on public hospital services in 2015-16 [43]. 
Non-government sources (individuals, private health insurance funds, and other non-
government sources) spent $55.8 billion on health in 2015-16 (32.7% of total health spending) 
[43]. Expenditure by individuals accounted for 52.7% of non-government expenditure and 
represented 17.3% of total health expenditure [43]. Forty seven percent of Australians are 
privately insured, and there is 100% public coverage through Medicare [115]. 
The most recent estimate contained in the published literature of the total annual direct cost of 
overweight and obesity in Australia in 2005 was estimated to be 21 billion Australian dollars 
and this estimate was substantially higher than previous estimates [116]. The authors concluded 
that there are financial incentives for individuals, governments and societies to address the 
obesity epidemic in Australia [116]. Over a decade later, the prevalence of severe obesity and 
the associated co-morbidity loads are increasing.  
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1.5.3 Some health economic policy challenges regarding obesity and bariatric surgery 
Against a multifactorial background of a worldwide epidemic, obesity is a profoundly complex 
global public health, economic and strategic policy problem [4, 2, 7, 12, 13]. It has been 
suggested that there is no magic bullet that will solve the problem of obesity, but numerous 
policies with modest beneficial effects, if enacted jointly, could result in meaningful 
change [117]. 
Examples of market failures relevant to obesity include imperfect information, negative 
externalities, and irrational behaviour [86]. Imperfect information leads to the health 
economic problem of asymmetry of information between the supplier (physician) and 
consumer (patient) [82]. Most studies regarding asymmetry of information investigate 
the physician’s superior knowledge (supplier-induced demand), rather than the 
consumer’s knowledge (demand-induced supply) [81]. 
In regard to irrational behaviour, the growing field that investigates the economics of 
risky behaviours reveal that time-inconsistent preferences can lead to excess weight. 
Such preferences are characterised by someone expressing the desire for a healthier 
lifestyle, but consistently succumbing to immediate gratification [84]. Suggestive 
evidence of time-inconsistent preferences is that the majority of obese men, and more 
than two-thirds of obese women, report having attempted to lose weight in the past year 
[86]. 
One way to solve this problem of time-inconsistent preferences is to offer obese 
individuals pre-commitment devices - the most dramatic pre-commitment device is 
bariatric surgery, which allows a person to pre-commit to eating less in the future by 
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having the size of their stomach surgically reduced and in other ways decreasing the 
pleasure associated with eating [117].  
1.6 Qualitative research methods in health economics – improving practice? 
Health economics is repeatedly scrutinised for its relevance and translation into healthcare 
policy making [97]. Over the past decade, there has been a call for health economists to 
effectively integrate combinations of qualitative and quantitative methods into their research 
toolkit to enrich their research methodologies and therefore improve their practice in health 
economic study design, data gathering and analyses, reporting, and ultimately research 
translation [118-123]. Additionally, health policy development, research, and management 
could benefit from more in-depth, textured descriptions of what actually happens in practice 
settings, healthcare markets, and patients’ lives [124, 125]. Nevertheless, recent evidence has 
found that only 9% of published health economic research adopts qualitative research methods 
[122, 125].  
My systematic review established that the health economic reporting of bariatric surgery is 
dominated by quantitative methods that adopt a narrow payer perspective [61]. Additionally, 
the EQ-5D suite of instruments dominates the cost-utility studies regarding bariatric surgery - 
the EQ-5D focuses on physical health rather than psychosocial health [61]. Qualitative research 
methods could improve our practice in health economic evaluation of bariatric surgery by 
eliciting costs and consequences that would not be captured with traditional quantitative 
methods. 
There is also a call for health economists to implement mixed-methods policy-relevant research 
that is embedded in and derived from real-world policy settings [119, 122, 126]. Mixed-
methods policy-relevant and translatable research can be successfully generated through 
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research partnerships between knowledge-users (e.g. government) and academic researchers 
[127]. 
1.7 Evidence gaps: health economic reporting of bariatric surgery 
Chapter 2 of this thesis contains a comprehensive systematic review of the health economic 
evaluation of bariatric surgery from 1995 to 2015 that included 77 partial and full economic 
evaluations of bariatric surgery [61]. The review found that the health economic reporting of 
bariatric surgery is characterised by heterogeneous approaches of inconsistent quality and 
identified key gaps and common themes in the reporting of bariatric surgery [61]. 
Some of the key gaps identified by this research included: only a limited spectrum of direct 
medical costs was considered in the majority of studies including a lack of consideration of the 
costs of many important longer term post-operative events like reoperations, complications and 
body contouring surgery; a paucity of information on indirect costs such as out-of-pocket 
expenses to patients and their families, work productivity gains and/or losses, and the impact 
of being waitlisted for bariatric surgery, and the rapid increase in severe obesity (compared to 
overall obesity) where demand for bariatric surgery was continually exceeding the increase in 
supply. The systematic review also found that bariatric surgery was cost-effective/cost-saving 
for severely obese with type 2 diabetes mellitus.  
1.8 Key research aims of this thesis 
As a health economist within the National Health and Medical Research Council partnership 
project team, the principal aims of my PhD research were to: 
• Provide critical baseline analyses of the evidence gaps and key themes regarding 
the health economic reporting of bariatric surgery, locally, nationally and 
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internationally; 
• Address key evidence gaps regarding the capture and measurement of the physical 
and psychosocial domains of health-related quality of life of people with obesity 
waiting for, or who have received bariatric surgery; 
• Use qualitative research methods to investigate bariatric surgery patients’ 
experiences to identify and prioritise health economic costs and consequences of 
bariatric surgery that are typically excluded from existing studies or not given 
appropriate priority; and 
• In collaboration with our NHMRC health partner, estimate the health service 
resource use and direct costs for patients (i) waiting for bariatric surgery, (ii) the 
index of surgery, and (iii) for up to three years post-surgery. 
 
1.9 Summary of the methods and structure of this thesis 
This thesis has provided much needed information for health economists and health policy 
decision makers regarding the key health economic evidence gaps for obesity and bariatric 
surgery internationally, nationally and in Tasmania. 
To achieve the research objectives of my PhD project, this thesis adopted a mixed-methods 
approach of both quantitative and qualitative research methods, within real-world policy 
settings, consistent with a call for health economists to implement mixed-methods policy-
relevant research that is embedded in and derived from real-world policy settings [21-23].  
First, validated guidelines and methodologies were followed in the systematic selection and 
narrative synthesis and analyses of the published literature regarding the health economic 
evaluation of bariatric surgery. The findings of this comprehensive systematic review informed 
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the methods of the remainder of this thesis. 
Second, the vastly different EQ-5D-5L and AQoL-8D multi-attribute utility instruments were 
systematically selected to investigate health state utility in two recruited cohorts of bariatric 
surgery patients. Patients who had received bariatric surgery many years previously in the 
private healthcare system (cross-sectional study) and patients who had waited for bariatric 
surgery for many years and who were then operated on as part of a government policy decision 
to reduce waiting lists (longitudinal study) were studied. 
Third, qualitative research methods were used to investigate bariatric surgery patients’ 
experiences to identify and prioritise health economic impacts of bariatric surgery that are 
typically excluded from existing studies. Over the past decade, there has been a call for health 
economists to effectively integrate combinations of qualitative and quantitative methods in 
their research toolkit to enrich their research methodologies and therefore improve their 
practice in health economics study design, data gathering and analyses, reporting, and 
ultimately research translation. 
Ten focus groups (n=49 participants) were conducted, transcribed verbatim and analysed 
thematically with the assistance of software. Themes were identified inductively through a 
dialogue between the qualitative data and pre-existing economic theory. 
Fourth, a strategic research alliance with our NHMRC project partner, the State Government 
of Tasmania’s Department of Health and Human Services was self-assembled with 
heterogeneous human capital. Quantitative research methods were adopted to construct and 
analyse a real-world resource use and cost database regarding resource use and costs to the 
Tasmanian public hospital system before and after bariatric surgery (n=105 patients; n=779 
episodes-of-care). 
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This thesis is structured in the following way. 
Chapter 1 has presented an overview of the obesity epidemic, bariatric surgery as a treatment 
option for obesity, and health economics as a separate and important discipline of economic 
inquiry. This chapter also presents the methods, key research objectives and structure of this 
thesis. 
Chapter 2 provides a comprehensive systematic review informed by broad selection criteria of 
the health economic evaluation of bariatric surgery from 1995 to 2015. A quality appraisal of 
the included studies against the Consolidate Health Economic Evaluation Reporting Standards 
checklist is also conducted. The findings of this study informed many aspects of the remainder 
of this thesis, and some of the future directions for research. Appendix 2A contains the 
published article [61]. 
Chapter 3 presents the thesis’ initial head-to-head comparison of two systematically selected 
and markedly different multi-attribute utility instruments, namely the AQoL-8D and EQ-5D-
5L, for a cross-sectional study of patients who received bariatric surgery in the private 
healthcare system many years previously. Appendix 3A contains the published article [28]. 
Chapters 4 and 5 are longitudinal studies that were based on a unique cohort of long-term 
waitlisted patients who were then provided with bariatric surgery. The choice of multi-attribute 
utility instruments for these studies were guided by the systematic review (Chapter 2) and the 
findings of Chapter 3. Chapter 5’s head-to-head comparison study extended the method of 
Chapter 3’s comparison of the two instruments. Appendices 4A and 5A contain the published 
articles [26, 27]. 
Chapters 6 and 7 present health economics studies that adopt qualitative research methods. The 
inspiration for the method of these studies was partly directed by the systematic review 
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(Chapter 2) that identified the limited scope of costs and consequences for most health 
economics reporting of bariatric surgery. Appendix 6A contains the published article from 
Chapter 6 [128]. 
Chapter 8 presents a quantitative cost-outcome study that was supported by a strategic research 
alliance with our Tasmanian State Government partners. A request for revisions has been 
received from PharmacoEconomics Open for the paper presented in Chapter 8. 
Chapter 9 presents a summary of this thesis, the conclusions of the research and the most 
promising directions for future research. 
Finally, Appendix 1 presents scholarly output that has been generated from this PhD research 
and thesis. 
1.10 Summary of scholarly output as a direct result of this thesis 
This PhD project has resulted in five publications in health economic, quality of life and 
disease-specific international journals (Chapters 2, 3, 4, 5 and 6 [26-28, 61, 128]), and two 
manuscripts have been submitted to international journals (Chapters 7 and 8). The relevant 
findings of each of the seven papers of this PhD project and thesis have been presented at 
national and international conferences. One of the published papers (Chapter 2) was also 
identified by a leading national private and public hospital group for an invited presentation at 
their National Conference and a letter of thanks was received for my presentation. Poster 
presentations regarding Chapters 4, 5 and 8 were awarded a prize at a highly-
regardedinternational conference. 
During my PhD research I have also been identified as an expert in my field. I have been invited 
to peer-review 5 publications (4 subsequently approved for publication) for 3 leading 
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international journals, namely, Value in Health (2 publications), Diabetes Medicine (2 
publications) and PharmacoEconomics Open (1 publication).  
My PhD research has also generated other scholarly projects with our critical health partner at 
the conclusion of this PhD project including a broader analysis of all long-term waitlisted 
patients who subsequently received elective surgery in the Tasmanian public health system due 
to a public policy decision to reduce waiting lists. Additionally, due to this thesis’ publications 
and advice, the AQoL-8D is being used for important research in other complex and chronic 
disease areas such as Multiple Sclerosis with translatable research findings.  
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Chapter 2: Diverse approaches to the health economic 
evaluation of bariatric surgery: a comprehensive 
systematic review 
Preface 
This chapter provides a comprehensive systematic review of the health economic evaluation of 
bariatric surgery from 1995 to 2015 (77 included studies). The findings of this published study 
informed many aspects of the remainder of this thesis, the work program for the NHMRC 
partnership project, and future directions for research beyond this thesis. 
Our study aimed to provide a systematic and critical analysis of the key themes and evidence 
gaps in the existing scholarly literature. Unlike previous systematic reviews we did not seek to 
capture homogenous studies for meta-analysis to inform a further cost-effectiveness study. As 
an important advance on existing systematic reviews, we aimed to adopt a broader approach to 
our systematic review with a view to identifying common themes and key evidence gaps across 
the depth and breadth of the health economics literature pertaining to bariatric surgery.  
We adopted a suite of gold-standard validated guidelines to assist with the systematic review’s 
data capture, extraction and interpretation.  
Some of the findings of the systematic review that guided this thesis were that only 13% of 
included studies adopted a broader societal perspective, the cost of complications and 
reoperations for bariatric surgery were not included in one-third of studies and when they were 
included, conservative estimates were generally adopted, out-of-pocket costs were largely 
ignored, the EQ-5D suite of multi-attribute utility instruments was prevalent in the health 
economic evaluation (cost-utility analyses) of bariatric surgery, and that only one study 
investigated publicly waitlisted patients.  
The systematic review’s quality appraisal against the Consolidated Health Economic 
Evaluation Reporting Standards checklist found heterogeneous approaches, inconsistent 
quality and key evidence gaps in the health economic reporting of bariatric surgery. A key 
evidence gap from the quality appraisal included that the estimation of resources and costs was 
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deficient. 
One of the key findings for NHMRC partnership project was that psychosocial health is a key 
driver for the success of bariatric surgery. The studies contained in Chapters 3, 4 and 5 use a 
multi-attribute utility instrument that particularly assesses and captures psychosocial health-
related quality of life for people with complex physical and psychosocial needs The choice of 
the two multi-attribute utility instruments for these studies was a direct result of the systematic 
review’s finding that most cost-utility analyses regarding bariatric surgery used the EQ-5D-5L 
multi-attribute utility instrument. 
This systematic review called for a more comprehensive investigation and reporting of health 
economic outcomes of bariatric surgery to identify aspects of the bariatric surgery patient’s 
journey that reached well beyond the primary surgery’s direct medical costs. Chapters 6 and 7 
harnessed the unique advantages of qualitative research methods to identify and contextualise 
crucial costs and consequences of bariatric surgery that have typically be omitted, or not 
provided with sufficient priority in the health economic investigation and reporting of bariatric 
surgery. 
The findings of the systematic review also informed the study in Chapter 8, including the 
investigation of the cost of complications and reoperations for bariatric surgery and robust unit 
costing methodologies (based on Australia’s Activity Based Funding model). 
This chapter has been published in Obesity Reviews (Appendix 2A). 
Impact factor: 7.89.  
Campbell JA, .Venn A, Neil A, Hensher M, Sharman A and Palmer AJ. Diverse approaches 
to the health economic evaluation of bariatric surgery: a comprehensive systematic review. 
Obesity Reviews. 2016 Sep;17(9):850-94. doi: 10.1111/obr.12424. Epub 2016 Jul 7. 
The published article found at the 
end of this chapter has been 
removed for copyright reasons. 
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Summary 
Background: Health economic evaluations inform healthcare resource allocation decisions for 
treatment options for obesity including bariatric/metabolic surgery. As an important advance 
on existing systematic reviews, we aimed to capture, summarise and synthesise a diverse range 
of economic evaluations on bariatric surgery. 
Methods: Studies were identified by electronic screening of all major biomedical/economic 
databases. Studies included if they reported any quantified health economic cost and/or 
consequence with a measure of effect for any type of bariatric surgery from 1995 to September 
2015. Study screening, data extraction and synthesis followed international guidelines for 
systematic reviews. 
Results: Six thousand one hundred eighty-seven studies were initially identified. After two 
levels of screening, 77 studies representing 17 countries (56% USA) were included. Despite 
study heterogeneity, common themes emerged, and important gaps were identified. Most 
studies adopted the healthcare system/third-party payer perspective; reported costs were 
generally healthcare resource use (inpatient/shorter-term outpatient). Out-of-pocket costs to 
individuals, family members (travel time, caregiving) and indirect costs due to lost productivity 
were largely ignored. Costs due to reoperations/complications were not included in one-third 
of studies. Body-contouring surgery included in only 14%. One study evaluated long-term 
waitlisted patients. Surgery was cost-effective/cost-saving for severely obese with type 2 
diabetes mellitus. Study quality was inconsistent. 
Discussion: There is a need for studies that assume a broader societal perspective (including 
out-of-pocket costs, costs to family and productivity losses) and longer-term costs (capture 
reoperations/complications, waiting, body contouring), and consequences (health-related 
quality of life). Full economic evaluation underpinned by reporting standards should inform 
prioritization of patients (e.g. type 2 diabetes mellitus with body mass index 30 to 34.9 kg/m2 
or long-term waitlisted) for surgery. 
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2.1 Introduction 
2.1.1 The health and economic burden of obesity 
Obesity is not only a major health concern, it is also an economic problem [1]. Excess weight 
gain is forecast to lead to an increased health burden from several diseases, most notably 
cardiovascular diseases, diabetes and cancers [1]. The economic burden of the obesity epidemic 
is substantial and far-reaching and includes the increase in medical and other obesity-related 
expenditures [1], decreased workplace productivity [2], negative impacts on family and 
relationships [3] and stigmatization and discrimination of the overweight and obese both 
individually and collectively [4]. 
Overweight and obesity in adults is commonly classified with body mass index (BMI) 
calculated as BMI = weight (kg)/height (m2). For adults, BMI ≥ 25 kg/m2 is classified as 
overweight and BMI ≥ 30 kg/m2 is obesity [5]. Worldwide prevalence of obesity has doubled 
since 1980 [5], and based on the latest available surveys, more than half (53%) of the adult 
population in the Organisation for Economic Co-operation and Development is estimated to be 
overweight or obese [6]. Among those countries where height and weight were measured, the 
proportion was even greater at 57% [6]. Furthermore, severe obesity (BMI ≥ 35 kg/m2) is 
increasing faster than obesity in adults and children [7]. 
A recent ground-breaking econometric study suggests that self-reported weight consistently 
underestimates the effects on government costs [8]. The study adopted the econometric 
instrumental variables approach to investigate the possibly causal effect of obesity on medical 
care costs by adjusting for endogeneity of weight (the correlation of obesity with medical care 
costs where the model may be informed by an under or over estimate of costs) and measurement 
error in weight (replace self-reported height and weight) [8]. Importantly, this study implied 
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that previous widely cited estimates have underestimated the causal impact of obesity on 
medical care costs. In turn, this implies underestimates of the economic rationale for 
government intervention to reduce obesity-related costs [8]. Treatments for overweight and 
obesity include dietary therapy, exercise/behavioral interventions, weight loss medications and 
bariatric (weight loss/metabolic [9]) surgery [10]. Bariatric surgery is a well-documented 
treatment for obesity worldwide with increasing prevalence in developed and developing 
countries, and the types of metabolic/bariatric operations are in continuous flux with different 
surgical options continuously evolving influenced by literature results, specific local conditions 
and the experience of surgical staff [11-13]. Many clinical and epidemiological studies have 
found that all types of bariatric surgery are clinically effective particularly for patient subgroups 
such as the severely obese and severely obese with type 2 diabetes mellitus (T2DM) [14]. As 
a rapidly evolving subspecialty of gastrointestinal surgery, bariatric surgical procedures 
involve gastric restriction (to augment early satiety and limit meal portions) or intestinal 
diversion (designed to reduce caloric absorption). Some bariatric procedures contain elements 
of restriction and diversion [15]. Bariatric medicine has developed as a clinical subspecialty in 
some countries, and others are calling for this level of specialization as a treatment option for 
obesity [16]. 
2.1.2 Economic evaluation of bariatric surgery 
Economics is a discipline concerned with the existence of limited resources and unlimited 
human wants and desires. Without enough resources to satisfy all the desires of all people, the 
challenge arises how to allocate those available resources among competing objectives [17]. 
Economic evaluation is defined as the comparative analysis of alternative courses of action in 
terms of both their costs and consequences. Economic evaluation is a vital resource allocation 
methodology because it provides decision makers with robust analyses to underpin decisions 
Chapter 2: Diverse approaches to the health economic evaluation of bariatric surgery: a 
comprehensive systematic review 
 
59 | P a g e  
about committing scarce healthcare resources to one use instead of another [18]. An economic 
evaluation needs to identify, measure, value and compare the costs and consequences of the 
alternatives being considered [18]. 
A recent study that investigated the incorporation of economic evidence and perspectives in 
Cochrane reviews argued that questions such as ‘at what cost is the outcome achieved?’, and 
‘what will be the economic impact of this intervention?’ are crucial if health systems are to use 
the resources they have available to their best advantage [19]. Many full economic evaluations 
conclude that bariatric procedures are a cost-effective treatment option for obesity [20-26]. In 
contrast, a recent critique opined that accumulating evidence suggested no economic benefit 
for bariatric surgery [27]. The critique also called for the consideration of patients who have a 
complication of obesity that was known to dramatically improve with weight loss surgery (e.g. 
diabetes and osteoarthritis) [27]. Further, for an intervention to be cost-effective, ability as well 
as willingness to pay must be met. The aim of this systematic review is to explore these 
conflicting observations. 
Specifically, our systematic review aims to: map what research has been conducted; identify 
common themes among heterogeneous studies; identify the major ‘knowledge gaps’ [28] by 
classifying and critically analysing variables that underpin both partial and full economic 
evaluation and by detailed investigation of the health economic metrics of full economic 
evaluation; and describe the overall quality of the research. It will also identify patient 
subgroups where bariatric surgery is found to be largely cost-effective and patient subgroups 
that warrant further health economic investigation. To date, systematic reviews of health 
economic outcomes for bariatric surgery have generally adopted narrow eligibility criteria and 
reported on limited primary studies, or have selected homogenous studies to retrieve data to 
model cost-effectiveness [15, 29-32]. Other systematic reviews have restricted eligibility by 
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assuming criteria such as long-term modelling of cost-effectiveness [33]. As an important 
advance on existing systematic reviews, our review adopts broad eligibility criteria to capture 
a disparate and comprehensive range of health economics studies that have investigated 
bariatric surgery as a treatment option for obesity. 
2.2 Methods 
2.2.1 Validated guidelines 
This systematic review has been performed and reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses guidelines [34]. The Campbell 
and Cochrane Economics Methods Group guidelines to incorporating economic evidence in 
reviews informed the bibliographic database search criteria, data extraction and synthesis [35]. 
No previous systematic review has critically appraised health economics evaluations for 
bariatric surgery for methodological quality against the Consolidated Health Economic 
Reporting Standards (CHEERS) statement [36]. The CHEERS statement consolidates previous 
health economics evaluation guidelines into one current useful reporting guidance and 
recognizes that economic evaluations require additional reporting space [36]. Included studies 
were graded as high, medium and low quality. All of the 24 items were given equal weight. 
For full economic evaluations, 20–24 points of the 24 point checklist were categorized as high 
quality, 15–19 points were deemed to be of medium quality and ≤14 points ranked as low 
quality (<60%). Methodological quality of partial economic evaluations was also considered, 
and percentages were calculated on a pro-rata basis where <60% of the relevant CHEERS 
statement for the particular study was rated low quality, 60–80% medium quality and >80% 
high quality. 
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2.2.2 Bibliographic databases and search terms 
A predefined search strategy was used to identify relevant articles published in both health 
economics and biomedical databases from 1995 to September 2015. Seven economic databases 
– American Economic Association (EconLit), Ideas, the Centre for Reviews and Dissemination 
(CRD), which includes the Database of Abstracts of Reviews of Effects (DARE), Health 
Technology Assessment Database (HTA), National Health Service Economic Evaluation 
Database (NHS EED) and the Cost-Effectiveness Analysis Registry (CEA Registry) and four 
biomedical databases – PubMed, MEDLINE, Embase and Scopus were initially searched 
between June–September 2014. A further search was conducted in September 2015 to capture 
studies from September 2014 to September 2015. Search terms were adopted from the 
databases' vocabulary tools where available such as Medical Subject Headings (MeSH terms) 
for PubMed/MEDLINE including ‘health care economics and organisations’ and ‘bariatric 
surgery’ and ‘quality of life’ and Emtree terms for EMBASE including ‘bariatric surgery’, 
‘economic aspect’ and ‘quality of life’. Scopus and the economic databases do not contain 
vocabulary tools, and the appropriate search terms were grouped together adopting the PICO 
convention, which references participants, interventions, comparisons and outcomes [37]. An 
example of the search strategy is provided in Table 1. To identify other relevant studies, a key 
word search of Google Scholar, citation lists and the bibliographies of review articles and the 
obtained studies were also scrutinized. 
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Table 1: Search strategy based on Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses methodology 
Long Search #1 AND #2 AND #3 NOT #4 
#1 Economic filters (outcome) "economic evaluation" OR cost OR effectiveness OR "cost effectiveness" OR 
"cost benefit” OR “cost analysis” OR "cost utility" OR CUA OR CBA OR CEA 
OR "health economic*" OR economic* OR “direct cost” OR “indirect cost” OR 
“intangible cost” OR “health care cost” OR ” OR “quality adjusted life year” 
OR QALY OR utility OR “economic benefit” OR “economic evaluation” in 
Title, Abstract or Keywords (outcome); 
 
#2 Participant/ 
#3 Intervention 
“bariatric surgery” OR “obesity surgery” OR “metabolic surgery” OR “weight 
loss surgery” OR “laparoscopic adjustable gastric band” OR “swedish 
adjustable gastric band” OR “gastric bypass” OR LAGB OR SAGB OR RYGB 
OR VGB OR “roux-en-Y” OR “gastric sleeve” in Title, Abstract or Keywords 
(participant and intervention); 
#4 Excluding NOT “animal” in Title, Abstract or Keywords  
MeSH and Emtree Search ("Health Care Economics and Organizations" explode all trees [MeSH] AND 
"Bariatric Surgery" explode all trees [MeSH];  "Bariatric Surgery" explode all 
trees [MeSH] AND "Quality of Life" explode all trees [MeSH]) 
("Bariatric Surgery" explode all trees [Emtree] AND "Economic Aspect" 
explode all trees [MeSH]; "Bariatric Surgery" explode all trees [MeSH] AND 
"Quality of Life" explode all trees [Emtree]) 
 
2.2.3 Study eligibility, selection of studies and data extraction 
Studies were included if they satisfied the criteria, (1) reported a quantified cost and/or 
consequence with a measure of effect for no surgery, ‘before and after’, conventional treatment 
or standard care (studies that only compared costs of one type of surgery against another type 
were excluded), for any type of bariatric surgery such as laparoscopic adjustable gastric 
banding (LAGB), Swedish adjustable gastric banding, vertical gastric banding, gastric banding, 
vertical banded gastroplasty, sleeve gastrectomy, gastric bypass and Roux-en-Y gastric bypass; 
(2) reported in English in the scholarly literature, and (3) participants include adults, 
adolescents or children. Other systematic reviews, studies that report health-related quality of 
life or health state utility only and studies that do not report an effect, were excluded. 
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From the initial yield, search results were put through two levels of screening prior to data 
extraction. Initial screening was open ended to retain as many relevant studies as possible. 
Titles and abstracts were screened for evidence of health economic analyses including cost and 
cost analysis, cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis, or 
health economics metrics such as changes in costs before and after surgery, costs per quality 
adjusted life year, costs per life year saved, costs per disability adjusted life year, time to 
breakeven or quantified changes in work productivity. A random sample of included and 
excluded studies after the initial screening was independently reviewed by two co-authors. 
After removing studies that fit the exclusion criteria during the first level of screening, the full 
text of the remaining studies was assessed against the inclusion criteria and any disagreements 
were resolved by consensus. 
2.2.4 Data extraction 
Data were extracted on authorship, year of origin, country of origin, type of bariatric surgery, 
study design, sample size, study population, discount rate, classification of studies as partial or 
full economic evaluations, health economics perspective (healthcare system/third-party payer, 
societal, not stated), time horizon, comparator (including before and after surgery), currency, 
clinical effectiveness measures, costs including costs of the initial procedure, healthcare 
resource use (hospital and community care), patient and family (out-of-pocket expenses 
[excluding direct medical], travel time, direct care giving) resource use in other sectors 
(including work productivity and pension status), cost-effectiveness and cost-utility metrics 
(e.g. incremental cost/quality-adjusted life year (QALY) gained, cost/life-year saved, cost/case 
T2DM remitted), reoperations, complications or body contouring surgery were also reported 
separately, and key summary measure(s) and key conclusion(s). 
The definitions of partial and full economic evaluations, willingness to pay thresholds, health 
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economics perspective and costs were derived from standard health economics sources [18, 
35]. Reoperations and complications were classified as any re-operative/revisional procedure 
or complication following the primary procedure (including peri-operative complications). 
2.3 Results 
2.3.1 Screening for study eligibility 
The electronic search yielded 6,187 studies. Biomedical databases generated 5940 studies, and 
economic databases generated 241 studies. A further six studies were identified through other 
sources. After removal of duplicates, 4,474 studies' titles and abstracts were reviewed against 
the eligibility criteria, and 4,216 studies were excluded. Two hundred fifty-eight full text 
articles were then assessed for eligibility and 181 were excluded, leaving 77 included studies. 
Figure 1 provides results of the search strategy based on Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses methodology. 
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Figure 1 Results of search strategy based on the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses methodology.  
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2.3.2 Overlap with previous systematic reviews 
The six previously performed health economic systematic reviews noted in our study contained 
29 studies. Our review contained 21 of these studies: the other eight did not satisfy our broad 
eligibility criteria. Twenty-one of these studies were published before 2009, and 16 of these 
studies were cost-effectiveness or cost-utility studies. Our review included 46 studies from 
2010 to 2014; 18 of these studies were full economic evaluations, and 28 were partial economic 
evaluations (eight of the full economic evaluations were included in the previously performed 
studies). 
2.3.3 Overview and synthesis of included studies 
A comprehensive description of the characteristics of all the included studies is shown in Table 
2. Subgroup analyses of included cost-effectiveness and cost-utility studies from 2009 stratified 
into diabetes cohort-specific studies and severe obesity cohort/s studies are provided in Tables 
3 and 4, respectively. Willingness to pay thresholds for different jurisdictions are reported in 
Table 4. The tables are provided at the end of the Results section. 
2.3.4 Distribution of region and type of surgery 
Studies also originated from Sweden [43, 84, 87, 90, 106, 114] 10% (n = 8), Australia [65-67, 
75, 97, 99] 8% (n = 6), UK [54, 58, 95, 96, 100, 101] 8% (n = 6), Canada [45, 49], and the 
remainder of the included studies each for France [54, 105] (n = 2),Germany [54], (Austria, 
Italy, Spain) [63], Spain [21], Norway [74], Portugal [93], the Netherlands [40, 57], Finland 
[25], South Korea [102], Brazil [80, 91] (n = 2) and Mexico [92]. Two studies reported data 
from three countries [54, 63] (Table 2). 
Reporting of bariatric procedures has evolved according to the relative distribution of 
procedures for the timeframe [11, 13]. In line with technical change [11, 115], included studies 
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from 1995 to early 2000 largely reported on open procedures such as Roux-en-Y gastric bypass, 
vertical banded gastroplasty and gastric bypass. Laparoscopic procedures such as LAGB and 
laparoscopic Roux-en-Y gastric bypass (LRYGBP) are reported from the early 2000s (Table 
2). 
2.3.5 Time horizon 
Seventy six studies reported a time horizon. Of those that reported a time horizon, 42% (n = 32) 
adopted a timeframe of ≤5 years [39, 44-51, 54-59, 61, 63, 65, 70, 73-75, 79, 80, 85, 86, 91, 
95-98, 100, 105] and 53% of these studies reported results for ≤2 years (n = 17) [44, 46-48, 50, 
51, 55-58, 61, 65, 74, 80, 86, 95, 96, 98] (mostly cost and cost analyses). Some cost and cost 
analyses reported a longer time horizon of 6–10 years (n = 12, 16%) [38, 43, 53, 69, 72, 81, 83, 
88, 89, 103, 107, 114] or 11–20 years (n = 3, 4%) [87, 90, 94]. In these studies, there was a 
significant loss of participants to follow-up in the later years for large samples [38, 83, 103] or 
analyses were informed by a small sample from a single study centre [56]. Modelling studies 
that generated cost-effectiveness or cost-utility metrics (n = 25, 33%) [10, 20-22, 24, 26, 40, 
42, 52, 54, 57, 60, 62-68, 71, 93, 99, 100, 102, 104] generally extrapolated data from 2 to 
5 years to longer term or lifetime [21, 24, 26, 40, 42, 66, 71, 93, 101], 10 years [82, 92] or 
<10 years [54] (Table 2). 
2.3.6 Study design and study population 
Just under half of the included studies adopted a retrospective, observational study design 
(n = 35, 45%) [38, 44, 45, 47-51, 53, 56, 60, 61, 69, 70, 72, 75, 76, 78-81, 83, 85, 86, 88, 89, 
91, 94-97, 103, 105, 107], and 34% of these studies originated from the USA. Cohort matching 
techniques included studies that matched the surgical cohort with a control by adopting 
rigorous propensity score matching methodologies [78, 88, 103, 116] or other methodologies 
by matching particular variables such as comorbidity (most commonly T2DM and 
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cardiovascular) and/or age and gender [89]. Two health economics studies were particularly 
embedded within a randomized control trial (RCT) [65, 66]. Nested cohorts from the Swedish 
Obese Subjects study investigated costs of in-patient care [41], sick leave and disability pension 
[39, 87], medication costs [117] and healthcare costs for patients with differing baseline 
glucose status [106]. Just over one-third of studies utilized modelling techniques to facilitate a 
full economic evaluation of the intervention (n = 29, 38%) [2, 10, 20-22, 24, 26, 40, 42, 52, 54, 
62-64, 66-68, 71, 73, 77, 82, 84, 92, 93, 99-102, 104]. Some collected economic data 
prospectively [46] (Table 2). 
The target population was generally the severe and/or morbidly obese [26, 60] middle-aged 
females [52, 71, 72, 91]. Studies that specifically targeted an obese male cohort included 
Veterans Administration studies [44, 69, 86, 88], and this study population was generally 
clinically more unwell with an additional or more severe comorbidity load than a corresponding 
female cohort [44, 88]. In contrast, other studies focused on a healthier cohort with no or limited 
comorbidities [42, 91]. Health economic metrics for people with T2DM [24, 47, 54, 63-66, 68, 
70, 76, 81-83, 91, 93, 100, 101, 106] were investigated, and recent studies stratified this 
subgroup further into established versus newly diagnosed people with diabetes [65, 68] (Table 
2, Table 3). Another recent study stratified patient groups according to baseline glucose status 
(euglycaemia, prediabetes and diabetes) [106]. A subgroup that also emerged as an important 
target population were severely obese adolescents, however, only two studies met the eligibility 
criteria albeit with limited data [67, 104]. Particular ethnic groups were also reported including 
Native Hawaiians [98] and South Koreans (or a predominantly Asian population) [102]. 
2.3.7 Data sources 
The Data sources included single site administrative data (hospital administrative data and 
medical records) [89, 95], large private insurance claims data or health plan data [70, 71, 103], 
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data linkage of government (tax-funded) insurance schemes [97], national surveys [68, 85], 
cost diaries [57], direct contact with physicians or primary care providers to augment 
administrative data [96], questionnaires [58], peer-reviewed journal articles [100], technical 
reports [54] and RCT data [65]. Many included studies sourced retrospective, longitudinal data 
from large administrative databases [22, 49, 60, 61, 69, 70, 78, 88, 103] and/or from a single 
hospital site [64, 86, 91, 95]. Studies from the USA analysed retrospective administrative data 
from either a single tertiary site or a large private insurance plan [70, 78, 83]. Two recent studies 
from the USA explicitly used a comparison sample that was not restricted to the morbid obesity 
diagnosis code [88, 94] (Table 2). 
2.3.8 Economic evaluation 
Included studies reported the results of 87 partial or full economic evaluations including cost 
and cost analysis (n = 41, 53%) [38-40, 43-51, 53, 55, 56, 58, 59, 61, 69, 70, 72, 74, 75, 80, 83, 
86-91, 95-98, 100, 103, 105-107, 114] cost-effectiveness analysis (n = 12, 16%) [10, 20, 26, 
42, 54, 57, 63-67], cost-utility analysis (n = 23, 29%) [10, 21, 22, 24, 26, 40, 42, 52, 54, 57, 62-
64, 66-68, 71, 82, 93, 99, 101, 102, 104], cost-benefit analysis (n = 3, 4%) [2, 73, 77] and return 
on investment (n = 8, 10%) [60, 73, 76, 78, 79, 81, 85, 94]. We found a cost analysis that 
claimed that bariatric surgery could be cost-effective when effectiveness measures were not 
included in the analysis [95]. 
Studies classified as partial economic evaluations reported health economics metrics such as 
cost per pound of weight loss [38], changes in preoperative and postoperative mean and/or 
median healthcare costs (including inpatient, laboratory tests, specialist visits, operating 
theatre, outpatient follow-up, medications) [70, 89] at particular time horizons (such as 
preoperative, post-operative monthly, six monthly and 12 monthly), changes in comorbidity-
related medical expenses including medications [46, 50, 56, 61, 86, 90, 97] (prescribed and 
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over-the-counter) and equipment (CPAP machinery [47]). Studies classified as full economic 
evaluations reported metrics such as cost per quality-adjusted life year [52, 93], cost per life 
year saved [66], cost per disability adjusted life year [67], cost per T2DM free year [63], cost 
per case of T2DM remitted [65], time to breakeven [2] or net benefit [2] (Tables 2, 3 and 4). 
The first included study to conduct a full economic evaluation of bariatric surgery was 
published in 1999, and this study was underpinned by clinical and cost data from 21 
participants [40]. The first widely cited robust study to conduct a full economic evaluation of 
treatment versus no treatment for bariatric surgery was published in 2002 [42]. This study 
adopted a deterministic decision model to compare the lifetime expected costs and outcomes 
between gastric bypass and no treatment of severe obesity from the payer perspective. 
Modelling studies were more prevalent since 2008, and modelling methodologies ranged from 
simple and complex decision tree/s [40, 52, 63], Markov models with memory or no memory 
[24, 64, 66-68], simulation models [2, 71, 92] and a combination of these approaches [82, 102]. 
These studies investigated the cost-effectiveness of different types of bariatric surgery 
compared with no surgery (do nothing [99]), standard care (e.g. T2DM) [66]) and medical 
management (e.g. intensive supervised very low-calorie diet regime [38]) (Tables 2, 3 and 4). 
2.3.9 Reporting of study perspective 
The perspective adopted was reported in 62% (n = 48) [2, 10, 20, 21, 24, 26, 40, 42, 44, 52-55, 
57, 60, 62-67, 69, 71-73, 76-78, 80-84, 86, 88, 89, 91-93, 97-102, 104, 105] of studies. Of these 
studies, only 13% (n = 10) [2, 20, 40, 52, 57, 67, 73, 77, 93, 99] reported employing a societal 
perspective. A healthcare system/third-party payer perspective was reported for 53% (n = 41) 
[2, 10, 21, 22, 24, 26, 42, 44, 53-55, 60, 62-66, 69, 71-73, 76, 78, 80-84, 86, 88, 89, 91, 97-
102, 104, 105] with three studies reporting more than one perspective [2, 73, 99]. Studies that 
did not explicitly report a perspective (n = 29, 39%) [38, 39, 43, 45-51, 56, 58, 59, 61, 68, 70, 
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74, 75, 79, 85, 87, 90, 94-96, 103, 106, 107, 114] generally adopted a healthcare system or 
third-party payer perspective (Table 2). 
2.3.10 Reporting of clinical effectiveness 
Effectiveness measures included health state utility values [22], percentage change in excess 
weight loss [57], change in BMI [72], percentage change in weight, medication consumption 
for comorbidities such as hypertension and diabetes mellitus [75], use of specialized equipment 
for sleep apnoea, systolic and diastolic blood pressure, and biochemical measures such as 
HbA1c and lipids [100]. Cost-effectiveness and cost-utility studies all reported effectiveness 
measures. Some partial economic evaluations also reported effectiveness measures separately 
[61, 86] (Table 2). 
2.3.11 Reporting of costs 
Reporting of costs for bariatric surgery was considerably heterogeneous. Levels of precision in 
the identification, measurement and valuation of costs ranged from micro or unit costing [100], 
average per diem costs [2, 95], seeking an expert opinion from surgeons/physicians/primary 
care providers [82, 102] or a combination of these approaches [54, 102]. Sample sizes ranged 
from 21 participants to over 29,000 participants at baseline, and at least one study concluded 
that a ‘small sample size’ precluded definitive findings [55] (Table 2). 
Healthcare resource/sector costs only (including hospital and primary care) were reported in 
just over three-quarters (77% [n = 58]) [10, 21, 22, 24, 26, 38, 42-46, 48-51, 53-56, 60-66, 68-
70, 72, 75, 76, 78, 80-84, 86, 88-92, 94-98, 100-106, 114] of the included studies and were 
generally limited to inpatient (including readmissions) and shorter-term outpatient costs [38, 
49, 52, 81, 95, 114]. Many studies reported changes in mean hospital costs (e.g. hospital care, 
hospital bed days, intensive care unit, nursing, medications and operating theatre) [41, 44, 69, 
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114]. Two studies investigated changes in median costs [70, 83]. 
Studies that investigated changes in medication costs only (n = 10, 13%) [43, 46-48, 50, 56, 75, 
86, 97, 98] were commonly sub-stratified into obesity-related comorbidities such as diabetes 
mellitus, cardiovascular disease, sleep apnoea and gastroesophageal reflux [46, 47, 97]. One 
study investigated changes in prescription medication costs for LGBP patients and considered 
a total of 81 unique medications used to treat 21 different medical conditions [46]. Another 
study investigated changes in medication use for an older cohort (>60 years) [75]. One study 
considered Native Hawaiians' prescription medication costs after LRYGBP [98]. 
More specifically, two studies that reported average monthly medication costs for a 2-year time 
horizon found a decrease in costs of 69% for diabetes medications (both studies) and a decrease 
in costs for cardio-vascular medications by 31% and 43% [43, 118] A recent study found that 
over a 1-year time horizon the annual costs of medications to treat diabetes were reduced by 
88% and hypertension medication costs were reduced by 65% [86]. Interestingly, the same 
study investigated a subset of patients with persistent hypertension and/or diabetes and 
subsequently found a decrease in costs of 69% in diabetes medications and 58% for anti-
hypertensives. Another study that investigated medication costs over a 4-year time horizon 
(2006–2009) for the entire Australian population that underwent LAGB surgery (n = 6040) 
found that the greatest absolute cost reductions in year two after LAGB were observed in 
medications to treat diabetes (47% reduction) and cardiovascular disease (17% reduction) [97]. 
In contrast, a recent Australian study that reported on the medication usage for an older cohort 
(>60 years) found that there was not a significant average medication reduction for obesity-
related comorbidities over the time of the study (2 years) [75]. Another study concluded that 
surgical obesity treatment lowers diabetes mellitus and cardiovascular medication costs but 
increases other medication costs (such as gastrointestinal tract disorder, anaemias and vitamin 
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deficiency medications), resulting in similar total costs for surgically and conventionally 
treated obese individuals for 6 years [43]. 
Patient and family costs and other sector costs were reported in a minority of studies (n = 19, 
25%) [2, 20, 39, 40, 52, 57-59, 67, 71, 73, 74, 77, 79, 85, 87, 93, 99, 107]. These costs 
comprised out-of-pocket costs to the individual (ranging from self-pay for the primary 
procedure, travel time [99] to incidental out-of-pocket costs) and costs to family members (such 
as direct care giving [58] or travel time) and were largely ignored. Similarly, there was a dearth 
of information on other sectors. However, a few studies investigated work 
productivity/participation [57, 74, 77], absenteeism, presenteeism [85] and pension status as a 
proxy for work productivity [39, 58, 59, 87]. To illustrate, a recent US-based study estimated 
the time to breakeven and 5-year net costs of LAGB taking both medical costs and costs arising 
because of absenteeism and presenteeism (productivity impacts) into account. The study found 
that by including productivity impacts, the time to breakeven was reduced by 6 months. After 
5 years, the inclusion of absenteeism and presenteeism increased savings by $4,780. Another 
study examined the cost-effectiveness of providing LAGB surgery to all morbidly obese adults 
in 2003 for the Australian population. The study incorporated conservative estimates of time 
for travel and travel costs where patients' time only was valued at 25% of the hourly wage rate 
and calculated based on the proportion of the Australian population employed, unemployed or 
not in the workforce. The study found that when LAGB surgery was extended to all Australians 
with BMI > 35 kg/m2, the mean incremental cost-effectiveness ratio (ICER) becomes 
$2,154/disability-adjusted life year averted. However, when time and travel costs for 
procedures and consultations were included for people BMI > 35 kg m−2, the change was 
$4,102/disability-adjusted life year averted ($417–$8,720). 
The cost(s) of waiting for surgery (wait-listed patients in the public sector) was not considered 
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in 76 studies [24]. A recent study claimed to be the first to attempt to quantify the potential 
impact of extensive waiting lists on both health costs and clinical outcomes [24]. The study 
analysed the consequences of a 3-year delay in providing bariatric surgery and revealed that 
the overall lifetime cost in the surgical arm may be slightly reduced in non-diabetic patients 
with moderate and severe obesity (BMI < 40 kg m−2), but the cost was increased in non-diabetic 
patients with morbid or super-obesity and people with diabetes (increase from €23 to €2,803). 
Comprehensive assessment of costs encompassing all sectors as incurred by the health system 
and patient and family and other sectors were reported in only 18% (n = 14) [2, 20, 40, 52, 57, 
67, 71, 73, 77, 79, 85, 93, 99, 107] of included studies. One of these studies found that the total 
social value for bariatric surgery was large for treated patients with incremental total social 
cost-effectiveness ratios typically under $10,000 (USD) per life year saved. The study found 
that the net social effect was large once improvements in life expectancy are taken into account 
[20]. 
2.3.12 Reporting of costs of complications and reoperations, and body contouring surgery 
The consideration of reoperations and complications following the primary procedure were not 
included in one-third of studies (n = 25, 33%) [2, 21, 38, 43, 47, 48, 56, 58, 59, 61, 70, 76, 77, 
81, 83, 86, 87, 91, 92, 97, 98, 104, 107]. Moreover, many studies that included complications 
and/or reoperations adopted a relatively short timeframe or assumed a probability of the event 
occurring as low. One study particularly investigated the requirement for intensive care support 
(and associated costs) either electively or emergently for primary (210 patients) or revisional 
(31 patients) procedures [51, 120]. The development of complications significantly affected 
the hospital cost, for example, the development of deep vein thrombosis or pulmonary 
embolism increased the cost from mean (SD) USD 29,290 ± 55,000 to 93,000 ± 77,700. This 
study also found that approximately 40% of patients that required intensive care unit 
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admission/s were men. 
The available evidence regarding the cost of complications (including early and late, minor and 
major) was inconsistent. Nevertheless, some of the included studies in our review provided 
estimates of these costs. Two studies that robustly quantified the costs of complications and 
reoperations over the short, medium and longer terms established that these ongoing costs 
could be higher than the cost of the initial procedure [26, 103]. The cost of the primary 
procedure ranged from $7,042 (2011 USD) for LAGB in South Korea, to $11,290 (2003 AUD) 
in Australia and to $26,315 (2011 USD) as an average cost for all procedures (Table 4). A full 
economic evaluation that estimated costs for early, late, minor and major reoperations and 
complications estimated a range of $426 to $41,708, with a cost of a late moderate reoperation 
for LAGB $11,115 (probability 4.9%) and LRYGBP $14,328 (probability 8.6%) (2006 USD) 
[26]. Similarly, a recent partial economic evaluation explored 6-year follow-up costs in surgery 
patients with a control group based on inpatient admissions (by DRG) recorded in a large US 
insurance administrative database. The study showed that the surgical group had significantly 
more admissions for digestive-related diagnoses in all six post-operative periods (annually for 
6 years) relative to the comparison group. The study assumed that a significant proportion of 
these admissions were likely follow-up procedures for bariatric surgery-related complications. 
The mean (SD) quantified costs for the surgical group's inpatient costs years 1 to 6 (USD 2005) 
were year 1: $4,193 (15,512), year 2: $5,186 (15,935), year 3: $4,666 (16,045), year 4: $4171 
(15,766), year 5: $4,302 (16,979) and year 6: $4,407 (23,166) (103). Clearly, these costs are 
substantial and approach the cost of the initial procedure. In contrast, a recent cost-effectiveness 
analysis assumed that the cost of bariatric surgery without complications was €4,915 (range: 
3,932–5,898) and the cost of bariatric surgery with complications was €5,766 (4,613–6,919) 
(2012 EURO) (24). 
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Body contouring surgery/bariplastic surgery costs [121, 122] were only included in 14% 
(n = 11) [24, 42, 44, 62, 68, 71, 74, 82, 84, 100, 114] of studies, and these costs were 
substantially underestimated in these studies by limiting costs to abdominoplasty or 
panniculectomy [24, 42, 44, 62, 68, 74, 82, 84, 100]. 
2.3.13 Health-related quality of life and health state utility values 
Cost-utility studies adopted health state utility values from multi-attribute utility instruments 
such as the EQ-5D [71], SF 12 or 36 [123] and 15D [25]. The EQ-5D dominated the valuation 
of health state utility values in these studies [124] (Table 2). Validated bariatric (such as the 
Bariatric Quality of Life [125]) or gastrointestinal-specific health-related quality of life 
instruments (such as the Gastrointestinal Quality of Life Index [126]) were generally not 
adopted; however, a recent cost-effectiveness study adopted the Bariatric Quality of Life [10]. 
2.3.14 Reporting of cost-effectiveness 
Cost-effectiveness and cost-utility studies (from 2009) that investigated people with diabetes 
(Table 3) found that bariatric surgery was cost-effective and in some cases cost-saving for the 
severely obese with T2DM [63-66, 68, 101]. All of these studies were undertaken from the 
health payer perspective, across differing time horizons, and their results were robust to 
changes in parameter assumptions. One study found that testing of model values and 
assumptions either maintained the dominant status of surgical therapy or shifted the economic 
status of surgical therapy from dominant to cost-effective ($13,400/QALY gained 2006 AUD) 
[66]. Another recent study that stratified a T2DM study population into 16 sub-groups based 
on sex and BMI classifications across a lifetime time horizon found that bariatric surgery was 
cost-saving in all four pre-specified diabetic cohorts (moderately, severely, morbidly and 
super-obese) in both male and female patients. The study's sensitivity analysis also found that 
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the most sensitive parameter of the cost variables was the annual cost of T2DM [24]. 
Similarly, for the severely, morbidly and super-obese cohorts (generally classified by these 
studies as 35.0–35.9 kg/m2, 40.0–49.9 kg/m2 and ≥ 50 kg/m2, respectively), bariatric surgery 
was cost-effective in the base-case analysis [20, 21, 26, 71, 82, 93, 99, 102, 127] (Table 3). 
Three of these studies adopted a societal perspective [20, 94, 100]. Incremental cost-
effectiveness ratios (cost/QALY gained) for cost-utility studies that reported in USD from 2010 
to 2014 revealed base-case valuations of ≤$6,500/QALY gained. One study was an exception 
and reported $17,300/QALY gained for ORYGBP (an open procedure). These valuations still 
fall well below the accepted willingness to pay threshold of ≤$50,000/QALY (Table 4). 
Additionally, cost-utility studies that reported in EUROs from 2010 to 2014 found that bariatric 
surgery was dominant in the base-case analysis. Sensitivity analyses generally showed that 
these results were robust. One study found that the largest observed changes to base-case 
analysis occurred after excluding cost offsets and increasing the rates of maintenance and 
complications; nevertheless, the reported ICER still fell below the jurisdiction's willingness to 
pay threshold [99]. One of these studies reported the range of complications and reoperations 
as early, late, minor and major [26]. 
 
2.3.15 Methodological quality 
Health economics reporting for bariatric surgery was generally deficient when graded against 
the new CHEERS statement. Table 2 and Figures 2a and b provide the individual scores for 
included studies and overall quality was ranked as medium. Full economic evaluations 
generally rated highly against the new criteria (n = 18) [10, 21, 22, 24, 26, 42, 54, 57, 62, 64-
66, 81, 82, 92, 99, 101, 102] (particularly from 2010). Six partial economic evaluations were 
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rated as low (five studies to 2008 and one study in 2012) [38, 44, 47, 55, 61, 84]. The individual 
scores revealed that methodological quality has improved over time (Figures 2a and b). Critical 
appraisal of methodological quality against the CHEERS checklist items revealed that 
individual items of ‘estimating of resources of costs’, ‘choice of model’ and ‘assumptions’, 
‘analytical methods’ and ‘study parameters’ were items where studies that rated low to medium 
generally did not rate adequately against the requirements of the individual criteria. 
 
Figure 2: (a) Methodological quality of partial economic evaluations rated against the Consolidated Health 
Economic Reporting Standards checklist: low (<60%), medium (60% - 80%) and high (>80%). (b) 
Methodological quality of full economic evaluations rated against the Consolidated Health Economic Reporting 
Standards checklist: low ( 14 points), medium (15 – 19 points) and high (20 - 24 points). 
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Table 2: Characteristics of included studies (n = 77). 
Key: AUD, Australian Dollar; BIA, budget impact analysis; BPD, British Pound; CBA, cost-benefit analysis; CCA, cost and cost analysis; CEA, cost-effectiveness analysis; CM, comorbidity; CT, conventional treatment; CUA, cost-
utility analysis; CVD, cardio-vascular disease; DM, diabetes mellitus; DR, discount rate; EURO, Euro; GB, gastric band; GBP, gastric bypass; GERD, gastro-oesophageal reflux disease; GID, gastro-intestinal disease; GP, general 
practitioner; GST, gastric stapling; HLP, hyperlipidaemia; HT, hypertension; ICER, incremental cost-effectiveness ratio; LAGB, laparoscopic adjustable gastric band; LRYGBP, laparoscopic Roux-en-Y gastric bypass; LSG, 
laparoscopic sleeve gastrectomy; LY, life years; Meds, medications; MO, morbid obesity code; NHP I and II, Nottingham Health Profile; NSAID, non-steroidal anti-inflammatory drug; ORD, obesity related diseases; PA, physical 
activity; PD, pulmonary disease; QALY, quality-adjusted life-years; RYGBP, Roux-en-Y gastric bypass; SAH, systemic arterial hypertension; SG, sleeve gastrectomy; SOS, Swedish Obese Subjects study; T2DM’, type 2 diabetes 
mellitus; TC, total costs; USD, United States Dollar; VAMC, Veterans Affairs Medical Centre; VAS, Visual Analogue Scale; VBG, vertical banded gastroplasty. 
Author, 
year, 
country, 
currency, 
time horizon, 
discount rate. 
Type of  
surgery. 
Target 
group. 
 
Main data 
source(s). 
 
Compa-
rator. 
(N=x) at 
baseline. 
Health 
care 
resource 
costs 
(hospital 
and 
primary 
care). 
Patient 
and 
family 
costs and 
other 
sector 
costs. 
HRQoL, 
HSUV. 
 
Persp-
ective. 
Reoper-
ation, 
complica
tion, 
body-
contour-
ing (BC) 
Study design, 
key effectiveness 
measure(s), 
key costs, 
partial or full economic 
evaluation. 
 
Econ-
omic 
evalu-
ation, 
quality 
rank 
and 
score (% 
or x/24). 
 
Key summary measure(s), 
key finding(s). 
Martin 1995, 
USA, USD, 6 
years. 
RYGBP. 
 
Morbid 
obesity 
BMI>40 
 
Single 
treatment 
centre 
database, 
patient bills. 
Very low 
calorie 
diet. 
201 
surgical, 
161 
Medical. 
Yes. No. No. Not 
stated. 
Not 
included, 
BC not 
included. 
Retrospective, observational, 
changes in BMI, direct 
medical costs hospital 
charges, pathology, 
radiology, surgeon, 
anaesthetics, diet, weekly 
behaviour therapy, partial 
economic evaluation. 
CCA, 
low. 
55% 
Cost/pound weight loss. First large-scale 
comparison of surgical versus medical 
intervention. Year 6: medical $1500/lb, 
surgical $750/lb. 
 
Narbro 1999,, 
Sweden, 5 
years. 
GB, 
VBG, 
GBP. 
 
Age 37-60, 
men BMI 
≥38, women 
BMI ≥34. 
 
Swedish 
national 
insurance. 
 
No 
surgery. 
369  
Surgical, 
371 
matched 
control. 
No. Yes. No. Not 
stated. 
Included, 
BC not 
included. 
SOS cohort (first 740 
consecutive cases), weight 
lost in kg, adjusted mean 
number of days of sick leave 
and disability pension, partial 
economic evaluation. 
CCA, 
medium 
60% 
Changes in sick leave and disability pension. 
Surgical treatment results in a decrease in sick 
leave and disability pension rates in 
participants aged 47-60.  
van Gemert 
1999, 
Netherlands, 
USD, 
lifetime, 
DR=5%. 
VBG. Morbid 
obesity 
BMI>40. 
 
Single 
treatment 
centre 
database, 
patient 
interviews, 
Institute of 
Public 
Health. 
No 
surgery. 
 
21. 
 
Yes. Yes. Yes. 
NHP I 
and II and 
VAS 
Societal. Included, 
BC not 
included. 
Model: decision tree, QoL 
scores, weight loss (kg) and 
BMI, direct costs of surgical 
treatment, revisional surgery, 
medical appointments, 
diagnostic tests, hospital 
costs, indirect costs of 
productivity losses, partial 
and full economic evaluation. 
COI, 
CUA, 
medium. 
15/24 
Cost/QALY. $4,004 to $3,928/QALY. Cost-
effectiveness more dominant when 
productivity gains included. 
 
Agren 2002, 
Sweden, 
(1996 USD), 
6 years. 
GB, 
VBG, 
GBP. 
Age 37-60, 
men BMI 
≥38, women 
BMI ≥34. 
Swedish 
hospital 
data 
register. 
CT. 
 
481 
surgical, 
481 
matched 
Yes. No. No. Not 
stated. 
Included, 
BC 
included. 
SOS cohort (first 962 
consecutive cases), average 
weight reduction, cost of in-
patient care as average cost 
CCA, 
medium. 
60% 
Mean inpatient care costs. TC (discounted) 
over 6 years surgical: $9,53310,156, control 
$2,5406,113. Average weight reductions of 
16% will not reduce hospitalisation costs over 
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DR=3%.   Control. 
 
per day, partial economic 
evaluation. 
6 years. A substantial share of costs is because 
of secondary plastic surgery. 
Craig 2002, 
USA, (2001 
USD), 
lifetime, 
DR=3%. 
 
GB. Age 35-55, 
BMI 40-50, 
non-
smokers 
without 
CVD, major 
psychiatric 
disorders. 
Healthcare 
cost and 
utilization 
project 
database. 
No 
surgery. 
NA Yes. No. Yes. 
Model 
Health 
care 
system/ 
third 
party 
payer 
Included, 
abdom-
inoplasty 
included. 
 
Model: deterministic decision 
model, lifetime with reduced 
BMI, direct medical costs, 
surgery, follow-up care, 
treatment of complications, 
treatment of obesity related 
diseases, full economic 
evaluation. 
CEA, 
CUA,  
high. 
21/24 
Cost/LY and Cost/QALY. GBP cost-effective. 
At age 55 years for BMI 40 (kg/m²) Cost/LY 
men $100,200; women $248,500; Cost/QALY 
men $35,600; women $16,100 and for BMI 50 
(kg/m²) Cost/LY men $30,700; women 
$38900; Cost/QALY men $13,300; women 
$5,400.  
Narbro 2002 
Sweden, SEK 
and (2001 
EURO), 6 
years. 
GB, 
VBG, 
GBP. 
 
Age 37-60 
years, men 
BMI ≥38, 
women BMI 
≥34. 
 
Question-
naires 
regarding 
prescribed 
medication 
use. 
 
CT. 510 
surgical, 
455 
Medical. 
 
Yes 
meds. 
No. No. Not 
stated. 
Not 
included, 
BC not 
included. 
SOS cohort (first 1294 
consecutive cases, only 
patients with complete 6 year 
follow up included), average 
weight loss of 16% in 6 
years, medication costs for 
DM, CVD, NSAIDs/Pain, 
PD, anaemia, GID and other, 
partial economic evaluation.  
CCA, 
high. 
80% 
Average annual medication costs. Surgical 
group lower medication costs for DM (69%) 
and CVD (31%). These savings balanced by 
increased medication costs for muscle 
inflammation, rheumatic disorders and pain, 
gastro-intestinal, anaemia and vitamin 
deficiency. 
Gallagher 
2003  
USA, USD, 2 
years. 
 
RYGBP. 
 
Severely 
obese 
(BMI>50)  
primarily 
men, mean 
age 522 
years who 
underwent 
RYGB. 
Veterans 
affairs 
medical 
records, 
admin 
database. 
Before 
and after. 
25. Yes. No. No. Health 
care 
system/ 
third 
party 
payer 
Included, 
BC  
included 
(pannicu-
lectomy). 
 
Retrospective, observational, 
direct medical inpatient and 
outpatient costs, partial 
economic evaluation. 
CCA, 
low. 
55% 
Mean changes in costs. Reduced obesity 
related expenditures and utilisation of health 
care resources. Cost of all care excluding peri-
operative charges 1 year post surgery 
$2,840622 per patient. Cost of undertaking 
RYGBP is offset by reduction of health care 
costs within the first year of surgery. 
Christou 2004 
, Canada, 
(1996 CAD), 
5 years. 
 
All types. Morbidly 
obese 
treated with 
bariatric 
surgery with 
6 matched 
controls per 
case. 
Single 
tertiary 
centre 
admin 
database, 
provincial 
insurance 
database. 
No 
surgery. 
1035 
surgery, 
5746 
matched 
control. 
 
Yes. No. No. Not 
stated. 
Included, 
BC not 
included. 
Retrospective, observational, 
weight loss as % initial 
excess weight loss and % 
initial BMI reduction, direct 
medical costs for each 
hospitalisation, physician 
visit and prescription 
medication, partial economic 
evaluation. 
CCA, 
medium. 
65% 
Mean health care utilisation and total direct 
costs. Total direct costs surgery $8813 (2344), 
control $11854 (21220). Mean total direct 
health care costs were significantly higher in 
the controls for all specific diagnostic 
categories. Exceptions were costs for digestive 
disorders where mean cost for bariatric 
patients was 68% higher than controls. 
Gould 2004, 
[46], USA, 
(2003 USD), 
6 months. 
 
LRYGBP 
 
Severely 
obese (mean 
BMI 512) 
primarily 
women 
medication 
CMs. 
Single 
study 
centre, 
bariatric 
surgery 
database. 
Before 
and after. 
50. Yes 
meds. 
No. No. Not 
stated. 
Not 
included, 
BC not 
included. 
Prospective, observational, 
cost of prescription 
medication online pharmacy 
website, partial economic 
evaluation. 
 
CCA, 
medium. 
60% 
CM-related medication expenses and monthly 
cost-savings. Monthly savings of all 
medications $120, DM $63, HT $37, 
hypercholestraemia $86, GERD $91, 
Depression $0. 
 
Monk 2004, 
[47], USA, 
USD, mean 
16 months. 
 
 
RYGBP 
 
Morbidly 
obese (mean 
BMI 57) 
primarily 
women. 
Single 
centre, 
hospital and 
follow up, 
pharmacy 
cost data. 
Before 
and after. 
64. Yes 
meds and 
CPAP 
use. 
 
No. No. Not 
stated. 
Not 
included, 
BC not 
included. 
Retrospective, observational, 
cost of monthly medications 
and CPAP equipment, partial 
economic evaluation. 
 
CCA, 
low. 
50% 
Comorbidity medications and medical 
equipment monthly savings. Monthly savings 
CPAP equipment $207, T2DM $71, HT $17, 
GERD $34, asthma $20, all CM $182. 
Potteiger ORYGBP BMI>40 Single Before 51. Yes No. No. Not Not Retrospective, observational, CCA, Reduction in number and cost of DM and anti-
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2004 [48], 
United States, 
USD, 14 
months. 
 
LRYGBP 
 
with obesity 
related DM 
and HT, or 
BMI>45. 
 
study centre 
database. 
and after. meds. stated. included, 
BC not 
included. 
prescription costs based on 
national wholesale pricing, 
direct hospital costs included 
clinicians, laboratory, 
hospital services, partial 
economic evaluation. 
medium. 
60% 
HT medications. DM average reduction in 
monthly medication costs of $109 and HT $34 
per month. Annualised pharmaceutical saving 
of $1,736. 
 
Sampalis 
2004 [49], 
Canada, (1996 
CAD), 5 
years. 
 
RYGBP, 
VBG. 
 
Morbidly 
obese (BMI 
508) 
treated with 
bariatric 
surgery with 
6 matched 
controls per 
case. 
Single 
tertiary 
study centre 
database, 
provincial 
health 
insurance 
database. 
No 
surgery 
1035 
surgery, 
5746 
control. 
 
Yes. No. No. Not 
stated. 
Included, 
BC not 
included. 
Retrospective, observational, 
% change in BMI, % change 
in EWL, direct hospital costs 
included all hospital charges, 
laboratory and clinician 
charges, partial economic 
evaluation. 
 
CCA, 
medium. 
75% 
Net reduction >$5.7 m for hospitalisations per 
1,000 patients treated, within 5 years after 
surgery. Initial costs of surgery can be 
amortised over 3.5 years. Cost ratio for 
control: bariatric year 1: 0.29, year 2: 1.43, 
year 3: 4.28, year 4: 4.47, year 5 5.21. 
Snow 2004 
[50], USA, 
USD, 2.5 
years. 
 
LRYGBP 
 
Age 55-75, 
morbidly 
obese (mean 
BMI 48) 
who 
underwent 
LRYGB. 
 
Insurance 
database, 
patient 
prescription 
verified 
physician/ 
primary 
care. 
Before 
and after. 
78. Yes 
meds. 
No. No. Not 
stated. 
Not 
included, 
BC not 
included. 
Retrospective, observational, 
medication cost obtained 
from 3 retail sources and 
averaged, partial economic 
evaluation. 
 
CCA, 
medium. 
60% 
Change in medication costs. Decrease of 72% 
in prescription medication costs per patient per 
month at 2 years. Average annual cost savings 
for 78 patients $240,566.  
 
Cendán 2005 
[51], USA, 
USD, ICU 
LOS (mean 
27 days). 
 
All types. Patient 
subgroup 
(19%) 
emergency 
or elective 
critical care. 
Single 
tertiary 
centre, 
hospital 
data ICU 
resources 
and costs, 
medical 
records. 
Before 
and after. 
241. Yes. No. No. Not 
stated. 
Included, 
BC not 
included. 
Retrospective, observational, 
direct hospital costs including 
ICU and/or advanced medical 
care unit, partial economic 
evaluation. 
 
CCA, 
medium. 
70% 
Costs for critical care admission (emergent and 
elective) following surgery and costs for each 
complication cluster (thromboembolic, 
pulmonary, anastomotic). DVT-PE increased 
cost of stay from $29,29055,000 to 
$93,00077,700; pulmonary from 
$17,20013800 to $69,00096,300; 
anastomotic from $27,420 43,200 to 
$56,200100,700. Approximately 20% require 
advance care units. 
Finkelstein 
2005, USA 
(2004 USD), 
USD, Time to 
break even 
(mean 9.5 and 
7.4 years) 
DR=3%. 
 
All types. Age 18-64 
years, 
reported 
working ≥35 
hours per 
week. 
BMI≥40 or 
BMI≥35<40 
with CMs. 
Medical 
Panel 
Expenditure 
Survey, 
National 
Health 
Interview 
Survey. 
No 
surgery. 
 
20329. Yes. Yes. No. Health 
care 
system/ 
third 
party 
payer 
 
Not 
included, 
BC not 
included. 
Model: two part simulation, 
estimated annual medical 
costs attributable to obesity 
for the surgery eligible and 
surgery ineligible populations 
and assumed price of the 
procedure $25,000, full 
economic evaluation. 
 
CBA, 
medium. 
18/24 
Assuming a 75% reduction in obesity 
attributable costs, time to break even (at 90th 
percentile of cost distribution) 5 years for 
medical and work loss costs. Simulations 
reveal that 5 or more years of follow up are 
most likely required for surgery to become 
cost-saving unless the employee bears a 
significant fraction of the total costs of the 
procedure. 
Jensen 2005, 
United States, 
(2004 USD), 
life course. 
 
GBP. 
 
Base-case 
morbidly 
obese white 
female, age 
40, 
BMI≥40. 
 
Published 
sources. 
 
Diet/PA 
for 2 
years at 
age 18 
and 
BMI≥35. 
346 
surgery 
212  
Diet/PA 
 
Yes. Yes. Yes. 
Model 
Societal. 
 
Included. 
BC not 
included. 
 
Model: decision tree, direct 
medical costs included 
operating room, nursing, 
equipment, anaesthesia, 
pharmaceuticals, diagnostics 
tests, ORD-related direct 
medical costs. Complication 
costs assumed $5,000, full 
economic evaluation. 
CUA, 
medium. 
17/24 
Cost/QALY. Base-case $7,126/QALY. GBP at 
age 40 is cost-effective compared with a diet 
and exercise based intervention at age 18 
among a cohort of obese white females.  
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Mehrotra 
2005, USA, 
(2001 USD), 
10 years. 
 
GBP, 
GST, 
other by 
ICD 
codes. 
 
Primary 
diagnosis of 
morbid 
obesity and 
weight loss 
surgery. 
 
Inpatient 
hospital 
discharge 
data, health 
department 
database, 
Census 
population 
estimates. 
Increases 
in 
charges 
by payer 
type. 
 
269. 
 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer 
Included. 
BC not 
included. 
 
Retrospective, observational, 
charges based on hospital or 
facility bills for patient care 
excluded professional fees 
such as surgeon or 
anaesthetic fees, partial 
economic evaluation. 
 
CCA, 
medium. 
70% 
Inflation adjusted total charges for weight loss 
surgery by payer type (Medicare, Medicaid, 
private insurance, Self-pay). Despite a 
significant decline in the average length of stay 
in hospital after surgery, the inflation-adjusted 
average charge per procedure doubled from 
$12,006 to $23,629 from 1990/92 to 2000/02. 
 
Ackroyd 
2006, France, 
Germany, 
UK, EURO, 
BPD, 5 years, 
DR=3.5%. 
AGB, 
GBP. 
 
BMI≥35 and 
T2DM in 
France, 
Germany 
and United 
Kingdom. 
 
HTA 
reports and 
HODaR 
Cardiff 
Research 
Consortium 
database. 
Expert 
opinion. 
CT for 
T2DM. 
 
1000. Yes. No. Yes. 
EQ-5D 
Health 
care 
system/ 
third 
party 
payer 
Included. 
BC not 
included. 
 
Model: decision tree 
deterministic linear 
algorithm, combined 
effectiveness of BMI 
reduction, T2DM remission 
and EQ-5D responses, unit 
costs in all countries based on 
identification of the main 
cost-driving inpatient and 
outpatient health care 
resources up to 5 years after 
surgery, full economic 
evaluation. 
CEA, 
CUA, 
BIA, 
high. 
23/24 
Cost/QALY. Cost/T2DM-free year. Budget 
impact for 1000 patients. AGB and GBP are 
cost-effective at 5 year follow-up and cost-
saving in Germany and France. Cost-effective 
in the UK with a moderate budget impact 
versus CT. Germany GBP: €-2,455/QALY, €-
2,208/T2DM free year, AGB:  €-1,305/QALY, 
€-576/T2DM free year; France GBP: €-
4,000/QALY, €-2,118/T2DM free year, AGB: 
€ 1,379/QALY, € 609/T2DM free year; UK 
GBP: ₤2,599/QALY, ₤1,376/T2DM free year, 
AGB: ₤3,251/QALY, ₤1,434/T2DM free year. 
Gorman 2006 
USA, USD, 2 
years. 
ORYGB, 
LRYGB. 
 
BMII≥40 
and BMI≥35 
with certain 
CMs. 
Health plan 
database 
and chart 
review. 
 
Before 
and after. 
19. Yes. No. Yes. 
SF-12 
Health 
care 
system/ 
third 
party 
payer 
Included. 
BC 
discussed 
but not 
included. 
 
Prospective, observational, 
charges paid extrapolated 
from claims data included 
unrelated medical visits (e.g. 
obstetrics), partial economic 
evaluation. 
 
CCA, 
low. 
55% 
Change in mean annual costs. Sample too 
small to draw definitive conclusions regarding 
cost reduction. Difference $-1,300 (5,000); p = 
0.29. 
 
Nguyen 2006, 
USA, USD, 2 
years. 
 
LAGB. Morbidly 
obese on 
medication 
for at least 
one or more 
CM of HT, 
HLP, 
GERD, DM. 
Single 
study centre 
database, 
medication 
history 
from patient 
and/or 
physician.  
Before 
and after. 
77. Yes, 
meds. 
No. No. Not 
stated. 
Not 
included. 
BC not 
included. 
 
Retrospective, observational,  
retail medication costs 
sourced from online 
pharmacy, partial economic 
evaluation. 
 
CCA, 
medium. 
65% 
Mean monthly medication costs. One month 
postoperative medication cost saving GERD 
(81%), DM (69%), HLP (53%) and HTN 
(43%).  
 
van Mastrigt 
2006, The 
Netherlands, 
(1999 
EURO), 1 
year. 
 
VBG, 
LAGB. 
 
Age 18-60, 
BMI>40 or 
BMI35-40 
with 
significant 
CM. 
Excluded 
psychiatric, 
previous 
upper 
abdominal 
surgery. 
RCT, 
hospital 
data and 
cost diaries. 
 
Before 
and after.  
LAGB 
versus 
VGB 
 
50  
VGB 
50  
LAGB 
 
Yes Yes Yes. 
EQ-5D 
Societal 
 
Included. 
BC not 
included. 
 
RCT, % EWL at 12 months 
and utility, costs individual 
direct medical and non-
medical cost use of unpaid 
help and productivity losses 
(friction cost method), full 
economic evaluation. 
CEA, 
CUA, 
medium. 
19/24 
Cost/%EWL and Cost/QALY. After one year, 
costs and QoL of two treatment modalities 
were found to be equal. €36,834/QALY. 
 
Hawkins 2007 
UK, BPD, 6 
LRYGBP 
LAGB 
NHS 
patients. 
Survey. 
 
Before 
and after. 
79. No. Yes. No. Not 
stated. 
Not 
included. 
Retrospective survey 
regarding paid employment 
CCA, 
medium 
Paid work and weekly hours worked. State 
benefits claimed before and after surgery. 
 83 | P a g e  
months.  BC not 
included. 
 
hours, intention to work and 
state disability benefits, 
partial economic evaluation. 
75% Average weekly time worked before 30.1 
hours, after 35.8 hours (p<0.01). One-quarter 
decrease in the number of state benefits 
claimed after surgery. 
Wagner 2007, 
USA, mean 
44 months. 
 
RYGBP 
 
Age<65, 
medically 
disabled 
morbidly 
obese 
receiving 
Medicaid. 
One study 
centre, 
Medicaid 
recipients. 
No 
surgery. 
38 
surgery 
16 
control 
No. Yes. Yes. 
SF-36 
 
Not 
stated. 
 
Not 
included. 
BC not 
included. 
 
Retrospective survey 
regarding patients who are 
working and not claiming 
Medicaid benefits. Mean 
excess BMI lost, partial 
economic evaluation.  
CCA, 
medium. 
70% 
Number and % Medicaid recipients who return 
to work. 37% Medicaid-funded patients 
returned to work compared to 6% of patients 
from the non-surgical control group. 
Cremieux 
2008, USA, 
(2005 USD), 
6 years, 
DR=3.07%. 
OGBP, 
OGB, 
LGBP, 
LGB. 
 
Morbidly 
obese, 
age>18 
years. 
 
Privately 
insured 
claims 
database 5 
million 
lives, 31 
companies. 
No 
surgery. 
3651 
surgery 
3651 
control 
 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer 
Included. 
BC not 
included 
Retrospective, observational, 
CM reduction (BMI data 
unavailable in insurance 
claims database), costs direct 
medical including 
prescription drug and medical 
service (inpatient, emergency 
department, outpatient, 
office), partial economic 
evaluation. 
ROI, 
medium. 
75% 
ROI. Initial investment approximately $26,000 
open and $17,000 laparoscopic surgery. Initial 
investment is returned within 4 years for open 
surgery and within 2 years for laparoscopic 
surgery.  
Hodo 2008, 
USA, USD, 1 
year. 
ORYGBP 
LRYGBP 
 
Morbidly 
obese with 
CMs, 
continuous 
enrolment 
for 12 
months. 
Managed 
care 
organisation 
database. 
 
Before 
and after. 
605. Yes. No. No. Not 
stated. 
 
Not 
included. 
BC not 
included. 
Retrospective, observational, 
Charlston CM index, 
medication use/costs, health 
service use/costs included 
office, inpatient and 
outpatient visits, emergency 
room, prescriptions, partial 
economic evaluation. 
CCA, 
low. 
50% 
Mean medication use and costs and claims for 
specific health services. Medication use and 
costs decreased within 6 months of bariatric 
surgery. Pharmacy costs decreased 28% in 6 
months after surgery. Health services use 
greatest decrease in claims (47%) for 
outpatient visits. 
Salem 2008, 
USA, (2004 
USD), 
lifetime, 
DR=3%. 
LAGB 
LRYGBP 
 
Base-case 
morbidly 
obese male 
and female 
BMI≥40, 
age 35 
years. 
Published 
and 
unpublished 
sources.  
No 
surgery. 
 
NA Yes. No. Yes. 
Model 
Health 
care 
system/ 
third 
party 
payer 
Included. 
Abdomi-
noplasty 
included. 
Model: deterministic decision 
analytic, survival and weight 
loss, direct medical costs, full 
economic evaluation. 
 
CUA, 
high. 
20/24 
Cost/QALY <$25,000 for both procedures. 
LRYGB and LAGB cost-effective when 
evaluating the full range of BMI values and 
estimates for adverse outcomes, weight loss 
and costs. 
Anselmino 
2009, Austria 
Italy, Spain, 
EURO, 5 
years, 
DR=3.5%. 
AGB, 
GBP. 
 
Patients 
with BMI 
≥35 and 
T2DM in 
Austria, 
Italy and 
Spain. 
 
Published 
and 
unpublished 
sources. 
 
CT. 
 
1000. Yes. No. Yes 
EQ-5D  
Health 
care 
system/ 
third 
party 
payer 
Included. 
BC not 
included. 
Model: decision tree, annual 
BMI variation and T2DM 
prevalence variation 
(medications and 
complications) up to 5 years 
after bariatric surgery. 
Adopted Ackroyd cost 
methodology, full economic 
evaluation. 
 
CEA and 
CUA, 
medium. 
18/24 
Cost/QALY, Cost/T2DM free year. Base-case 
AGB and GBP inpatients with baseline T2DM 
cost-saving in Italy and Austria and cost-
effective in Spain. Worst case €/QALY AGB 
Austria €-1,680/QALY; Italy €638/QALY; 
Spain €3,142/QALY. Worst case GBP Austria  
€-301/QALY; Italy €94/QALY; Spain 
€4,347/QALY. Worst case €/T2DM-free-year 
AGB Austria €-741/T2DM-free-year; Italy 
€281/ T2DM-free-year; Spain €1,390/ T2DM-
free-year. Worst case GBP Austria  
€-159/T2DM-free-year; Italy €50/ T2DM-free-
year; Spain €2,302/ T2DM-free-year. 
Ikramuddin 
2009, USA, 
RYGBP. 
 
Severely 
obese with 
Single 
academic 
Standard 
care. 
2223 
 
Yes. No. Yes. 
EQ-5D 
Health 
care 
Included. 
BC not 
Model: CORE Diabetes 
model (Markov structure) 
CEA, 
CUA, 
Cost/QALY. Cost/LY gained. $21,973/QALY 
and $29,676 LY gained. RYGBP cost-effective 
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(2007 USD), 
35 years, 
DR=3%. 
 
T2DM, 
matched 
cohort. 
medical 
centre, 
published 
and 
unpublished 
sources. 
567 
(T2DM 
or pre-
diabetes) 
system/ 
third 
party 
payer 
included. 
 
used Monte Carlo simulation 
and tracker clinical endpoints  
included, BMI, HbA1c, 
lipids, SBP and medication 
use, direct medical costs from 
published sources, full 
economic evaluation. 
high. 
20/24 
in the treatment of T2DM. Sensitivity analyses 
indicated surgery is not cost-effective over 
shorter time horizons, or if the negative quality 
of life impacts of increased BMI is ignored. 
 
Keating 2009, 
Australia, 
(2006 AUD), 
2 years. 
LAGB. Class I and 
II (BMI>30 
and <40) 
recently 
diagnosed 
<2 years 
T2DM. 
RCT: 
resource 
use trial 
data and 
medical 
records. 
Unit costs 
private 
hospitals, 
specialists, 
MBS and 
PBS. 
CT. 30  
surgery 
30 
control 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer 
Included. 
BC not 
included. 
 
RCT: within trial efficacy 
results included remission of 
diabetes, within trial 
intervention costs included 
LAGB surgery costs, 
mitigation of complications, 
outpatient medical, medical 
investigations, pathology, 
weight loss therapies and 
medication, full economic 
evaluation. 
CEA, 
high. 
22/24 
Within trial cost efficacy cost/case of T2DM 
remitted. Time horizon of 2 years an additional 
$16,600 of direct health care investment is 
required to remit an additional case of recently 
diagnosed T2DM through LAGB. CT 
$25,000/case of T2DM remitted. 
Keating 2009, 
Australia, 
(2005 AUD), 
lifetime (or 
age 99 years), 
DR=3%. 
LAGB. Class I and 
II (BMI>30 
and <40) 
recently 
diagnosed 
<2 years 
T2DM. 
Published 
within trial 
RCT cost 
and efficacy 
data. Other 
published 
sources 
including 
MBS and 
PBS. 
CT. 30  
surgery 
30 
control  
Yes. No. Yes. 
EQ-5D 
Health 
care 
system/ 
third 
party 
payer 
Included. 
BC not 
included. 
 
Model: builds on a within 
trial CEA by extrapolating 
cost and outcomes. Markov 
model that is representative 
of the natural history of 
T2DM, mean annual health 
care costs for people with 
T2DM, full economic 
evaluation. 
 
CEA, 
CUA, 
high. 
24/24 
Cost/LY gained. Cost/QALY. Mean healthcare 
saving of $2,400 and 1.2 additional QALY’s 
per patient. Surgery dominant intervention for 
managing recently diagnosed T2DM in class 
I/II obese patients in Australia. 
 
Ananthap-
avan 2010, 
Australia, 
AUD, 
lifetime, 
DR=3%. 
LAGB. Severely 
obese 
(BMI≥35) 
privately 
insured 
adolescents 
(age 14-19 
years). 
Medical 
records for 
resource 
use and 
published 
sources for 
unit costs.  
Standard 
care. 
Data 
from 28 
adolesc-
ents 
modeled 
for 4120 
severely 
obese. 
Yes. Yes. No. Societal. Included. 
BC not 
included. 
 
Model: Markov, change in 
BMI, direct medical resource 
use of 28 patients and 
extrapolated for eligible 
population, time spent by 
both parents for travel and 
consultation accompanying 
their adolescent, cost offsets 
using disease costs estimates, 
full economic evaluation. 
CEA, 
CUA, 
high. 
21/24 
Cost/DALY saved. Cost/BMI unit saved. Cost 
$130 million resulted in incremental savings of 
55,400 BMI units at 3 years after surgery. 
$4,400/DALY. LAGB cost-effective for 
adolescents. 
 
Campbell  
2010, USA, 
(2006 USD), 
lifetime, 
DR=3%. 
LAGB, 
LRYGB. 
 
Morbidly 
obese adults 
aged 18-74 
years 
BMI≥35 
with CMs or 
BMI≥40. 
Published 
sources 
supple-
mented by 
clinical 
expert 
opinion. 
No 
surgery. 
NA Yes. No. Yes. 
EQ-5D 
 
Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC not 
included. 
 
 
Model: Markov, cumulative 
change in BMI, direct 
medical inpatient and 
outpatient costs, full 
economic evaluation. 
 
CEA, 
CUA, 
high. 
23/24 
Cost/QALY. Cost/LY saved. 
Both LAGB and LRYGB versus no treatment 
<$25,000/QALY gained but highly sensitive to 
model assumptions. ICERs lower for 
individuals with higher initial BMIs and higher 
for older individuals. ICERs for men generally 
higher than for women. 
Hoerger 2010, 
USA, (2005 
USD), 
lifetime (or 95 
years), 
GBP, 
GB. 
 
Severely 
obese adults 
BMI≥35 
with newly 
diagnosed 
National 
Health and 
Nutrition 
Examin-
ation 
No 
surgery. 
NA Yes. No. Yes. 
Model 
Not 
stated.  
 
Included. 
Abdomi-
noplasty 
included. 
 
Model: simulation - expanded 
Centres for Disease Control 
and Prevention-RTI Diabetes 
Cost-Effectiveness Model to 
incorporate bariatric surgery, 
CUA, 
high. 
22/24 
Cost/QALY, Cost/case of T2DM remitted. 
Newly diagnosed T2DM: bypass surgery 
$7,000/QALY, banding surgery 
$11,000/QALY. Established diabetes: bypass 
surgery $12,000/QALY, banding surgery 
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DR=3%. 
 
or 
established 
DM. 
 
Survey and 
published 
sources. 
 
diabetes remission and 
improvement along micro 
(nephropathy, neuropathy and 
retinopathy) and macro 
vascular (CHD and stroke) 
pathways, direct costs of 
newly diagnosed and 
established T2DM, full 
economic evaluation. 
$13,000/QALY. Relative to the newly 
diagnosed diabetic population, bariatric 
surgery led to fewer life-years gained and 
higher incremental cost-effectiveness ratios 
within the established diabetic population. 
Maciejewski 
2010, USA, 
(2006 USD), 
6 years. 
All types. Morbidly 
obese 
mostly high 
risk older 
males 
(veterans). 
Multisite 
Veterans 
Affairs 
Medical 
Centres. 
 
No 
surgery 
846. 
 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC not 
included. 
 
Retrospective, observational, 
costs inpatient and outpatient 
healthcare utilization and 
expenditures (including 
medications), partial 
economic evaluation. 
CCA, 
medium. 
80% 
Mean inpatient, outpatient and total costs. 
Unadjusted inpatient expenditures averaged 
$1,805 per person 3 years before surgery, 
increased to $27,536 in the surgical year, and 
declined in the years after surgery (mean 
$5,538 1 year after surgery and $2,374 3 years 
after surgery; unadjusted average outpatient 
expenditures $985 3 years before surgery, 
$3,050 in the surgical year, $1,865 1 year after 
surgery, $1,203 3 years after surgery). Average 
overall expenditures $6,029 3 years prior to 
surgery, $36,176 in the surgical year, $11,893 
1 year after surgery, $6,787 3 years after 
surgery. 
Makary 2010, 
USA, USD, 
3.5 years. 
All types. Aged 18-64 
years, with 
T2DM who 
underwent 
bariatric 
surgery. 
Large 
insurance 
database 
across 7 
states. 
 
Before 
and after. 
2235. Yes. 
 
No. No. Not 
stated.  
 
Not 
included. 
BC not 
included. 
 
Retrospective, observational, 
use of diabetes medications at 
specified post-operative time 
points, total direct health care 
costs defined as total payout 
by the insurer for health care 
claims included 
hospitalisations, procedures, 
medications, outpatient visits, 
consultations and other, 
partial economic evaluation. 
CCA, 
medium. 
65% 
Changes in median annualised costs per 
patient. Baseline average cost per patient 
$6,376, total annual healthcare costs in the first 
3 years after surgery increased by 9.7% ($616) 
in year 1, decreased by 34.2% ($2,179) in year 
2 and decreased by 70.5% ($4,498) in year 3. 
Metformin greatest medication decrease with 
52.9% taking metformin 3 months before 
surgery and 8.4% taking it 1 year after surgery. 
McEwen 
2010, USA, 
USD, 2 years 
and lifetime. 
DR=3%. 
 
ORYGBP 
LRYGBP 
 
Morbidly 
obese adults 
who 
underwent 
bariatric 
surgery. 
Claims 
single 
managed 
health care 
plan, seven 
bariatric 
centres of 
excellence, 
post-
operative 
survey data. 
Standard 
care. 
221. Yes. Yes. Yes 
EQ-5D 
Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC 
included. 
 
Model: simulation, change in 
BMI, change in utility 
(preoperative quality of life 
assessed postoperatively), 
total direct medical costs 
subdivided into 7 mutually 
exclusive categories 
outpatient pharmacy, 
inpatient, outpatient clinic, 
diagnostic testing, laboratory 
testing, emergency room, and 
other, full economic 
evaluation. 
CUA, 
medium. 
18/24 
Cost/QALY. At 2 years $49,000/QALY 
gained. Over lifetime $1,400/QALY gained. 
Long term cost-effectiveness appears to 
depend on the natural history and cost of late 
postsurgical complications and the natural 
history and cost of untreated morbid obesity. 
 
Mullen 2010, 
USA, (2007 
USD), 85 
months. 
ORYGBP 
LRYGBP 
 
 
 
Claims and 
membership 
enrolment 
metro-
No 
surgery. 
224. Yes. No. No. Health 
care 
system/ 
third 
Included: 
DRG not 
specific 
to 
Retrospective, observational, 
change in BMI, costs all 
hospital, outpatient services, 
professional services and 
CCA, 
medium. 
70% 
Comparison of average annual costs. RYGB 
breakeven point for surgery 3.5 years and 
surgery cohort used fewer healthcare resources 
after surgery. 
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 politan 
health plan. 
party 
payer. 
bariatric 
surgery. 
BC not 
included. 
pharmacy charges, partial 
economic evaluation. 
 
 
Perryman 
2010, USA, 
(2008 USD), 
2.5 years. 
DR=4%. 
LAGB. Age>18 
years and 
bariatric 
surgical 
eligibility 
criteria: 
BMI≥35 
with CMs 
and 
BMI≥40. 
Employees’ 
retirement 
system 
database, 
published 
sources. 
No 
surgery. 
14,100. Yes. Yes. No. Health 
care 
system/ 
third 
party 
payer. 
Societal. 
 
Included. 
BC not 
included. 
Model: dynamic input-output, 
theoretical candidates for 
LAGB calculated based on 
national data and eligibility 
criteria for LAGB, direct 
health costs and related 
absenteeism, impacts 
comprise the costs and 
benefits of direct, indirect and 
induced economic impacts, 
full economic evaluation. 
CBA, 
ROI, 
medium. 
18/23 
Payback period and average annual ROI. 
Economic impact assessment. Payback period 
23-24 months from the payer perspective, 
employer perspective 17-19 months. From a 
societal perspective the impact on total 
business activity for Texas (over 5 years) 
included gains of $195.3 million in total 
expenditures, $93.8 million in gross product, 
and 1,354 person-years of employment. 
Roger-
Anderson 
2010, 
Norway, 2 
years. 
DS. Age 18-60, 
Morbidly 
obese (BMI 
BMI≥35 
with CMs or 
BMI≥40) 
accepted for 
DS at single 
study centre. 
Self-report 
of paid 
workforce 
particip-
ation. 
 
Before 
and after. 
51. No. Yes. Yes 
SF36 
 
Not 
stated. 
Not 
included. 
BC 
included 
(pannicu-
lectomy). 
Prospective self-report of 
paid workforce participation, 
% excess BMI loss, paid 
work on scale 0-100% where 
100% is full-time work (37.5 
hours per week), partial 
economic evaluation. 
CCA 
medium. 
70% 
Hours of paid work per week. Number of 
patients who performed paid work was 
unchanged year 0 to year 1. Increased from 
54.9% at year 0 to 66.7% at year 2. Percentage 
of the patients performing paid work at year 2 
was lower than the population norm (82%). 
 
Chang 2011, 
USA, (2010 
USD), 
lifetime, 
DR=3%. 
All types  
 
BMI≥35, 
two groups 
with/without 
ORD. 
National 
Health and 
Nutrition 
Examin-
ation 
Survey, 
published 
sources. 
No 
surgery. 
NA Yes. No. Yes  
BQL 
Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC not 
included. 
 
Model: Mixed Proportional 
Hazards model and 
simulation, costs from 
published studies included 
average costs without 
revision, average costs of 
medical complication and 
reoperation and perioperative 
death, and relationship 
between BMI and associated 
costs of ORDs, full economic 
evaluation. 
CEA, 
CUA, 
high. 
22/24 
Cost/LY and Cost/QALY. For BMI≥35 
<$4,000/QALY, Cost-saving for super obese 
(BMI≥50) with obesity related CMs. 
Sensitivity analysis BMI 30-35 found that 
ICER increases $350/QALY gained for non-
ORD group and $500/QALY gained for the 
ORD group. Sensitivity analysis found that 
costs-effectiveness analyses are particularly 
sensitive to cost data. 
 
Clough 2011, 
Australia, 
25.5 months. 
LAGB. Bariatric 
surgery 
patients 
age>60 
years, mean 
BMI 42.2. 
 
Single 
surgeon's 
clinic/ 
hospital 
records, 
LapBase 
database. 
 
Before 
and after. 
113. Yes 
meds 
No. Yes 
SF36 
Not 
stated. 
Included. 
BC not 
included. 
 
Retrospective, observational,   
change in medication use for 
comorbidities including 
diabetes, HT, sleep apnoea, 
hyperlipidaemia, reflux, 
asthma/COAD partial 
economic evaluation. 
CCA, 
medium. 
70% 
Mean medication use at baseline, significant 
average medication reduction (diabetes, HT, 
sleep apnoea, hyperlipidaemia, reflux, 
asthma/COAD) was not shown in this study. 
Marked improvement in QoL after LAGB 
surgery in the obese elderly was the key 
positive finding. 
Cremieux 
2011, USA, 
(2010 USD), 
124 months. 
 
GBP, 
RYGBP, 
LAGBP. 
 
Age 18-64 
years, 
BMI≥35, 
DM. 
 
Admini- 
strative 
claims 
database, 
13.5 million 
lives, 58 
companies. 
No 
surgery. 
2059 
surgery 
2059 
control 
 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Not 
included. 
BC not 
included. 
 
Retrospective, observational,  
medication utilisation, total 
direct healthcare costs and 
medication claims, 
investment in bariatric 
surgery is the sum of all 
incremental costs incurred in 
ROI, 
medium. 
75% 
ROI. Updated analysis confirms that on 
average cost savings begin to accrue to third 
party payers at 3 months after surgery for 
T2DM patients. Surgery costs were fully 
recovered at 47 months (95% CI 34-61) for 
laparoscopic surgeries.  
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 the month before, the month 
of and the month after 
surgery, relative to the total 
healthcare costs of control 
patients, partial economic 
evaluation. 
Ewing 2011, 
USA, (2008 
USD), 
DR=3,5,10%. 
LGBP, 
LAGB. 
 
Bariatric 
surgery 
patients 
from a 
single site. 
Admini-
strative 
hospital 
data from 
single site, 
published 
sources. 
No 
surgery. 
150. Yes. Yes. No. Societal. Not 
included. 
BC not 
included. 
Model: input-output model of 
a regional economy, ongoing 
improvements in worker 
productivity, costs expressed 
in terms of lost output, labour 
income, employment, and 
indirect business taxes, full 
economic evaluation. 
CBA, 
medium. 
17/24 
Net Present Value. Net benefit $1.3 (DR=10%) 
to $9.9 B (DR=3%) USD to a regional 
economy. Net benefit consists of upfront costs 
of surgical treatment and ongoing gains from 
improvements in worker productivity. 
Finkelstein 
2011, USA, 
(2008 USD), 
USD, 5.7 
years.  
 
LAGB. Age 18-64 
years and 
diabetes 
subsample. 
LAGB 
mean 
BMI=44.5, 
comparison 
sample 
mean 
BMI=44.8. 
Admini-
strative 
claims 
database. 
No 
surgery. 
7,310 
surgery 
7,310 
control 
 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC not 
included. 
 
Retrospective, observational, 
Cost quarterly payments of 
total, inpatient (both facility 
and physician), non-inpatient 
including hospital, outpatient, 
physician office, emergency 
department), and prescription 
medication claims, partial 
economic evaluation. 
ROI, 
medium. 
75% 
Breakeven time horizon for LAGB sample and 
diabetes subsample. Initial payments for 
LAGB were fully recovered within 4 years and 
in just over 2 years for the diabetes subsample. 
 
Finkelstein 
2011, United 
States, USD, 
5 years. 
 
LAGB. Age 18-64 
years, DM 
subsample. 
 
 
Medical 
Expenditure 
Panel 
Survey and 
National 
Health and 
Wellness 
Survey, 
published 
sources. 
No 
surgery. 
2298. 
 
Yes. Yes. No. Not 
stated. 
Included. 
BC not 
included. 
 
Retrospective observational, 
estimation of elasticities for 
absenteeism, presenteeism,  
direct medical costs, 
absenteeism costs and 
presenteeism costs, partial 
economic evaluation. 
ROI, 
medium. 
75% 
Time to breakeven for LAGB sample and 
diabetes subsample. Inclusion of indirect costs 
does not substantially change the breakeven 
period from 2 years found in previous study. 
Beyond the breakeven period there are 
additional indirect cost savings that accrue to 
employers. After 5 years net savings increase 
from $26,570($9,000) to $34,000($10,380). 
 
Kelles 2011, 
Brazil (2005 
USD), 2 
years. 
 
RYGBP. 
 
Morbidly 
obese 
patients who 
underwent 
bariatric 
surgery, 
mean 
BMI=43. 
HMO 
database. 
 
Before 
and after. 
382. Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC not 
included. 
 
Retrospective observational, 
direct medical costs, partial 
average cost calculated as 
total cost minus costs 3 
months before and after 
surgery, partial economic 
evaluation. 
CCA, 
medium. 
65% 
Mean cost of surgery and mean total cost of 
healthcare services per patient. Partial average 
cost almost doubled after the operation ($392 
versus $678). Patients presenting with HT, 
DM, BMI≥50 and aged >50 years have 
significantly higher costs than patients without 
these conditions. 
Klein et al 
2011, USA, 
(2007 USD), 
90 months, 
DR=3.4%. 
All types. 
 
Aged 18-65 
years, 
BMI≥35, 
DM. 
Admini-
strative 
claims 
covering 
8.5 million 
lives 40 
companies. 
No 
surgery. 
808 
surgery 
808 
control 
 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Not 
included.  
BC not 
included. 
 
Retrospective, observational, 
3 outcome measures 
diagnostic claims for 
diabetes, claims for diabetes 
medication, average total 
costs of diabetes medication 
and supplies, costs direct 
medical including medication 
ROI, 
high. 
80% 
ROI. Therapeutic benefits of bariatric surgery 
on diabetes translate into considerable 
economic benefits. Surgery costs were 
recovered at 30 months (for open and 
laparoscopic surgeries). 
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costs, partial economic 
evaluation. 
 
Maklin 2011, 
Finland, 
(2010 
EURO), 10 
years, 
DR=3%. 
GBP, 
SG, 
GB. 
 
Morbidly 
obese with 
higher 
prevalence 
of T2DM. 
 
Admini-
strative 
hospital 
data, expert 
opinion of 
surgeons, 
population 
health 
survey, 
published 
sources 
Standard 
care. 
 
NA Yes. No. Yes  
15D 
Health 
care 
system/ 
third 
party 
payer. 
Included. 
Abdomi-
noplasy 
included. 
 
Model: decision tree and 
Markov model, decline in 
BMI based on EWL data, 
T2DM and sleep apnoea, 
costs based on average costs 
for each procedure type in the 
DRG and average annual 
costs for both treatment 
groups, excluding cost of 
medication, full economic 
evaluation. 
CUA, 
High. 
22/24 
Cost/QALY. Bariatric surgery cost-effective. 
Mean costs were €33,870 and €50,495 and 
mean QALYs 7.63 and 7.05 for bariatric 
surgery and ordinary treatment respectively. 
Bariatric surgery dominant in sensitivity 
analysis. Strong dominance of bariatric surgery 
over ordinary treatment was removed if BMI at 
baseline was 38. 
 
Bleich 2012, 
USA, (USD), 
6 years. 
All types. Age 18-64 
years with 
T2DM. 
Admini-
strative 
insurance 
data from 7 
plans. 
Before 
and after. 
6,376. 
 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Not 
included. 
BC not 
included. 
 
Retrospective, observational,  
costs included inpatient, 
outpatient, pharmacy and 
other (professional office and 
professional other), partial 
economic evaluation. 
 
CCA, 
Medium. 
80% 
Means and medians for costs and utilisation 
measures for individuals with DM before and 
after surgery. Total mean costs for up to 6 
years after having bariatric surgery, individuals 
with T2DM are more likely to have higher 
health care expenditures (total mean costs were 
$9,326 presurgery, $13,400 1 year after 
surgery, and $13,644 6 years after surgery), are 
more likely to have hospitalisations but are less 
likely to have primary care and specialist visits 
compared with their respective costs and 
utilization before surgery. 
Borg et al 
2012, 
Sweden, 
SEK, 10 
years. 
All types. Overweight 
and obese 
from the 
adult 
Swedish 
population 
BMI>25, 
age 15-84 
years. 
Published 
sources. 
Before 
and after. 
NA Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Included. 
Costs of 
follow-up 
plastic 
surgery 
included. 
Model: Markov and micro-
simulation, changes in BMI, 
costs attributable risks to 
obesity related comorbidities, 
costs inpatient costs, full 
economic evaluation.  
 
BIA, 
low. 
55% 
Comparing no surgery with 3,000 surgeries per 
year results in a net budget impact of a average 
of SEK 121 million per annum or SEK 40,000 
per patient. This implies that a 55% of the cost 
of surgery, has been offset by a reduction in 
the excess treatment costs of obesity related 
diseases. 
 
Finkelstein 
2012, United 
States, USD, 
5 years. 
 
LAGB. Age 18-64 
years. DM 
subsample. 
 
Medical 
Expenditure 
Panel 
Survey and 
National 
Health and 
Wellness 
Survey. 
Published 
sources. 
No 
Surgery. 
2,298. Yes. Yes. No. Not 
stated . 
 
Included. 
BC not 
included. 
 
Retrospective, observational, 
estimation of elasticities for 
absenteeism presenteeism 
direct medical costs, cost 
estimates for absenteeism and 
preseneteesim, partial 
economic evaluation. 
ROI, 
medium. 
80% 
Time to breakeven and 5 year net costs of 
LAGB. Using all three cost categories 
(medical expenditures, absenteeism and 
presenteeism), the time to breakeven is 
reduced from 16 to 14 quarters (6 months). 
Beyond the breakeven period estimated 
savings are much larger when indirect costs are 
considered. 
Ghiassi 2012, 
USA, USD, 1 
year. 
RYGBP Morbidly 
obese with 
DM and HT 
who had 
undergone 
RYGBP and 
Medical 
records of 
consecutive 
patients at a 
single site – 
Veteran’s 
Before 
and after. 
106. Yes 
meds 
No. No. Health 
care 
system/ 
third 
party 
payer. 
Not 
included. 
BC not 
included. 
 
Retrospective, observational,  
progression, improvement, or 
remission of DM or HT was 
determined at 1 year after 
surgery and %EWL, costs 
current Veterans Affairs 
CCA, 
medium 
70%. 
Mean annual costs meds. The annual costs of 
medications to treat HT was reduced by 65% 
at 1 year of surgery and 88% for DM. In a 
subset of patients with persistent HT of DM 
after surgery, cost reduction 58% for HT and 
69% for DM. 
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taking DM 
and HT 
meds. Mean 
BMI=47. 
Mainly male 
cohort. 
Affairs 
health care 
system. 
pharmacy subsidised cost for 
each medication, partial 
economic evaluation. 
Gripeteg 
2012, 
Sweden, 20 
years. 
GB, 
GBP, 
VBG. 
 
SOS cohort: 
Age 37-60 
years, men 
BMI≥38, 
women 
BMI≥34. 
Swedish 
Social 
Insurance 
Agency. 
 
Standard 
Care. 
2901. No. Yes. No. Not 
stated. 
Not 
included. 
BC not 
included. 
 
SOS cohort, % weight 
change, incidence and 
number of disability pension 
days, partial economic 
analysis. 
CCA, 
medium 
75% 
Incidence of disability pension and number of 
disability pension days over 10 years. Bariatric 
surgery may be associated with favourable 
effects on disability pension for up to 19 years 
in men whereas neither favourable nor 
unfavourable effects could be detected in 
women.  
Maciejewski 
2012, USA, 
USD, 6 years. 
RYGBP. 
 
Morbidly 
obese 
mainly high 
risk older 
male 
patients 
(veterans). 
Multisite 
VAMCs. 
 
No 
surgery. 
847  
surgery 
847 
control 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC not 
included. 
 
Retrospective, observational, 
costs total veterans affairs 
expenditure sum of inpatient 
and outpatient expenditures, 
partial economic evaluation. 
 
CCA 
high 
85% 
Mean inpatient, outpatient and total costs. 
Adjusted total expenditures converged in the 3 
years after surgery, from $4,397 higher in the 
first 6 postsurgical months to similar 
expenditures in the 31 to 36 postsurgical 
months. Bariatric surgery was not associated 
with reduced expenditures in this cohort of 
older, predominantly male patients 3 years 
after the procedure. 
 
Michaud 
2012, USA, 
(2010 USD), 
46 years 
DR=3%. 
Focus on 
RYGBP. 
Age 50 
years, 
BMI>40 or 
BMI35-40 
with 
qualifying 
CMs and 
BMI 30-35 
with 
qualifying 
pre-existing 
conditions – 
DM. 
Published 
sources. 
No 
surgery. 
NA Yes. Yes. No. Societal. Included. 
BC not 
included. 
 
Model: Future Elderly Model 
(micro-simulation model), % 
weight loss, health care costs 
(private, Medicare and 
Medicaid); tax revenue; 
social security expenditures 
(disability and old-age 
pensions), full economic 
evaluation. 
CEA 
high 
24/24 
Net present value per capita amongst eligible 
patients. Cost/LY gained. Present value of total 
medical costs for people who have had 
bariatric surgery is reduced by $4,649: $3,247 
accrues to Medicare, $276 to Medicaid and 
$1,126 to other (private) sources. On balance, 
bariatric surgery generates substantial private 
value for those treated. Net public fiscal effects 
are modest, primarily because the size of the 
population eligible for treatment is small. Net 
social effect is large once improvements in life 
expectancy are assumed. 
Myers 2012 
USA, USD, 8 
years. 
 
LRYGBP Severely 
obese BMI 
40-60, aged 
35-60 years. 
Single site 
and single 
surgeon. 
State 
managed 
health 
insurance 
agency. 
No 
surgery. 
39 
surgery 
911  
no 
surgery  
Yes. 
 
No. No. Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC not 
included. 
 
Retrospective, observational, 
% EWL, medical costs 
included all medical claims 
(office visits, ED, 
laboratory/pathology, 
physical and occupational 
therapy, sleep facilities and 
remaining) except pharmacy 
claims. Pharmacy costs 
included direct 
pharmaceutical expenditure, 
partial economic evaluation. 
CCA, 
high. 
85% 
Changes in mean medical and pharmacy costs 
per person per year. Combining total costs 
across the eight years of the study total 
medical costs for the non-surgical group were 
$73,212. The surgical group’s costs were 
$77,894, which included the $25,000 cost of 
the surgery. Surgery costs may begin to be 
recouped within the first 4 years after surgery 
with continued effects 6 years after surgery. 
Neovius 2012, 
Sweden, 
(2011 USD), 
GB, 
GBP, 
VBG. 
SOS cohort: 
Age 37-60 
years, men 
National 
Patient 
Register 
CT. 
 
2,010 
surgery 
2,037 
Yes 
meds. 
No. No. Not 
stated. 
Included. 
BC not 
included. 
SOS study, % weight loss, 
hospitalisation frequency, 
hospital days by year and 
CCA, 
high. 
90% 
Health care use and medication cost. 
Surgically treated patients used more inpatient 
and non-primary outpatient care during the 
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20 years. BMI ≥38, 
women BMI  
≥34. 
and 
Prescribed 
Drug 
Register 
 
control 
 
 non-primary outpatient care, 
partial economic evaluation. 
 
first 6 year period after undergoing bariatric 
surgery but not thereafter. Drug costs from 
years 7 to 20 were lower for surgery patients 
than for controls. From year 7 to year 20, the 
surgery group incurred a mean annual drug 
cost of $930; control patients $1,123. 
Sussenbach, 
2012, Brazil, 
(2011 USD), 
3 years. 
RYGBP 
 
 
Bariatric 
surgery 
patients 
with T2DM, 
SAH and 
dyslipid-
aemia. 
Single 
study centre 
medical 
charts. 
 
Before 
and after. 
194. Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Not 
included. 
BC not 
included. 
 
Retrospective, observational, 
improvement or resolution of 
CMs (three groups), costs 
excluded costs of the surgery, 
preoperative costs followed 
the recommendations of 
standardised guidelines for 
each CM, postoperative costs 
calculated according to 
information on medical charts 
e.g. doctors visits, 
examinations and tests and 
medications, partial economic 
evaluation. 
CCA, 
medium. 
70% 
Annual costs before and after surgery. Annual 
median expenses for medications, professional 
care and examinations in the preoperative 
period were $1,706, In the postoperative 
period these expenses were $1,174 in the first 
12 months, $713 for 13-24 months and $431 
for 25 to 36 months. 
Zanela 2012, 
Mexico, 
(2011 PESO), 
10 years, 
DR=4.5%. 
 
All types. Adults, class 
II obese 
(BMI≥35), 
at least one 
CM, 
previous 
failed CT. 
Mexican 
Social 
Security 
Institute 
DRG list. 
Mexican 
National 
Institute of 
Public 
Health. 
No 
surgery. 
150 
surgery 
150 
control 
Yes. No. No. Health 
care 
system/ 
third 
party 
payer. 
Not 
included. 
BC not 
included. 
 
Model: discrete event 
simulation, comorbidity 
resolution at a different rate 
over time (resolution and re-
incidence of T2DM, HT and 
hypercholesterolemia), costs 
inpatient, outpatient, 
pharmacy partial economic 
evaluation. 
 
ROI, 
high. 
90% 
ROI time or cost of breakeven point 6.8 years. 
Total costs for the surgical group were 52% 
less than conventional treatment group 
after 10 years. Bariatric surgery reduced the 
cost of treating T2DM, HT, and 
hypercholesterolemia by 59%, 53%, 
and 65%, respectively. ROI for bariatric 
surgery in patients with T2DM as the only 
comorbidity was 4.4 years. 
Faria 2013, 
Global/Portug
al, EURO, 
lifetime, 
DR=3%. 
GB, 
GBP. 
Morbidly 
obese with 
and without 
CMs, 
Baseline 
mean 
BMI=46.9. 
Administ-
rative 
hospital 
data and 
published 
sources. 
 
CT. NA Yes. Yes Yes. Societal. Included. 
BC not 
included. 
 
Model: Markov, weight loss 
and control of comorbidities, 
societal costs extracted from 
published sources and an 
institutional database, full 
economic evaluation. 
CUA, 
medium. 
19/24 
Cost/QALY. Compared to the best medical 
management, in the global population of 
patients with a BMI of >35 kg/m2, surgery 
rendered 1.9 extra QALYs and saves on 
average €13,244 per patient. Younger patients, 
patients BMI 40-50 kg/m², and patients 
without ORD derive greater benefit. 
Finkelstein 
2013, USA, 
USD, 10 
years, 
 
LAGB 
LRYGB 
 
Morbidly 
obese who 
underwent 
bariatric 
surgery and 
DM 
subsample. 
Insurance 
claims 
database 
 
No 
surgery 
9,631 
surgery; 
9,639  
No 
surgery –
MO code 
sample; 
DM 
2,447. 
Yes No No Not 
stated 
Included. 
BC not 
included. 
 
Retrospective, observational,  
Costs person-specific 
quarterly payments of total, 
impatient (facility and 
physician), non-inpatient 
(including payments for 
hospital outpatient, 
physician’s office visits, and 
ED), and prescription drug 
claims, partial economic 
evaluation. 
ROI 
medium. 
80% 
Time to breakeven and net costs. Net costs and 
time to breakeven resulting from bariatric 
surgery are less favourable than has been 
reported in prior studies. Even with a more 
conservative and likely more accurate 
comparison sample, the business case for 
LAGB appears favourable. Without the morbid 
obesity code comparison sample, time to 
breakeven for LAGB increases to 5.25 years 
with a 5 year net cost of $690.  
Karim 2013, 
UK, 2 years. 
LAGB Obese 
adults 
BMI≥35, 
Single site 
hospital 
database. 
Before 
and after. 
73. Yes. No. No. Not 
stated. 
 
Included. 
BC not 
included 
Retrospective, observational, 
utilisation and costs hospital 
admissions, outpatient 
CCA, 
medium. 
70% 
Changes in utilisation of hospital services and 
associated costs. Total estimated costs savings 
ranged between $32,593 and $41,177 per 
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age 18-65 
years who 
underwent 
LAGB. 
Individual 
case notes.  
 clinics, medications (DM, HT 
and analgesia), partial 
economic evaluation. 
 
annum. 
Karim 2013, 
UK, GBP, 2 
years. 
 
LAGB, 
LRYGB, 
LSG. 
 
Morbidly 
obese 
patients age 
25-65 years 
who 
underwent 
bariatric 
surgery. 
Single site 
hospital 
medical 
records and 
patients’ 
GPs. 
Before 
and after. 
88. Yes. No. No. Not 
stated . 
 
Included. 
BC not 
included. 
 
Retrospective, observational, 
costs hospital inpatient, 
outpatient clinic and meds, 
partial economic evaluation. 
 
 
CCA, 
medium. 
70% 
Summary of annual cost savings. Total annual 
cost savings ₤30,404. Annual cost savings 
medications ₤11,452, hospital admissions 
₤16,420 and ₤2,532 outpatient clinics. 
Keating 2013, 
Australia 
(2009 AUD), 
4 years. 
LAGB. Population 
of 
Australians 
undergoing 
LAGB in 
2007. 
Australian 
government 
Medicare 
database. 
Before 
and after. 
9,542. Yes 
meds. 
No. No. Health 
care 
system/ 
third 
party 
payer 
Not 
included. 
BC not 
included. 
Retrospective, observational, 
costs pharmaceutical data 
classified into 8 therapeutic 
categories. Unit costs paid by 
Medicare, partial economic 
evaluation. 
 
CCA, 
high. 
90% 
Mean annual costs per person for prescription 
medication. Net reduction in pharmaceutical 
utilisation from 10.5 to 9.6 pharmaceuticals 
prescribed per person/year, and costs 
decreased from $517 to $435. 
Lam 2013, 
USA, USD, 1 
year.  
LRYGBP 
 
Morbidly 
obese 
Native 
Hawaiians 
who 
underwent 
LRYGB. 
Medical 
records 
from single 
site. 
Before 
and after. 
50. Yes 
meds. 
No. No. Health 
care 
system/ 
third 
party 
payer. 
Not 
included. 
BC not 
included. 
 
Retrospective, observational, 
successful weight loss >50% 
excess body weight lost at 
one year postoperatively, 
costs medications from online 
pharmacy for 30 day supply 
of prescription medications, 
partial economic evaluation.  
 
CCA, 
Medium 
70%. 
Average monthly and annual cost changes of 
prescription medications. Average number of 
prescription medications decreased from 3.5 
per patient preoperatively to 1.1/patient at one 
year, monthly cost saving $196. 
Lee 2013, 
Australia, 
(2003 AUD), 
lifetime, 
DR=3%. 
LAGB Population 
study: 
morbidly 
obese 
Australians 
BMI>35 
and 
BMI>40 
Published 
sources. 
 
No 
surgery. 
NA Yes. Yes. 
 
No. Health 
care 
system/ 
third 
party 
payer 
Societal. 
Included. 
BC not 
included.  
 
Model: Markov, costs 
intervention costs from 
previous published studies, 
time and travel costs 25% of 
hourly wage rate and disease 
costs, full economic 
evaluation. 
 
CEA, 
high. 
23/24 
Cost/DALY averted. For BMI>35 
$2,154/DALY averted. LAGB cost-saving 
when provided to all individuals with BMI>40. 
Cost-effective when extended to all individuals 
with BMI>35, but at a substantial aggregate 
cost. Results highly sensitive to changes in the 
likelihood of long-term complications. 
Pollock 2013, 
UK, BPD, 5 
years. 
LAGB.  
 
Morbidly 
obese 
patients 
with newly 
diagnosed 
<2 years 
T2DM. 
RCT data. 
Published 
sources. 
 
Standard 
care. 
100  
surgery 
100 
no 
surgery 
Yes No No Health  
care 
system/ 
third 
party 
payer. 
Included. 
Abdomi-
noplasty 
included. 
Model: budget impact model, 
reduction in BMI, HbA1c and 
SBP, costs inpatient, 
outpatient and medications, 
partial economic evaluation. 
 
CCA, 
medium 
80% 
 
Cost savings of ₤913 per patient for LAGB 
over 5 years compared with standard medical 
management for newly diagnosed T2DM. 
Pollock 2013, 
UK, (2010 
BPD), 40 
years, 
DR=3.5% 
LAGB BMI = 30-
40, recently 
diagnosed 
T2DM. 
RCT data. 
Published 
sources 
 
Standard 
care. 
1000. Yes. No. Yes. Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC not 
included. 
 
Model: CORE diabetes and 
nonparametric bootstrapping, 
RCT data: glycaemic control 
at the end of two years, % 
change HbA1c, weight, SBP 
and DBP, waist 
circumference, fasting lipids,  
costs inpatient, outpatient 
CUA, 
high. 
23/24 
Cost/QALY. LAGB is a highly cost-effective 
treatment in obese patients with T2DM in the 
UK setting compared with standard medical 
management 
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LAGB and diabetes 
medications and 
complications, full economic 
evaluation. 
Song 2013, 
South Korea,  
(2011 USD), 
lifetime, 
DR=5%. 
LAGB 
LRYGBP 
LSG 
 
Severely 
obese 
Korean 
adults over 
30 with 
BMI 3040 
(severe 
obesity for 
Asian 
population 
BMII≥30) 
Hospital 
adminis-
trative, 
medical 
charts, 
survey of 
bariatric 
surgeons, 
National 
Health 
Insurance 
Statistics 
No 
surgery. 
 
NA Yes. No. Yes. 
EQ-5D 
 
 
Health 
care 
system/ 
third 
party 
payer. 
Included.  
BC not 
included. 
 
Model: combined decision 
tree and Markov, change in 
mean BMI, utility weights, 
costs inpatient, outpatient and 
medications, full economic 
evaluation. 
 
CUA, 
high. 
24/24 
Cost/QALY. ICER of bariatric surgery 
compared with conventional treatment was 
US$1,771/QALY, suggesting that bariatric 
surgery was cost-effective in South Korea. 
Wang 2013, 
USA, USD, 
lifetime, 
DR=3%. 
 
LRYGBP 
ORYGBP 
LAGB 
 
Individuals 
eligible for 
bariatric 
surgery 
based on 
BMI≥35. 
Reference 
case 53 year 
old female 
BMI=44. 
Adminis-
trative 
claims 
database 
and 
published 
sources. 
No 
surgery. 
NA Yes. No. Yes. 
SF- 12 
and  
EQ-5D 
Health 
care 
system/ 
third 
party 
payer. 
Included. 
BC not 
included. 
 
Model: decision analytic first 
5 years then natural history 
model, changes in BMI and 
utility, costs estimated 
lifetime direct medical costs 
associated with the three 
procedures compared with no 
surgery, full economic 
evaluation. 
CUA 
high. 
23/24 
Cost/QALY. $6,600/QALY for LRYGB, 
$6,200/QALY for LAGB, $17,300/QALY for 
ORYGB. Bariatric surgery produced additional 
life expectancy (80-81 years) compared to no 
surgery (78 years). 
 
Weiner 2013, 
USA (2005 
USD), 6 
years. 
 
LAGB, 
LGBP, 
OGBP, 
other 
restrictive 
and 
unknown. 
 
Patients 
who 
underwent 
bariatric 
surgery, 
age18 
years, 1:1 
matched. 
Health 
insurance 
plans. 
 
No 
surgery. 
29,820. 
 
Yes. No. No. Not 
stated. 
Included. 
BC not 
included. 
 
Retrospective, observational, 
costs medical and pharmacy 
claims data, partial economic 
evaluation. 
 
CCA 
high. 
95% 
Changes in mean costs. Regression adjusted 
ratios. Total costs were greater in the bariatric 
surgery group during the second and third 
years following surgery but were similar in 
later years. Bariatric surgery group’s 
prescription and office visit costs were lower 
and their inpatient costs were higher. Surgical 
group costs years 1 to 6 Y1 $8,905 (18,814), 
Y2 $9,908 (19,273), Y3 $9,211 (19,263), Y4 
$9,051 (19,520), Y5 $9,386 (21,137), Y6 
$9,259 (26,909).  
Castilla 2014, 
Spain, (2012 
EURO), 
lifetime, 
DR=3%. 
GBP Patients 
who 
underwent 
bariatric 
surgery age 
18-55 years. 
Spanish 
NHS, 
published 
sources. 
No 
surgery. 
79. Yes. No. Yes. 
SF-36 
EQ-5D 
OP 
MA II 
Health 
care 
system/ 
third 
party 
payer. 
Not 
included. 
BC not 
included. 
Model: discrete event 
simulation, change in utility, 
costs direct medical costs 
from Spanish NHS, full 
economic evaluation. 
 
CUA, 
high. 
22/24 
Surgery group gained 5.63 QALYs. Lifetime 
savings €13,944. The total cost of the 
intervention branch is close to half the cost of 
the non-intervention branch (€17,431 vs 
€31,425). 
Bairdain 
2015, United 
States, USD, 
7 years, 
DR=3%.  
LRYGBP Severely 
obese 
adolescents 
who 
underwent 
bariatric 
surgery. 
Children’s 
hospital 
database. 
No 
surgery. 
11. Yes. No. Yes. 
EQ-5D 
Health 
care 
system/ 
third 
party 
payer. 
Not 
included. 
BC not 
included. 
Model: Markov, costs direct 
medical preoperative, 
perioperative and 
postoperative (clinic and 
ancillary charges), full 
economic evaluation. 
CUA, 
medium. 
16/24 
 
Cost/QALY at year 7 $36,570/QALY. At a 
WTP threshold of $100,000/QALY, bariatric 
surgery was not cost effective in the first three 
years, but became cost-effective after three 
years ($80,065/QALY in year 4 and 
$36,570/QALY in year 7). 
Borisenko GBP,  Scanadan- No NA Yes. No. Yes. Health Included. Model: Markov, BMI CUA, Over a lifetime surgery led to savings of €8408 
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2015, 
Sweden, 
(2012 
EURO), 
lifetime, 
DR=3%. 
SG, 
GB. 
avian 
obesity 
surgery 
registry and 
published 
sources. 
surgery. EQ-5D care 
system/ 
third 
party 
payer. 
BC 
included. 
reduction, CVD, T2DM, 
complications, utility, costs 
cost of surgery with and 
without complications, 
annual cost T2DM and CVD 
(e.g. stroke, MI, TIA), full 
economic evaluation. 
high. 
23/24 
and generated an additional 0.8 LY and 4.1 
QALYs per patient. Base-case bariatric 
surgery cost saving. All four specified diabetic 
cohorts were cost saving (moderately, 
severely, morbidly and super obese). Time 
delay in surgery led to significant losses of 
clinical benefits (in the range of 0-0.6 LY and 
0.2-1.2 QALYs). Losses of clinical benefits 
higher in males and diabetic patients. 
Czernichow 
2015, France, 
EURO, 4 
years. 
GB 
62.5%, 
GBP, 
SG. 
Obese 
patients who 
had 
undergone 
primary 
bariatric 
surgery. 
National 
claims 
insurance 
database. 
Before 
and after. 
350. Yes. No. Yes. Health 
care 
system/ 
third 
party 
payer 
(stated 
societal) 
Included. 
BC not 
included. 
Retrospective, observational, 
costs direct costs. All items 
of health care consumption 
eligible for reimbursement 
and associated costs were 
assessed for each study 
period at current prices, 
partial economic evaluation. 
CCA, 
high. 
95% 
Annual total direct cost per patient before and 
after bariatric surgery. Annual per capita 
reimbursed health expenses evolved from 
€2,633 (3,124) year (T-2) to €3,755 (5,037) 
year (T+2) with differences according to the 
type of surgery. Most items of medical 
consumption started to decrease in T+2. 
Keating 2015, 
Sweden, 
(2013 USD), 
15 years. 
GB, 
GBP, 
VBG. 
SOS cohort: 
Age 37-60 
years, men 
BMI ≥38, 
women BMI  
≥34. 
Stratified for 
baseline 
glucose 
status. 
National 
prescribed 
drug 
register and 
question-
naires. 
National 
patient 
register 
(inpatient 
and 
outpatient). 
CT. 
 
4,030 
patients 
2,836 
eugly-
cemic 
591 pre-
diabetes 
603 
diabetes 
Yes. No. No. Not 
stated. 
Included. 
BC not 
included. 
 
SOS study, baseline glucose 
status, costs inpatient, non-
primary outpatient and 
medications, partial economic 
evaluation. 
 
CCA, 
high. 
100% 
Adjusted mean differences for 15 year 
aggregated drug, outpatient, inpatient, and total 
healthcare costs. Drug costs were lower in the 
surgery group for pre-diabetes ($10,194 vs 
$13,186; –$3,329 [–5,722 to –937]; p=0·007) 
and diabetes ($14,346 vs $19,511; –$5,487 [–
7,925 to –3,049]; p<0·0001) subgroups than in 
the CT group. Total healthcare costs were 
higher for patients with euglycaemia or pre-
diabetes in the surgery group than in the CT 
group, but we detected no difference between 
the surgery and CT groups for patients with 
diabetes.  
Warren 2015, 
USA, USD, 
10 years. 
All types Obese 
T2DM 
eligible for 
bariatric 
surgery and 
control 
group 
T2DM 
American 
Diabetic 
Association 
estimates 
No 
surgery. 
Surgery 
eligible 
group 
1,000 
(surgery 
200, no 
surgery 
800) 
control 
1,000 
Yes. Yes. No. Not 
stated 
Not 
included. 
BC not 
included. 
Retrospective, observational, 
resolution of T2DM, costs 
direct costs (inpatient and 
outpatient medical costs) 
included, indirect costs 
reduced work productivity 
and mortality, partial 
economic evaluation. 
CCA, 
medium. 
75% 
Total, direct and indirect costs of bariatric 
surgery. The projected annual costs of T2DM 
per person is between $1,700 and $2,100. 
Considering only the direct medical costs of 
T2DM, the 10 year aggregate cost savings 
compared with the control group is $2.7 
million/1000 patients; the total (direct and 
indirect) cost savings is $5.4 million/1000 
patients. 
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Table 3A: Characteristics of cost-effectiveness and cost-utility studies that investigated people with diabetes who underwent bariatric surgery versus conventional treatment  
Reference, currency 
study population 
DR Cost of the procedure Economic metric (cost-
effectiveness studies: base case) 
Economic metric (cost-utility 
studies: base case) 
Sensitivity analyses 
Anselmino 2009, EURO. 
Study population: AGB and GBP for 
BMI  35 and T2DM 
 
3.5% 
 
Base case input - average cost per patient:  
GBP: Austria: €6,361; Italy: €7,831; Spain: €8,344.  
AGB: Austria: €4,785; Italy: €7,759; Spain: €5,995. 
GBP: Austria: €-740/ T2DM free 
year; Italy: €-637/ T2DM free 
year; Spain: €1,362/ T2DM free 
year. AGB: €/T2DM free year: 
Austria: €-1,201; Italy: € 
452;Spain: €611. 
GBP: Austria: €-740/QALY gained; 
Italy: €-637/gained; Spain: 
€1,362/gained. 
AGB: Austria: €-1,201/QALY 
gained; Italy: €-452/QALY gained; 
Spain: €611/QALY gained. 
 
Worst case AGB remains cost-saving, GBP breakeven in 
Austria, Both procedures breakeven in Italy, Both cost-
effective in Spain with accepted cost-effectiveness 
threshold of €30,000/QALY gained. 
Ikramuddin 2009, (2007 USD). 
Study population: RYGBP Mean BMI 
48.4 and DM. 
 
3% Base case input: cost of initial surgery and follow-up: 
$24,289. Major reoperation (early) $38,960, moderate 
reoperation (early) $23,851, major reoperation (late) 
$42,896, moderate reoperation (late) $14,736, any 
complicated weighted average $14,663. 
Base case: $29,676/life-year 
gained. 
Base case: $21,973/QALY gained. Reduced effects on A1C, exclusion of lipid effects, 
lower and higher DR (0 and 6%) and lower costs of 
treatment. ICERs remained under $50,000/QALY gained 
WTP threshold in most cases. Only when time horizon 
greatly reduced and QoL impact of increased BMI was 
excluded ICERs exceeded the threshold. 
Keating 2009 (2006 AUD). 
Study population: RCT LAGB and CT 
BMI ˃ 30 - < 40 recently diagnosed 
T2DM. 
NA Mean cost per patient over trial period: Cost of LAGB 
surgery (private hospital): $8,527. Mitigation of 
surgical complications (lap-band removal, revisions, 
port infection) $866. 
AUD$16,000/additional case of 
T2DM remitted. 
USD$11,840/additional case of 
T2DM remitted. 
NA No. 
Keating 2009, Australia, (2006 AUD). 
Study population:  
LAGB with CT BMI ˃ 30 - < 40 
recently diagnosed T2DM. 
3% Cost of the procedure based on Keating 2009 within 
trial costs. Complications unit cost: gastric prolapse 
$5,758; band erosion $14,691; port infection $2,695; 
band removal $5,134. 
Cost/life-year gained 
Dominant 
Cost/QALY gained 
Dominant 
Worst-case scenarios for the intervention effect and the 
annual cost of treating T2DM shifted the economic 
status of surgical therapy from dominant to cost-effective 
$39,700/QALY gained and $13,400/QALY gained 
respectively. 
Hoerger 2010, United States, (2005 
USD). 
Study population: LAGB and GBP to 
CT severely obese with newly 
diagnosed DM and severely obese 
with established DM. 
3% Surgery and first year of costs: GBP $23,871 ($6,612 – 
$55,261); LAGB $15,169 ($2,857 – $30,186). 
NA Patients with newly established 
diabetes: 
GBP $7,000/QALY gained;  
LAGB: $11,000/QALY gained 
 
Patients with established diabetes: 
GBP: $12,000/QALY gained; 
LAGB: $13,000/QALY gained. 
Varying surgery costs had a larger impact on GBP than 
the LAGB ICERs. Varying follow-up costs had a bigger 
impact on the LAGB than GBP cost-effectiveness ratios. 
Varying change in BMI from surgery had very little 
effect but varying the direct QoL improvement per unit 
of BMI loss from 0.017 to 0 had the biggest impact on 
cost-effectiveness ratios. All cost-effectiveness ratios 
were <$40,000/QALY. 
Pollock 2013, United Kingdom, (2010 
BPD). 
Study population: 
LAGB severely obese with DM for 
mean 1 year SD standard deviation 4 
months. 
3.5% Total mean (standard deviation) direct costs of LAGB 
surgery base case including inpatient, outpatient, costs 
of complications, revision and reversal: ₤23,562 
(₤22,754 – ₤24,496). 
NA ₤3,602/QALY gained.  One-way sensitivity analyses DR 0 and 6%, time 
horizon, unit costs, HbA1c, SBP and BMI benefits base 
case was broadly insensitive. Worst case scenario 
revealed a mean outcome that would not be considered 
cost-effective at WTP threshold of ₤20,000/QALY 
Worst case revealed ₤36,377/QALY gained. Conversely 
best case revealed dominance. 
Borisenko 2015, Sweden, (2012 
EURO). 
Study pop: 16 cohorts of 41 year old 
non-smoking males and females with 
BMI group and T2DM. Results on 
other severe obesity multiple cohorts 
also considered. 
3% Cost of bariatric surgery without complications €4,915 
(39 – 5,898); cost of bariatric surgery with 
complications €5,766 (4,613 – 6,919).  
NA Bariatric surgery is cost saving in 
all 4 pre-specified diabetic cohorts 
(moderately, severely, morbidly and 
super-obese).  
One-way sensitivity analysis for all cohorts showed that 
four parameters can affect the cost saving effect of 
surgery (1) the magnitude of the effect of surgery, (2) 
start age (better to operate patients when they are 
younger), (3) BMI (better to operate when BMI is 
lower), and (4) inclusion of an annual visit to a surgeon 
during the follow-up program from year three and 
onwards. Change of cost variables with 50 % variations 
did not influence the cost saving effect of surgery. The 
most sensitive parameter from cost variables was the 
annual cost of type 2 diabetes. 
Key: AGB, adjustable gastric band; British Pound, BPD; DM, diabetes mellitus; DR, discount rate; EURO, Euro; GBP, gastric bypass; ICER, incremental cost-effectiveness ratio; LAGB, laparoscopic adjustable gastric band; LRYGBP, laparoscopic Roux-en-Y 
gastric bypass; LSG, laparoscopic sleeve gastrectomy; QALY, quality-adjusted life-years; RYGBP, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; T2DM, type 2 diabetes mellitus; WTP, willingness to pay  
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Table 3B: Characteristics of cost-effectiveness and cost-utility studies that investigated people with severe/super-obesity who underwent bariatric surgery versus conventional treatment 
Reference/currency 
study population 
DR Cost of the procedure Economic metric (cost-
effectiveness studies – base 
case) 
Economic metric (cost-utility 
studies base case) 
Sensitivity analyses 
Campbell 2010, United States, (2006 
USD). 
Study population: 
BMI  40 kg/m² and  BMI  35 kg/m² 
with comorbidities who underwent 
LAGB and LRYGBP versus no 
treatment. 
3% Cost of initial surgery and follow-up  
LAGB $15,465; LRYGB $23,157. Cost of early and 
late major and minor reoperations for both procedures 
range $426 to $41,708. 
Aggregate patient population age 
40 yrs: LAGB $9,300/life years 
saved; LRYGB $10,200/life 
years saved 
Super-obesity BMI >50 kg/m²: 
female both LAGB and LRYGB 
dominating; male LAGB 
$600/life-years saved; LRYGB 
$1,700/life-years saved. 
Aggregate patient population age 
40 yrs: LAGB $5,400/QALY 
gained; LRYGB $5,600/QALY 
gained 
Super-obesity BMI >50 kg/m²: 
female both LAGB and LRYGB 
dominating;  
male LAGB $400/QALY gained;  
LRYGB $1,100/QALY gained. 
Alternative sources of efficacy estimates, patients 
assumed to regain half their cumulative BMI lost after 5 
years over the following 5 year period. Multiple one way 
sensitivity analyses then conducted to changes in 
efficacy, rates of adverse events and costs. Overall 
parameter uncertainty tested with regard to treatment 
efficacy, rates of complications, costs and utilities. 
Results robust to reasonable variation in model 
parameters. 
 
McEwen 2010, United States, USD. 
Study population: 
Mean BMI 51 kg/m² with co-
morbidities LRYGBP and ORYGBP 
3% Average cost for LRYGBP $10393; average cost for 
ORYGBP $11,705. 
NA 2 year time horizon $48,622/QALY 
gained; lifetime time horizon 
$1,425/QALY gained. 
Sensitivity analysis for age, sex, race, pre-surgical BMI, 
diabetes status and type of surgical procedure. Bariatric 
surgery was cost-effective under most scenarios, but less 
cost-effective in men, white patients, less obese patients, 
and when performed as an open procedure. 
 
Chang 2011, United States, (2010 
USD). 
Study population: severely obese with 
obesity related diseases and without 
obesity related diseases who 
underwent bariatric surgery. 
3% Average cost of bariatric surgery $26,315. Cost of 
surgical complications $1,083, cost of early 
reoperation $30,074, cost of perioperative death 
$46,782. 
Obesity related diseases for BMI 
35 - 40 kg/m²: $6,468/life-year 
saved; without obesity related 
disease for BMI 35 - 40 kg/m² 
$13,249/life-year saved. 
 
Obesity related diseases for BMI 
35-40 kg/m²: $2,413/QALY gained; 
without obesity related disease for 
BMI 35-40 kg/m² $3,872/QALY 
gained. 
 
Obesity related diseases for BMI  
50 kg/m² cost-saving; without 
obesity related disease for BMI  
50 kg/m² $1,904/QALY gained. 
Direct medical costs for the base-case were derived from 
one published study. Varying the cost data with data 
from other published studies yielded changes from base-
case. This sensitivity analyses was only reported for 
people with obesity-related comorbidities. Cost data 
from one study revealed cost-saving for all incremental 
cost-effectiveness ratios. Cost data from another study 
revealed similar results for BMI 35-40 kg/m² and higher 
pre-surgery BMIs revealed cost-saving. 
Maklin 2011, Finland, (2010 EURO). 
Study population: 
BMI at baseline 47 kg/m² (range: 38-
59 kg/m²), age 43 years, men 35% 
(range 9-50), LAGB (2%), GBP 
(68%), SG(30%). 
 
3% Average costs of procedures: gastric bypass €14,672; 
SG €14,752; LAGB €13,210.  
 
 
NA All surgical procedures showed 
strong dominance. 
Surgery remained dominant when the parameter values 
for mortality, probability for reoperation, 
abdominoplasty or co-morbidities, EWL or weight gain 
after surgery were varied. Increasing the costs of surgery 
did not remove the dominance. Worst case scenario was 
evaluated using the most pessimistic parameter values on 
effectiveness and costs of bariatric surgery. Dominance 
was also not removed in the worst case scenario. Only 
variation in BMI at baseline seemed to have an effect on 
results. Strong dominance of bariatric surgery if BMI set 
at 38 kg/m². 
Michaud 2012, United States, (2010 
USD). 
Study population: 
a) current eligibility: BMI > 40 kg/m², 
or BMI 35-40 with qualifying 
comorbidties; and 
(b) extended eligibility: BMI > 35 
kg/m² and BMI 30-35 kg/m² with 
qualifying comorbidities 
RYGBP. 
3% Bariatric surgery (focus on RYGBP) total economic 
cost which includes treatment cost, additional medical 
expenditures, deadweight loss minus additional 
earnings: $12,666. 
Current eligibility: $8,171/life 
years gained. 
 
Extended eligibility: 
$10,579/life-years gained. 
 
 
NA For the current eligibility population variation in the 
effectiveness of bariatric surgery, lowering effectiveness 
by 10% cuts life expectancy gains by 0.55 years and 
cost/life years increases $16,405/life-years. Changing the 
assumption of permanent weight loss to 50% weight 
regain cost-effectiveness remains low $12,318/life-year. 
The results for bariatric surgery appear to be robust to 
variation in the effectiveness of treatment. 
Faria 2013, Global/Portugal, EURO 
Study population: 
severely obese with obesity-related 
diseases and without obesity-related 
3% Expected cost LAGB €41,056 and GBP €29,254. NA Compared with the best medical 
management , in the global 
population of patients with a 
BMI35 kg/m², GBP renders 1.9 
Stratified for patient subgroups based on age, BMI, 
T2DM and absence of co-morbidities. Younger patients 
<40 years cost saving. T2DM dominance of GBP. 
Patients with the most benefit are those in the 
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diseases. extra QALYs and saves on average 
€13,244 per patient 
intermediate weight group BMI 40 50 kg/m². Patients 
with BMI 30-35 kg/m² GBP cost effective 
€13,071/QALY gained. For the global population GBP is 
cost-saving from 8 years onwards. 
Lee, 2013 , Australia, (2003 AUD). 
Study population: 
LAGB. BMI˃35 kg/m² and BMI ˃40 
kg/m². 
3% Cost of initial LAGB surgery cost/person $11,290. BMI ˃40 kg/m² dominant 
(95%CI: dominant – $588). 
BMI˃35 kg/m² $2,154/DALY 
averted (95%CI: dominant - 
$6,033). 
NA Altered DR to 0 and 6 %. Increased annual probability for 
each complication by order of one magnitude. Tested the 
stable weight loss assumption. Uncertainty analyses to 
assess the level of parameter uncertainty. The largest 
observed changes to base case analyses occurred after 
excluding cost offsets; and increasing the rates of 
maintenance and complication by order of magnitude 
results still fell below the WTP threshold $50,000/DALY. 
Song 2013, South Korea,  
(2011 USD). 
Study population: 
Asian population severely obese 30 - 
<40 kg/m² in South Korea. 
5% Cost of initial procedure: LAGB $7,042; LRYGB 
$13,000 and LSG $9,511. 
NA $1,771/QALY gained Sensitivity analyses altered discount rates (0% and 3%), 
costs (two-way), utility weights, time horizon. Bariatric 
surgery was dominant with 0% and 3% discount rates 
however when time horizon reduced by 15 years showed 
the largest change to $17,639/QALY gained.  
Wang 2013, United States, USD. 
Study population: 
Average individual undergoing 
bariatric surgery 53 year old female 
BMI 44 kg/m². 
 
 
3% Total cost < 31 days: LRYGBP $16,691; ORYGBP 
$20,675: LAGB $14,159 
NA LRYGBP $6,000/QALY gained;  
ORYGBP $17,300/QALY gained; 
LAGB $6,200/QALY gained. 
Results were sensitive to alternative weight change 
scenarios. For full weight regain 15 years after the 
procedure LRYGBP $24,100/QALY gained; ORYGBP 
$59,500/QALY gained; LAGB $26,700/QALY gained. 
One way sensitivity analysis showed that parameters 
with the largest impact were BMI at baseline, age at the 
time of procedure and gender. ICERs higher with men. 
LAGB cost-saving at baseline BMI of 54 and above. The 
ICER estimates for bariatric surgery appear to be cost-
effective under most modelled scenarios 
Castilla 2014, Spain, (2012 EURO). 
Study population: 
Average BMI 50.7 kg/m² (range: 36.6 
– 76.3) 
 
3% Cost of GBP €8,240. 
 
 Dominates Analysis of covariance showed that T2DM-related 
parameters account for most of the variability in 
incremental cost (approximately 25%). Only the 
variability of the base utility associated with the lowest 
BMI had a noteworthy impact on the variability of the 
incremental effectiveness of the intervention (8%). 
Results at different time horizons 5 years: dominates; 10 
years €4,045/QALY gained; 15 years €90/QALY gained; 
20 year dominates. 
Key: AGB, adjustable gastric band; BPD, British Pound; DM, diabetes mellitus; DR, discount rate; EURO, Euro; GBP, gastric bypass; ICER, incremental cost-effectiveness ratio; LAGB, laparoscopic adjustable gastric band; LRYGBP, laparoscopic Roux-en-Y 
gastric bypass; LSG, laparoscopic sleeve gastrectomy; QALY, quality-adjusted life-years; RYGBP, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; T2DM, type 2 diabetes mellitus; WTP, willingness to pay 
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Table 4: Generally accepted cost effectiveness (willingness to pay) thresholds for United States, United Kingdom, Sweden, Canada and Australia. 
Country Cost-effectiveness threshold  Comment 
United States 
(USD) 
 
$50,000 - $100,000/QALY 
gained  
The United States has legislated against the explicit use of cost-QALY thresholds. 
Recent evidence suggests that if one had to select a single threshold outside the context 
of an explicit resource constraint or opportunity cost, use either $100,000 or $150,000.  
United Kingdom 
(BPD) 
 
₤20,000/QALY gained 
and 
₤20,000 – ₤30,000/QALY gained 
The National Institute for Health and Care Excellence has never identified an 
incremental cost-effectiveness ratio above which interventions should not be 
recommended and below which they should. However, in general, interventions with an 
incremental cost-effectiveness ratio of less than £20,000 per QALY gained are 
considered to be cost effective. As the incremental cost-effectiveness ratio of an 
intervention increases in the £20,000 to £30,000 range, an advisory body's judgment 
about its acceptability as an effective use of National Health Service resources should 
make explicit reference to relevant factors outlined by the Institute. 
Sweden 
(EURO) 
 
€57,000/QALY gained  Relevant government authorities have suggested a threshold of SEK 500,000 
(approximately €57,000). 
Canada 
(CAD) 
 
$20,000 – $100,000/QALY 
gained  
$124,000/QALY gained  
Health-care programmes, which cost less than US$12,800 (CAN$20,000) per QALY are 
highly cost effective, but weak if the ratio exceeds US$64,000 (CAN$100,000).  
Australia 
(AUD) 
 
 
$50,000/QALY gained  
Pharmaceutical Benefits Advisory Committee was unlikely to recommend a drug for 
listing if the incremental cost-effectiveness ratio (cost per life-year) exceeded AUD 
$76,000. 
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2.4 Discussion 
This comprehensive systematic review synthesized disparate studies that investigated 
important health economic aspects of bariatric surgery as a treatment option for obesity. As an 
important advance on existing systematic reviews, our review included substantially more 
studies across the depth and breadth of the health economics literature than previous systematic 
reviews. We did not limit our review to full economic evaluations (cost-effectiveness and cost-
utility studies). Despite the considerable heterogeneity of included studies and conflicting 
results from some individual studies for study populations such as T2DM, we found that 
common themes emerged. These themes included: bariatric surgery was generally considered 
cost-effective versus non-surgical interventions as a treatment option for people with morbid 
obesity; bariatric surgery was highly cost-effective and possibly cost-saving for severely obese 
patients with T2DM (mostly from observational and pre and post studies); only a limited 
spectrum of direct medical costs was considered in the majority of studies; disparate time 
horizons and cost information/data sources have been used; a wide range of methodological 
quality was an issue; a lack of consideration of the costs of many important longer term post-
operative events like reoperations, complications and body contouring surgery; major gaps 
regarding the cost-effectiveness of bariatric surgery in particular target populations such as 
obese adolescents and men; and a paucity of information on indirect costs such as out-of-pocket 
expenses to patients and their families, work productivity gains and/or losses, and the impact 
of being waitlisted for 3 years on clinical and economic outcomes and the potential impact on 
patient prioritization decisions coupled with the concept of affordability of bariatric surgery, 
and the disproportionate increase in severe obesity where demand for bariatric surgery was 
continually exceeding the increase in supply. 
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2.4.1 Type 2 diabetes mellitus 
A key finding of our systematic review was that bariatric surgery for the severely obese with 
T2DM was mostly cost-effective (mainly from observational and pre-post studies). 
Another theme that emerged was that bariatric surgery as a treatment option for newly 
diagnosed T2DM was more cost-effective (or cost-saving) than for those with established 
comorbidity [65, 66, 68, 106]. A cost-effectiveness study based on small single-centred RCT 
data made the point that their results actually underestimated the cost-effectiveness of surgical 
therapy because they did not attempt to capture healthcare savings associated with the reduction 
of other obesity related morbidities or the improvements of quality of life associated with 
weight loss [65]. 
Contemporary debate about bariatric surgery as a treatment option for obesity is focused on the 
prioritization of particular patient groups where there are demonstrated clinical and economic 
benefits. A recent editorial argued that the indications for bariatric surgery should be viewed 
in terms of individual patient benefit without anticipating that there would be cost savings to a 
healthcare system by offering this treatment and that bariatric surgery clearly benefits some 
patients [27]. Patients considered for bariatric surgery should have a complication of obesity 
that is known to dramatically improve with weight loss surgery [27]. Examples include diabetes 
and osteoarthritis [27]. Nevertheless, we argue that policy and decision makers are increasingly 
asking not only whether an intervention works, but also whether it offers value for money 
[128]. More specifically, is the intervention cost-effective or even cost-saving. Bariatric 
surgery was identified as being highly cost-effective or even cost-saving for the severely obese 
with T2DM in the majority of studies. Bariatric surgery in early T2DM was found to be cost-
saving, indicating that diversion of scarce healthcare resources should be considered for 
bariatric surgery for severely obese with T2DM. 
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Importantly, our review also highlighted the conflicting results of two recent studies that were 
informed by Swedish Obese Subjects study Swedish and Scandinavian clinical and cost data. 
The first study [24] modelled lifetime cost-utility analysis from the Swedish health payer 
perspective and revealed that bariatric surgery was cost-saving in all of the pre-specified 
diabetic cohorts (moderately, severely, morbidly and super-obese). In contrast, the second 
study (informed by long-term Swedish Obese Subjects data and cost data from Swedish 
sources) found no difference between the surgical and conventional treatment groups for 
patients with diabetes [106]. We also explored the cost-effectiveness results for all full 
economic evaluations of people with T2DM from 2009–2015. All of these studies found that 
bariatric surgery was cost-effective for severely obese people with T2DM. Additionally, 
sensitivity analyses found that the results were robust to changes in model parameters. 
Accordingly, we argue that health economics studies that investigate bariatric surgery as a 
treatment option for people with T2DM should adopt full (rather than partial) economic 
evaluation underpinned by longer time horizons and be undertaken from a societal perspective. 
Furthermore, health economics effort should focus on bariatric surgery as a treatment option 
for people with T2DM with a BMI 30–34.9 kg/m2 (non-severely obese). 
2.4.2 Body contouring/bariplastic surgery 
Our review has identified a major gap in the health economics reporting of bariatric surgery 
where body contouring/bariplastic surgery is a significant longer-term cost for many patients 
who experience massive weight loss after the intervention. This emerging and additional 
burden to the individual and/or society was not appropriately captured in the health economics 
reporting. 
Patients requiring body contouring surgery after bariatric surgery have been described as a new 
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and unique population that is difficult to manage, with 96% of post-bariatric surgery patients 
developing multiple redundant skin flaps [129]. An unfortunate consequence of massive weight 
loss is the persistence of large quantities of excess and often inelastic skin and subcutaneous 
tissue. These produce a hindrance to mobility, poor cosmesis, difficulties with wound healing, 
intertrigious dermatitis, compromised hygiene and potentially worsened overall patient body 
image despite weight loss [130]. Body contouring surgery that includes, but is not limited to, 
panniculectomy, (circumferential) abdominoplasty, breast reduction or lift, brachioplasty, and 
thigh lift serves to remove this excess tissue that remains after massive weight loss. Following 
body contouring surgery, significant improvements in self-image and quality of life, as well as 
hygiene, mobility and overall daily functioning have been reported [130]. 
Our review found that only 14% of included studies considered the costs of body 
contouring/bariplastic surgery in their analyses. Body contouring surgery as a follow-up 
procedure was first identified in this review's included studies over a decade ago. A 2002 study 
investigated the costs of in-patient care over 7 years among surgically and conventionally 
treated obese patients and concluded that a substantial fraction of the total hospital cost for 
surgical treatment of obesity emerged during the years after surgery [114]. Complications and 
sequelae of bariatric surgery cause some of these costs, but a substantial share is because of 
secondary plastic surgery [114]. A recent study from the UK, which reviewed funding models 
and access for bariplastic surgery, highlighted that there was very little in the literature on the 
prevalence of bariplastic surgery after bariatric surgery [121]. The only available and recent 
evidence based on a survey of 100 patients who had completed post-bariatric body contouring 
surgery in the Spanish public health system found that the cost of post-bariatric surgery body 
contouring treatment in a public health system unit was €8,264 (1.66 operations per patient) 
and that severe complications increase the average cost per patient 2.96 times [129]. 
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Importantly, the study indicated that it provided conservative estimates (public health system 
costs) and the rate of complications was high (up to 50%), and that although the more severe 
complications are rare, these represent high costs (mean €24,463). Surveyed patients also 
undervalued the surgery's total costs (by 17.58% or €2,034). These costs are substantially 
higher than cost estimates currently included in cost-effectiveness and/or cost-utility studies 
that provided estimates based on abdominoplasty only (e.g. €2,604) [24]. 
Additionally, an enormous disparity exists between the number of people who desire a body 
contouring surgery and those who actually received it. Two recent studies noted that a majority 
of post-bariatric surgery patients desire body contouring surgery, particularly in certain body 
areas such as waist/abdomen, upper arms, and chest/breast. Financial resources and coverage 
from third-party payers may be an underlying cause for the discrepancy [122, 131]. From the 
literature, it was ascertained that bariatric surgery patients will opt to pay for body contouring 
surgery years after the initial procedure. Although many persons who have had a bariatric 
procedure will elect to have excess skin removed at a later date (at their own cost) after reaching 
a targeted weight, one study found that no such procedures occurred during the 2-year study 
period [55]. The most recent evidence suggests that body contouring surgery is the final stage 
of the massive weight loss patient's journey and that the obese patient's journey is not complete 
until redundant tissue is removed [132]. This study also found that around 70% of massive 
weight loss patients are left with redundant folds of tissue that impact on their quality of life 
and that these folds are heavy and cumbersome, and present functional and aesthetic problems. 
The surgical interventions to address these issues are much more complex than abdominoplasty 
and include procedures such as total body lift, upper or lower body lift, brachial lift, contouring 
of the trunk and medial thigh lift. [132]. 
Our review recommends that the longer term costs of massive weight loss (quality of life issues 
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regarding redundant skin flaps and/or a desire for body contouring surgery) and the actual cost 
of body contouring surgery (generally at the patient's own cost) should be properly considered 
in full economic evaluations of bariatric surgery. 
2.4.3 Waiting for surgery and relationship to patient prioritisation 
Our review found that of 77 included studies, only one study investigated the impact of time 
delay on the clinical and economic outcomes of bariatric surgery. This is a key knowledge gap 
in the health economic reporting of bariatric surgery and is inextricably linked to the policy 
concept of patient prioritization for bariatric surgery. Recent scholarly literature found that 
public sector waiting times are years in duration in some countries and that there are physical 
(worsening of comorbidities and further weight gain) and psychosocial impacts for patients 
waiting for bariatric surgery [133, 134]. 
Constrained public sector budgets are one part of a tremendously complex system-wide 
healthcare landscape that results in severely and super-obese bariatric surgery candidates (with 
significant obesity-related comorbidities) experiencing multiyear wait times. A key reason for 
these multiyear wait times is the disproportionate rate of increase in severe obesity. To 
illustrate, a recent study identified that the National Health Service provision of bariatric 
surgery in the UK is ‘dwarfed by the rising tide of morbid obesity’ [135]. The study found that 
the number of National Health Service operations has ‘soared’ with a rise of over 300% from 
2006-2007 to 2010-2011. Similarly, a recent Canadian study found that severe obesity has 
increased in prevalence by 400% (from 1 % to 4.3%) over two decades and is rising at a 
disproportionally faster rate than obesity. Additionally, the study indicated that to try and meet 
this increased demand, the number of publicly funded bariatric surgeries in Canada has 
increased 12-fold over two decades and that despite this trend, demand for surgery greatly 
exceeds supply [136]. The experience in the UK and Canada suggests that governments are 
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increasingly funding bariatric surgery as a treatment option for people who meet clinical 
guidelines but that the increased demand for surgery is exceeding the increase in supply. It 
seems likely that funders' perceptions of ‘affordability’ are changing as bariatric surgery has 
increasingly become accepted as more than a cosmetic procedure and as the scale of the 
epidemic of severe obesity has become clearer. 
As mentioned previously, a recent critique suggested that the indications for bariatric surgery 
should be viewed in terms of the individual patient benefit without anticipating that there will 
be cost savings to a healthcare system by offering this treatment. Nevertheless, further studies 
of affordability of bariatric surgery are warranted. Additionally, full economic evaluation of 
bariatric surgery as a treatment option could particularly investigate subgroups of patients that 
are languishing on public sector waiting lists for bariatric surgery such as patients with T2DM, 
CVD and/or severely or super obese. 
2.4.4 Inclusion of complications and reoperations 
Our review found that one-third of the included studies either ignored the costs and/or 
consequences of complications and reoperations, studies that accounted for reoperations and 
complications generally only accounted for short-term events, considered an incomplete list of 
complications or assumed relatively low probabilities of any of these the adverse events 
occurring. Additionally, many studies did not assume weight regain as an adverse event. 
Longer-term costs of bariatric surgery have therefore probably been underestimated, and the 
value for money for bariatric surgery subsequently overestimated. 
A recent systematic review and meta-analysis concluded that overall complication rates 
associated with bariatric surgery range from 10% to 17% and reoperation rates approximately 
7% [137]. Other studies claim that these complication rates are much higher (up to 33%) and 
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that the rates of longer term complications are largely unknown because many patients present 
to non-specialist bariatric centres (rather than the short term complications that generally refer 
to the specialist surgeon) [138]. A study that explored the rates of complications and ‘what a 
general surgeon needs to know’ suggested that band erosion can occur early or years after 
surgery and in some series the reported incidence rate (when it is reported to a specialist centre) 
is up to 33% [138]. Another recent study on the costs of the major complications of leaks and 
bleeding following sleeve gastrectomy found that median additional costs for leaks were 
€9,284 (range €1,748–125,684) and €4,267 (range €1,524–40,022) for bleeding (2014 EURO) 
[139]. 
Clearly, complications and reoperations after the primary procedure are not uncommon, and 
the ongoing costs are potentially substantial. This is not appropriately reflected in many health 
economics analyses to date. Nevertheless, it is recognized that the issue of under reporting of 
complications and reoperations is a multidisciplinary problem. A recent Cochrane review 
concluded that assessing the risks of different bariatric procedures is still hampered by a lack 
of consistency and quality of evidence in the reporting of adverse outcomes and reoperation 
rates and that most studies followed participants for only 1 or 2 years; therefore, the long-term 
effects of surgery remain unclear [140]. 
The Cochrane review suggested that a core set of important adverse outcomes should be 
identified so that a standardized approach to reporting adverse outcomes can be developed 
[140]. Recently released standardized outcomes reporting clinical guidelines for metabolic and 
bariatric surgery partially addressed these issues from a clinical perspective [141]. We 
recommend that a consistent approach should also be adopted in all health economics reporting 
of bariatric surgery to ensure that relevant events are appropriately and consistently accounted 
for. 
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2.4.5 Health economics perspective, and reported costs and cost-effectiveness 
A key finding of our review was that few studies were informed by the societal perspective. 
The actual resources included and unit costs employed in an analysis depend on its perspective 
[142]. In taking a societal perspective, one seeks to count all costs and benefits of medical 
interventions regardless of to whom they accrue [143]. In turn, the adoption of a narrow 
perspective in most health economics reporting of bariatric surgery with in-patients costs 
and/or a subset of outpatients costs such as clinic follow-up or laboratory testing only included 
directly translates to significant costs/cost offsets not being considered. Specifically, there is a 
paucity of identified out-of-pocket costs, costs to family members and other sectors (such as 
work force participation/productivity, absenteeism and presenteeism). Our review's included 
studies that employed a societal perspective were informed by a limited spectrum of these 
societal costs and/or benefits (such as productivity impacts or time-related costs); nevertheless, 
these studies found that the inclusion of these costs/cost offsets impacted on the results of the 
study. 
Further, a recent health economics study argues that ignoring important costs and benefits in 
an economic evaluation will lead to an inefficient allocation of resources, in the short-term as 
well as the long-term perspective [144]. Another study makes the fundamental point that the 
economic burden of obesity is such that society incurs substantial indirect costs including years 
of disability, increased mortality before retirement, early retirement, disability pensions, and 
work absenteeism or reduced productivity. The study also suggests that the monetary value of 
lost productivity is several times larger than medical costs [145]. Thus, there is limited 
information available to policy makers and/or funders within public health systems to make 
fully informed decisions from a broader societal perspective as is appropriate given the wide-
ranging impacts of obesity on society. 
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Another key finding of our review is that reported costs were very heterogeneous because the 
included studies' cost structures were largely informed by differing health economics 
perspective, time horizon and information sources. Similarly, there is a major knowledge gap 
in the assessment of costs of waiting for surgery. This narrow focus could be partly attributed 
to available data. Many studies relied on retrospective observational data from either large 
administrative databases such as healthcare plans or insurance data or single site administrative 
data such as hospital data. Measurement and valuation of identified costs also varies 
significantly across studies. To illustrate, some studies adopt broad average costs, other studies 
micro cost each input (for example each laboratory test and surgeons' time in the operating 
theatre). Costs are valued in different years and currencies and over different time horizons. 
Many studies inflate or deflate cost valuations to a base year, but some studies do not. 
The way in which available resources are allocated against competing priorities is crucial in 
affecting how much health is generated overall and who receives healthcare interventions and 
who goes without. Cost-effectiveness analysis is a tool that can assist policy makers with 
resource allocation [146]. Nevertheless, caution needs to be exercised when comparing results 
of cost-effectiveness studies given variation in methodology such as perspective, time horizon, 
HRQoL instruments employed and the discount rates used [82]. We compared cost-
effectiveness results with common outcomes and found that bariatric surgery was generally 
cost-effective and reported incremental cost effectiveness ratios less than the jurisdiction's 
willingness to pay thresholds irrespective of variations in methodology. Sensitivity analyses 
also showed that the bariatric surgery was cost-effective when varying changes in key 
assumptions such as BMI, age, time horizon and discount rate. Costs were also varied in 
sensitivity analyses; however, these studies largely only included direct medical costs, while 
costs of complications, reoperations and body contouring surgery were either substantially 
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understated or ignored. One study's sensitivity analyses revealed that substantial changes in 
cost estimates had a major effect on the ICER value. 
The choice of cost-effectiveness threshold is crucial in determining the value of healthcare 
interventions [110]. International willingness to pay thresholds vary as described in Table 4, 
and we acknowledge that there is ongoing debate in health economics about setting thresholds 
(e.g. using the World Health Organization-recommended cost-effectiveness thresholds of 1–3 
GDP per capita versus cost-effectiveness thresholds reflecting opportunity costs). A recent 
study has suggested that rather than settling on a single threshold, it would be preferable to use 
multiple thresholds, ideally ones based on the available resources for the relevant decision 
maker and possible alternative uses of those resources. For example, decision makers in 
resource-poor settings would have a lower willingness to pay threshold [108]. 
Another key finding of our systematic review is that while many studies have addressed cost-
effectiveness, no studies addressed the issue of affordability. As mentioned previously, it seems 
likely that funders' perceptions of ‘affordability’ have begun to change. We recommend that 
full economic evaluations of bariatric surgery not only consider a jurisdiction's willingness to 
pay, but also consider the results within the context of affordability under constrained 
government budgets. 
A recent systematic review that investigated the costs of obesity described the disparate cost 
methodologies as comparing ‘apples and oranges’ and concludes that decision makers need to 
be aware of the different purposes and weaknesses of studies when interpreting cost outcomes 
[147]. Our review on the health economics reporting of bariatric surgery found considerable 
heterogeneity in reporting of costs for bariatric surgery. We therefore recommend thorough 
investigation and reporting of costs against a standardized framework such as the CHEERS 
checklist. We also recommend robust full economic analyses underpinned by a broad societal 
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perspective and long-term time horizon. 
2.4.6 Methodological quality 
With the increasing number of publications available, transparency and clarity in reporting are 
important factors when reviewing the health economics literature [36]. Our review identified a 
wide range of methodological quality of included studies. We also identified that 
methodological quality has improved over time. To continue the trend in improved 
methodological quality, we recommend that the CHEERS statement is followed in future health 
economics assessments of bariatric surgery in order to further improve the quality of design, 
analysis and reporting. 
2.4.7 Strengths and limitations 
The key strength of our study was the comprehensive analysis of a disparate range of studies 
that report on health economics outcomes for bariatric surgery. We have systematically 
categorized, summarized, synthesized and analysed 77 studies. Our study aimed to provide a 
critical analysis of the key themes and evidence gaps in the existing scholarly literature. 
Heterogeneity of the literature was also a weakness; nevertheless, we did not seek to capture 
homogenous studies for meta-analysis to inform a further cost-effectiveness study. As an 
important alternative to inform the existing literature, we aimed to adopt a broader approach to 
our systematic review with a view to identifying common themes and key evidence gaps across 
the depth and breadth of the health economics literature. 
2.5  Conclusions 
Our comprehensive systematic review found that health economics reporting of bariatric 
surgery was characterised by heterogeneous approaches. Other key findings included a 
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deficiency in reporting of important cost factors (because of the dominance of the healthcare 
system/third-party payer perspective, data sources and time horizons) and key complications 
and ongoing surgical costs (such as revisions, reversals and remedial body contouring surgery) 
in many studies. Bariatric surgery in particular subgroups of patients may be considerered to 
be cost-effective (and in some cases cost saving) such as severely obese and/or newly 
diagnosed T2DM. 
Subgroups of patients that warrant further health economic investigation were identified, in 
particular adolescents, long-term waitlisted patients (particularly severely obese with T2DM) 
and severely obese men (generally a higher comorbidity load). 
Therefore, we conclude that health economists investigating bariatric surgery should strive to 
undertake full economic evaluations that would rate at the highest levels for methodological 
quality against the CHEERS statement, underpinned by a societal perspective and broad life 
course costs and consequences. Only through such a robust approach will accurate measures 
of cost-effectiveness be established, and more reliable and targeted decision-making be 
implemented. Further, thorough investigation of costs and consequences will drive more 
accurate reporting of bariatric surgery complications and reoperations (including body 
contouring surgery). 
Evidence from economic evaluation is used in healthcare decision-making if the evidence is 
accessible and acceptable [148]. Health economics reporting of bariatric surgery as a treatment 
option for obesity should serve to enhance clinical appraisal with robust and accessible health 
economic evidence. It is incumbent on the health economics community to educate decision 
and policy makers (who allocate scarce healthcare resources) about the different strengths and 
weaknesses of health economics reporting for bariatric surgery and to ensure that decisions are 
based upon the best quality and most relevant evidence available. 
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Contemporary debate about bariatric surgery as a treatment option for obesity is focused on the 
prioritization of particular patient groups for whom there are demonstrated clinical and 
economic benefits. There is also emerging debate on the impact of waiting times on patients' 
physical and psychosocial health, and their associated costs. The heterogeneity of the literature 
notwithstanding, on the basis of this review, there are clear signals to support the allocation of 
scarce resources to particular patients groups such as severely obese with T2DM. Health 
economists should also endeavour to investigate particular patient groups through robust full 
economic evaluation in order to provide more and better evidence in subgroups such as non-
severely obese with T2DM, severely obese adolescents that are emerging as potentially cost-
saving from a longer-term societal perspective and patients waiting long periods on public 
waiting lists for bariatric surgery. 
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Chapter 3: A head-to-head comparison of the EQ-5D-5L 
and AQoL-8D multi-attribute utility instruments in 
patients who have previously undergone bariatric surgery. 
Preface 
Chapter 3 presents the first head-to-head comparison of two different multi-attribute utility 
instruments, namely the AQoL-8D and EQ-5D-5L, for a cross-sectional study of patients who 
received bariatric surgery in the private healthcare system many years previously (median 
(inter-quartile range) time since surgery 5 (3-8) years).  
The systematic review in Chapter 2 found that the EQ-5D is the most commonly used multi-
attribute utility instrument in cost-utility analyses of bariatric surgery, however, the 
classification system of the EQ-5D focuses on physical health, and has been shown to be 
relatively insensitive to changes in the psychosocial domains of health. Nevertheless, 
psychosocial health is an important consideration for people with severe obesity who have 
undergone bariatric surgery. 
This study followed a systematic process in the selection of the two different multi-attribute 
utility instruments, supported by evidence-based rationale grounded in a comprehensive review 
and analysis of the multi-attribute utility instrument literature. The selection of the instruments 
was also discussed at formal meetings of the broader partnership project research team which 
comprised health economists, bariatric surgeons, allied-health clinicians, epidemiologists, 
government policy decision-makers and qualitative researchers.  
There were key methodological justifications for selecting the two instruments. These 
justifications included that a small number of instruments dominate the economic evaluation 
literature with 63% of peer reviewed studies using the EQ-5D, and bariatric surgery cost-utility 
studies are dominated by the EQ-5D (3L and 5L). Nevertheless, the descriptive system of the 
EQ-5D-5L and AQoL-8D differ significantly, particularly with regard to the psychosocial 
domains of health where the AQoL-8D was developed with psychometric principles and 
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subsequent testing. As a single multi-attribute utility instrument, the AQoL-8D captures the 
vast majority of domains of health considered crucial for people who are considering or who 
have undergone bariatric surgery. 
The published paper presented in this chapter found that psychosocial health is one of the key 
drivers for people who have undergone bariatric surgery and that the AQoL-8D preferentially 
captured and assessed psychosocial health for people who had received bariatric surgery many 
years previously. This paper also explored the international dominance of the EQ-5D in the 
clinical and economic evaluation literature and suggested that the choice of multi-attribute 
utility instrument should be influenced by the innate sensitivities of the instrument to the 
relevant domains of health for the particular study 
The findings from this study also guided the health-related quality of life studies contained in 
Chapters 4 and 5. These were longitudinal studies for long term publicly waitlisted patients 
who then received bariatric surgery. 
This chapter has been published in The Patient – Patient Centered Outcomes Research 
(Appendix 3A).  
Impact factor: 2.67. 
Campbell JA, Palmer AJ, Venn A, Sharman M, Otahal P, Neil A. A head-to-head comparison 
of the EQ-5D-5L and AQoL-8D multi-attribute utility instruments in patients who have 
previously undergone bariatric surgery The Patient – Patient Centered Outcomes Research. 
2016 Aug;9(4):311-22. doi: 10.1007/s40271-015-0157-5. 
The published article found at the 
end of this chapter has been 
removed for copyright reasons. 
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Abstract 
Background: Psychosocial health status is an important and dynamic outcome for bariatric/metabolic 
surgery patients, as acknowledged in recent international standardised outcomes reporting guidelines. 
Multi-attribute utility-instruments (MAUIs) capture and assess an individual’s health-related quality-
of-life (HRQoL) within a single valuation, their utility. Neither MAUIs nor utilities were discussed in 
the guidelines. Many MAUIs (e.g. EQ-5D) target physical health. Not so the AQoL-8D. 
Objectives: Our objective was to explore agreement between, and suitability of, the EQ-5D-5L and 
AQoL-8D for assessing health state utility, and to determine whether either MAUI could be 
preferentially recommended for metabolic/bariatric surgery patients. 
Methods: Utilities for post-surgical private-sector patients (n = 33) were assessed using both 
instruments and summary statistics expressed as mean [standard deviation (SD)] and median 
[interquartile range (IQR)]. Interchangeability of the MAUIs was assessed with Bland-Altman analysis. 
Discriminatory attributes were investigated through floor/ceiling effects and dimension-to-dimension 
comparisons. Spearman’s rank measured associations between the 
instruments’ utility values and with the body mass index (BMI). 
Results: Mean (SD) EQ-5D-5L utility value was 0.84 (0.15) and median 0.84 (IQR 0.75–1.00). Mean 
(SD) AQoL-8D utility value was 0.76 (0.17) and median 0.81 (IQR 0.63–0.88). Spearman’s rank was 
r = 0.68; (p\0.001); however, Bland–Altman analysis revealed fundamental differences. Neither 
instrument gave rise to floor effects. A ceiling effect was observed with the EQ-5D-5L, with 36 % of 
participants obtaining a utility value of 1.00 (perfect health). These same participants obtained a mean 
utility of 0.87 on the AQoL-8D, primarily driven by the mental-super-dimension score (0.52). 
Conclusions: The AQoL-8D preferentially captures psychosocial aspects of metabolic/bariatric surgery 
patients’ HRQoL. We recommend the AQoL-8D as a preferred MAUI for these patients given their 
complex physical/psychosocial needs. 
Key points for decision makers 
Psychosocial health status has been increasingly identified as an important health-related quality of life 
outcome measure for the morbidly obese population who receive bariatric surgery. 
Compared with the EQ-5D-5L, the AQoL-8D’s descriptive/classification system (and subsequent utility 
valuation) preferentially captures psychosocial health status for people who have received bariatric surgery. 
While the EQ-5D dominates the clinical and economic evaluation literature, choice of multi-attribute utility 
instrument should be influenced by the innate sensitivities of the instrument to the relevant domains of health 
for the study population. 
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3.1  Introduction 
Obesity is a worldwide problem. Its extensive health repercussions include a high prevalence 
of psychological comorbidities, and it also has substantial negative economic impacts [1]. 
Many clinical and epidemiological studies find the most efficacious therapy for morbid obesity 
is metabolic/bariatric surgery [2, 3]. A systematic review of the impact of bariatric surgery on 
health-related quality-oflife (HRQoL) found physical HRQoL was improved to a significantly 
greater degree than mental HRQoL [4]. Furthermore, the psychosocial health status of bariatric 
surgery patients is dynamic [5]. This recent study found an initial improvement in mental health 
followed by deterioration between 4 and 9 years post-surgery. Potential reasons for this 
diminution of HRQoL were postulated to include disappointment from unrealistic expectations 
about surgical treatment, unforseen changes in eating behaviour, medical sequelae after surgery, 
dissatisfaction with body appearance and excess skin, and the reoccurrence of psychiatric 
disorders [5, 6]. 
The need to assess the psychosocial health status of bariatric surgery patients in the short, 
medium and longer terms has been increasingly identified [4–7], and underpins the quality-of-
life component of recent guidelines on standardised outcomes reporting for bariatric surgery 
patients from the American Society for Metabolic and Bariatric Surgeons (ASMBS) [8, 9]. The 
guidelines made no specific recommendations regarding the most appropriate HRQoL 
instrument, the recommendation being only to use a ‘‘validated instrument(s)’’. Importantly, 
the measurement of psychosocial health or any domain of health is wholly dependent on the 
sensitivity of the instrument employed to assess that domain. 
Health state utility values (HSUVs), or utilities, are important health economic metrics that 
assess the strength of preference for an individual’s health state relative to perfect health and 
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death. Utilities are assessed relative to a 0.00–1.00 scale where 1.00 represents perfect health 
and 0.00 death [10]. The utility value therefore indicates the strength of preference for quality 
versus quantity of life [11], and quality-adjusted life-years (QALYs) can be calculated as the 
product of time spent in a health state and its utility. QALYs are a unit of benefit used in 
economic evaluation, namely cost-utility analysis (CUA) and, in principle, may be used to 
measure the HRQoL component of the burden of disease [10, 12]. Clinicians have also found 
that measuring health utilities is of benefit to patient– clinical assessment, relationships, 
communication and management [13]. Furthermore, utilities have been shown to be 
independent predictors of patient outcomes, including all-cause mortality and development of 
complications [14]. 
Multi-attribute utility instruments (MAUIs) are designed to rapidly and simply assess an 
individual’s HSUV through application of pre-established formulae/weights to the array of 
responses to the MAUI’s questions. Generic and disease-specific non-utility instruments may 
also be reduced to a single number; however, this number does not have independent meaning 
[10]. MAUIs thus differ fundamentally from generic HRQoL instruments. 
Many MAUIs target physical health. For example, four of the five items in the EQ-5D, a well 
utilised international measure, relate to physical health. In contrast, 25 of the 35 items in the 
recently developed Assessment of Quality of Life (AQoL)-8D relate to psychosocial health 
[12]. Utility values assessed by MAUIs are not equivalent [15, 16], with the difference between 
the descriptive/classification systems of the MAUIs the principal determinant [15]. Differences 
in descriptive/classification systems are estimated to explain an average of 66 % of the 
difference between utilities obtained by MAUIs, and 81 % of the difference between the 
utilities of the EQ-5D-5L and AQoL-8D [15]. MAUIs are thus ‘imprecisely related’, a finding 
that threatens the comparability of economic evaluations that employ different instruments [17]. 
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A small number of MAUIs dominate the economic evaluation literature [17]. A review of the 
Web of Science database (2005–2010) found that, of 1663 studies employing an MAUI, 63 % 
used the EQ-5D [15, 17]. Arguably, this finding reflects the recommendations of the UK 
National Institute for Health and Care Excellence (NICE) guidelines to use the EQ-5D as the 
preferred measure of HRQoL in adults [18]. These guidelines also acknowledge that the EQ-
5D ‘‘may not be an appropriate measure of health-related utility in all circumstances’’ [19]. 
Emerging research is investigating the concept of ‘bolt-on’ dimensions to the EQ-5D in an 
attempt to broaden the classification system of this instrument [20, 21]. 
To inform debate on the choice of instrument for a particular patient group, it is important to 
compare different preference-based measures of health [22]. In particular, it is necessary to 
consider the applicability of the descriptive/ classification systems. Our study investigated a 
‘head-to-head’ cross-sectional comparison of the EQ-5D-5L [23] and AQoL-8D [24] MAUIs 
for patients who have previously undergone bariatric surgery. The EQ-5D-5L and AQoL-8D 
have not been specifically validated for patients who have undergone bariatric surgery. This 
study explored agreement between, and suitability of, the AQoL-8D and EQ-5D-5L for 
assessing health state utility in patients who have received bariatric surgery to determine 
whether either instrument could be preferentially recommended in this study population. 
 
3.2  Methods 
3.2.1 Participants 
Participants were individuals who had previously received bariatric surgery [predominantly 
laparoscopic adjustable gastric band (LAGB)] in the private sector (n = 33) in Tasmania, 
Australia. Clinical and socio demographic data were obtained during recruitment for a focus 
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group designed to explore patient experiences following bariatric surgery. Participants were 
recruited with the aim of ensuring an appropriate mix of demographic/ clinical characteristics. 
Each participant was sent both MAUIs for self-completion at home 2 weeks before their focus 
group [13, 25]. All data were de-identified. Questionnaire responses were independently 
entered into a database by two authors and cross-checked before utilities were generated. Ethics 
approval was granted by the University of Tasmania’s Health and Medical and Social Sciences 
Human Research Ethics Committees 
3.2.2 Instruments 
The EQ-5D-5L [23] is a recent augmentation of the EQ- 5D-3L [26], and the AQoL-8D [27] 
is the latest in the suite of AQoL instruments (AQoL-4D/6D/7D/8D) [28]. Table 1 provides a 
detailed comparison of the characteristics of both instruments. The EQ-5D-5L was developed 
to address the limited sensitivity (lack of descriptive richness and serious ceiling effects [29]) 
of the EQ-5D-3L. The EQ-5D-5L includes two additional levels for each of the five dimensions 
in the EQ-5D [30]. Nevertheless, it has the second lowest number of health states of the major 
MAUIs at 55 (3125). The EQ-5D-3L has the lowest, at 243. The EQ-5D-5L retains an optional 
visual analogue scale (EQ-VAS) in which patients rate their current health state on a scale of 
0–100 (worst/best imaginable) [31]. 
The AQoL-8D is the fourth and most comprehensive of the AQoL suite of instruments, 
developed to achieve increased sensitivity in psychosocial dimensions of health, which was 
relatively neglected in other MAUIs, including earlier versions of the AQoL [10]. Both patient 
and public involvement were utilised during the construction of the AQoL-8D, a key element 
of robust MAUI development according to a recent systematic review by Stevens [33]. 
Psychometric principles were also employed during construction of the AQoL instruments, the 
only MAUIs to do so [32]. These key features of the AQoL-8D were not identified in the 
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Stevens [33] review. The AQoL-8D contains 35 questions and encompasses the largest number 
of health states of any existing MAUI (2.4 9 1023).  
3.2.3 Data analysis 
Baseline socio-demographic and clinical data are presented descriptively as mean [standard 
deviation (SD)] and/or median [interquartile range (IQR)] for continuous variables and 
frequency (%) for categorical variables. Body mass index (BMI) was calculated as weight 
(kg)/[height (m)]2.  
HSUVs were generated for the EQ-5D-5L using the UK ‘crosswalk’ value set with the EQ-
5D-5L version mapped (crosswalked) onto the 3L version through the preferred non-parametric 
model [34]. For the AQoL-8D, we used a scoring algorithm incorporating Australian weights 
published on the AQoL group’s website (http://www.aqol.com. au). We assessed questionnaire 
completion by measuring the proportion of participants who completed the questionnaire and 
for whom an individual utility value could be generated. 
Summary statistics of the HSUVs for each MAUI were assessed as mean (SD) and median 
(IQR) given the skewed nature of the data. Strength of correlation between the instruments’ 
utility values for the sample was tested using Spearman’s correlation coefficient, with 
Spearman’s rho of greater than 0.50 or less than -0.50 considered strong, values between -0.49 
to 0.30 and 0.30 to 0.49 considered moderate; and between -0.30 and 0.30 weak [35]. To 
determine interchangeability between the instruments, pairwise agreement between the utility 
values for each instrument for each participant was assessed using a scatterplot and through the 
Bland–Altman (BA) method of differences [36]. The difference between the two measures was 
plotted against the mean measurement for those two instruments for each individual, along 
with the limits of agreement (the range of values that would be expected to include 95 % of 
individual differences) [31]. 
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An MAUI should be able to produce utility valuations for various health states with a 
significant degree of accuracy to effectively detect and represent differences between 
individuals [31]. Discriminatory attributes of the instruments were therefore assessed globally 
and then at dimensional levels. Globally, the extent of floor (worst health: -0.594 EQ-5D-5L 
and ?0.09 AQoL-8D) and ceiling effects (perfect health: 1.0 each instrument) was determined, 
and then utility values obtained on the alternate instrument were explored. At the dimensional 
level, summary statistics were obtained for the summary scores for each individual dimension 
of the AQoL-8D and its super-dimensions. The distribution of responses across the levels (1–
5 or 6) of each of three psychosocial-related dimensions within each instrument was then 
explored. These dimension-to-dimension comparisons [22] encompassed anxiety/depression, 
self-care and pain/discomfort for the EQ-5D-5L, comprising one item each; and mental 
comprising eight, four and three items each, respectively. 
The association between ‘current BMI’ and utility valuation obtained with each instrument was 
investigated by testing strength of correlation using the Spearman’s correlation coefficient. 
Statistical analyses were undertaken using IBM  SPSS (version 22) or R (version 3.0.2).  
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Table 1: Comparison of the dimensions and content of the EQ-5D-5L and AqoL-8D multi-
attribute utility instruments. 
Characteristics EQ-5D-5L 
 
AQoL-8D 
Development team 
and year finalised 
EuroQol Research Foundation, EuroQol 
Executive Office, Rotterdam, The 
Netherlands. 
(http://www.euroqol.org), 2011. 
Centre for Health Economics, Monash 
University, Melbourne, Victoria, Australia. 
(http://www.aqol.com.au), 2011. 
Number of health 
states described 
3,125. 2.4 X 10²³. 
Number of pages and 
questions 
Two pages: EQ-5D-5L descriptive system 5 
questions and EQ-5D Visual Analogue Scale. 
Three pages: aqol1 to aqol35. 
Mean completion 
time 
< 1 minute. 5.45 minutes [27] 
Valuation technique 
 
Non-parametric indirect modelling technique 
and UK “crosswalk” set, [34] 
Time Trade Off (Australian sample) [27] 
Total number of 
dimensions 
Five dimensions, one item in each. Each item 
has five levels of functioning scored as 1 (best) 
to 5 (worst). Participants choose one level for 
each item to describe their health status on the 
day of interview. Provides health state values 
as 11111 (best) to 55555 (worst). 
Eight dimensions of between three to eight 
items, 35 items in total. Each item (aqol1 to 
aqol 35) has four to six levels scored as 1 
(best) to 6 (worst). Participants choose one 
level for each item to describe health status 
over the past week. 
Number of 
dimensions of 
physical health 
Four dimensions – mobility, self-care, usual 
activities and pain/discomfort. 
Three dimensions – (1) independent living 4 
items (household tasks, getting around, 
mobility, self-care); (2) senses 3 items (vision, 
hearing, communication); and (3) pain 3 items 
(frequency of pain, degree of pain, pain 
interference). [10]. 
Number of 
dimensions of 
psychosocial health 
 
One dimension – anxiety/depression with five 
levels of severity:  
(1) I am not anxious or depressed, 
(2) I am slightly anxious or depressed, 
(3) I am moderately anxious or depressed, 
(4) I am severely anxious or depressed,  
(5) I am extremely anxious or depressed. 
Five dimensions – (4) happiness 4 items 
(contentment, enthusiasm, degree of feeling 
happiness, pleasure); (5) coping 3 items 
(energy, being in control, coping with 
problems); (6) Relationships 7 items 
(relationship with family and friends, social 
isolation, social exclusion, intimate 
relationship, family and community role); (7) 
self-worth 3 items (feeling like a burden, 
worthlessness, confidence); (8) mental health 8 
items (feelings of depression, trouble sleeping, 
feelings of anger, self-harm, feeling despair, 
worry, sadness, tranquillity/agitation) [10]. 
Super-dimensions of 
physical and psycho-
social health 
No super-dimensions. Two super-dimensions: physical super-
dimension (PSD) and mental super-dimension 
(MSD). PSD includes independent living, 
senses and pain; MSD includes happiness, 
coping, relationships, self-worth and mental 
health [10] 
Visual Analogue 
Scale 
Yes. No. 
Range of reported 
utility scores from 
best possible health 
to worst possible 
health state 
Range: states worse than dead <0 to full health 
1.00, anchoring at dead=0. Scored range: -
0.594 to 1.00 (UK crosswalk value set). 
Range: full health 1.00 to anchoring at dead=0. 
Scored range:  +0.09 to 1.00. 
Available population 
norms 
Ten countries in the crosswalk value set from 
EQ-5D-3L: Denmark, France, Germany, 
Japan, Netherlands, Spain, Thailand, United 
Kingdom, United States, Zimbabwe [34]. 
Australia [50]. 
Australia. 
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3.3  Results 
3.3.1 Participants clinical and socio-demographic characteristics 
Table 2 provides the participants’ clinical and socio-demographic characteristics. Mean (SD) 
age was 56 (11) years, and two-thirds (n = 22; 67 %) were female. Mean (SD) of the maximum 
recorded BMI (before surgery) was 43.7 (7.3) kg/m2, and mean (SD) current BMI (at 
recruitment) was 32.8 (7.7) kg/m2. One-third of participants had obtained university 
qualifications and one-quarter were educated to year 10. Most participants (n = 32; 97 %) had 
received an LAGB, and 12 % (n = 4) of these participants had undergone a secondary procedure 
such as a revision. Median (IQR) number of years since primary surgery was 5.0 (3.0–8.0). 
Table 2: Baseline sociodemographic characteristics of participants. 
Characteristics Private patients 
after surgery (n=33) 
Age years 
Mean (SD) 
56 (11) 
Gender 
(n=x, %) 
Male (n=11, 33%) 
Female (n=22, 67%) 
BMI (kg/m²) maximum 
(before surgery) 
Mean (SD) 43.7 (7.3) 
BMI (kg/m²) current  
(at recruitment) 
Mean (SD) 32.8 (7.7) 
Years since primary 
procedure 
Mean (SD) 
Median (IQR) 
6 (6) 
5 (3-8) 
Highest level of 
education * 
Category (%) 
category 1 (24.5) 
category 2 (15) 
category 3 (27.5) 
category 4 (33) 
LAGB 
(n=x, %) (n=32, 97%) 
Laparascopic  
(n=x, %) (n=33, 100%) 
Secondary Procedure 
(n=x, %) (n=4, 12%) 
Data presented as mean (standard deviation (SD)) or n (%) unless 
otherwise indicated. 
BMI, body mass index; IQR inter-quartile range; LAGB, 
laparoscopic adjustable gastric band. 
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3.3.2 Questionnaire practicality 
All participants completed both MAUIs. The EQ-5D-5L was completed without omissions or 
additions (such as multiple responses to one question). In contrast, one participant attempted 
to select two response items to two questions and modify those items when completing the 
AQoL 8D. These nonconformities had no impact on our ability to assess the utility of this 
participant. As advised by the AQoL group, we used the worst response for utility generation. 
3.3.3 Construct validity 
Frequency distributions of the individual utility values for both instruments are provided in 
Figure 1a, b. Utilities obtained through both MAUIs showed a distribution towards perfect 
health, more so for the EQ-5D-5L than the AQoL-8D. There was no significant difference in 
mean and median utility values of both instruments, with a strong correlation overall. The range 
and IQR for the EQ-5D-5L (0.40–1.00 and 0.75–1.00) and the AQoL-8D (0.35–0.95 and 0.63–
0.88) were the same (Table 3), but each was higher for the EQ-5D-5L, reflecting its greater 
negative skew. In turn, the AQoL-8D’s assessed range and IQR for our study population 
compared with the potential scored range, measured as the difference between the floor to 
ceiling levels of +0.09 to 1.00, is proportionally larger than for the equivalent measure of the 
EQ-5D-5L. The inclusion of 1.00 in the EQ-5D-5L’s range and IQR also reflect the ceiling 
effects of this instrument within our study population as detailed below. 
The mean (SD) and median utility values tended to be higher [0.84 (0.15); 0.84] for the EQ-
5D-5L than for the AQoL-8D [0.76 (0.17); 0.81], respectively (Table 3). A strong correlation 
was obtained between the utilities for the EQ-5D-5L and AQoL-8D (Spearman’s rho 0.68; 
p<0.001). The EQ-VAS gave rise to mean (SD) and median (IQR) ratings of 76 (17) and 80 
(70–90), respectively. 
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3.3.4 Sensitivity 
A scatterplot of individual utility values (Fig. 1c) demonstrated two distinct groupings around 
0.8 and 1.0 for the EQ-5D-5L. The BA plot (Fig. 1d) revealed a relatively wide limit of 
agreement (0.55) and systematic variation, notably a negative trend in the difference between 
individual participant utility values by mean value. No floor effects were identified for either 
instrument, nor were there ceiling effects for the AQoL-8D (Table 3). However, a ceiling effect 
was observed for over one-third (n = 12; 36 %) of participants with the EQ-5D-5L.  
Table 4 provides the EQ-VAS rating scores and AQoL- 8D global utility values for each 
participant scoring perfect health using the EQ-5D-5L. One participant (number 11) rated 
themselves as experiencing perfect health on the EQVAS; however, their AQoL-8D utility 
valuation was high but not perfect (0.93). Overall, the mean (SD) and median (IQR) EQ-VAS 
ratings were 83 (10) and 84 (79–90), and the mean (SD) and median (IQR) AQoL-8D utility 
values were 0.87 (0.08) and 0.88 (0.84–0.93). Table 5 provides summary statistics for the 
individual and super-dimension scores of the AQoL-8D for the entire sample. The maximum 
score for the mental health dimension at 0.73 was markedly lower than for all other dimensions. 
The maximum score in the other seven individual dimensions was at least 0.96, six scoring 
1.00. In turn, the maximum mental super-dimension score was 0.79. The mental health and 
mental super-dimensions also recorded the lowest mean (SD) and median (IQR) scores, at 0.62 
(0.12) and 0.63 (0.52–0.73) and 0.44 (0.17) and 0.45 (0.27–0.54), respectively. Table 6 
provides AQoL-8D individual and super- dimension scores for those recording perfect health 
using the EQ-5D-5L. One of these participants (Table 4, participant 11) achieved the maximum 
score (1.00) for the physical super-dimension (PSD). Given their AQoL-8D utility valuation 
was 0.93, this participant’s overall health status was diminished due to psychosocial impacts. 
The maximum mental super-dimension (MSD) score within this group was 0.71. The mean 
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(SD) scores for the AQoL-8D PSD and MSD were 0.89 (0.07) and 0.52 (0.13), respectively. 
The findings are also reflected at the individual dimensions level of physical and psychosocial 
health. The physical health dimensions gave rise to the highest scores [independent living 0.97 
(0.04), senses 0.92 (0.06), pain 0.95 (0.09)], and the psychosocial dimensions the lowest scores 
[happiness 0.85 (0.07), coping 0.87 (0.08), relationships 0.85 (0.12), self-worth 0.90 (0.08), 
mental health 0.65 (0.09)]. 
Table 7 provides a dimension-to-dimension comparison for each of three individual 
psychosocial-related dimensions of the EQ-5D-5L and AQoL-8D. The EQ-5D-5L showed a 
larger proportion of participants at Level 1 than theAQoL-8D for each dimension, and less 
dispersion overall. There were no participants rated at Level 4 or above within the psychosocial 
dimensions for the EQ-5D, unlike the AQoL-8D. 
A moderate association was found between ‘current BMI’ and utility valuations for both the 
EQ-5D-5L and AQoL-8D with Spearman’s rho -0.37; p = 0.03 and -0.39; p = 0.02, respectively. 
 
Table 3: Descriptive statistics of EQ-5D-5L abd AqoL-8D utility valuations, EQ-VAS scores 
and percent achieving worst or best health states. 
MAUI (n = 33) Mean (SD) Median (IQR) Minimum % on floor Maximum % on ceiling 
EQ-5D-5L 0.84 (0.15) 0.84 (0.75-1.00) 0.41 0 1.00 36 % (n = 12) 
AQoL-8D 0.76 (0.17) 0.81 (0.63–0.88) 0.35 0 0.95 0 
EQ-VAS 76 (17) 80 (70-90) 30 0 100 8 % (n = 1) 
      IQR, interquartile range MAUI, multi-attribute utility instrument; SD, standard deviation;. 
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Table 4: EQ-VAS rating and AqoL-8D utility valuation for each individual assessed in perfect 
health through the EQ-5D-5L. 
Participant EQ-5D-5L 
utility value 
EQ-VAS  
rating 
AQoL-8D  
utility value 
 
1  1.00 85 0.82 
2  1.00 80 0.95 
3  1.00 90 0.90 
4  1.00 80 0.84 
5  1.00 65 0.85 
6 1.00 90 0.95 
7  1.00 83 0.94 
8  1.00 90 0.84 
9  1.00 75 0.80 
10  1.00 90 0.92 
11  1.00 100 0.93 
12 1.00 70 0.66 
 
Mean (SD) 
Median (IQR) 
 
1.0 
1.0 
 
83 (10) 
84 (79-90) 
 
0.87 (0.08) 
0.88 (0.84-0.93) 
       IQR = interquartile range; SD, standard deviation; VAS, visual analogue scale. 
 
Figure 1: Distribution of (a) EQ-5D-5L utility scores and (b) AqoL-8D utility scores. (c) 
Scatterplot of participants’ utility scores for EQ-5D-5L and AqoL-8D. (d) Bland-Altman 
method of differences for utility scores between the EQ-5D-5L andAQoL-8D, all participants 
(n = 33) 
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Table 5: AQoL-8D individual and super dimension scores for the entire sample (n = 33). 
 
AQoL-8D dimension or super 
dimension 
(n = 33) 
Mean (SD) 
 
Median (IQR) Minimum Maximum 
Dimensions of physical health (3)     
Independent Living 
 
0.90 (0.14) 0.96 (0.85 – 1.00) 0.51 1.00 
Senses 
 
0.88 (0.10) 0.85 (0.82 – 0.95) 0.63 1.00 
Pain 
 
0.78 (0.20) 0.80 (0.63 – 0.95) 0.29 1.00 
Dimensions of psychosocial health(5) 
 
    
Happiness 
 
0.81 (0.11) 0.85 (0.75 – 0.89) 0.50 0.97 
Coping 
 
0.82 (0.13) 0.87 (0.77 – 0.90) 0.39 0.96 
Relationships 
 
0.77 (0.16) 0.82 (0.60 – 0.89) 0.49 1.00 
Self-Worth 
 
0.83 (0.14) 0.86 (0.75 – 0.92) 0.46 1.00 
Mental Health 
 
0.62 (0.12) 0.63 (0.52 – 0.73) 0.37 0.79 
Super-dimensions (2) 
 
    
Physical super dimension (PSD) 
 
0.73 (0.19) 0.75 (0.63 – 0.87) 0.34 1.00 
Psychosocial super dimension (MSD) 0.44 (0.17) 
 
0.45 (0.27 – 0.54) 0.10 0.73 
 
 
  
IQR, inter quartile range; MSD, Psychosocial super dimension; PSD, Physical super dimension, SD, standard deviation. 
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Table 6: AQoL-8D individual dimension and super dimension scores for each individual 
assessed in perfect health through the EQ-5D-5L. 
Table 7: Distribution of levels of response for EQ-5D-5L individual dimensions of 
anxiety/depression, self-care, pain/discomfort with the AQoL-8D individual dimensions of 
mental health independent living and pain. 
EQ-5D-5L AQoL-8D 
Dimension* Anxiety/ 
Depression 
(1) 
Self-care 
(2) 
Pain/ 
Discomfort 
(3) 
Mental 
Health 
(1) 
Independent 
Living 
(2) 
Pain 
(3) 
Level 
1 64 % 97 % 49 % 24 % 63 % 43 % 
2 24 % 3 % 30 % 39 % 24 % 39 % 
3 12 % 0 18 % 30 % 8 % 15 % 
4 0 0 3 % 5 % 5 % 3 % 
5 0 0 0 2 % 0 0 
6 NA NA NA 0 0 NA 
* all columns add to 100%; NA, not applicable.
AQoL-8D dimension 
or super-dimension 
(n = 12) 
Mean (SD) Min Max 
Dimensions of physical 
health (3) 
Independent Living 0.97 (0.04) 0.90 1.00 
Senses 0.92 (0.06) 0.84 1.00 
Pain 0.95 (0.09) 0.72 1.00 
Dimensions of 
psychosocial health (5) 
Happiness 0.85 (0.07) 0.73 0.97 
Coping 0.87 (0.08) 0.71 0.96 
Relationships 0.85 (0.12) 0.66 1.00 
Self-Worth 0.90 (0.08) 0.70 1.00 
Mental Health 0.65 (0.09) 0.43 0.78 
Super dimensions (2) 
Physical super 
dimension (PSD) 
0.89 (0.07) 0.80 1.00 
Psychosocial super 
dimension(MSD) 
0.52 (0.13) 0.27 0.71 
SD, standard deviation. 
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3.4 Discussion 
To the best of our knowledge, our study is the first to investigate a ‘head-to-head’ comparison 
of the EQ-5D-5L and AQoL-8D MAUIs in patients who have undergone bariatric surgery. Our 
study’s key finding was the divergent sensitivity of the instruments in assessing health state 
utility in this patient group, a difference arguably due to their ability to assess and capture 
psychosocial HRQoL impacts. This finding is crucial because psychosocial health status has 
been identified as a significant outcome for the morbidly obese population who receive 
bariatric surgery [4–6, 8, 9]. 
We found 36 % of participants were assessed as having perfect health on the EQ-5D-5L, but 
none on the AQoL- 8D. The mean utility valuation of the patient group scoring perfect health 
on the EQ-5D-5L was 0.87 using the AQoL-8D, the lower utility driven by less than perfect 
scores on the AQoL-8D MSD and, in all but one instance, the PSD. The assessed range for the 
EQ-5D-5L as a proportion of the potential scored range was less than for the AQoL-8D at 16 
% [0.25/(1 - (-0.594))] and 27 % [0.25/(1 - 0.09)], respectively, indicating greater 
discriminatory attributes of the latter for this study population. These findings are partially 
explained by differences in the classification/descriptive systems and scoring algorithms of the 
two instruments. Additionally, the value sets are derived from two different populations, 
namely Australia and the United Kingdom, suggesting that these differences could also be 
partially explained by the different population sets. 
EQ-5D-5L and AQoL-8D utility values were highly correlated by rank ordering (Spearman’s 
rho 0.68); however, high correlation does not imply close agreement and is blind to the 
possibility of systematic bias [36]. We observed pairwise disagreement in utility values 
assessed for a given individual and evidence of systematic bias. In turn, the utility valuations 
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obtained with these instruments in the population who underwent bariatric surgery are non-
interchangeable. Our finding of non-interchangeability between the EQ-5D-5L and the AQoL-
8D is consistent with a lack of pairwise agreement between the EQ-5D-3L and the AQoL-4D 
[25]. 
One of the key drivers for the development of the EQ- 5D-5L was to address serious ceiling 
effects of the EQ 5D-3L [23], with over 45 % of participants scoring perfect health in some 
studies [37, 38]. The severe ceiling effects of the EQ-5D-3L reflected difficulties in its ability 
to measure small and medium changes in health [23]. In an investigation of the EQ-5D-5L 
compared with the EQ-5D-3L across eight patient groups, the ceiling effect was reduced from 
20 % (EQ-5D-3L) to 16 % (EQ-5D-5L), on average. Importantly, this study found that ceiling 
effects were higher for chronic diseases such as diabetes. In this population, the ceiling effect 
reduced from 34 % (EQ-5D-3L) to 28 % (EQ-5D-5L). In contrast, the ceiling effects for 
depression were reduced from 12 % (EQ-5D-3L) to 6 % (EQ-5D-5L) [30]. Arguably, this is a 
direct reflection of the specific question on depression/anxiety in the EQ-5D and underpins the 
importance of the descriptive systems employed. 
Whilst floor/ceiling effects were not investigated in studies of bariatric surgery patients that 
employed the EQ- 5D-3L [39–41], over one-third of participants reported perfect health on the 
EQ-5D-5L in our study. This is a finding comparable to the extent of ceiling effects reported 
in recent studies that used the EQ-5D-5L for chronic conditions, including diabetes (n = 117 
[42] and n = 289 [43]), end-stage renal disease (n = 150 [44]), and chronic hepatic disease (n 
= 1088 [45]), and consistent with the comparative findings above. 
The ongoing ceiling effects measured in this and other studies indicate the limitations of the 
breadth of the EQ- 5D. Furthermore, research concerning the development of ‘bolt-on’ items 
for the EQ-5D has argued that these items could facilitate greater sensitivity for specific 
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conditions, and further research has been encouraged [20]. However, it has also been noted that 
the use of ‘bolt-on’ items may lead to ‘‘some variations in measurement between conditions 
and detract from the advantages of using a generic instrument’’ [20]. We postulate that 
inclusion of one or more ‘bolt-on’ items may render results non-interchangeable, even with 
other ‘EQ-5D’ analyses and, in turn, the current dominance of this instrument irrelevant. 
We found the mean, median and maximum scores of the AQoL-8D mental health and MSD 
were low relative to other AQoL-8D dimension scores for both the entire sample and the ceiling 
effect’s subgroup for the EQ-5D. We also found greater dispersion for the AQoL-8D than the 
EQ-5D-5L across the three most comparable individual dimensions potentially impacting 
psychosocial health. We contend that together these findings support the greater sensitivity of 
the AQoL-8D than the EQ-5D towards psychosocial health. 
In regard to the moderate correlations observed between utilities obtained from each instrument 
and ‘current BMI’, we contend that this finding is reflective of weight status being just one 
factor contributing to the HRQoL of people who have received bariatric surgery. This position 
is consistent with the most recent evidence, which does not support a direct link between long-
term weight reduction and continued improvement/decline in mental health after bariatric 
surgery [5, 6]. Psychosocial support, alongside weight loss maintenance, are important 
management components for the HRQoL of this group of individuals in the longer term. 
Economic evaluations of interventions that affect HRQoL commonly employ CUA that 
prioritise interventions according to the costs per QALY gained [15]. We found that significant 
differences in the EQ-5D-5L and AQoL-8D descriptive systems impact their sensitivity 
towards psychosocial domains of health. We also found that the utility values obtained cannot 
be used interchangeably. Impacts on psychosocial health for bariatric surgery patients 
have been identified as a vital outcome. Our findings thus have implications for the choice 
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of utility instrument employed for clinical assessment and/or economic evaluation in the 
population for whom bariatric surgery is a consideration. 
As noted previously, NICE’s recommendation to use the EQ-5D for utility assessment is 
tempered by whether use of the EQ-5D is considered appropriate; a lack of content 
validity, including missing key health dimensions, is a primary concern [18]. If the 
nominated choice of instrument lacks sensitivity within a particular health context (or 
health domain), interventions affecting health states where the instrument’s sensitivity 
is low will be disadvantaged [32], a potential bias of particular importance for healthcare 
decision makers. For people who are morbidly obese considering or having undergone 
bariatric surgery, the impact of any intervention will not be fully captured unless the 
nominated MAUI is sensitive to psychosocial health. 
In turn, while the EQ-5D dominates the clinical/economic evaluation literature, its 
prevalence should not influence the choice of instrument in this (or other) study 
population(s). Rather, the choice of MAUI should be influenced by the sensitivity of the 
instrument to a patient group’s health profile. In turn, we argue that the AQoL-8D should 
be further assessed for its responsivneness (compared to the EQ-5D-5L) in a prospective 
cohort study of morbidly obese subjects prior to receiving their bariatric surgery and at 
a more proximal timepoint following the bariatric surgery. 
Within the ASMBS’s recently published outcomes reporting guidelines for bariatric and 
metabolic surgery [8, 9], the EQ-5D was classified as one of several frequently used 
generic HRQoL instruments within this population; however, the ASMBS was unable to 
provide specific guidance as to a preferred HRQoL instrument(s), as previously noted. No 
reference was made to MAUIs per se; a situation we believe is an important oversight. If 
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a MAUI and associated utility valuation comprehensively assesses and captures the 
physical and psychosocial domains of health for bariatric surgery patients, use of such an 
instrument could fulfil ASMBS HRQoL requirements. Related economic evaluations 
would also be underpinned by robust utility valuation, and thus facilitate defensible 
resource allocation. 
Respondent burden is also a necessary consideration in instrument choice. The ASMBS 
document argues that HRQoL instruments with more items are less likely to be completed 
by patients, whereas instruments with fewer items are completed at higher rates. We 
expected the EQ-5D-5L would achieve a higher level of completion given that it comprises 
30 fewer items than the AQoL-8D. Additionally, the average time for completion for the 
EQ-5D-5L (1 min), is approximately 4 min faster than that for the AQoL-8D (Table 1). Our 
study showed a 100% response rate for both instruments and subsequent generation of 
individual utility values. Nevertheless, we acknowledge that our study participants were 
fully engaged through focus group involvement and that this may have influenced the 
completion rate of the MAUIs for our study. As participant levels of education were 
relatively evenly spread, this should not confound questionnaire completion. 
The ASMBS document also recommends, with reference to a 2011 review of HRQoL 
instruments measuring bariatric surgery [46], the use of a combination of HRQoL 
instruments to capture psychosocial impacts. The 2011 review found that while several 
generic and obesity specific instruments have been developed and/or used in bariatric 
surgery, all have limitations [46]. The review investigated the content validity of one 
MAUI (EQ-5D) and other generic and disease-specific instruments, including the SF-36, 
Nottingham Health Profile and IWQoL-lite. The review consequently proposed a 
conceptual framework for a bariatric surgery-specific HRQoL instrument that comprised 
Chapter 3: A head-to-head comparison of the EQ-5D-5L and AQoL-8D multi-attribute 
utility instruments in patients who have previously undergone bariatric surgery. 
190 | P a g e
20 items, 19 of which, including all of the psychosocial domains of health, are included in 
the AQoL-8D. The item not included in the AQoL-8D pertained to eating. This conceptual 
framework subsequently underpinned the development of the disease specific quality-
of-life instrument, the ‘bariatric and obesity-specific survey’ (BOSS) [47]. The BOSS is not 
an MAUI. The BOSS-42 (the final version of this instrument) contains 42 items, seven 
more than the AQoL-8D. 
Thus, our study found that a single MAUI instrument, the AQoL-8D, is sensitive to the 
psychosocial as well as the physical domains of health for people who have undergone 
bariatric surgery, and it captures the vast majority of domains considered crucial in this 
population. While the length of the AQoL-8D may be an initial deterrent, this concern 
must be balanced against the sensitivity of this instrument to mental health [48] and 
physical health dimensions. Further, the use of a combination of up to three or four 
HRQoL instruments could be more burdensome and time consuming for the study 
population than the use of a single comprehensive instrument. 
The major strength of this study is the use of a homogeneous group of bariatric surgery 
patients to minimise confounding due to patient characteristics in the identification of 
similarities and key differences between the EQ-5D-5L and AQoL-8D. The key limitation 
of this study is the sample size (n = 33). Nevertheless, we found that about one-third of 
the participants scored perfect health on the EQ-5D-5L, which is consistent with other 
studies of chronic disease with larger samples. Another limitation is that we did not 
include a disease-specific instrument because of concerns about the potential impact of 
respondent burden on both the quantitative and the qualitative components of the 
broader study. In lieu of a disease specific instrument, we compared the utility valuations 
of ‘current BMI’. One further limitation could be attributed to the utilities estimated from 
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the EQ-5D-5L crosswalk value set [49]. Another limitation is that the value sets for the 
two MAUIs are derived from two different populations (Australia for the AQoL-8D and 
United Kingdom for the EQ-5D-5L). Finally, given this study was exploratory, larger 
confirmatory studies are justified. We also suggest that a comparison between the AQoL-
8D and SF-6D would be of value. 
3.5 Conclusions 
Before selecting a generic MAUI, researchers should fully understand the instruments’ 
descriptive/classification systems and the innate sensitivities of the MAUI in their context. 
Given the relative importance of the psychosocial health in the population contemplating or 
having undergone bariatric surgery, the choice of MAUI may be crucial. For bariatric surgery, 
the AQoL-8D more fully captured and assessed the psychosocial aspects of these patients’ 
HRQoL as compared with the EQ-5D-5L. Additionally, the AQoL-8D was sensitive to the 
physical aspects of these patients’ HRQoL. We recommend the AQoL-8D as a preferred MAUI 
to the EQ-5D-5L for patients undergoing bariatric surgery given their complex physical and 
psychosocial needs. 
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Chapter 4: An exploratory study of long-term publicly waitlisted 
bariatric surgery patients’ quality of life before and 1 year after 
bariatric surgery, and considerations for healthcare planners. 
Preface 
This chapter is one of two longitudinal studies (Chapters 4 and 5) that were based on a unique 
cohort of long-term waitlisted patients (mean (standard deviation) years on the waiting list 6.5 
(2) years) who were then provided with bariatric surgery due to a public policy decision to
reduce waiting lists. This longitudinal study’s cohort of patients purposely contrasts with 
Chapter 3’s cross-sectional study and cohort of patients who had received bariatric surgery 
many years previously (median (interquartile range) 5 (3 – 8) years) in the private healthcare 
system. 
Chapter 2’s comprehensive systematic review established that only one study (of the 77 
included studies) investigated the impact of time delay on the clinical and economic outcomes 
of bariatric surgery. This key knowledge gap is also linked to the policy issue of patient 
prioritisation for bariatric surgery. The systematic review also suggested that constrained 
public sector budgets are one part of a tremendously complex system-wide healthcare 
landscape that results in people with severe and super-obesity (generally with significant 
obesity-related comorbidities) experiencing multiyear wait times.  
Chapter 4’s selection of the EQ-5D-5L and AQoL-8D multi-attribute utility instruments was 
also guided by the systematic review (Chapter 2) and the findings of Chapter 3 that established 
the AQoL-8D (compared to the EQ-5D-5L) was sensitive to the complex psychosocial health 
for people who had undergone bariatric surgery many years previously.  
Chapter 4’s published study is the first study to measure health state utility values (both 
instruments) and individual and super dimension scores (AQoL-8D) for the increasingly 
prevalent study population of long-waiting public sector bariatric surgery patients who carry 
complex physical and psychosocial health related quality of life needs, before and 1 year after 
surgery.  
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This study investigates health-related quality of life before, 3 months and one year after 
bariatric surgery using both the EQ-5D-5L and AQoL-8D for severely obese long-waiting 
public healthcare bariatric surgery patients. The derivation of utilities for this important 
subgroup of bariatric surgery patients is extremely useful for informing current policy decisions 
and as an input to future economic evaluations.  
The study’s finding of statistically improved health-related quality of life for long-waiting 
public healthcare sector patients following bariatric surgery is important, as is information 
about how the AQoL-8D and EQ-5D-5L instruments perform in this study population. It was 
identified that the AQoL-8D preferentially captured and assessed psychosocial health when 
compared with the EQ-5D-5L. Additionally, the finding that the psychosocial dimensions of 
health drove the health-related quality of life improvements is also crucial in understanding the 
value of surgical benefits obtained for patients. Another key finding of this study was the 
maintenance of the quality of life gain out to 1 year post operatively. 
This study provided much needed policy advice to the NHMRC project partner regarding the 
health gains that can still be realised when long-waiting bariatric surgery patients are ultimately 
treated. The study suggested that long-waiting bariatric patients should not be ‘written-off’ by 
healthcare planners: they can still realise significant improvements in health-related quality of 
life outcomes when ultimately treated, and this should be factored into patient prioritisation 
decisions. 
This chapter has been published in PharmacoEconomics – Open (Appendix 4A). A fee waiver 
was granted for this publication. 
Impact factor: PharmacoEconomics – Open is a new journal, nevertheless, the impact factor 
of PharmacoEconomics (the companion journal) is 3.63. 
Campbell JA, Hensher M, Neil A, Venn A, Wilkinson S, and Palmer AJ. An Exploratory 
Study of Long-Term Publicly Waitlisted Bariatric Surgery Patients’ Quality of Life Before and 
1 Year After Bariatric Surgery, and Considerations for Healthcare Planners. 
PharmacoEconomics-Open. 2017:1-4. DOI:10.1007/s41669-017-0038-z 
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Abstract 
Background: Long-term publicly waitlisted bariatric surgery patients typically experience debilitating 
physical/psychosocial obesity-related comorbidities that profoundly affect their quality of life. 
Objectives: We sought to measure quality-of-life impacts in a study population of severely obese 
patients who had multiyear waitlist times and then underwent bariatric surgery 
Methods: Participants were recruited opportunistically following a government-funded initiative to 
provide bariatric surgery to morbidly obese long-term waitlisted patients. Participants self-completed 
the EQ-5D-5L and AQoL-8D questionnaires pre- and postoperatively. Utility valuations (utilities) and 
individual/super dimension scores (AQoL-8D only) were generated. 
Results: Participants’ (n = 23) waitlisted time was mean [standard deviation (SD)] 6.5 (2) years, body 
mass index reduced from 49.3 (9.35) kg/m2 preoperatively to 40.8 (7.01) 1 year postoperatively (p = 
0.02). One year utilities revealed clinical improvements (both instruments). AQoL-8D improved 
significantly from baseline to 1 year, with the change twice that of the EQ-5D-5L [EQ-5D-5L: mean 
(SD) 0.70 (0.25) to 0.78 (0.25); AQoL-8D: 0.51 (0.24) to 0.67 (0.23), p = 0.04], despite the AQoL-
8D’s narrower algorithmic range. EQ-5D-5L utility plateaued from 3 months to 1 year. AQoL-8D 1-
year utility improvements were driven by Happiness/Coping/Self-worth (p<0.05), and the 
Psychosocial super dimension score almost doubled at 1 year (p<0.05). AQoL-8D revealed a wider 
dispersion of individual utilities. 
Conclusions: Ongoing improvements in psychosocial parameters from 3 months to 1 year post-surgery 
accounted for improvements in overall utilities measured by the AQoL-8D that were not detected by 
EQ-5D-5L. Selection of a sensitive instrument is important to adequately assess changes in quality of 
life and to accurately reflect changes in quality-adjusted life-years for cost-utility analyses and resource 
allocation in a public healthcare resource-constrained environment. 
 
Key points for decision makers 
 
Psychosocial health status is an important health-related quality of life (HRQoL) outcome for long-waiting 
bariatric surgery patients. Whilst the EQ-5D is prevalent in the economic evaluation of bariatric surgery, 
compared with the EQ-5D-5L, the AQoL-8D preferentially captures and assesses psychosocial health for this 
study population 
 
If used in the clinical setting, utility valuations and individual and super dimension scores could provide both 
clinicians and healthcare decision-makers with important information regarding HRQoL impacts for people 
who have waited many years in the public health system for their bariatric surgery 
 
Long-waiting bariatric patients should not be ‘written-off’ by healthcare planners; they can still realise 
significant improvements in HRQoL outcomes when ultimately treated, and this should be factored into patient 
prioritisation decisions. 
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4.1 Introduction 
Obesity is a profoundly complex global public health, economic, and strategic policy problem 
[1–5]. Bariatric (obesity or metabolic) surgery is generally considered the most efficacious and 
cost-effective treatment intervention for people with intractable severe or morbid obesity, 
particularly for subgroups of patients such as people with type 2 diabetes [6–13]. A recent 
comprehensive systematic review of 77 diverse health economics studies that reported on 
bariatric surgery from 1995 to 2015 found the EQ-5D is the prevalent multi-attribute utility 
instrument (MAUI) used in cost-utility analyses of bariatric surgery worldwide, and the impact 
of time delay for publicly waitlisted patients on the clinical, quality-of-life, and economic 
outcomes of bariatric surgery has been largely ignored [14].  
As an important subgroup of bariatric surgery patients, long-term morbidly obese, publicly 
waitlisted, bariatric surgery patients generally experience increased physical and psychosocial 
comorbidity loads that ultimately translate to ‘sicker’ patients demanding proportionally more 
of the scarce healthcare dollar [14–17]. Recent qualitative evidence has indicated that waiting 
for bariatric surgery can lead to development of new or worsening obesity-related comorbidity 
or decline in mobility and be emotionally challenging (‘frustrating’, ‘depressing’, ‘stressful’) 
[18]. Additionally, the need to assess the psychosocial health status of bariatric patients in the 
short, medium, and longer terms has been increasingly identified [19] and recognised as crucial 
for bariatric surgery patients [20–24]. Moreover, the psychosocial health status of bariatric 
surgery patients is dynamic, some studies suggesting an improvement up to 4 years and 
declining thereafter [22, 24]. Other studies suggest that quality of life significantly improves 
up to 1 year and is maintained at 2 years [25]. Importantly, there is a paucity of quantitative 
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evidence concerning the health-related quality of life (HRQoL) impacts for the group of long-
waiting, public healthcare patients who then undergo bariatric surgery. 
Within resource-constrained healthcare budgets, funders’ perceptions of ‘affordability’ are 
changing as bariatric surgery has increasingly become accepted as more than a cosmetic 
procedure for obesity and as the scale of the epidemic of severe obesity has become clearer 
[14]. Furthermore, the allocation of public-sector budgets is one part of a tremendously 
complex healthcare landscape that results in severely obese bariatric surgery candidates (with 
complex obesity-related comorbidities that translate to diminished HRQoL) experiencing 
multiyear wait times [14, 15]. A key reason for these multiyear wait times is the 
disproportionate rate of increase in severe obesity, and therefore the ever increasing demand 
for bariatric surgery surpassing the relatively static supply [17, 26]. 
Recent evidence has highlighted the differences and disagreements regarding the prioritisation 
of quality-of-life outcomes by health professionals and patients [27], revealing that patients 
prioritised seven quality of life items, none of which were prioritised by professionals. 
Surgeons prioritised only one quality-of-life outcome (versus four to 11 in the other health 
professionals’ subgroups, e.g. nurses and dieticians) [27]. These findings highlight the 
importance of individual, self-reported patient assessments of HRQoL in the bariatric surgery 
population.  
Standardised outcomes reporting guidelines for metabolic and bariatric surgery were developed 
by the American Society of Metabolic and Bariatric Surgeons (ASMBS) to drive consistency 
of reporting clinical and HRQoL outcomes within the field [20, 21]. These guidelines 
acknowledge that whilst bariatric surgery produces marked weight loss and improvement of 
physical comorbidities, the impact on HRQoL is less well established [20, 21]. The guidelines 
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did not provide specific recommendations regarding the reporting of health state utility values, 
also described as utility valuations or utilities [24].  
Utility valuations are important health economic metrics that assess the strength of preference 
for an individual’s health state relative to perfect health and death, and importantly have 
inherent independent meaning [24, 28]. Utilities are assessed relative to a 0.00–1.00 scale, 
where 1.00 represents perfect health and 0.00 represents death, and therefore indicates the 
strength of preference for quality versus quantity of life [29]. Utilities are also a vital 
component of cost-utility analysis (a commonly used form of full economic evaluation that 
assesses the incremental costs of an intervention versus the incremental gains in quality-
adjusted life-years) [12, 29, 30]. 
MAUIs are designed to rapidly and simply assess an individual or study population’s utility 
valuation(s) through the application of pre-established formulae/weights to the array of patient-
reported responses to the instrument’s questions (generally self-reported through, for example, 
clinic visits, mail-outs, or the Internet) [24, 31, 32]. Based on patient-reported responses to 
MAUIs’ questionnaires, the algorithm of a given instrument generates utility valuations. Many 
instruments generate utilities that are less than zero described as a health state perceived to be 
worse than death (e.g. the most recent EQ-5D-5L UK value set range: -0.281 to 1.0 [33, 34]). 
Most instruments report minimal clinically important differences or minimal important 
differences for their utilities [35–37].  
The EQ-5D-5L is an internationally prevalent MAUI used in the assessment of patient-reported 
quality-of-life outcomes and full economic evaluations of treatment interventions (including 
bariatric surgery) [14, 38]. Recent evidence has suggested that for the EQ-5D-3L (precursor to 
the 5L), a 1.0-unit decrease in body mass index (BMI) is associated with a 0.0051- to 0.0075-
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utility point increase. For a 1.0-unit decrease in BMI, the study reported a 0.0051 increase in 
utility when adjusted for baseline presence of comorbidity (stepwise approach); a 0.0052 
increase in utility when adjusted for age, sex, and baseline BMI; a 0.0068 increase in utility 
when adjusted for age, sex, baseline BMI, and baseline comorbidity; and a 0.0075 increase in 
utility associated with the primary (baseline) analysis [39]. 
The AQoL-8D MAUI is informed by psychometric principles and testing and has been found 
to preferentially capture psychosocial health for people who had already undergone bariatric 
surgery many years previously in the private healthcare system {median [interquartile range 
(IQR)] 5 (3–8) years} [24, 40, 41]. This study also found that the AQoL-8D and EQ-5D-5L 
instruments were not interchangeable for the study population and that body weight is just one 
factor contributing to the complex HRQoL [24]. A recent study that investigated cross-
sectional quality-of-life data using the Moorehead–Ardelt Quality of Life Questionnaire II also 
found that quality of life after bariatric surgery is not just dependent on weight loss [42]. 
Nevertheless, the Moorehead–Ardelt Quality of Life Questionnaire II is not an MAUI. 
Another recent study suggested that clear preoperative predictive markers of well-defined 
postoperative success following bariatric surgery would be invaluable and facilitate a more 
refined and evidence-based mechanism by which to select patients for bariatric surgery [43]. 
The study found that it is important to explore the relationships between preoperative clinical 
parameters and HRQoL in those morbidly obese patients who are eligible for bariatric surgery, 
and that identifying those clinical and psychosocial predictors of success assumes great 
significance when selecting (or prioritising) patients for bariatric surgery [43]. A recent 
systematic review that investigated quality-of-life outcomes for bariatric surgery patients found 
that the SF-36 was the most commonly used HRQoL instrument in the review’s 13 included 
studies (control group was one of the inclusion criteria) [25]. Utility valuations were not 
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generated in these studies [25]. Importantly, utility valuations have been shown to be 
independent predictors of patient outcomes in patients with type 2 diabetes, including all-cause 
mortality and development of complications [44]. Clinicians have also found that measuring 
utilities is of benefit to patient– clinical assessment, relationships, communication, and 
management [32]. 
Our study arose from a targeted State Government of Tasmania, Australia, policy decision to 
reduce Tasmanian public hospital surgical waiting lists. This initiative provided us with a novel 
and exploratory opportunity to recruit a cohort of morbidly obese, long-term waitlisted, 
bariatric surgery patients who then underwent bariatric surgery as a result of this policy 
initiative. This provided us with the opportunity to investigate an important and increasingly 
prevalent study population of bariatric surgery patients who inherently carry complex physical 
and psychosocial HRQoL needs. We aimed to investigate the physical and psychosocial 
HRQoL changes in these patients by using the EQ-5D-5L and AQoL-8D MAUIs to generate 
utility valuations (both instruments), and the AQoL-8D’s individual dimensional scores 
(namely, Independent Living, Senses, Pain, Happiness, Coping, Relationships, Self-worth, and 
Mental Health) and super dimensional scores (namely, the composite Physical super dimension 
of Independent Living, Senses, and Pain; and the composite Psychosocial super dimension of 
Happiness, Coping, Relationships, Self-worth, and Mental Health) preoperatively and at two 
postoperative time points (namely, 3 months and 1 year). We also aimed to explore the HRQoL 
benefits of bariatric surgery for long-term waitlisted patients and concomitance with BMI 
changes. We further aimed to investigate whether the MAUIs would reveal significant 
psychosocial HRQoL impacts at 1 year postoperatively. We also aimed to explore whether 
utility valuations and individual and super dimension scores could provide healthcare decision-
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makers with important information regarding HRQoL impacts for people who had waited many 
years in the public health system for their bariatric surgery. 
4.2    Methods 
4.2.1 Study design 
(i) Recruitment of participants 
A Tasmanian government policy decision was made in 2014 to allocate additional and targeted 
public funds to provide morbidly obese, long-term waitlisted patients with bariatric surgery in 
2015. The policy decision provided us with an opportunity to recruit bariatric surgery patients 
who had waited for their surgery in a public healthcare system for many years. Appropriate 
ethics approvals were obtained from our University’s Health and Medical Human Research 
Ethics Committee before commencement of our study’s recruitment of participants. 
We subsequently invited patients who were identified for bariatric surgery to participate in our 
study. Participants were provided an information package and consent materials before their 
bariatric surgery pre-admission clinic. The process for participants’ questionnaire completion 
after consenting to participate in the study is outlined in Sect. 4.2.1.(ii). 
Participants who consented to participate in our quality-of-life study underwent publicly 
funded laparoscopic adjustable gastric banding (LAGB) surgery by the same surgeon in the 
Hobart Private Hospital. Laparoscopic banding was carried out using Apollo APS or APL 
bands, with adjustment ports attached to the left anterior rectus sheath [45]. Postoperative fluid 
diets were maintained for 3 weeks, with subsequent transition to normal foods, accompanied 
by instruction on eating technique and exercise 
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(ii) The multi-attribute utility instruments and questionnaire completion 
Our earlier study comparing the EQ-5D-5L and AQoL-8D MAUIs for people who had 
undergone LAGB surgery many years previously provided a detailed summary of the divergent 
characteristics of the two purposively selected MAUIs [24]. Table 1 provides an overview of 
these characteristics. In summary, the EQ-5D-5L is an internationally prevalent instrument 
(e.g. from 2005 to 2010, the EQ-5D was used in 63% of economic evaluations) [38]; the EQ-
5D instrument is prevalent in the full economic evaluation of bariatric surgery [14]; it describes 
3125 health states (compared with 243 health states of the EQ-5D-3L precursor to the 5L); four 
of the five instrument’s health domains/classifications focus on physical HRQoL; and it takes 
less than 1 min to complete the EQ-5D-5L’s questionnaire. The EQ-5D-5L also contains a 
visual analogue scale (EQ-VAS). In contrast, the AQoL-8D’s classification system is 
supported by psychometric principles and testing, and 25 of the instrument’s 35 items capture 
and assess five (from eight) psychosocial domains of health (Happiness, Coping, Self-worth, 
Relationships, and Mental Health). The AQoL-8D describes billions of health states and takes 
5 min to complete [40, 41]. 
Participants were asked to self-complete both instruments’ questionnaires before their bariatric 
surgery at the pre-admission preoperative clinics (generally one to two weeks before their 
surgery) and at two postoperative reportable time points, namely 3 months and 1 year after 
their bariatric surgery. Postoperative questionnaires were mailed out for self-completion with 
an explanatory cover letter and reply paid envelope enclosed. The order of instrument 
completion was not included in the explanatory letter, nor monitored at the pre-admission 
clinics. We evaluated the EQ-5D-5L and AQoL-8D questionnaire completion by assessing the 
overall proportion of participants who completed the questionnaire(s) at the study’s three time 
points for whom an individual utility value could be generated (outlined in Sect. 2.2).  
Chapter 4: An exploratory study of long-term publicly waitlisted bariatric surgery patients’ 
quality of life before and 1 year after bariatric surgery, and considerations for healthcare 
planners. 
 
219 | P a g e  
Table 1: Comparison of the dimensions and content of the EQ-5D-5L and AqoL-8D multi-
attribute utility instruments. 
Characteristics EQ-5D-5L 
 
AQoL-8D 
Number of health 
states described 
3,125. 2.4 * 10²³. 
 
Total number of 
dimensions 
 
Five dimensions, 1 item in each. Each item has 
5 levels of severity scored as 1 (best) to 5 
(worst). 
 
 
Eight dimensions of between 3 to 8 items, 35 
items in total. 25 of the 35 items capture and 
assess psychosocial domains of health. 
 
Number of 
dimensions of 
physical health 
Four dimensions: mobility, self-care, usual 
activities and pain/discomfort. 
Three dimensions: (1) Independent Living, 4 
items (household tasks, getting around, 
mobility, self-care); (2) Senses, 3 items 
(vision, hearing, communication); and (3) 
Pain, 3 items (frequency of pain, degree of 
pain, pain interference). 
Number of 
dimensions of 
psychosocial health 
 
One dimension: anxiety/depression with five 
levels of severity:  
(1) I am not anxious or depressed,  
(2) I am slightly anxious or depressed,  
(3) I am moderately anxious or depressed,  
(4) I am severely anxious or depressed,  
(5) I am extremely anxious or depressed. 
Five dimensions – (4) Happiness, 4 items 
(contentment, enthusiasm, degree of feeling 
happiness, pleasure); (5) Coping, 3 items 
(energy, being in control, coping with 
problems); (6) Relationships, 7 items 
(relationship with family and friends, social 
isolation, social exclusion, intimate 
relationship, family role and community role); 
(7) Self-worth, 3 items (feeling like a burden, 
worthlessness, confidence); (8) Mental health, 
8 items (feelings of depression, trouble 
sleeping, feelings of anger, self-harm, feeling 
despair, worry, sadness, tranquillity/agitation). 
Super dimensions of 
physical and 
psychosocial health 
No super dimensions. Two super dimensions: Physical super 
dimension (PSD) and Psychosocial super 
dimension (MSD). PSD includes independent 
living, senses and pain; MSD includes 
happiness, coping, relationships, self-worth 
and mental health. 
 
4.2.2 Data analysis 
Participants with patient-reported HRQoL assessments for one or both instruments, for at least 
one time point where the MAUI algorithm (either instrument) could generate the instrument’s 
utility valuations or scores were included in the analyses (Table 2). 
Baseline socio-demographic and clinical data were analysed descriptively as mean [standard 
deviation (SD)] for continuous variables and frequency (%) for categorical variables. BMI was 
calculated as weight (kg)/[height (m)]2. Percentage total weight loss was calculated as weight 
loss (kg)/initial weight (kg) x 100, and percentage excess weight loss was calculated as total 
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weight loss/{initial weight - [25 x height (m)2]} x100. Height and weight data were collected 
from medical records at the study’s three time points. 
Utility valuations were generated for the EQ-5D-5L using the most recent UK value based on 
directly elicited preferences [33, 34] (range: -0.281 to 1.00 utility points) and for the AQoL-
8D using the most recent Australian scoring algorithm available on the AQoL group’s website 
(http://www.aqol.com.au) (range: +0.09 to 1.0 utility points). Summary statistics of both 
MAUIs’ utility valuations and EQ-VAS were assessed as mean (SD) and median (IQR), and 
for individual and super dimension scores (AQoL-8D), they were assessed as mean (SD). 
A minimal clinically important difference or minimal important difference is the smallest 
difference in score in the outcome of interest which patients perceive as beneficial and which 
would mandate a change in the patient’s management [46, 47]. A recently reported composite 
minimal important difference for the EQ-5D-5L of selected chronic health conditions including 
hypertension, heart disease, arthritis, asthma or chronic obstructive pulmonary disease, cancer, 
diabetes, chronic back pain, and anxiety or depression has been calculated as 0.04 utility points 
[35]. 
We adopted this recent EQ-5D-5L composite measure for our study because of the array of 
complex physical and psychosocial health conditions included in the measure of minimal 
important difference. There is no reported minimal important difference for the AQoL-8D; 
however, there is a reported minimal important difference for the AQoL-4D. This is a 
composite measure that also includes chronic health conditions [37]. We therefore 
conservatively reported a minimal important difference for the AQoL-8D as the upper bound 
of the confidence interval (CI) of the AQoL-4D’s minimal important difference (95% CI: 0.03–
0.08), namely, 0.08 points [37]. 
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AQoL-8D Australian population norms for the total population and the 45- to 54-year-old age 
group were sourced from recently derived and published norms for the instrument [48]. 
Given that the MAUI-generated data are not normally distributed and also the relatively small 
sample size, this study employed the Wilcoxon signed rank test to test for statistical 
significance at the 5% level (p<0.05). The Wilcoxon signed rank test for significance is the 
nonparametric counterpart of the paired t test, and corresponds to a test of whether the median 
of the differences between paired observations is zero in the population from which the sample 
is drawn [49]. 
We undertook sensitivity analyses on the subgroup of individuals who fully completed both 
MAUIs’ questionnaires for all three reported time points (called ‘full-completers’) to test the 
robustness of all results including significance testing. 
Statistical analyses were undertaken using IBM SPPS (version 22) or R (version 3.0.2). 
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4.3 Results 
4.3.1 Participants’ clinical and socio-demographic characteristics and questionnaire 
completion 
Twenty-three participants were recruited to the study and completed at least one of the MAUIs’ 
questionnaires at one of the reportable time points to enable the generation of utility valuations 
(both instruments) and individual and super dimension scores (AQoL-8D only) (Table 2). 
For these participants (n = 23), mean (SD) age was 50 (10) years, 43% were males, and mean 
(SD) time on the public waiting list for bariatric surgery was 6.5 (2.0) years. Table 2 (supported 
by Appendix) also provides results regarding changes in BMI, percentage total weight lost, and 
percentage excess weight lost. At 1 year postoperatively, the percentage of total weight lost 
was mean (SD) 16% (7.1%). BMI decreased from mean (SD) 49.3 (9.3) kg/m before surgery 
to 43.5 (7.2) (3 months) to 40.8 (7.0) (1 year) after surgery, giving rise to a significant reduction 
of 8.5 BMI units preoperatively to 1 year postoperatively (p = 0.02). 
Appendix provides the socio-demographic characteristics of all participants (n = 23), the 
subgroup of full-completers of both questionnaires at all three reportable time points (n = 9), 
and the subgroup of participants who did not fully complete all questionnaires at the three 
reportable time points (n = 14). There was no substantial difference in age or sex [all 
participants (n = 23) males 43%; full-completers (n = 9) males 44%; partial-completers (n = 
14) males 42%]. The order of magnitude for the number of years on the public waiting list was 
also similar. The postoperative obesity classifications and mean (SD) BMI measures were 
similar between the subgroups, and the magnitudes of change between obesity classifications 
were also similar between the subgroups. 
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Questionnaire completion for the entire cohort across the three reported time points is outlined 
in detail in Table 2. Overall, utility valuations could be assessed for 75% (103/138) of 
participants for both MAUIs across all time points, and for the individual and super dimension 
scores for the AQoL-8D. Additionally, there was a 67% completion rate at baseline (31/46) 
and a 76% (35/46) completion rate at 1 year. Subgroup analyses were conducted for full-
completers of both instruments’ questionnaires across all three time points (n = 9) (outlined 
below and Tables 2 and 3). 
4.3.2 Changes in both instruments utility valuations compared to BMI 
Table 2 provides summary results for changes in BMI, utility valuations (both instruments), 
and EQ-VAS scores at the three reported time points. Figure 1 also provides a schematic 
representation of utility changes for the entire cohort (n = 23) and full-completers (n = 9). 
Figure 2 provides the distribution of utility valuations at the individual level for both 
instruments (Fig. 2a EQ-5D-5L and Fig. 2b AQoL-8D) 1 year after surgery. 
Our study’s key finding was that change in both instruments’ summary utility valuations and 
also the EQ-VAS scores reported clinical improvements that exceeded the minimal important 
difference for all participants (n = 23) (EQ-5D-5L 0.08 utility points; AQoL-8D 0.16 utility 
points; EQ-VAS 16 points) from before surgery to 1 year after surgery. Importantly, the change 
in utility valuations derived for the AQoL-8D was twice that for the EQ-5D-5L (0.16 vs. 0.08 
utility points) for the 1-year time horizon. Further, the AQoL-8D utility change from baseline 
to 1 year was statistically significant (p = 0.04), whereas only a trend was observed for the EQ-
5D-5L (p = 0.25) (Table 2; Fig. 1). When we compared preoperative versus 1-year 
postoperative utility increases to BMI reductions over the same time horizon, we found that for 
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every 1.0-unit reduction in BMI, the AQoL-8D utility valuation increased 0.02 units, compared 
with a 0.01 increase in utility for the EQ-5D-5L. 
Another important finding was that from 3 months to 1 year postoperatively, the mean EQ-
5D-5L utility valuation showed a slight decrease, by 0.02 utility points, whereas the mean 
AQoL-8D utility valuation gave rise to the third of the identified increases in utility for this 
instrument across the three time points (+0.06 utility points). An increase was also observed 
in the EQ-VAS scores from 3 months to 1 year. Notwithstanding these general trends, all 
changes from the reported 3 months to 1 year time point were not statistically significant 
(Table 2). 
After surgery, utility valuations at the individual level for both instruments were not normally 
distributed and the AQoL-8D revealed a wider dispersion (Fig. 2). 
Subgroup analyses revealed that the orders of magnitudes, general trends, and significance 
testing of all our findings were robust when only the full-completers (n = 9) were analysed 
(Tables 2, 3). For example, from before surgery to 1 year after surgery, we found that the 
AQoL-8D’s improvement in utility score 1 year after surgery was 0.15 points and the BMI 
reduction was 8.0 BMI units as compared with 0.16 utility points and a BMI reduction of 8.5 
BMI units for the entire cohort (Tables 2 and 3). 
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Table 2: Comparison of study participants (total participants n = 23) BMI, summary health state 
utility valuations for the EQ-5D-5L and the AQoL-8D, and EQ-VAS scores before and 3 months and 
1 year after bariatric surgery, and sensitivity analyses for full completers (n = 9). 
(n=23) 
 
Before 
surgery 
3 months 
after surgery 
 
1 year 
after surgery 
Change in mean  
from 3 months to 1 
year after surgery 
and  
ToS**(p0.05) 
Change in mean 
from before 
surgery to 1 year 
after surgery and 
ToS** (p0.05) 
Years on public  
waiting list  
Mean (SD) 
 
 
6.5 (2.0) † 
    
 
BMI (kg/m²) 
Mean (SD) 
 
 
(n=21) 
49.3 (9.3)* 
 
 
(n=21) 
43.5 (7.2) 
 
(n=22) 
40.8 (7.0) 
 
-2.7 BMI points 
p=0.40 
 
- 8.5 BMI points 
p=0.02** 
%TWL  
Mean (SD) 
 
 
NA 
 
NA 
 
 
16% (7.1) 
 
NA 
 
16% 
%EWL  
Mean (SD) 
 
NA 
 
NA 
 
34% (14.9) 
 
NA 
 
34% 
MAUIs’ HSUVs 
and 
EQ-VAS scores 
(n=x) 
 
Before 
surgery 
3 months 
after surgery 
 
1 year 
after surgery 
Change in mean  
from 3 months to 1 
year after surgery 
and  
ToS**(p0.05) 
Change in mean 
from before 
surgery to 1 year 
after surgery and 
ToS** (p0.05) 
 
EQ-5D-5L 
Mean (SD) 
 
Median (IQR) 
 
 
(n=16) 
0.70 (0.25) 
 
0.73 (0.54 - 0.91) 
 
(n=19) 
0.80 (0.25) 
 
0.84 (0.59 – 0.86) 
 
(n=18) 
0.78 (0.25) 
 
0.86 (0.67 – 0.93) 
 
 
- 0.02 utility points 
p=0.92 
 
 
+0.08 utility points 
p=0.25 
AQoL-8D 
Mean (SD) 
 
 
Median (IQR) 
 
(n=15) 
0.51 (0.24) 
 
 
0.51 (0.29 – 0.78) 
(n=18) 
0.61 (0.24) 
 
 
0.58 (0.43 – 0.78) 
(n=17) 
0.67 (0.23) 
 
 
0.67 (0.48 – 0.86) 
 
+0.60 utility points 
p=0.66 
 
+0.16 utility points 
p=0.04** 
EQ-VAS 
Mean (SD) 
 
 
Median (IQR)  
 
(n=16) 
57 (25) 
 
 
65 (34 – 73) 
(n=19) 
67 (24) 
 
 
65 (48 – 90) 
(n=18) 
73 (19) 
 
 
80 (56 – 90) 
 
+6 points 
p=0.31 
 
+16 VAS score 
p=0.08 
Sub group analysis* 
(n=9) 
 
Before 
surgery 
Three months 
after surgery 
 
One year 
after surgery 
Change in mean  
from 3 months to 1 
year after surgery 
and  
ToS**(p0.05) 
Change in mean 
from before 
surgery to 1 year 
after surgery and 
ToS** (p0.05) 
BMI (kg/m²) 
Mean (SD) 
 
 
47.6 (7.4) 
 
43.6 (6.1) 
 
39.6 (6.4) 
 
4.0 BMI points 
 
 
-8.0 BMI points 
%TWL  
Mean (SD) 
 
NA 
 
NA 
 
 
16.6% (7.3) 
 
NA 
 
16.6 % 
%EWL  
Mean (SD) 
 
 
NA 
 
NA 
 
36.3% (15.8) 
 
NA 
 
36.3 % 
EQ-5D-5L utility 
Mean (SD) 
 
 
0.69 (0.21) 
 
0.80 (0.15) 
 
0.73 0.20) 
 
-0.07 utility points 
p =0.52 
 
+0.04 utility points 
p =0.26 
AQoL-8D utility 
Mean (SD) 
 
 
0.45 (0.19) 
 
0.57 (0.21)† 
 
0.60 (0.22) 
 
+0.03 utility points 
p =0.07 
 
+0.15 utility points 
p=0.01** 
 
EQ-VAS 
Mean (SD) 
 
59 (22) 
 
66 (22) 
 
67 (21) 
 
+1 VAS score 
 
 
+ 8 VAS score 
p =0.18 
BMI, body mass index; EWL, excess weight lost; HSUV, health state utility value; IQR, inter-quartile range; MAUI, multi-attribute utility 
instrument; NA, not applicable; SD, standard deviation; ToS, test of significance, TWL, total weight lost; VAS, visual analogue scale. 
† One long-term waitlisted patient’s time on the waiting list not available; * Full-completers subgroup analysis before and 3 months and 1 
year after bariatric surgery; ** ToS Wilcoxon rank test (p0.05). 
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  Table 3: Comparison of AqoL-8D individual and super dimension scores before and 3 months and 1 year after surgery  
  (total participants, n = 23), Australian population norms an subgroup (sensitivity analysis). 
 
 
(n=23) 
 
Before 
surgery 
(n=15) 
mean (SD) 
 
Three 
months 
after 
surgery 
(n=18) 
 
One year 
After surgery 
(n=17) 
 
Improvement in 
mean score 
preoperatively 
to 3 months and 
1 year 
postoperatively. 
 
Australian population norms 
 
Subgroup (sensitivity) analysis 
(n=9) 
45 – 54 year 
age group 
Total Before 
surgery 
One year  
after surgery 
Test of 
significance* 
(p0.05) 
AQoL-8D individual and 
super-dimensions 
         
Individual dimensions of 
physical health 
         
Independent Living 
 
0.69 (0.22) 0.75 (0.19) 0.79 (0.20) +0.06; 0.10 0.93 (0.12) 0.94 (0.11) 0.65 (0.20) 0.73 (0.21) p=0.14 
 
Senses 
 
0.81 (0.13) 0.83 (0.13) 0.84 (0.11) +0.02; 0.03 0.88 (0.10) 0.91 (0.10) 0.81 (0.14) 0.86 (0.12) p=0.29 
Pain 
 
0.56 (0.34) 0.62 (0.32) 0.67 (0.31) +0.06; 0.11 0.84 (0.21) 0.86 (0.19) 0.51 (0.31) 0.61 (0.30) p=0.22 
Individual dimensions of 
psychosocial health 
 
         
Happiness 
 
0.65 (0.16) 0.75 (0.15) 0.77 (0.13) +0.10; 0.12 0.77 (0.16) 0.80 (0.15) 0.61 (0.16) 0.76 (0.11) p=0.01** 
Coping 
 
0.67 (0.15) 0.76 (0.15) 0.79 (0.12) +0.09; 0.12 0.80 (0.16) 0.83 (0.15) 0.62 (0.10) 0.78 (0.09) p=0.01** 
Relationships 
 
0.62 (0.16) 0.67 (0.18) 0.71 (0.18) +0.05; 0.09 0.78 (0.16) 0.79 (0.16) 0.59 (0.17) 0.66 (0.16) p=0.08 
Self-worth 
 
0.65 (0.21) 0.76 (0.18) 0.75 (0.19) +0.11; 0.10 0.84 (0.16) 0.85 (0.15) 0.73 (0.19) 0.73 (0.18) p=0.03** 
Mental Health 
 
0.54 (0.12) 0.60 (0.15) 0.62 (0.19) +0.06; 0.08 0.67 (0.17) 0.69 (0.17) 0.53 (0.09) 0.59 (0.18) p=0.25 
Super dimensions 
 
         
Physical super dimension 
 
0.51 (0.29) 0.56 (0.27) 0.62 (0.26) +0.05; 0.11 0.79 (0.20) 0.83 (0.18) 0.46 (0.27) 0.55 (0.24) p=0.13 
Psychosocial super 
dimension 
0.25 (0.15) 0.37 (0.25) 0.41 (0.25) +0.12; 0.16 0.47 (0.24) 0.50 (0.24) 0.20 (0.11) 0.34 (0.23) p=0.008** 
HSUV 
 
0.51 (0.24) 0.61 (0.24) 0.67 (0.23) +0.10; 0.16 0.77 (0.20) 0.80 (0.19) 0.45 (0.19) 0.60 (0.22) p=0.01** 
      HSUV, health state utility valuation;  
      * Wilcoxon signed rank test significant at p  0.05 
      ** Significant result at (p < 0.05)  
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Figure 1: Comparison of the EQ-5D-5L and AqoL-8D health state utility valuations before surgery and 
3 months and 1 year after surgery. 
 
Figure 2: Frequency distributions of utility valuations at the individual level for the EQ-5D-5L (n = 
18) (a); and AQ-l-8D (n = 17) (b) for the entire cohort 1 year after bariatric surgery. 
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4.3.3 Assessment of individual domains of HRQoL: AQoL-8D individual and super 
dimension scores 
Table 3 provides a comparison of the AQoL-8D’s individual dimensions (Independent Living, 
Senses, Pain, Happiness, Coping, Self-worth, Relationships, and Mental Health) and Physical 
and Psychosocial super dimensions for the three reported time points, and subgroup analyses 
and significance testing for the full-completers subgroup from before surgery to 1 year after 
surgery. 
A key finding for our particular study population of long-term waitlisted patients a year after 
bariatric surgery was that all individual and super dimension scores within the AQoL-8D 
improved. The individual psychosocial dimensions of Happiness, Coping, and Self-worth 
improved the most over this time horizon (0.12, 0.12, and 0.10 point improvements, 
respectively). The individual physical dimensions of Independent Living and Pain also 
improved (0.10 and 0.11 points, respectively). Additionally, Happiness and Coping approached 
general population norms [48]. These results were robust to subgroup analysis of full-
completers of all three questionnaires (Table 3). Importantly, significance testing of the full-
completers’ results revealed that Happiness (p = 0.01), Coping (p = 0.01), Self-worth (p = 
0.03), and the Psychosocial super dimension (p = 0.008), and the summary AQoL-8D utility 
valuation (p = 0.01) were statistically significant (Table 3). 
4.4 Discussion 
Our exploratory study is the first study to investigate the HRQoL impacts using both the EQ-
5D-5L and AQoL-8D for a study population of severely obese, long-term publicly waitlisted 
patients who were then able to access bariatric surgery in 2015 because of a 2014 State 
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Government public policy decision to reduce waiting times and to surgically treat long-waiting 
patients. 
Our exploratory study suggested that the participants’ responses to the EQ-5D-5L and AQoL-
8D (76% response rate at 1 year of n=18 EQ-5D-5L) and n=17 (AQoL-8D)) generated clinical 
improvements in utility valuations and EQ-VAS scores from before surgery to 1 year after 
surgery (EQ-5D-5L utility valuation from 0.70 to 0.78; AQoL-8D 0.51 to 0.67), where the 
minimal important differences were exceeded.  
Another important finding was that the AQoL-8D’s increase in utility valuation (0.16 utility 
points) was twice that of the EQ-5D-5L increase (0.08 utility points) at 1 year, with the AQoL-
8D result statistically significant (and robust to subgroup analyses of the full-completers), 
albeit, for a small and exploratory cohort of long term publicly waitlisted patients who 
underwent bariatric surgery due to a public policy decision to reduce waiting lists. 
4.4.1 Public resource allocation to bariatric surgery: waiting lists and patient prioritisation 
Our exploratory study’s key findings highlighted two important and inextricably linked points 
regarding the assessment and utilisation of utility valuations for long-term waitlisted patients 
who subsequently undergo bariatric surgery. First, choice of an appropriate MAUI to 
preferentially capture and assess HRQoL for this study population is crucial. Second, 
suboptimal public resource allocation decisions regarding the ‘optimal’ amount of bariatric 
surgery will likely occur if utility valuations, as an input measure of health impact for health 
economic evaluation (specifically cost-utility analyses), are generated by an instrument that is 
not sensitive to this study population’s complex HRQoL. 
Health economic evaluation is an important resource allocation methodology because it 
provides decision-makers with comparable analyses to underpin decisions about committing 
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scarce healthcare resources to one use instead of another [14]. Cost-utility analyses of bariatric 
surgery to date have been dominated by use of the EQ-5D MAUIs [14]. Economic evaluation 
of interventions which affect HRQoL commonly employ cost-utility analyses which prioritise 
interventions according to the cost per quality-adjusted life-year. The estimation of quality-
adjusted life-years is increasingly based upon the utility valuations predicted from an MAUI 
[50]. One of our exploratory study’s key findings was that the AQoL-8D’s utility 
changes/impacts from before surgery to 1 year after surgery were twice the magnitude of the 
EQ-5D-5L. Additionally, the EQ-5D-5L reported a plateauing utility valuation from 3 months 
to 1 year, in contrast to the AQoL-8D, which revealed a clinical improvement. If the nominated 
instrument lacks sensitivity within a particular health context (or health domain), interventions 
(such as bariatric surgery) affecting health states where the chosen instrument’s sensitivity is 
low, will likely be disadvantaged [24, 50]. 
A recent study that investigated EQ-5D-5L utility valuations for patients who had undergone 
surgery at a Canadian Bariatric Centre for Excellence (n = 304 before surgery, n = 138 after 
surgery, 45% completion rate after surgery) found that mean utility valuation before and 1 year 
after surgery was 0.65 (before)/0.90 (after) utility points (for ‘other’ bariatric surgery) and 0.70 
(before)/0.90 (after) utility points (for Roux-en-Y bariatric surgery) [51]. These results are 
similar to the order of magnitude of our exploratory study’s EQ-5D-5L preoperative results. 
We note that the higher postoperative valuation for the Canadian study could be explained by 
the use of the Candadian scoring algorithm was used, or the low completion rate, arguably of 
patients who would rate themselves closer to perfect health (45% of patients only responding 
1 year postoperatively), and the EQ-5D-5L’s inability to detect health impacts closer to perfect 
health (ceiling effects). 
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In contrast, our study’s AQoL-8D preoperative summary utility valuations of mean (SD) 0.51 
(0.24) indicated a significantly diminished HRQoL for our study population before surgery that 
was also reflected in the AQoL 8D’s individual and super dimension scores. In turn, the AQoL-
8D’s ability to preferentially capture HRQoL (compared with the EQ-5D-5L) for our study 
population of long-term waitlisted patients who then subsequently underwent bariatric surgery 
is reflected in the reduced utility valuations. 
One of the key findings of our earlier research that conducted a head-to-head comparison of 
the two instruments was that the EQ-5D-5L and AQoL-8D are not interchangeable for people 
who had undergone bariatric surgery many years previously [24]. This study of long-term 
waitlisted patients also suggests that the AQoL-8D preferentially captures HRQoL and that the 
two instruments are not interchangeable for long-term waitlisted patients who subsequently 
undergo bariatric surgery. 
Recent evidence has found that utility valuations measured by the major MAUIs differ 
[namely, the EQ-5D-5L, SF-6D, Health Utilities Index (HUI) 3, 15D and AQoL-8D] [50]. 
Most of these differences can be explained by the descriptive/classification systems of the 
MAUIs. These ‘dominating’ differences are estimated to explain an average of 66% of the 
difference between utilities obtained by the MAUIs (i.e. EQ-5D-5L, SF-6D, HUI 3, 15D, and 
AQoL-8D) and 81% of the difference between the utilities of the EQ-5D-5L and AQoL-8D 
[50]. In turn, our study’s findings reflect the relative sensitivities of the EQ-5D-5L’s and 
AQoL-8D’s classification systems to our study population’s physical and psychosocial 
domains of health. The AQoL-8D’s changes in utility valuation were predominantly driven by 
the AQoL-8D’s individual psychosocial dimensions and Psychosocial super dimension scores. 
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The AQoL-8D’s utility valuations differed significantly from before surgery to 1 year after 
surgery, predominantly driven by the AQoL-8D’s individual psychosocial and Psychosocial 
super dimension scores. Cost-utility analyses of the health impacts for long-term waitlisted 
patients who subsequently undergo bariatric surgery should appropriately reflect these health 
impacts. Our findings are particularly important because cost-utility analyses of bariatric 
surgery are dominated by the EQ-5D MAUIs [14]. 
In summary, long-term publicly waitlisted patients are an important and emerging subgroup of 
bariatric surgery patients, yet there is a paucity of evidence regarding longitudinal HRQoL 
impacts for this population if they are successful in getting publicly funded bariatric surgery. 
Our findings show that previously long-waiting patients with substantially diminished HRQoL 
did show significant improvements in HRQoL after surgery. This is important in that it shows 
clearly that long-waiting patients should not be ‘written off’—they can still realise significant 
improvements in HRQoL outcome when ultimately treated. A recent cost-utility study from 
Sweden, the first study to quantify the potential impact of extensive waiting times on the costs 
and clinical outcomes of bariatric surgery, highlighted the necessity of reducing waiting lists 
and removing unnecessary barriers to allow greater utilisation of surgery for patients 
unresponsive to conservative medical management [10]. Nevertheless, addressing this issue, 
given the large gap between the demand for and supply of publicly funded bariatric surgery, 
which has resulted in protracted wait times for the procedure in countries such as Australia, 
Canada, and the UK [17, 52] and the longest of any surgical procedure in Canada (average 5 
years) [17], would require significant commitment and investment. 
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4.4.2 Weight status is only one factor contributing to complex HRQoL for long-term 
waitlisted patients who undergo bariatric surgery 
Another important finding of our study is that the AQoL-8D’s individual and super dimension 
scores identify psychosocial health as an important driver of holistic postoperative health 1 
year after bariatric surgery. The AQoL-8D’s Psychosocial super dimension almost doubled in 
magnitude from before surgery to 1 year after surgery, and this change was statistically 
significant. This result is validated by a recent systematic review of the literature regarding the 
quality-of-life outcomes of bariatric surgery, where the SF-36 was the most commonly used 
HRQoL instrument and the quality-of-life subscale for mental health showed improvements in 
three of the six included SF-36 studies [25]. Notably, none of these studies generated utility 
valuations or scores. Our study’s AQoL-8D Psychosocial super dimension result is also 
validated by recent literature which suggests that psychosocial health status increases up to 4 
years after bariatric surgery, but declines after this timeframe [22, 23]. Utility valuations have 
also been found to be independent predictors of health impacts [44]. Our study’s results also 
support our earlier findings that if the choice of MAUI appropriately captures the individual 
and study population’s physical and psychosocial health status through the sensitivity of the 
MAUI’s dimensions/classification system, then the MAUI’s predictive qualities could be a 
useful clinical measurement tool to rapidly and conveniently assess the intervention’s likely 
health impacts in individuals and for the study population [24].  
Our study also found that relative to BMI unit reductions, the AQoL-8D recorded 0.02-utility 
point increases for 1.0-BMI unit reductions, and for the EQ-5D-5L, 0.01- utility point increases 
for 1.0-BMI unit reductions. A recent study found that for the EQ-5D-3L, for a 1.0-unit BMI 
reduction there was a 0.0051–0.0075 increase in utility. Notwithstanding the differing 
classification systems and utility valuations of the two MAUIs, the AQoL-8D recorded a 
greater utility increase per unit of BMI reduction. We contend that this difference was driven 
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by the impact of psychosocial health—the AQoL-8D’s broader (depth and breadth) 
psychosocial classification system captured and assessed domains of health that are not ‘weight 
change’ or ‘BMI change’ related. Our findings are also supported by a recent cross-sectional 
study that compared quality of life measured by the Moorehead–Ardelt Quality of Life 
Questionnaire in obese patients 12–18 months after bariatric surgery that found there is a 
limited relationship between BMI and HRQoL [42]. 
In summary, we contend that the importance of psychosocial factors in driving the measured 
improvements in HRQoL should not be lost on policy-makers in allocating resources. Much 
recent debate on bariatric surgery has focused on the physical health impacts of weight loss, 
especially on its potential to avoid or mitigate the worst effects of diabetes. However, if much 
of the real health gain observed derives from psychosocial impacts, this may have important 
consequences for patient selection and prioritisation decisions. 
4.4.3 Increased mobility 
We also found that the AQoL-8D’s individual physical dimensions of Independent Living and 
Pain improved from before surgery to 1 year after surgery. A recent study that conducted 
proportional analysis for the EQ-5D 5L has found that mobility significantly increases 1 year 
after bariatric surgery [51]. The increases in the AQoL-8D individual physical dimensions of 
health and the Physical super dimension further support these findings. 
Only 10 of the 35 items of the AQoL-8D capture and assess the physical domains of health that 
inform the individual physical dimensions of Independent Living, Senses, and Pain. A recent 
study suggests that the AQoL-8D’s descriptive system is preferential to psychosocial health 
rather than physical health [53]. 
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4.4.4 Supporting qualitative evidence 
Some of our study’s participants participated in long interviews for an associated qualitative 
study regarding the support needs of patients waiting for publicly funded bariatric surgery [18]. 
The findings of this study indicated that waiting for bariatric surgery was commonly associated 
with a range of deleterious consequences including weight gain and deteriorating physical and 
psychosocial health [18]. These qualitative findings both support and provide further 
contextualisation and nuance to our study’s baseline AQoL-8D utility valuations and individual 
and Psychosocial and Physical super dimension scores that revealed substantially reduced 
summary utility valuations and scores that were well below the relative Australian population 
norms (Table 3). Our study has shown that our cohort’s HRQoL was substantially diminished 
before surgery, and this qualitative evidence also suggests it is likely that utility valuations and 
individual and super dimension scores could have been measurably lower for our unique cohort 
if long-waiting patients were left untreated. 
4.4.5 Limitations 
There are a number of limitations to our study. The first limitation is sample size. Nevertheless, 
our study was exploratory and we were provided with a novel opportunity to recruit participants 
from the long-term waitlisted patients subsequently fast-tracked for bariatric surgery through a 
government policy decision to reduce waiting lists. The second limitation is that all participants 
were operated on by the same surgeon in the same hospital. This could affect the 
generalisability of our results if scaled up to all bariatric surgery patients. The third limitation 
is that there is no control arm in the study. The observational nature of our study did not enable 
the recruitment of a control arm to elicit utility valuations. The fourth limitation is the use of 
the UK value set for the EQ-5D-5L because there is no Australian value set available for the 
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instrument. A fifth limitation is that overall, 25% of partcipants did not respond to the survery 
instruments suggesting that there could be a non-response bias particularly given the size of 
the study sample. The final limitation is that the sample is also at risk of participant selection 
bias, which could also affect the generalisability of our results. Recent evidence has found that 
public sector waiting times are years in duration in some countries and that there are physical 
(worsening of comorbidities and further weight gain) and psychosocial impacts for patients 
waiting for bariatric surgery. 
A strength of our study is the high response rate of 75% to the questionnaires across all three 
reportable time points. Additionally, our study is an exploratory study of long-term waitlisted 
patients and could inform larger confirmatory studies of HRQoL (particularly assessed through 
utilities derived from generic MAUIs) for long-term waitlisted patients who subsequently 
undergo bariatric surgery. 
4.5  Conclusions 
Our exploratory study of long-term waitlisted patients recruited opportunistically following a 
government policy decision to reduce waiting lists suggests that long-waiting bariatric surgery 
patients should not be ‘written off’ by healthcare planners; they can still realise significant 
improvements in HRQoL outcomes when ultimately treated, and this should be factored into 
patient prioritisation decisions. Addressing this issue given the large gap between the demand 
for and supply of publicly funded bariatric surgery in many countries would require significant 
commitment and investment. 
Ongoing improvements in psychosocial parameters from 3 months to a year post-surgery 
explained improvements in overall utility valuation measured by the AQoL-8D that were not 
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detected by EQ-5D-5L. Selection of a sensitive instrument is crucial to adequately measure 
changes in utility valuation and to accurately reflect changes in quality-adjusted life-years 
generated for cost-utility analyses. Cost-utility analyses for long term waitlisted patients for 
bariatric surgery should employ utility valuations from MAUIs that are sensitive to physical 
and psychosocial health changes. Only through comprehensive assessments of HRQoL impacts 
before and after surgery can we robustly inform public resource allocation decisions. We found 
that the AQoL-8D preferentially captures these health impacts compared with the EQ-5D-5L. 
Nevertheless, we also suggest that a larger confirmatory multi-centre study would be 
appropriate to test the findings of our exploratory single-centre study.  
Coupled with BMI assessment, pre-surgery utility valuations should be investigated as 
independent predictors of post-surgery HRQoL (particularly psychosocial health status) for 
morbidly obese, long-term waitlisted, bariatric surgery patients. 
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Appendix 
Appendix: Participants’ clinical and socio-demographic characteristics before and 1 year after surgery 
for the total fast-track cohort, the subgroup of participants who fully completed both MAUIs at all 3 
time points, and the subgroup of participants who were not full completers (n = 14). 
Characteristics 
 
Fast track cohort 
(n=23) 
Full-completers 
(n=9) 
Partial completers 
(n=14) 
Age years 
Mean (SD) 
 
50 (10) 
 
48 (11) 
 
52 (9) 
Sex 
(n = x, %) 
 
 
Male (10, 43 %) 
Female (13, 57 %) 
 
Male (4, 44 %) 
Female (5, 56 %) 
 
Male (6, 42 %) 
Female (8, 58 %) 
Number of years on  
public waiting list  
 
Mean (SD) 
 
 
 
 
6.5 (2.0) ** 
 
 
 
 
7.3 (2.5) 
 
 
 
 
6.1 (1.6) 
 
Number of participants  
in obesity category  
(n = x, %) 
 
Before surgery 
BMI  30 – 34.9 kg/m² (Class I) 
BMI  35 – 39.9 kg/m² (Class II) 
BMI  40 – 49.9 kg/m² (Class III) 
BMI  50 kg/m² * 
 
12 months after surgery 
BMI  30 – 34.9 kg/m² (Class I) 
BMI  35 – 39.9 kg/m² (Class II) 
BMI  40 – 49.9 kg/m² (Class III) 
BMI  50 kg/m²  
 
 
 
 
 
(1, 4 %) 
0 
(13, 57 %) 
(9, 39 %) 
 
 
(2, 10 %)  
(7, 33 %) 
(9, 43 %) 
(3, 14 %) 
 
 
 
 
 
0 
0 
(7, 78 %) 
(2, 11 %) 
 
 
(2, 14 %) 
(3, 21 %) 
(3, 21 %) 
(1, 11 %) 
 
 
 
 
 
(1, 7 %) 
0 
(6, 43 %) 
(7, 50 %) 
 
 
(3, 21 %) † 
(2, 14 %) 
(6, 43 %%) 
(2, 14 %%) 
BMI (kg/m²) 
Before surgery  
Mean (SD) 
 
 
 
49.3 (9.35)  
 
 
 
47.6 (7.4) 
 
 
 
49.9 (10.6) 
 
After surgery 
Mean (SD) 
 
 
43.5 (7.17) 
 
 
 
39.6 (6.4) 
 
 
 
41.6 (7.5) † 
 
% Total weight lost  
Mean (SD) 
 
16 (7.1) 
 
 
 
NA 
 
NA 
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Chapter 5: An exploratory study: A head-to-head comparison of 
the EQ-5D-5L and AQoL-8D for long-term publicly waitlisted 
bariatric surgery patients before and 3 months  
after bariatric surgery. 
 
Preface 
This chapter is the second of two longitudinal studies (Chapters 4 and 5) that were based on a 
unique cohort of long-term waitlisted patients (mean years on the waiting list 6.5 (standard 
deviation) 2.0 years) who were then provided with bariatric surgery due to a public policy 
decision to reduce waiting lists.  
Chapter 2 found that the EQ-5D is the most commonly used multi-attribute utility instrument 
in cost-utility analyses of bariatric surgery, however, the classification system of the EQ-5D 
focuses on physical health. In parallel with the previously published study (Chapter 4) that 
investigated the one year health impacts in long-term waitlisted patients, this current study also 
aimed to consolidate the findings of Chapter 3. Chapter 5 extends method of Chapter 3 by 
investigating all 13 dimensions (rather than 6 dimensions) of the two multi-attribute utility 
instruments supported by a longitudinal study design with a different cohort of bariatric surgery 
patients. 
In support of the findings from the previously published head-to-head comparison in Chapter 
3, Chapter 5 particularly highlights the depth and breadth of the AQoL-8D’s classification 
system as compared to the EQ-5D-5L. These findings support the superior discriminant 
sensitivity of the AQoL-8D across the individual dimensions of physical and psychosocial 
health. 
Dimensional comparisons found the individual dimensions that revealed the most similar 
distribution for both instruments were Pain/Discomfort (EQ-5D-5L) and Pain (AQoL-8D). 
Nevertheless, the AQoL-8D provided evidence of change in other domains of health that could 
be affected by pain, such as sleep, which impacts the Mental Health dimension. 
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This study also established clinically significant changes in psychosocial health even 3 
months after surgery. Chapter 5 also revelaled that people who languish for long periods 
on the public waiting list can endure the same substantially diminished health-related 
quality of life as someone with metastatic cancer or prolonged heart disease.  
The studies that comprise Chapters 4 and 5 of this thesis also investigated the emerging 
literature regarding the predictive capabilities of multi-attribute utility instruments in patient-
centred bariatric care. Prediction is more likely to be accurate when the instrument used 
for prediction takes account of the full range of the complex physical and psychosocial 
problems associated with the problem. This study’s findings suggest that the AQoL-8D is 
more likely to provide correct prediction than the EQ-5D-5L. 
This study provided much needed policy advice to the NHMRC project partner regarding the 
health gains that can still be realised when long-waiting bariatric surgery patients are ultimately 
treated, even there months after surgery. The study also provides the health economics 
community with further evidence (consolidating Chapter 3) that the AQoL-8D preferentially 
captures and assesses physical and psychosocial health-related quality of life for the broader 
bariatric surgery study population. 
Chapter 5 has been published in PharmacoEconomics – Open (Appendix 5A). A fee waiver 
was granted for this publication. 
Impact factor: PharmacoEconomics – Open is a new journal, nevertheless, the impact factor 
of PharmacoEconomics (the companion journal) is 3.63. 
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Abstract 
Background: Choice of a multi-attribute utility instrument (MAUI) that appropriately assesses an 
intervention’s health-related quality-of-life (HRQoL) impacts is a vital part of healthcare resource 
allocation and clinical assessment. 
Objectives: Our exploratory study compared the EuroQo (EQ)-5D-5L and Assessment of Quality of 
Life (AQoL)-8D MAUIs, which were used to assess the effect of bariatric surgery for a convenience 
cohort of long-term publicly waitlisted, severely obese patients. 
Methods: The study was conducted at the Hobart Private Hospital (Tasmania, Australia). To compare 
the sensitivity and instrument content of the two MAUIs, we used dimensional comparisons by 
investigating the distribution of patient-reported responses (number/percentage) across the MAUIs’ 
levels and dimensions; summary health-state utility valuations (utilities); and individual/super-
dimension scores (AQoL-8D) to investigate discriminatory power and HRQoL improvements 
preoperatively and 3 months postoperatively 
Results: Participants’ (n = 23) overall MAUI completion rate was 74%. Postoperative total weight loss 
was 9.9%.  EQ-5D-5L utilities were relatively higher pre- and post-operatively than AQoL-8D utilities 
[mean standard deviation (SD) EQ-5D-5L 0.70 (0.25) to 0.80 (0.25); AQoL-8D 0.51 (0.24) to 0.61 
(0.24)]. AQoL-8D Psychosocial super dimension was relatively low postoperatively [0.37 (0.25)], 
driving the instrument’s lower utility. These results were supported by the dimensional comparisons 
that revealed an overall greater dispersion for the AQoL-8D. Nevertheless, there were clinical 
improvements in utilities for both instruments. AQoL-8D utilities were lower than population norms; 
not so the EQ-5D-5L utilities. The AQoL-8D dimensions of Happiness, Coping, and Self-worth 
improved the most. 
Conclusions: AQoL-8D more fully captured the impact of obesity and bariatric surgery on HRQoL 
(particularly psychosocial impacts) for long-term waitlisted bariatric surgery patients, even 3 months 
postoperatively. AQoL-8D preoperative utility revealed our population’s HRQoL was lower than 
people with cancer or heart disease. 
 
Key points for decision makers 
 
The Assessment of Quality of Life (AQoL)-8D may have superior discriminatory sensitivity compared to the 
EuroQol (EQ)-5D-5L for long-term waitlisted severely obese bariatric surgery patients. 
There is potential for sub-optimal healthcare resource allocation if the selected multi-attribute utility 
instrument does not appropriately assess health-related quality-of-life (HRQoL) impacts for the bariatric 
surgery study population 
As an important and increasingly prevalent study population of bariatric surgery patients who inherently 
carry complex physical and psychosocial HRQoL needs, long-term waitlisted severely obese bariatric surgery 
patients showed improvements in HRQoL even 3 months postoperatively 
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5.1  Introduction 
Demand for publicly funded bariatric care in many countries is high; however, capacity is 
limited by healthcare funding decisions. Consequently, bariatric (metabolic, obesity or weight-
loss) surgery waiting lists are long [1, 2]. Prolonged delays generally exist for people waitlisted 
for primary bariatric surgery in public health systems in many countries, including Australia 
[3–5]. 
Whilst it is acknowledged that these protracted multi-year wait times are detrimental to the 
bariatric surgery candidate’s physical and psychosocial health [2, 6, 7], recent evidence has 
established that weight status is just one factor contributing to the complex health-related 
quality-of-life (HRQoL) needs of people who have received bariatric surgery [8, 9]. 
Nevertheless, there is a paucity of quantitative evidence regarding HRQoL impacts for long-
term waitlisted bariatric surgery patients who have experienced multiyear wait times on public 
waiting lists and then undergo bariatric surgery [10, 11]. 
Multi-attribute utility instruments (MAUIs) are a HRQoL assessment tool designed to rapidly 
and conveniently, assess and capture an individual’s health-state utility values through 
application of pre-established formulae/weights to the array of responses obtained on the 
MAUI’s questionnaire [9]. A MAUI is developed and defined with particular characteristics, 
including the number of questionnaire items; the depth and breadth of the 
descriptive/classification system; the number of health states described; the number of 
individual and super dimensions (if there are super dimensions); and the algorithmic range. 
For example, the number of health states described for the EuroQol (EQ)-5D-3L and 5L, Health 
Utilities Index (HUI) 3, 15D, Short-Form 6 Dimension (SF-6D), Quality of Well-Being (QWB) 
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and Assessment of Quality of Life (AQoL)-8D MAUIs range from 243; 3125; 972,000; 3.1 x 
1010; 18,000; 945; and 2.4 x 1023, respectively [12]. Additionally, many MAUIs target physical 
health within their descriptive/classification systems. For example, for the EQ-5D-5L, one of 
its five dimensions relates to psychosocial health (Anxiety/Depression) and four out of five 
relate to physical health (Mobility, Self-care, Usual Activities and Pain) [13]. In contrast, for 
the AQoL-8D, three of the instrument’s eight dimensions relate to physical health (Independent 
Living, Senses and Pain), and five of the eight dimensions relate to psychosocial health 
(Coping, Relationships, Self-worth, Happiness and Mental Health), and 25 of the 35 items 
(questions) inform the AQoL-8D’s five psychosocial dimensions [14, 15]. The SF-6D 
describes six dimensions, namely Physical Functioning, Role Limitations, Social Functioning, 
Pain, Mental Health and Vitality [12, 16]. Both the AQoL-8D and SF-6D describe composite 
physical and psychosocial dimensions, namely the Physical and Psychosocial super dimensions 
(AQoL-8D), and the Physical and Mental Component Summaries (SF-6D) [14, 17]. 
A small number of MAUIs dominate the economic evaluation literature. These include the EQ-
5D-3L (pre-cursor to the EQ-5D-5L), HUI 3 and SF-6D. A review of 1,663 studies between 
2005 and 2010 found that these three instruments accounted for 63%, 9.9%, and 8.8% of the 
total, respectively [12]. Four other instruments in the review, the 15D, HUI 2, AQoL, and 
QWB, were used in 7%, 4.6%, 4.2%, and 2.5% of the studies, respectively [18]. 
A recent cross-sectional study of patients who had received bariatric surgery in the private 
healthcare system many years previously [median [interquartile range (IQR)] 5 (3-8) years] 
found that the AQoL-8D and EQ-5D-5L instruments were not interchangeable for the study 
population [9]. Another recent study that investigated the 1-year health impacts for long-term 
waitlisted bariatric surgery patients (and complementary to this study using the same cohort of 
patients), suggested that the AQoL-8D preferentially captured HRQoL for the study population 
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1 year after surgery [11]. Importantly, this 1-year study did not directly compare the 
distributions of patient-reported responses across the depth and breadth of the MAUIs’ 
dimensions of health (dimensional comparisons) [11]. As a single MAUI instrument, the 
AQoL-8D captures the vast majority of domains considered crucial for people who are 
considering, or who have undergone, bariatric surgery [9]. 
The choice of MAUI should be influenced by the sensitivity of the instrument to a patient 
group’s health profile [9, 12]. If the choice of instrument does not appropriately capture and 
assess the individual’s and study population’s health profiles (particularly for complex physical 
and psychosocial HRQoL), vital healthcare information about a clinical intervention’s health 
impact will be omitted from important resource allocation and planning decisions [9]. 
Utility valuations are key health economic metrics that are an input measure in the assessment 
of quality-adjusted life years (QALYs) [19]. Utility valuations measure the strength of 
preference for a particular health state and are represented as a number on a scale where 1.0 
represents the best possible health state and 0.0 represents death. In principle, values less than 
zero are possible when a health state is worse than death [20]. Utility values assessed by MAUIs 
are not equivalent, with the difference between the descriptive/classification systems of the 
MAUIs the principal determinant [12]. Additionally, differences in descriptive/classification 
systems are estimated to explain an average of 66% of the difference between utilities obtained 
by MAUIs, and 81% of the difference between the utilities of the EQ-5D-5L and AQoL-8D 
[12]. 
MAUIs were not initially developed for clinical use; however, utility valuations can also be 
used to inform and/or predict clinical outcomes [21]. Clinicians have found that measuring 
utilities is of benefit to patient–clinical assessment, relationships, communication, and 
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management [22]. Many MAUIs (including the EQ-5D-5L and 3L, AQoL-4D, SF-6D, 15D 
and HUI) report minimal clinically important differences or minimal important differences for 
their utility valuations [23–28]. A minimal clinically important difference is the smallest 
difference in score in the outcome of interest that patients perceive as beneficial and which 
would mandate a clinical change in the patient’s management (both individually and 
collectively for a particular study population) [22, 23, 29, 30]. 
There is a paucity of evidence regarding short-term HRQoL impacts for people who have 
received bariatric surgery [31, 32]. A study published in 2007 provided 3-month (range 3–6 
months) HRQoL impacts of bariatric surgery using the SF-36 [33]. A second study published 
in 2001 provided 1-, 3- and 6-month HRQoL impacts of bariatric surgery using the SF-36, 
bariatric analysis and reporting outcome system (BAROS) and Moorhead-Ardelt quality-of-
life questionnaires [34]. Both studies found short-term improvements in the quality of life 
scores (however, these studies did not generate, nor investigate, utility valuations) after 
bariatric surgery. 
Whilst it is acknowledged that integrating patient-reported outcomes (PROs) in clinical 
practice has the potential to enhance patient-centred care [35], PROs are not yet routinely 
collected in bariatric care. A recent systematic review that identified and investigated 
prospective bariatric surgery studies that used validated PRO measures found that for PRO data 
to influence practice, well-designed and reported studies are required [36]. In turn, there is a 
potential for MAUIs to address this key gap regarding PROs in bariatric care subject to the 
particular MAUI’s capacity to capture, assess and describe the relevant health states of the 
study population. 
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The main objective of this exploratory study was to directly compare the discriminatory power 
of two different MAUIs, namely the EQ-5D-5L and the AQoL-8D, which were used to assess 
the effect of bariatric surgery using a cohort of long-term publicly waitlisted, severely obese 
patients who underwent bariatric surgery as part of a government policy initiative to reduce 
waiting lists. As a secondary objective, we also aimed to investigate the role of the two MAUIs 
in the analysis of individual patient health states. 
The EQ-5D suite of instruments dominates the clinical and economic literature, including that 
for bariatric surgery [14, 18]. Nevertheless, the AQoL-8D has been shown to have preferential 
psychometric properties compared to comparative MAUIs in study populations where the 
assessment of psychosocial health status is crucial, for example, intensive care unit (ICU) 
admissions (compared with SF-6D) [22] and people who had undergone bariatric surgery 
(compared with the EQ-5D-5L) [9, 11]. Additionally, a recent study that presented results from 
one of the broadest comparative surveys in terms of the range of diseases (arthritis, asthma, 
cancer, depression, diabetes, hearing loss and heart disease) and six MAUIs (EQ-5D-5L, SF-
6D, HUI 3, 15D, QWB and AQoL-8D), and countries (Australia, the USA, the UK, Canada, 
Norway, and Germany) found that the AQoL-8D is the most sensitive instrument for measuring 
mental health [37]. This study also found that the pain component of the EQ-5D-5L has a 
greater impact than it does in any other instrument, and that the EQ-5D-5L is the most sensitive 
instrument for measuring pain [37] 
Our exploratory study also investigated the relative magnitudes of the global utility valuations 
[12], clinical improvements of the utility valuations for both instruments, and also the impacts 
on individual domains of health through the AQoL-8D’s individual and super-dimension 
scores.  
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In parallel with our previously published study that investigated the 1-year health impacts in 
long-term waitlisted patients [11], this current study aimed to investigate the distribution of the 
patient-reported responses of the two MAUIs for this population of public healthcare long-
waiting bariatric surgery patients who inherently carry complex physical and psychosocial 
HRQoL needs. 
5.2  Methods 
5.2.1 Study design 
(i) Recruitment of participants 
Recruitment of our study participants is described in detail in our previously published study 
[11]. In summary, a Tasmanian government policy decision was made in 2014 to allocate 
additional and targeted public funds to provide morbidly obese, long-term waitlisted patients 
with bariatric surgery in 2015 [38]. All participants underwent laparoscopic adjustable gastric 
band (LAGB) surgery by the same surgeon in the Hobart Private Hospital. Laparoscopic 
banding was carried out using Apollo APS or APL bands, with adjustment ports attached to 
the left anterior rectus sheath [39]. Postoperative fluid diets were maintained for 3 weeks, with 
subsequent transition to normal foods, accompanied by instruction on eating technique and 
exercise. 
All data were de-identified. Ethics approval was granted by the University of Tasmania’s 
Health and Medical Human Research Ethics Committee (HMHREC) before our study’s 
recruitment of participants. 
(ii) The multi-attribute utility instruments and questionnaire completion 
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The selection and attributes of the EQ-D-5L and AQoL-8D MAUIs used in this study have 
previously been described in detail [11]. Another earlier study comparing the EQ-5D-5L and 
the AQoL-8D MAUIs for people who had undergone LAGB surgery many years previously 
provided a detailed summary of the divergent characteristics of the two purposively selected 
MAUIs [9, 11]. In summary, the two markedly different MAUIs were selected on the following 
basis: the EQ-5D-5L is the internationally prevalent instrument in economic evaluation 
(including the economic evaluation of bariatric surgery) [40]; four of the five instrument’s 
health domains/classifications (and items) focus on physical HRQoL; and it takes less than 1 
min to complete the EQ-5D-5L’s questionnaire [13]. The EQ-5D-5L also contains a visual 
analogue scale (EQ-VAS) [22]. In contrast, the AQoL-8D’s classification system is supported 
by psychometric principles and testing, and 25 of the instrument’s 35 items capture and assess 
five (from eight) psychosocial domains of health, and three physical domains of health. The 
AQoL-8D describes billions of health states and takes 5 min to complete [14, 15, 41]. 
Participants were asked to self-complete both instruments’ questionnaires before their bariatric 
surgery at the pre-admission preoperative clinics and at 3 months postoperatively. 
Postoperative questionnaires were mailed out for self-completion with an explanatory cover 
letter and reply-paid envelope enclosed. We evaluated EQ-5D-5L and AQoL-8D questionnaire 
completion by assessing the overall proportion of participants who completed the 
questionnaire(s) at the study’s two time points for whom an individual utility value could be 
generated. 
5.2.2 Data analysis 
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Participants with patient-reported HRQoL assessments for one or both instruments, for at least 
one time point where the MAUI algorithm (either instrument) could generate the instrument’s 
utility valuations or scores were included in the analyses.  
Descriptive baseline socio-demographic, clinical data, utility valuations and dimensional 
scores were presented as mean [standard deviation (SD)] and/or median (IQR) for continuous 
variables and frequency (%) for categorical variables. Body mass index (BMI) was calculated 
as weight (kg)/[height (m2)] and classified as obese (BMI 30–34.9 kg/m2), severely obese (BMI 
35–39.9 kg/m2), morbidly obese (BMI 40–49.9 kg/m2), and super obese (BMI 50 kg/m2) [42]. 
(i) Discriminant sensitivity: dimensional comparisons (both instruments) and 
dimensional scores (AQoL-8D). 
The relative discriminatory power of the instruments was investigated using two 
methodologies. 
First, we calculated the distribution of participant responses across the levels and dimensions 
(the depth and breadth) of both instruments. This was achieved by collating the participant-
reported response for each item and then calculating the percentage distribution of responses 
for each dimension [9, 16]. To illustrate, for the EQ-5D-5L individual dimension of 
Anxiety/Depression, the numbers of participants who gave each response level (1, 2, 3, 4 or 5) 
were converted to a percentage of the total number of participants in order to derive a ‘five-
level frequency distribution’. Detailed calculations for each item and dimension are provided 
in Appendix 1 [see the electronic supplementary material (ESM)]. Additionally, schematic 
representations of the dimensional comparisons were expressed as a percentage by calculating 
the average percentage before and after surgery. For example, the schematic representation of 
the physical dimensions of both instruments compared the average score of Mobility, Self-care, 
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Usual Activities and Pain for the EQ-5D-5L and Independent Living, Sense and Pain for the 
AQoL-8D for each level before and after surgery.  
Second, impacts on the individual domains of physical and psychosocial HRQoL were 
investigated through the AQoL-8D’s summary scores for the eight individual dimensions and 
two super dimensions. The EQ-5D-5L generates a single utility valuation for an individual; 
however, it does not generate individual or summary scores for each and every one of its five 
separate dimensions. 
(ii) Analyses of summary utility valuations and EQ-VAS scores 
Utility valuations were generated for the EQ-5D-5L using the most recent UK value based on 
directly elicited preferences, the valuation ranging from - 0.281 to 1.0 utility points [43, 44]. 
All five questions require a valid response to generate a utility score. EQ-5D population norms 
are sourced from UK data because there are no available Australian population norms [45]. For 
the AQoL-8D, we used the current version of the scoring algorithm incorporating Australian 
weights published on the AQoL group’s website (http://www.aqol.com.au) (valuation range 
+0.09 to 1.0 utility points). For the AQoL-8D’s scoring algorithm, an overall utility valuation 
can be generated with ten missing values scattered over all dimensions. Australian population 
norms were sourced from recently published valuations [41]. Individual and super-dimensional 
scores are also generated with the AQol-8D’s scoring algorithm. 
A minimal clinically important difference (or minimal important difference) is the smallest 
difference in score in the outcome of interest which patients perceive as beneficial and which 
would mandate a change in the patient’ management [23, 29, 30]. A recently reported 
composite minimal important difference for the EQ-5D-5L for chronic health conditions was 
reported as 0.04 utility points [46]. There is no established minimal important difference for 
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the AQoL-8D; however, a minimal important difference for the AQoL-4D has previously been 
reported as 0.06 utility points, with a 95% confidence interval of 0.03–0.08 utility points [24]. 
This study conservatively adopted the upper bound of 0.08 utility points as the proxy minimal 
important difference for comparison of the pre- and post-operative AQoL-8D utility valuations. 
The established minimal important difference for the EQ-VAS is 10 points [47]. It has been 
suggested that with the expanded use of HRQoL endpoints (for example, analyses of utility 
valuations and scores within vastly different MAUI classification systems), the interpretation 
of HRQoL in the context of minimal important differences is imperative [23]. In turn, our study 
has included the interpretation of minimal important differences in its comparison of the EQ-
5D-5L and AQoL-8D MAUIs. 
Statistical analyses were undertaken using IBM SPPS (version 22) or R (version 3.0.2). 
 
5.3  Results 
5.3.1 Participants’ characteristics and questionnaire completion 
Twenty-three participants were recruited to the study. For these participants, mean (SD) age 
was 50 (10) years, 43% were males, and mean (SD) and median (IQR) time on the public 
waiting list for bariatric surgery was 6.5 (2.0) and 6.3 (5.0–7.8) years, respectively. 
Table 1 provides pre- and postoperative results for BMI, percentage total weight lost and 
percentage excess weight lost. Before surgery 39% of participants were classified as super 
obese (BMI 50 kg/m2) and 57% were classified as morbidly obese (BMI 40–49.9 kg/m2). 
After surgery, there was a 26% reduction in the super-obesity category. Similarly, after surgery, 
the morbidly obese category was reduced by 17%. 
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In regard to questionnaire completion, there was a 74% completion rate of questionnaires 
overall [Tables 2, 3 and 4; Appendix 1 (see the ESM)]. 
Table 1: Number of participants (n=23) in obesity categories before and after surgery. 
 
  
Before surgery 
 
 
After surgery* 
 
Change 
 
BMI    
   Mean (SD) 49.3 (9.4) 43.5 (7.2) - 5.8 
   Median (IQR) 45.5 (41.6 – 55.4) 43.2 (38.7 – 49.6) - 2.3 
BMI (n = x; %)    
   BMI  30 34.9 kg/m² (Class I) (1, 4%) (2, 9%) (+ 1, + 6%) 
   BMI  35 39.9 kg/m² (Class II) 0 (7, 30%) (+ 7, + 33%) 
   BMI  40 - 49.9 kg/m² (Class III) (13, 57%) (9, 39%) (- 4, - 17%) 
   BMI  50 kg/m² ** (9, 39%) (3, 13%) (- 6, - 26%) 
Weight (kg)    
   Mean (SD) 139.7 (31.4) 125.9 (26.9) - 13.8 
   Median (IQR) 134.0 (118.8 – 161.5) 124.5 (106.9 – 142.2) - 8.1 
% Total weight lost    
   Mean (SD) NA 9.9 (6.2) NA 
   Median (IQR) NA 11.0 (3.7 – 15.0) NA 
% Excess weight lost    
   Mean (SD) NA 21.5 (13.1) NA 
   Median (IQR) NA 24.7 (12.6 – 28.2) NA 
      BMI, body mass index; IQR, interquartile range; SD standard deviation 
      N = 21*: 2 participants 3 month weight not available 
      ** super obese (50kg/m2) 
 
 
5.3.2 Sensitivity: dimensional comparisons 
The relative discriminatory power of the instruments was investigated using the dimensional 
comparisons outlined in section 2.2.1. 
Table 2 (supported by Appendix 1 in the ESM) presents the ‘before’ and ‘after’ surgery 
distribution of participant responses for both MAUIs’ 13 individual dimensions/domains of 
health across levels 1–5 (EQ-5D-5L) and levels 1 to 4–6 (AQoL-8D). Figure 1a–c also provide 
a schematic representation of the comparative distribution of the participants’ responses across 
levels 1–6 for all dimensions (Figure 1a), and for the physical dimensions of health for both 
instruments (EQ 5D-5L: Mobility, Self-care, Usual Activities and Pain; AQoL-8D: 
Independent Living, Senses and Pain) (Figure 1b), and the psychosocial dimensions of health 
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for both instruments (EQ-5D-5L: Anxiety/Depression; AQoL-8D: Coping, Mental Health, 
Relationships, Self-worth, Happiness) (Figure 1c). 
None of the participants responded to level 6 for the AQoL-8D items that provided for a level 
6 response [namely Independent Living (one item), Senses (two items: vision and hearing), 
Mental Health (one item) and Relationships (one item)] (Table 2 and Appendix 1). Table 2 and 
Figure 1a–c (supported by Appendix 1) revealed a more even dispersion of participant 
responses for the AQoL-8D than the EQ-5D-5L both pre- and postoperatively. The AQoL-8D 
more clearly distinguished between health states that are close to full health for the study 
population (Table 2, Figure 1a–c, Appendix 1). 
More specifically, postoperatively participants recorded 80% (76/95) of responses for the EQ-
5D-5L at level 1 (perfect health: I have no problems) and level 2 (I have slight problems), the 
highest recorded response at level 1 being 74% for Self-care (decreased from 81% before 
surgery) (Table 2; Appendix 1). These results highlight the EQ-5D-5L’s inability to distinguish 
between health states close to full/perfect health (utility score 1.0). Additionally, for the EQ-
5D-5L’s only psychosocial dimension of health (Anxiety/Depression), participants did not 
record responses at level 4 (I am severely anxious or depressed), nor level 5 (I am extremely 
anxious or depressed), indicating that the EQ-5D-5L’s only psychosocial dimension is 
relatively limited. Before surgery, only 6% of participants recorded both levels 4 and 5 for 
Anxiety/Depression (Table 2, Appendix 1, and Figure 1c). Participants recorded responses at 
level 4 (16%) for one of the EQ-5D-5L’s individual dimensions (Pain) after surgery (Table 2; 
Appendix 1). 
In contrast, participants’ postoperative responses to the AQoL-8D questionnaire were less 
concentrated in the upper levels (i.e. more evenly dispersed across the levels), with only 58% 
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(365/630) of responses recorded at levels 1 and 2 (Table 2, Figure 1a, and Appendix 1), the 
highest level being 41% for Senses. 
Participants also recorded responses at level 4 for all the AQoL-8D’s individual dimensions, 
and participants also recorded responses at level 5 for both Pain and Mental Health. 
Additionally, the lowest percentage of participants scored at level 1 for the AQoL-8D’s 
individual dimensions of Happiness (15%), Coping (19%) and Mental Health (26%) (Table 2; 
Appendix 1). Nevertheless, Happiness and Coping substantially improved and approached 
population norms (Table 3), and this result is also revealed with the improvement of 
participants’ preoperative scores at level 1 in Happiness (from 3% to 15%) and Coping (from 
11 to 19%) (Table 2; Appendix 1).  
The individual dimension that had the most similar distribution for both instruments across 
levels 1–5 was Pain/Discomfort for the EQ-5D-5L (level 1: 26%, level 2: 32%, level 3: 26%, 
level 4: 16% and level 5: 0%) and Pain for the AQoL-8D (level 1: 35%, level 2: 19%, level 3: 
31%, level 4: 13%and level 5: 2%) (Table 2; Appendix 1). Three of the 35 AQoL-8D items 
contribute to the dimension of Pain. These items capture and assess how often the respondent 
suffers for the first Pain item ‘serious pain’, for the second Pain item the severity of ‘pain or 
discomfort’, and for the third Pain item of how often pain interferes with usual activities. The 
EQ-5D-5L individual dimension of Pain/Discomfort assesses the level of severity of 
pain/discomfort (no pain/discomfort, slight, moderate, severe, extreme). 
5.3.3 Sensitivity: comparison of changes in utility valuations 
Table 4 provides summary statistics for the changes in both instruments’ utility valuations 
preoperatively to 3 months postoperatively. The EQ-5D-5L revealed relatively higher 
summary utility valuations than the AQoL-8D both before and after surgery. Specifically, the 
Chapter 5: An exploratory study: a head-to-head comparison of the EQ-5D-5L and AQoL-8D 
for long-term publicly waitlisted bariatric surgery patients before and 3 months after bariatric 
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order of magnitude of  the EQ-5D-5L’s mean utility valuations were 0.19 utility points greater 
than the mean AQoL-8D utility valuations  preoperatively and 3 months postoperatively. The 
AQoL- 8D particularly showed low summary utility valuations before surgery [EQ-5D-5L 0.70 
(0.25); AQoL-8D 0.51 (0.24)].  
Three months after surgery, the summary utility valuations revealed clinical improvements for 
both instruments.  Nonetheless, the AQoL-8D showed substantially lower postoperative 
summary utility valuations than the EQ-5D-5L. More specifically, the EQ-5D-5L utility value 
increased by 0.10 points from mean (SD) 0.70 (0.25) to 0.80 (0.25). Similarly, the AQoL-8D 
utility value increased by 0.10 points from 0.51 (0.24) to 0.61 (0.24) (Table 4).  After surgery, 
the EQ-5D-5L utility valuations approached comparable population norms, but not so the 
AQoL-8D’s utility valuations. The UK general population mean for the EQ-5D-5L is 0.86 [45], 
and for the AQoL-8D the general Australian population norm is 0.80 (0.19), and for the 45–
54-year age group, it is 0.77 (0.20) [41] (Table 4).  
Table 4 also provides mean (SD) pre- and postoperative EQ-VAS scores of 57 (25) to 67 (24) 
points, the difference equalling the established EQ-VAS minimal important difference of 10 
points. 
5.3.4 AQoL-8D individual/super-dimension scores 
Table 3 provides the AQoL-8D’s individual and super-dimension scores before surgery and 3 
months after surgery,  and the Australian population norms at the individual dimensional level 
for the general population and the 45–54-year age group. Additionally, Figure 2a, b provide a 
schematic representation of the individual and super-dimensional scores compared with the 
general Australian population norm. The EQ-5D-5L does not generate individual or super-
dimension scores.  
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Improvements were observed for all eight individual dimension scores and the two super-
dimension scores even 3 months after surgery. Three months after surgery, the Physical super 
dimension improved 0.05 points to mean (SD) 0.56 (0.27) points and the Psychosocial super-
dimension score improved 0.12 points to 0.37 (0.25) points. Of the eight individual dimensional 
scores, Self-worth and Happiness improved the most 3 months after surgery by revealing gains 
of 0.11 points (Self-worth) and 0.10 points (Happiness). The postoperative scores for 
Happiness 0.75  (0.15) and Coping 0.76 (0.15) also approached both the 45–54-year age group 
and general population norms.  Happiness was only 0.02 points less than the 45–54-year age 
group population norm and Coping was only 0.04 points less than the 45–54-year age group 
population norm. 
Other individual dimensional scores that improved by 0.05 points after surgery were Coping 
(0.09 points), Mental Health (0.06 points) and Relationships (0.05 points), which contribute to 
the Psychosocial super dimension. With regard to the Physical super dimension, Independent 
Living and Pain both improved 0.06 points and Senses showed a smaller improvement of 0.02 
points (Table 3). 
As mentioned previously, the cohort’s HRQoL before surgery was substantially lower in 
comparison to population norms (Table 3; Figure 2a, b). Individual dimensional scores 
improved 3 months postoperatively, but did not substantially approach Australian population 
norms, with the exception of two dimensions: Happiness and Coping (Table 3; Figure 2a). The 
Psychosocial and Physical super dimensions’ scores, while improved, were still substantially 
lower than the Australian general population norm at- 0.13 and - 0.27 points, respectively. The 
Physical super-dimension score was driven by the Pain dimension scoring 0.24 points less than 
the general population norm. Independent Living and Relationships also revealed large 
differences, scoring -0.19 and - 0.13 points from the general population norm. Similarly, 
Chapter 5: An exploratory study: a head-to-head comparison of the EQ-5D-5L and AQoL-8D 
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Mental Health/Self-worth and Senses also revealed scores of 0.09/0.09 and 0.08 less than their 
Australian general population norm equivalents, respectively. In contrast, the individual 
dimensions of Happiness and Coping approached both the general and 45–54-year age group 
population norms (Table 3; Figure 2a, b). 
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Table 2: Dimensional comparisons of response rates (%) for all individual dimensions of the EQ-5D-5L and AQoL-8D before surgery and 3 
months after bariatric surgery. 
 EQ-5D-5L       
 
 
 
AQoL-8D 
 
       
Physical super dimension Psycho-social super dimension   
 Mobility Personal  
Care 
Usual 
Activities 
 
Pain/ 
Discomfort 
Anxiety/ 
Depress-ion 
 Independ-
ent Living  
(4 items) 
Pain 
 
(3items) 
Senses 
 
(3items) 
Coping 
 
(3 items) 
Mental  
Health 
(8 items) 
Happiness 
 
(4 items) 
Relation-
ships 
(7 items) 
Self  
Worth 
(3 items) 
Before surgery  
(n=16) 
     Before 
surgery 
(n=15) 
 
 
 
 
   
 
   
 Level 1 38% 81% 50% 31% 25%,   Level 1 27 % 29 % * 31 %  11 % 19 %* 3 % 24 % * 18 %* 
 Level 2 25% 6% 13%, 13% 38%   Level 2 17 % 20 % 40 % 36 % 23 % 33 % 31 % 20 % 
 Level 3 31% 13% 25% 25% 25%   Level 3 30 % 27 % 29 % 29 % 36 % 42 % 29 % 33 % 
 Level 4 6% 0 13% 31% 6%   Level 4 18 % 18 % 0 20 % 15 % 17 % 9 % 24 % 
 Level 5 0 0 0 0 6%   Level 5 8 % 7 % 0 4 % 8 % 5 % 8 % 4 % 
 Level 6 NA NA NA NA NA   Level 6 0 NA 0 NA 0 NA 0 NA 
After Surgery 
(n=19) (%point change †) 
     After 
surgery 
(n=18) 
 
 
 
 
   
 
   
 Level 1 53% (+ 15) 74% (-7) 53%(+3) 26% (-5) 47% (+22)   Level 1 26% (-1) 35% (+6) *41% (+10) 19% (+8) 26%* (+7) 15% (+12) 33% (+9) 30% (+12) 
 Level 2 26% (+1) 21% (+15) 32%(+19) 32% (+19) 37% (-1)   Level 2 31% (+14) 19% (-1) 30% (-10) 44% (+8) 24% (+1) 38% (+5) 34% (+3) 26% (+6) 
 Level 3 21% (-10) 5% (- 8) 16% (- 9) 26% (+1) 16% (-9)   Level 3 29% (-1) 31% (+4) 26% (-3) 24% (-5) 44% (+8) 39% (-3) 23% (-6) 31% (-2) 
 Level 4 0 (-6) 0 (0) 0 (0) 16% (-15) 0 (-6)   Level 4 14% (-4) 13% (-5) 4% (+4) 13% (-7) 4%(-11) 8% (-9) 10% (+1) 13% (-11) 
 Level 5 0 (0) 0 (0) 0 (0) 0 (0) 0 (-6)   Level 5 0 (-8) 2% (-5) 0 (0) 0 (0) 1% (-7) 0 (-5) 0 (-8) 0 (-4) 
 Level 6 NA NA NA NA NA   Level 6 0 (0) NA 0 (0) NA 0 (0) NA 0 (0) NA 
Detailed calculations supporting Table 2 are contained in Appendix 1 
AQoL-8D items: AQoL-8D Independent Living: 4 aqol items: household tasks levels 1-5, getting around levels 1-6, mobility levels 1-6, self-care levels 1-5; AQoL-8D Pain: 3 aqol items: frequency of pain levels 1-4, 
degree of pain levels 1-4, pain interference levels 1-5; AQoL-8D Senses: 3 aqol items: vision levels 1-6, hearing levels 1-6, communication levels 1-4;  AQoL-8D Coping: 3 aqol items: energy levels 1-5, being in control 
levels 1-5, coping with problems levels 1-5; AQoL-8D Mental Health: 8 aqol items: feelings of depression levels 1-6, trouble sleeping levels 1-5, feelings of anger levels 1-5, self-harm levels 1-5, feeling despair levels 
1-5, worry levels 1-5, sadness levels 1-5, tranquillity/agitation levels 1-5; AQoL-8D Happiness: 4 aqol items: contentment levels 1-5, enthusiasm levels 1-5, degree of feeling happiness levels 1-5, pleasure levels 1-5; 
AQoL-8D Relationships:7 aqol items: relationship with family and friends levels 1-6 and levels 1-5, social isolation levels 1-5, social exclusion levels 1-5, intimate relationship levels 1-5, family role levels 1-5 community 
role levels 1-4; and AQoL-8D Self-worth:3 aqol items: feeling like a burden levels 1-5, worthlessness levels 1-5, confidence levels 1-5. 
AQoL, Assessment of quality of life 
*  Columns add to 99 or 101% due to rounding 
†Figure in brackets after surgery reflects the percentage point change (i.e. ‘after surgery’ minus ‘before surgery’) 
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Table 3: Comparison of the AqoL-8D individual and super-dimension scores before surgery and 3 
months after surgery (total participants; n=23), and Australian population norms for total population 
and 45-54 year age group. 
 
 
 
 
Before bariatric surgery 
(n=15) 
 
After bariatric surgery 
(n=18) 
 
 
Improvement  
in mean score 
preoperatively 
to three months 
postoperatively  
 
Australian 
population norms 
 
(45–54 
years) 
Total 
AQoL-8D individual 
and super-dimensions 
 
Mean (SD) 
 
Min Max Mean (SD) 
 
Min Max Change Mean (SD) Mean (SD) 
Dimensions of physical 
health 
  
         
Independent Living 
 
0.69 (0.22) 0.39 1.00 0.75 (0.19) 0.41 1.00 + 0.06  0.93 (0.12) 0.94 (0.11) 
Senses 
 
0.81 (0.13) 0.56 1.00 0.83 (0.13) 0.59 1.00 + 0.02 0.88 (0.10) 0.91 (0.10) 
Pain 
 
0.56 (0.34) 0.16 1.00 0.62 (0.32) 0.21 1.00 + 0.06 0.84 (0.21) 0.86 (0.19) 
Dimensions of 
psychosocial health 
 
         
Happiness 
 
0.65 (0.16) 0.32 0.85 0.75 (0.15) 0.51 1.00 + 0.10 0.77 (0.16) 0.80 (0.15) 
Coping 
 
0.67 (0.15) 0.39 0.96 0.76 (0.15) 0.51 1.00 + 0.09 0.80 (0.16) 0.83 (0.15) 
Relationships 
 
0.62 (0.16) 0.47 1.00 0.67 (0.18) 0.47 1.00 + 0.05 0.78 (0.16) 0.79 (0.16) 
Self-worth 
 
0.65 (0.21) 0.35 1.00 0.76 (0.18) 0.39 1.00 + 0.11 0.84 (0.16) 0.85 (0.15) 
Mental Health 
 
0.54 (0.12) 0.28 0.73 0.60 (0.15) 0.36 0.96 + 0.06 0.67 (0.17) 0.69 (0.17) 
Super-dimensions 
 
         
Physical super 
dimension 
 
0.51 (0.29) 0.18 0.97 0.56 (0.27) 0.22 1.00 + 0.05 0.79 (0.20) 0.83 (0.18) 
Psycho-social super 
dimension 
0.25 (0.15) 0.08 0.49 0.37 (0.25) 0.12 0.97 + 0.12 0.47 (0.24) 0.50 (0.24) 
Utility value for AQoL-
8D 
 
0.51 (0.24) 0.20 0.83 0.61 (0.24) 0.29 1.00 + 0.10 0.77 (0.20) 0.80 (0.19) 
Max, maximum; Min, minimum; SD, standard deviation. 
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Table 4: Summary statistics for EQ-5D-5L and AQoL-8D at baseline (before surgery), difference between the two measures at baseline, and 
changes in the participants’ scores over 3 months of follow up (total participants; n = 23). 
 
 
  
 
 
EQ-5D-5L  
(baseline)  
(n=16) 
EQ-5D-5L  
(after surgery) 
(n=19) 
EQ-5D-5L change 
(after surgery - 
baseline) 
AQoL-8D  
(baseline) 
(n=15) 
AQoL-8D  
(after surgery) 
(n=18) 
AQoL-8D  
change (after 
surgery - 
baseline) 
Difference in 
baseline/after 
surgery scores: 
(EQ-5D-5L - 
AQoL-8D) 
EQ-VAS 
(baseline) 
(n=16) 
EQ-VAS  
(after surgery) 
(n=19) 
EQ-VAS change 
(baseline to three 
months) 
Mean 
 
0.70 0.80 0.10 0.51 0.61 0.10 0.19 / 0.19 57 67 10 
SD 
 
0.25 0.25 0 0.24 0.24 0 0.01 / 0.10 25 24 (1) 
Median 
 
0.73 0.84 0.11 0.51 0.58 0.07 0.22 / 0.29 65 65 0 
IQR 
 
0.54 – 0.91 0.59 - 0.86 NA 0.29 – 0.78 0.43 – 0.78 NA NA 34 – 73 48 – 90 NA 
Minimum 
 
0.24 0.46 0.22 0.20 0.29 0.09 0.04 / 0.17 15 27 12 
Maximum 
 
1.00 1.00 0 0.83 1.00 0.17 0.17 / 0 95 99 4 
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Appendix 1 – Electronic Supplementary Material: Detailed calculations of the dimensional comparisons of response rates for all individual 
dimensions of the EQ-5D-5L and AQoL-8D 
EQ-5D-5L 
 
       
 
 
 
AQoL-8D 
 
       
Physical super dimension components Psychosocial superdimension components   
 Mobility Personal  
Care 
Usual 
Activities 
 
Pain/ 
Discomfort 
Anxiety/ 
Depression 
 Independent 
Living  
(4 items) 
Pain 
 
(3 items) 
Senses 
 
(3 items) 
Coping 
 
(3 items) 
Mental  
Health 
(8 items) 
Happiness 
 
(4 items) 
Relationships 
 
(7 items) 
Self  
Worth 
(3 items) 
Before surgery 
(n=16)  
(% = X/16) 
      Before surgery 
(n=15) 
(% = X/[15*items]) 
 
 
 
 
   
 
   
 Level 1 38 %, (6/16) 81 %,(13/16) 50 %, (8/16) 31 %, (5/16) 25 %, (4/16)   Level 1 27 %, (16/60) 29 %, (13/45) 31 %, (14/45) 11 %, (5/45) 19 %, (23/120) 3 %, (2/60) 24 %, (25/104)** 18 %, (8/45) 
 Level 2 25 %, (4/16) 6 %, (1/16) 13 %, (2/16) 13 %, (2/16) 38 %, (6/16)   Level 2 17 %, (10/60) 20 %, (9/45) 40 %, (18/45) 36 %, (16/45) 23 %, (27/120) 33 %, (20/60) 31 %, (32/104) 20 %, (9/45) 
 Level 3 31 %, (5/16) 13 %, (2/16) 25 %, (4/16) 25 %, (4/16) 25 %, (4/16)   Level 3 30 %, (18/60) 27 %, (12/45) 29 %, (13/45) 29 %, (13/45) 36 %, (43/120) 42 %, (25/60) 29 %, (31/104) 33 %, (15/45) 
 Level 4 6 %, (1/16) 0 13 % , (2/16) 31 %, (5/16) 6 %, (1/16)   Level 4 18 %, (11/60) 18 %, (8/45) 0 20 %, (9/45) 15 %, (18/120) 17 %, (10/60) 9 %, (9/104) 24 %, (11/45) 
 Level 5 0 0 0 0 6 %, (1/16)   Level 5 8 %, (5/60) 7 %, (3/45) 0 4 %, (2/45) 8 %, (9/120) 5 %, (3/60) 8 %, (7/104) 4 %, (2/45) 
 Level 6 NA NA NA NA NA   Level 6 0 NA 0 NA 0 NA 0 NA 
After surgery 
(n=19) 
(% = X/19) 
      After surgery 
(n=18) 
(% = X/[18*items]) 
 
 
 
 
   
 
   
 Level 1 53 %, (10/19) 74 % (14/19) 53 %, (10/19) 26 %, (5/19) 47 %, (9/19)   Level 1 26 %, (19/72) 35 %, (19/54) 41 %,(22/54)* 19 %, (10/54) 26 %, (38/144) * 15 %, (11/72) 33 %(41/125)** 30 %, (15/54) 
 Level 2 26 %, (5/19) 21 % (4/19) 32 %, (6/19) 32 %, (6/19) 37 %, (7/19)   Level 2 31 %, (22/72) 19 %, (10/54) 30 %, (16/54) 44 %, (24/54) 24 %, (35/144) 38 %, (27/72) 34 %, (43/125) 26 %, (13/54) 
 Level 3 21 %, (4/19) 5 %, (1/19) 16 % (3/19) 26 %, (5/19) 16 %, (3/19)   Level 3 29 %, (21/72) 31 %, (17/54) 26 %, (14/54) 24 %, (13/54) 44 %, (63/144) 39 %, (28/72) 23 %, (29/125) 31 %, (15/54) 
 Level 4 0 0 0 16 %, (3/19) 0   Level 4 14 %, (10/72) 13 % (7/54) 4 %, (2/54) 13 %, (7/54) 4 %, (6/144) 8 %, (6/72) 10 %, (12/125) 13 %, (5/54) 
 Level 5 0 0 0 0 0   Level 5 0 2 %, (1/54) 0 0 1 %, (2/144) 0 0 0 
 Level 6 NA NA NA NA NA   Level 6 0 NA 0 NA 0 NA 0 NA 
Notes:  
AQoL-8D Independent Living: 4 aqol items: household tasks levels 1-5, getting around levels 1-6, mobility levels 1-6, self-care levels 1-5;  
AQoL-8D Pain: 3 aqol items: frequency of pain levels 1-4, degree of pain levels 1-4, pain interference levels 1-5; 
AQoL-8D Senses: 3 aqol items: vision levels 1-6, hearing levels 1-6, communication levels 1-4; 
AQoL-8D Coping: 3 aqol items: energy levels 1-5, being in control levels 1-5, coping with problems levels 1-5;  
AQoL-8D Mental Health: 8 aqol items: feelings of depression levels 1-6, trouble sleeping levels 1-5, feelings of anger levels 1-5, self-harm levels 1-5, feeling despair levels 1-5, worry levels 1-5, sadness levels 1-5, 
tranquillity/agitation levels 1-5; 
AQoL-8D Happiness: 4 aqol items: contentment levels 1-5, enthusiasm levels 1-5, degree of feeling happiness levels 1-5, pleasure levels 1-5; 
AQoL-8D Relationships:7 aqol items: relationship with family and friends levels 1-6 and levels 1-5, social isolation levels 1-5, social exclusion levels 1-5, intimate relationship levels 1-5, family role levels 1-5  
community role levels 1-4 
AQoL-8D Self-worth:3 aqol items: feeling like a burden levels 1-5, worthlessness levels 1-5, confidence levels 1-5. 
* percentage adds to 101 or 99 due to rounding 
** 1 missing response: algorithm allows 2 missing responses to generate health state utility values 
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Figure 1: (a) Distribution of participants’ responses (%) for levels (L) 1–5 for all dimensions of EQ-5D-5L and 
AQoL-8D before surgery and 3 months after surgery; (b) Distribution of participants’ responses (%) for Levels 
(L) 1–5 for the combined physical dimensions of EQ-5D-5L (Usual Activities, Self-care, Mobility, Pain) and 
AQoL-8D (Independent Living, Senses, Pain) before surgery and 3 months after surgery. c Distribution of 
participants’ responses (%) for Levels (L) 1–5 for the combined psychosocial dimensions of EQ-5D-5L 
(Anxiety/Depression) and AQoL-8D (Coping, Mental Health, Happiness, Relationships, Self-worth) before 
surgery and 3 months after surgery. 
Figure 1a 
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EQ-5D-5L five individual dimensions: Usual Activities, Self-
care, Mobility, Pain and Anxiety/Depression. 
AQoL-8D eight individual dimensions: Independent Living, 
Senses, Pain, Happiness, Coping, Relationships, Self-worth, 
Mental Health. 
EQ-5D-5L four physical dimensions: Usual Activities, Self-
care, Mobility and Pain. 
AQoL-8D three physical dimensions: Independent Living, 
Senses and Pain. 
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Figure 1: (a) Distribution of participants’ responses (%) for levels (L) 1–5 for all dimensions of EQ-5D-5L and 
AQoL-8D before surgery and 3 months after surgery; (b) Distribution of participants’ responses (%) for Levels 
(L) 1–5 for the combined physical dimensions of EQ-5D-5L (Usual Activities, Self-care, Mobility, Pain) and 
AQoL-8D (Independent Living, Senses, Pain) before surgery and 3 months after surgery. c Distribution of 
participants’ responses (%) for Levels (L) 1–5 for the combined psychosocial dimensions of EQ-5D-5L 
(Anxiety/Depression) and AQoL-8D (Coping, Mental Health, Happiness, Relationships, Self-worth) before 
surgery and 3 months after surgery. 
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Figure 2: (a) Comparison of 
before surgery and 3 months 
after bariatric surgery AQoL-
8D scores and Australian 
Population norms (APN) for 
the individual psychosocial 
dimensions (Happiness, 
Coping, Relationships, Self-
worth, Mental Health) and the 
Psychosocial super dimension. 
 
(b) Comparison of before 
surgery and 3 months after 
bariatric surgery AQoL-8D 
scores and Australian 
Population norms 
(APN) for the individual 
physical dimensions 
(Independent Living, Senses, 
Pain) and the Physical super 
Dimension. 
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5.4  Discussion 
Our study is important because it is the first study to investigate the relative discriminatory 
power using dimensional comparisons of all 13 individual dimensions of the EQ-5D-5L and 
AQoL-8D for patients who endured multiyear wait times in a public health system and then 
underwent bariatric surgery. 
As an important and emerging subgroup of bariatric surgery patients, our cohort also delivered 
an important and novel opportunity to provide clinicians with a better understanding of the 3-
month postoperative impact of bariatric surgery on long-term waitlisted patients’ complex 
physical and psychosocial domains of health. 
5.4.1 A head-to-head comparison of the EQ-5D-5L and AQoL-8D revisited 
In support of our findings from our previously published cross-sectional head-to-head 
comparison of privately treated patients who received bariatric surgery many years previously 
[9], this current longitudinal study revealed that the AQoL-8D preferentially captured and 
assessed the physical and psychosocial HRQoL for our cohort of long-term waitlisted patients 
who subsequently underwent bariatric surgery, even 3 months after their surgery.  
Amongst other direct comparisons of the discriminatory power of the two instruments, our 
earlier head-to-head  study’s comparison of the patient-reported distribution of the levels of 
response compared three (total six) individual comparable dimensions of both instruments 
(EQ-5D-5L: Anxiety/Depression, Self-care, Pain/Discomfort; AQoL-8D: Mental Health, 
Independent Living, Pain) [9]. In contrast, this current paper’s head-to-head comparison 
conducted a longitudinal investigation for a study population of long-term publicly waitlisted 
bariatric surgery patients who underwent bariatric surgery as a targeted government policy 
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decision to reduce waiting lists. Compared with our earlier study’s examination of six 
individual dimensions, we investigated the patient-reported distributions of responses for the 
dimensional comparisons of all 13 individual dimensions of health for both instruments. 
Consequently, this study included an additional four (of the five) psychosocial domains of 
health for the AQoL-8D’s classification system. 631 
This current study particularly highlighted the depth and breadth of the AQoL-8D’s 
classification system as compared to the EQ-5D-5L. Table 2 and Appendix 1 (see the ESM), 
coupled with schematic representations (Figure 1a–c) of the dimensional comparisons, 
revealed that the AQoL-8D assessed and captured HRQoL across the broad classification 
system and through the levels (1 to 4–6) (there were no reported responses for level 6 for the 
AQoL-8D) given the relative dispersion of participants’ responses away from perfect health. 
This is particularly highlighted with many of the responses for the EQ-5D-5L at level 1 (perfect 
health/ceiling effect) and level 2, compared to the AQoL-8D only recording just over half of 
the responses at levels 1 and 2. These findings support the superior discriminant sensitivity of 
the AQoOL-8D across the individual dimensions of physical and psychosocial health for the 
study population and as assessed in our previously published work [9].  
This study’s dimensional comparisons also found the individual dimension that revealed the 
most similar distribution for both instruments was Pain/Discomfort (EQ-5D-5L) and Pain 
(AQoL-8D). Therefore, our study’s results suggest that both instruments were sensitive to the 
individual health domain of pain for the study population. Nevertheless, the AQoL-8D 
provided evidence of change in other domains of health that could be affected by pain, such as 
sleep, which impacts the Mental Health dimension. 
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Another key finding of our current study was that the pre- and postoperative summary utility 
valuations for the EQ-5D-5L were substantially higher (and indeed approached general 
population norms after surgery) than the summary utility valuations of the AQoL-8D. The 
AQoL-8D’s relatively low preoperative and 3-month postoperative summary utility valuation 
revealed two important findings: first, the instrument’s superior discriminant sensitivity 
relative to the EQ-5D-5L for the study population due to the AQoL-8D’s ability to 
preferentially capture domains of health that are relevant for the study population; and second, 
the substantially lower (particularly preoperative) HRQoL for the long-term publicly waitlisted 
bariatric surgery patients. These findings also accord with evidence that suggests in practice all 
MAUIs which purport to measure utility give numerical values that differ significantly [12, 
41]. 
5.4.2 Utility valuations 
Another key finding of our current study was that change in global utility valuations from 
before to 3 months after bariatric surgery exceeded the established minimal important 
differences for both instruments, and for the EQ-VAS. The instruments’ summary utility 
valuations highlighted these long-term waitlisted bariatric surgery patients’ considerably 
diminished physical and psychosocial health status before surgery, and the postoperative 
summary utility valuations revealed a clinical short-term improvement within the 3-month 
timeframe. Nevertheless, as discussed previously, compared to the EQ-5D-5L, the AQoL-8D 
revealed substantially lower pre- and postoperative utility valuations that did not approach 
population norms. 
In particular, this study highlighted the substantially diminished preoperative AQoL-8D utility 
valuation for our study population. To provide a comparative perspective of the severity of our 
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study population’s diminished health state, a recent investigation that used data from a 
multinational (Australia, Canada, Germany, Norway, the UK and USA) cross-sectional survey 
found that for composite study populations of people with cancer or heart disease, the AQoL-
8D mean (SD) utility valuation for cancer was 0.655 (0.22), and for heart disease, it was 0.667 
(0.23) [48]. 
Therefore, our current study’s findings particularly revealed that the preoperative AQoL-
8D utility valuation for our cohort of severely obese long-term waitlisted patients was 
over 0.15 utility points less than that for a study population with cancer or heart disease. 
In other words, people who languish for long periods on the public waiting list can endure 
the same substantially diminished HRQoL status as someone with metastatic cancer or 
prolonged heart disease.  
As an independent measure of HRQoL, there is emerging literature that suggests that 
utility valuations could be independent predictors of health outcomes. A study that 
investigated the predictive qualities of utility valuations derived from the EQ-5D in 
patients with diabetes found that they were useful in predicting for health events, 
including cardiovascular events (e.g. stroke, hospitalisation for angina), other major 
diabetes-related complications (e.g. heart failure, amputation, renal dialysis and lower 
extremity ulcer) and death from any other cause [21]. Bariatric surgery patients carry 
complex physical and psychosocial comorbidity loads, and the assessment of utility 
valuations in routine clinical care could provide a better understanding of this complexity 
at an individual patient level, informing preoperative and ongoing postoperative care. 
Prediction is more likely to be accurate when the instrument used for prediction takes 
account of the full range of the complex physical and psychosocial problems associated 
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with the problem. Our study’s findings suggest that the AQoL-8D is more likely to provide 
correct prediction than the EQ-5D-5L. 
5.4.3 AQoL-8D’s individual and super dimension scores 
Another key finding of our current study was the substantially lower AQoL-8D dimensional 
scores before surgery and improvements in these dimensional levels after surgery. Happiness 
and Coping improved the most after surgery and indeed approached population norms. 
Additionally, Self-worth also revealed a substantial change. All other individual dimensions 
improved, but did not substantially approach population norms. Recent evidence has found that 
body weight is only one contributing factor to the complex physical and psychosocial HRQoL 
needs of bariatric surgery patients [8].  
5.4.4 Integrating patient-reported outcomes in clinical practice 
The International Society for Quality of Life Research has developed a clinical users guide 
to encourage the routine collection of PROs which ‘‘are rarely collected in routine clinical 
practice’’ [49]. Recent evidence has also found that integrating PROs in clinical practice 
has the potential to enhance patient-centred care. Within this broader and evolving 
context of patient-centredness in clinical care, our exploratory study highlighted the 
clinical relevance of MAUI analyses for long-term waitlisted patients who subsequently 
undergo bariatric surgery.  
This study found that psychosocial health drove a relatively lower utility valuation for the 
AQoL-8D, despite clinical improvements. We suggest that bariatric clinicians could also 
further investigate and subsequently integrate and implement utility valuation’s 
predictive qualities, and individual and super-dimension scores to further enhance 
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patient-centred clinical care. Further studies could assess the feasibility of adopting a 
MAUI that preferentially captures and assesses physical and psychosocial HRQoL into the 
routine clinical assessment of these patients. We previously identified in our earlier 
published work that the AQoL-8D preferentially captured physical and psychosocial 
health for patients who had undergone bariatric surgery (in the longer term) [9], a 
position reinforced by our current analysis. Through MAUI analyses, our current study 
established clinically significant changes in psychosocial health (albeit from a relatively 
low baseline to post-surgical dimensional scores that were still relatively low) that 
warrant additional attention after surgery to improve overall postoperative health. 
Additionally, our current study’s dimensional comparisons highlighted the EQ-5D-5L’s 
relative insensitivity in distinguishing between health states close to full (or perfect) 
health for long-term waitlisted patients who had very recently undergone bariatric 
surgery. 
5.4.5 Limitations 
There are limitations to our study. The first limitation is small sample size. Nevertheless, our 
study was exploratory and we were provided with a novel opportunity to recruit participants 
from the long-term waitlisted patients subsequently fast-tracked for bariatric surgery through a 
government policy decision to reduce waiting lists. Our exploratory study of long-term 
waitlisted patients should inform larger confirmatory studies to test the validity of the EQ-5D-
5L and AQoL-8D, and the short-term health impacts for long-term waitlisted patients. 
Nevertheless, we also acknowledge that a substantial commitment would need to be made at 
the public policy level to recruit a similar cohort of long-waiting patients. Other MAUIs such 
as the SF-6D could also be considered for larger confirmatory studies. The second limitation 
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is that all participants were operated on by the same surgeon in the same hospital. This could 
affect the generalisability of our results if scaled up to all bariatric surgery patients. On the 
other hand, this circumstance could also be a strength given the homogenous nature of the 
sample.  
The third limitation is that there is no control arm in the study. The observational nature of our 
study did not enable the recruitment of a control arm to elicit utility valuations; however, the 
key objective of this study was to compare the two MAUI. The final limitation is that the 
sample is at risk of participant selection bias, which could also affect the generalisability of our 
results.  
A relative strength of our study is the high overall response rate of 74% to the questionnaires 
across the two time points.  
The limitations of our study concur with our complementary study of the same cohort [11] 
5.5  Conclusions 
Within the small sample limitations of our exploratory study and to address the key objective 
of our study, which was a head-to-head comparison of the instruments, compared to the EQ-
5D-5L, the AQoL-8D preferentially captured the complex physical and psychosocial short-
term health changes for long-term publicly waitlisted patients who very recently underwent 
bariatric surgery. Importantly, researchers should understand a MAUIs 
descriptive/classification system and the innate sensitivities of the MAUI in regard to the 
particular study population, in this case long-term waitlisted patients who then undergo 
bariatric surgery. We recommend the AQoL-8D as a preferred MAUI over the EQ-5D-5L for 
bariatric surgery patients, given their complex physical and psychosocial needs.  
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In regard to our secondary objectives, utility valuations and dimensional scores (AQoL-8D 
only) revealed substantially lower health status for long-term waitlisted patients both before 
and after surgery, but with clinical short-term HRQoL improvements even 3 months after 
surgery. AQoL-8D preoperative utility valuation particularly revealed our study population’s 
HRQoL was substantially lower than that of people with cancer or heart disease. 
Dimensional comparisons, utility valuations, and individual and super-dimension scores could 
provide the clinician with both individual patient and cohort valuations that could lead to 
improved patient-centred care by identifying health domains requiring additional attention.  
Routine integration of comprehensive MAUI analyses could provide clinicians with additional 
and independent assessments and predictors of HRQoL and in turn, enhance patient-centred 
care. 
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Chapter 6: A qualitative investigation of the health economic 
impacts of bariatric surgery for obesity, and implications for 
improved practice in health economics. 
Preface 
Chapter 6 presents a qualitative health economics study to investigate the experiences of people 
waiting for, or who had received bariatric surgery.  
Chapters 6 and 7 harnessed the advantages of qualitative research methods to identify and 
contextualise crucial costs and consequences of bariatric surgery that have typically been 
omitted, or not provided with sufficient priority in the health economic investigation and 
reporting of bariatric surgery. 
The inspiration for the method of this qualitative study was partly generated from a conceptual 
synthesis of my PhD research’s earlier studies and partly from a broader review of the 
published literature during my PhD research. In regard to the earlier studies of this thesis, 
Chapter 2’s published systematic review identified the limited scope of costs and consequences 
for most health economic evaluation and reporting of bariatric surgery. The review 
recommended a more comprehensive investigation and reporting of health economic outcomes 
of bariatric surgery to identify aspects of the bariatric surgery patient’s journey that reached 
well beyond the primary surgery’s direct medical costs. Additionally, published Chapters 3, 4 
and 5 established that psychosocial health is a vital consideration for people who are waiting 
for and then undergo bariatric surgery. 
In regard to a broader review of the literature during my PhD research, I have found that over 
the past decade there has been a call for health economists to effectively integrate combinations 
of qualitative and quantitative methods into their research toolkit to enrich their research 
methodologies and therefore improve their practice in health economic study design, data 
gathering and analysis, reporting and ultimately research translation. Chapter 6 is consistent 
with this call for health economists to use qualitative methods in their research. In summary, 
this study employed qualitative research methods to broaden the evaluative space for the 
economic evaluation of bariatric surgery. The study achieved its objectives by frequent 
comparison of emergent thematic categories of the qualitative data (focus groups n=10; n=49 
Chapter 6: A qualitative investigation of the health economic impacts of bariatric surgery for 
obesity, and implications for improved practice in health economics. 
313 | P a g e
participants) with the pre-existing economic theories of emotional capital, economic 
perspective, and externalities. 
The study identified that emotional capital is a key consideration and that some patients 
experienced financial hardship to access their surgery. This finding particularly consolidates 
the findings of Chapters 3, 4 and 5 of this thesis that identified that psychosocial health is an 
important consideration for people waiting for or who undergo bariatric surgery. It also follows 
the recommendations of Chapter 2. 
This study was published in the highly regarded international health economics journal 
Health Economics. Please note that the Reference and Abstract style of this paper reflects 
the journal’s style. 
Impact factor: 2.3 
Campbell JA, Ezzy D Neil A, Hensher M, Venn A, Sharman MJ, and Palmer AJ. A qualitative 
investigation of the health economic impacts of bariatric surgery for obesity, and implications 
for improved practice in health economics. Health Economics. 2018 Aug;27(8):1300-1318. 
The published article found at the 
end of this chapter has been 
removed for copyright reasons. 
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Summary 
Obesity is an economic problem. Bariatric surgery is cost-effective for severe and resistant 
obesity. Most economic evaluations of bariatric surgery use administrative data sources and 
narrowly-defined direct medical costs in their quantitative analyses. Increased prevalence of 
severe obesity and resource-constrained healthcare budgets means demand far outstrips supply 
for bariatric surgery. In turn, additional allocation of healthcare resources to bariatric surgery 
(particularly public) could be further motivated by new and convincing health economic 
evidence that supports the provision of bariatric surgery. We postulated that qualitative 
research methods would elicit important health economic dimensions of bariatric surgery that 
would typically be omitted from the current economic evaluation framework, nor be reported 
and therefore not considered by policy-makers with sufficient priority. We listened to patients: 
focus group data was analysed thematically with software assistance. Key themes were 
identified inductively through a dialogue between the qualitative data and pre-existing 
economic theory (perspective; externalities; emotional capital). We identified the concept of 
emotional capital where participants described life-changing desires to be productive and 
participate in their communities postoperatively. After self-funding bariatric surgery, some 
participants experienced financial distress. To improve health economic practice, we 
recommend a mixed-methods approach to the economic evaluation of bariatric surgery. This 
could be operationalised within the current framework in helath economic model 
conceptualisation and construction, through to the separate reporting of qualitative results to 
supplement quantitative analysis. 
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6.1 Introduction 
6.1.1 Obesity and bariatric surgery 
(i) The health and economic burden of obesity 
Obesity is not just a public health problem, it is an economic problem (Ruhm, 2012, Cawley 
and Meyerhoefer, 2012, Wang et al., 2011, Cawley, 2015, Cawley, 2011, Lehnert et al., 2013, 
Gortmaker et al., 2011).  
Overweight and obesity are defined by the World Health Organization (WHO) as ‘abnormal 
or excessive fat accumulation that may impair health’ (WHO, October 2017). For adults, the 
WHO defines overweight and obesity as  overweight is a body mass index (BMI)  25 kg/m²; 
and obesity is a BMI  30 kg/m² (WHO, October 2017). Obesity is further categorised into 
three classes: Class 1 obesity (obesity) is defined as BMI 30.0 – 34.9 kg/m²; Class 2 obesity 
(severe obesity (Cawley, 2015)) is defined as BMI 35.0 – 39.9 kg/m²; and Class 3 obesity is 
defined as BMI  40.0 kg/m² (World Health Organisation, 2016, Keating et al., 2015). Recent 
clinical literature also describes a fourth class of obesity that is categorised as ‘super-obesity’ 
defined as a BMI of  50.0 kg/m² (Gould et al., 2006, Peterson et al., 2017).  
The current rates of obesity have been described as epidemic and severe obesity is increasing 
more rapidly than obesity (WHO, October 2017, Bray et al., 2017, Cawley, 2015). Nearly two-
thirds (63.4%) of Australian adults are overweight or obese, with Tasmania recording the 
highest prevalence of the Australian States and Territories (67.5%) and the prevalence trends 
are increased in areas of socio-economic disadvantage (AIHW, 2017, Huse et al., 2017, 
Keating et al., 2015). 
The economic burden of the obesity epidemic and its associated comorbidities places undue 
stress on healthcare systems (Withrow and Alter, 2011, Fallah‐Fini et al., 2017, Cawley, 2015, 
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Meyerhoefer and Cawley, 2016). People with obesity have medical care costs approximately 
30% greater than their normal weight peers (Withrow and Alter, 2011). Additionally, medical 
care costs rise exponentially in the range of Class 2 and Class 3 obesity (BMI 35 kg/m²) 
(Cawley et al., 2015). The most recent scholarly estimate of the total annual direct cost of 
overweight and obesity in Australia was estimated to be 21 billion Australian dollars in 2005 
and this estimate was substantially higher than previous estimates (Colagiuri et al., 2010). 
The economic burden of the obesity epidemic also extends well beyond the healthcare sector 
into societal domains including work productivity (Neovius et al., 2008, Wagner et al., 2007, 
Puhl, 2011, Lehnert et al., 2013, Goettler et al., 2017), and personal and family impacts arising 
from discrimination and stigmatisation of the overweight and obese both individually and 
collectively, poorer relationships and social engagement (Temple Newhook et al., 2013, 
Cawley, 2011). Some studies suggest that the costs of lost productivity due to obesity are 
several times larger than medical care costs (Wagner et al., 2007, Finkelstein et al., 2011). 
(ii) Bariatric surgery as a treatment option for obesity 
Bariatric (metabolic; weight loss) surgery is considered the most clinically efficacious 
treatment option for intractable severe and morbid obesity and bariatric surgery is increasing 
in prevalence (Buchwald and Oien, 2009, Buchwald and Oien, 2013, Angrisani et al., 2015a). 
Bariatric surgery results in greater weight loss and improvement in obesity-related 
comorbidities when compared with non-surgical intervention, regardless of the type of bariatric 
surgical procedure used (Colquitt et al., 2014, Angrisani et al., 2015b, Celio and Pories, 2016). 
Generally, bariatric surgery is recommended for people with resistant Class 3 obesity or 
resistant Class 2 obesity with obesity-related comorbidity (National Health and Medical 
Research Council, 2013, National Heart Lung and Blood Institute. United States Department 
of Health and Human Services, 1998, National Institute for Health and Care Excellence, 2014).  
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Demand for bariatric surgery far outstrips the supply of bariatric surgery places, particularly in 
public healthcare systems (Padwal et al., 2014, Gregory et al., 2013, Sharman et al., 2017, 
Campbell et al., 2016a, Campbell et al., 2017) Based on eligibility criteria, a recent Australian 
study determined that the potential demand for publicly- and privately-funded bariatric surgery 
in Australia was 882,441 adults aged between 18-65 years, with 45.8% of these potential 
bariatric surgery candidates having no private health insurance (Sharman et al., 2017). A recent 
Australian Institute of Health and Welfare (AIHW) study regarding weight loss surgery 
reported that in 2014–15, there were more than 22,700 weight loss surgery separations in 
Australia, most of which involved a primary procedure (79.4%) (AIHW, 2017). The majority 
of these bariatric surgery separations (88.0% or 20,000 separations) occurred in private 
hospitals (AIHW, 2017). Long-term publicly waitlisted bariatric surgery patients have recorded 
substantially diminished health-related quality of life (Campbell et al, 2017). 
Constrained public sector budgets contribute to the incapacity of the Australian public health 
system to address the problems of severe obesity increasing more rapidly than obesity 
(Campbell et al., 2016a, Willis et al., 2016). The problem of demand for bariatric surgery far 
outstripping supply, and constrained public sector budgets is reflected internationally (Owen-
Smith et al., 2013, Gill et al., 2014, Gagner, 2017, Hall, 2015, Campbell et al., 2017). 
Economic evaluation of bariatric surgery generally finds the intervention to be cost-effective 
for people with severe obesity compared to non-surgical interventions, and possibly cost-
saving as an intervention for severely obese people with type 2 diabetes (Borisenko et al., 2015, 
Campbell et al., 2016a). Nevertheless, our recent comprehensive systematic review of the 
health economic reporting of bariatric surgery that included 77 heterogeneous partial and full 
health economic evaluations found that most of the included studies were informed by 
administrative quantitative data and analyses, a narrow payer perspective rather than a broader 
Chapter 6: A qualitative investigation of the health economic impacts of bariatric surgery for 
obesity, and implications for improved practice in health economics. 
 
318 | P a g e  
societal perspective, and that out-of-pocket costs and productivity gains or losses were largely 
ignored (Campbell et al., 2016a). In turn, our review called for a more comprehensive 
investigation and reporting of the health economic outcomes of bariatric surgery to identify 
aspects of the bariatric surgery patient’s journey that reached well beyond the primary surgery’s 
direct medical costs (Campbell et al., 2016a). 
6.1.2 Pre-existing theories: emotional capital, economic perspective and externalities 
The pre-existing economic theories of emotional capital, perspective and externalities were 
adopted to inform the theory building of our qualitative study that investigated bariatric surgery 
patients’ experiences whilst waiting for (mean (range) years 5 (2-7)), or following their 
bariatric surgery (mean (range) years 6 (0-31)). These concepts are explored below. 
An important economic school of thought advocates that there is no behaviour that is not 
interpretable as economic (Becker 1962; Becker 2013). In turn, the concept of emotional capital 
was introduced by Gendron (2004) defined as ‘… the set of resources (emotional 
competencies) that inhere to the person useful for his or her cognitive, personal, social and 
economic development’. Emotional capital is vital for a person’s well-being and achievement 
in life, and crucial for an organisation’s success and survival: emotional capital shapes and 
conditions a person’s entire life (Gendron 2004; Gendron 2007). It has been postulated that 
emotional capital is a ‘booster capital’: a capital which potentiates or energises the human, 
social and cultural capitals. Additionally, emotional capital is critical to enable human capital 
formation, accumulation, and, its optimal exploitation for individuals (Gendron, 2004, 
Andrade, 2015). Emotional capital should be considered as a ‘capital’, a real asset in which 
people, institutions and the society should invest, as it has major returns for individuals (to 
allow well-being and sustainable personal development) and for society (social cohesion) for 
(individual and social) life (Gendron, 2007). 
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Health economic evaluation provides healthcare policy-makers and planners with analyses to 
underpin decisions about committing scarce healthcare resources to one use instead of another. 
They require costs and consequences be identified, measured valued and compared between 
alternatives (Drummond et al., 2015). Very few economic evaluations of bariatric surgery 
employ a broader societal perspective, and out-of-pocket costs and productivity losses are 
largely ignored. (Campbell et al., 2016a). 
External effects (externalities/spillovers) relate to the consequences of an action by one 
individual or group as they have an impact on others (Henderson, 2011, Culyer, 2014). The 
obesity epidemic imposes large external costs on society in the form of high medical costs and 
lower productivity which decrease social welfare: the costs of obesity extend to non-obese 
individuals (Cawley, 2015).  
6.1.3 Qualitative research in health economics: improving health economics practice? 
Over the past decade, there has been a call for health economists to effectively integrate 
combinations of qualitative and quantitative methods into their research toolkit to enrich their 
research methodologies and therefore improve their practice in health economic study design, 
data gathering and analyses, reporting, and ultimately research translation (Coast, 1999, Coast 
et al., 2004, Kelly et al., 2005, Smith et al., 2009, Obermann et al., 2013, Husbands et al., 2017). 
Additionally, health policy development, research, and management could benefit from more 
in-depth, textured descriptions of what actually happens in practice settings, healthcare 
markets, and patients’ lives (Greenhalgh et al., 2016, Weiner et al., 2011). Nevertheless, recent 
evidence has found that only 9 % of published health economic research adopts qualitative 
research methods (Obermann et al., 2013, Weiner et al., 2011). Importantly, qualitative 
research methods could particularly identify nuanced and policy-relevant arguments regarding 
health economic impacts because major sources of relevant information, such as detailed 
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knowledge of processes and context, goes untapped (Obermann et al., 2013).  
For example, little has been done to highlight the benefits of using qualitative approaches to 
inform health economic model development: the validity and reliability of health economic 
models are constantly under scrutiny leading people to question the results (Husbands et al., 
2017). It has been proposed that health economic modellers should consider the opportunities 
that qualitative methods provide to them. These opportunities include the application of 
qualitative techniques to model development processes in order to identify where problems are 
occurring and guidance is needed, and to contribute to the structural development of individual 
models (Husbands et al., 2017, van Voorn et al., 2016). In regard to health economic model 
conceptualisation (for health economic evaluation), patient involvement has been 
acknowledged as an important area requiring further research (Husbands et al., 2017, van 
Voorn et al., 2016). (Roberts et al., 2012). Furthermore, international guidelines regarding the 
conceptualisation of health economic models stated that consultations with patients may 
deepen understanding of the values and preferences relevant to the problem (ISPOR Taskforce 
2) (Roberts et al., 2012).  
There is also scope for augmenting the essential elements of economic evaluation with 
additional qualitative data to inform the context of the study (Kelly et al., 2005). Recently, 
qualitative methods have been used to inform trial design for a Health Technology Assessment 
with particular regard to patient narratives about the emotional, social and material 
environment (Morgan et al., 2015, Hoddinott et al., 2014).  
There is also a call for health economists to implement mixed-methods policy-relevant research 
that is embedded in and derived from real-world policy settings (Obermann et al., 2013, Coast 
et al., 2004, Daniels et al., 2016). Mixed-methods policy-relevant and translatable research can 
be successfully generated through research partnerships between knowledge-users (e.g. 
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government) and academic researchers (Jose et al, 2016). 
6.1.4 Qualitative research methods: improving our practice 
The key objective of our study was to employ qualitative research methods to identify and/or 
inform the context of important health economic costs or consequences of bariatric surgery that 
would typically be omitted or not provided with sufficient priority within current economic 
evaluation frameworks. To achieve our main objective we listened to patients - we adopted 
qualitative research methods to gather and interpret patient-relevant data in an attempt to 
answer the following questions: 
(1) Could qualitative research methods improve practice in health economic evaluation 
by supplementing quantitative methods to identify and put into context health 
economic costs and consequences of bariatric surgery that have typically been 
omitted or not fully understood within current economic evaluation frameworks?;  
(2) Could qualitative research methods improve practice in the model conceptualisation 
and development phase of economic evaluation?; 
(3) Could qualitative research methods improve practice in health economics by 
supplementing quantitative findings with qualitative findings in words and not 
numbers?; and  
(4) Could the health economics findings from our qualitative study translate to the 
additional allocation of healthcare resources to bariatric surgery? 
6.2 Materials and Methods 
6.2.1 Study design 
(i) Patient-relevant information 
A study that has investigated patients as the ‘missing stakeholder group’ in the development of 
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health economic modelling found that patients said “health care calculations are too narrow, 
excluding various second-order costs and benefits from treatments of chronic diseases 
simultaneously, and for whom cost-effectiveness analyses could be positive that are otherwise 
negative” (van Voorn et al., 2016). Additionally, stakeholder involvement is considered to be 
a critical aspect of good modelling practice and patients are important stakeholders who can 
add to health economic modelling (van Voorn et al., 2016). A focus-group style approach to 
include patient perspectives for model conceptualisation has been advocated within health 
economic modelling guidelines (Roberts et al., 2012).  
Our qualitative health economics study conducted focus groups to gather qualitative data about 
bariatric surgery patients’ experiences to elicit health economic impacts that would be omitted 
or not fully understood in the current economic evaluation framework for bariatric surgery.  
Many economists share a certain conception that the process of scientific inquiry is the use of 
increasingly sophisticated mathematics to derive formal statements in mathematical language, 
and qualitative research that describes its research in words and not numbers is mostly ignored 
in this framework (Obermann et al., 2013). Our qualitative study also considers the value of 
describing the qualitative research findings in words and not numbers, in addition to the 
quantitative findings. 
(ii) Participant recruitment and focus group structure 
This study was conducted in Tasmania, an island state of Australia, which has a population of 
approximately 500,000 people with 67.5 % of adults classified as overweight or obese (AIHW, 
2017). 
Ethics’ approvals for the study were obtained from our University’s Social Sciences Human 
Research Ethics Committee. Detail regarding the focus group recruitment methodology is 
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outlined in previous published work (Sharman et al., 2015). In summary, recruitment of focus 
group participants was achieved by advertising the study through local newspapers and radio. 
Letters were also sent to target groups of public and private bariatric surgery patients ensuring 
a mix of demographic and clinical characteristics. A priori we determined that significantly 
more females than males have bariatric surgery and most bariatric surgery is privately funded 
in Australia, for these reasons the groups were same sexed and separated by surgery funding 
type (Sharman et al, 2015). To ensure confidentiality, identifying details of participants were 
not shared between investigators. Table 1 provides an outline of focus group categories. 
Table 1: Classification of focus groups (North and South of the State of Tasmania) 
Focus groups 
(n=49 
participants; 
(n=participants 
per group)) 
Structure 
1 (5) Females private health system greater than 3 years after bariatric surgery (South) 
2 (7) Females private system less than three years after bariatric surgery (North) 
3 (6) Females public system after bariatric surgery (South) 
4 (2) Females waitlisted for bariatric surgery (South) 
5 (2) Males waitlisted for bariatric surgery (South) 
6 (7) Males private system after bariatric surgery (South) 
7 (4) Females waitlisted for bariatric surgery (North) 
8 (7) Males public and private system after bariatric surgery (North) 
9 (2) Males waitlisted for bariatric surgery (North) 
10 (7) Females private health system greater than 3 years after bariatric surgery (South) 
 
(iii) Economic data collection from focus groups 
In regard to the focus groups’ procedures, the pre-existing theories supported the initial 
development of health economics questions and prompts for the focus groups’ discussion 
schedule. Meetings were convened with the qualitative research team (DE, MS), project lead 
(AV), and health economists (JC, AP, AN, MH) to discuss the gathering of health economic 
data from focus group discussions.  
To elicit a broad range of health economic information the initial discussion schedule included 
a range of topics regarding costs and consequences before and after bariatric surgery. Two 
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authors (JC and MS) discussed the progress of the ten focus groups as they were conducted 
(over a three month timeframe) and revised the health economic questions and prompts during 
these discussions in liaison with the broader research team. These questions and prompts 
guided the semi-structured focus group discussions to elicit the health economic data for 
thematic analysis. 
Semi-structured focus group discussion techniques were used during the focus groups. Each 
focus group was no longer than 1.5 hours in duration, all were audio-recorded, transcribed 
verbatim and names were de-identified. 
6.2.2 Data analysis 
Thematic analysis underpinned by grounded theory (Strauss and Corbin, 1990, Strauss and 
Corbin, 1998, Liamputtong and Ezzy, 2005, Ezzy, 2013) informed the development of this 
study’s sub and central themes through the process of open, axial and selective coding of the 
focus group transcripts. This thematic analysis was descriptive and interpretive and facilitated 
by use of software (QSRInternational, 2010). Table 2 provides an outline of the process of 
coding in thematic analysis.  
More specifically, we adopted a sophisticated approach during grounded theory that mixed 
both inductive and deductive methods whereby the themes do not emerge from the data 
uninfluenced by pre-existing theory: there is an ongoing dialogue between data and theory in 
which emerging theories are repeatedly tested against the data (Ezzy, 2013). Our study used 
this process of frequent comparison of emergent thematic categories with the pre-existing 
economic theories of emotional capital, perspective and externalities.  
During coding development, JC discussed the emergent themes with the other qualitative and 
health economic investigators. An audit trail was kept for the project that comprised of a journal 
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of question development, focus group sessions and refinement of questions, all coding sessions, 
memos, reflective notes, emails, group meetings, and individual meetings with the first author.  
Focus group participants’ experiences are highlighted with quotations and longer verbatim 
quotes are italicised and indented. 
 
Table 2: Coding in grounded theory and thematic analysis* 
 
Open coding: 
• Explore the data. 
• Identify the units of analysis. 
• Code for meanings, feelings, actions. 
• Make metaphors for data. 
• Experiment with codes. 
• Compare and contrast events, actions and feelings. 
• Break codes into subcategories. 
• Integrate codes into more inclusive codes. 
• Identify the properties of codes. 
Axial coding: 
• Explore the codes. 
• Examine the relationships between codes. 
• Specify the conditions associated with a code. 
• Review data to confirm associations and new codes. 
• Compare codes with pre-existing theory. 
Selective coding: 
• Identify the core code or central story in the analysis. 
• Examine the relationship between the core code and 
other codes. 
• Compare coding scheme with pre-existing theory. 
*Source: Adopted from Qualitative Analysis: Practice and Innovation Douglas Ezzy (2013) 
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Focus group participants’ baseline socio-demographic and clinical data are presented 
descriptively as mean (standard deviation (SD)) for continuous variables and frequency (%) 
for categorical variables. Body mass index (BMI) was calculated as weight (kg)/[height (m)]². 
Percentage total weight lost (%TWL) was calculated as (lost weight / initial weight) *100 and 
percentage excess weight lost (%EWL) was calculated as (lost weight) / (initial weight – [25 * 
height (m)²]) *100. 
6.3 Results 
6.3.1 Participant characteristics 
Participant clinical and sociodemographic characteristics are provided in Table 3. 
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Table 3: Participants’ clinical and socio-demographic characteristics 
Characteristics 
(n=49) 
 
Participants who had 
undergone bariatric surgery 
(n=41) 
Participants waitlisted 
for bariatric surgery 
(n=8) 
Age years 
Mean (SD) 
 
55 (11) 
 
54 (8) 
 
Sex 
(n=x, %) 
 
Male (n=15, %) 
Female (n=26, %) 
 
(n=2, 25%) 
(n=6, 75%) 
Years since primary procedure 
Mean (SD) 
Median (IQR) 
 
6.3 (5.6) 
5.0 (3.0 – 9.0) 
 
NA 
Years on waiting list 
Mean (SD) 
Median (IQR) 
 
NA 
 
5.3 (2.1) 
6.0 (4.25 – 7.0) 
BMI (kg/m²) maximum†  
(before surgery) 
Mean (SD) 
Median (IQR) 
 
 
 
45.9 (8.2) 
46.0 (40.0 – 49.0) 
 
 
NA 
BMI (kg/m²) current †† 
(at recruitment) 
Mean (SD) 
Median (IQR) 
 
 
34.1 (8.9) 
32.0 (28.4 – 36.7) 
 
 
41.0 (18.5) 
43.8 (39.9 – 48.4) 
Weight (kg) 
Maximum (before surgery) 
Mean (SD) 
Median (IQR) 
Current (at recruitment) 
Mean (SD) 
Median (IQR) 
 
 
130.2 (27.7) 
130.0 (108.0 – 146.0) 
 
96.4 (25.4) 
92.0 (82.0 – 111.0) 
 
 
NA 
 
 
128.2 (43.8) 
113.5 (103.8 – 130.8) 
% Total weight lost  
Mean (SD) 
Median (IQR) 
% Excess weight lost  
Mean (SD) 
Median (IQR) 
 
25.7 (12.5) 
24.3 (15.8 – 37.5) 
 
60.6 (28.8) 
63.5 (43.1 – 76.6) 
 
 
NA 
Number of participants  
(Maximum weight: before surgery) 
(n = x, %) 
BMI < 25 kg/m² 
BMI  25 – 29.9 kg/m²  
BMI  30 – 34.9 kg/m²  
BMI  35 – 39.9 kg/m²  
BMI  40 – 49.9 kg/m²  
BMI  50 kg/m² ** 
 
 
 
0 
0 
(1, 2%) 
(9, 22%) 
(21, 51%) 
(10, 24%) ** 
 
 
 
NA 
 
 
 
 
(at recruitment) 
(n = x, %) 
BMI < 25 kg/m² 
BMI  25 – 29.9 kg/m²  
BMI  30 – 34.9 kg/m²  
BMI  35 – 39.9 kg/m²  
BMI  40 – 49.9 kg/m²  
BMI  50 kg/m² ** 
 
 
(4, 10%) 
(12, 29%) 
(10, 24%) 
(7, 17%) 
(5, 12%) 
(3, 7%) ** 
 
 
0 
0 
0 
(1, 14%) 
(4, 57%) 
(2, 29%)*** 
 
Highest level of education*  
Category (%) 
category 1 = year 10 or less; category 2 
= year 11 and/or 12; category 3 = 
certificate, diploma or trade; category 4 
= university. 
 
category 1 (11, 27%) 
category 2 (6, 15%) 
category 3 (13, 32%) 
category 4 (11, 27%) * 
 
 
(2, 25%) 
0 
(6, 75%) 
0 
LAGB (n=x, %) 
 
(n=40, 98%) NA 
Secondary Procedure (n=x, %) (n=6, 15%) NA 
*Highest level of education: category 1 = year 10 or less; category 2 = year 11 and/or 12; category 3 = 
certificate, diploma or trade; category 4 = university. SD = standard deviation, IQR = interquartile range. 
** adds to 101% or 99% due to rounding, *** (n=7) one height not recorded. † self-reported weight. †† 
height and weight recorded before focus group session. 
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6.3.2 Thematic analysis of focus group data 
The central theme that emerged from the interpretive analyses of our focus group data was that 
we identified important health economic outcomes regarding bariatric surgery that would have 
been omitted and/or not provided sufficient priority using the health economist’s traditional 
quantitative toolkit, and within the current economic evaluation framework for bariatric 
surgery. 
Key sub themes that were identified thematically are reported in detail below. 
(i) Emotional costs and benefits: emotional capital 
This study has revealed that participants’ emotional reflections in the lead up to and after their 
bariatric surgery, and the transformation in most participants’ preparedness to socially engage 
after surgery were vital health economic considerations. To illustrate, many participants 
described a complex socio-emotional personal journey from ‘feeling judged’ and ‘stared at’, 
and ‘not wanting to leave the house’ before bariatric surgery, to actively participating with their 
families, friends, work colleagues and broader society after their bariatric surgery. These 
findings support the emergence of the key theme of emotional capital as a capital and as a 
‘potentiator’ for human capital. The emotional costs of being severely obese are substantial 
and influence morbidly obese bariatric surgery candidates’ everyday private, participatory and 
broader social lives: their holistic well-being.  
Before bariatric surgery many participants recalled ‘feelings’ and ‘emotions’ that drove them 
to social isolation, disengagement and self-persecution. One participant described an ‘equation’ 
of how overweight people were perceived by society ‘equation: overweight, dumb, stupid’. 
Some participants expressed the point that ‘it’s all about how you feel, that’s what it comes 
down to’ and many participants echoed agreement during these discussions. For example, one 
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participant described ‘obsessive’ negative thoughts about herself: 
‘I didn’t have any… secondary [health] issues... My thoughts were quite obsessive; 
…Basically,… I couldn’t continue to be the way I was… because of the way I felt about 
myself and the way that other people felt about me. … I had no secondary health issues to 
address – that wasn’t the reason at all.’ (female, post-surgery private system). 
Another participant also described the substantial impact that their obesity had on them socially 
and their preparedness to socially engage: 
‘You don’t want to get up in the morning. You don’t want to go and do what you should 
do. And actually I ate more, worrying about it.’ 
But the emotions that you feel – and I’d become reclusive – which I’d always been an 
outgoing person, but I became that way. I didn’t want to be in public. And I most 
definitely didn’t want to eat in public because the size that I got, I’m thinking, 
“Everybody’s looking at me.” They’re thinking, “Why is she even eating? (female, 
post-surgery private system). 
Focus group discussions revealed a deeper context and nuance regarding the wide-ranging 
drivers to the participants’ social isolation were particularly dominant during the waiting list 
focus groups. Most of the study’s waitlisted participants languished on the public waiting list 
for many years and they shared their entrenched feelings of frustration and what particularly 
drove them to situations where they ‘can’t go out of the house’. To illustrate, a male participant 
who had experienced a multiyear waiting time said: 
   ‘Your feelings are just shot ‘cause you think, I can’t go out of the house because every 
time I go out of the house I feel like crap. Um you get stared at all the time when you 
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go through town. They just – just – it wrecks ya.’ (male, waiting list) 
One participant who had been on the public waiting list for many years described the barriers 
to participating in paid employment. The participant mentioned that these barriers included 
things like not being able to ‘get clothes for a start’. Interestingly, this participant did not 
attribute his inability to participate in paid employment because of his weight status, 
nevertheless, the issues he described ‘medications, diabetes, incontinence’ were clearly weight-
related: 
   ‘I haven’t worked since 2011.’ 
   [Interviewer] Okay. Because of your … weight? 
   Yep. Well not necessarily because of the weight but because of everything .Um not being 
able to get clothes for a start. the medications, my incontinence, um the diabetes, and 
then the weight on top of it.’ (male, waiting list public system) 
Nonetheless, there were a few people who said that they were seeking bariatric surgery for 
physical ‘health benefits’ only. These people did not describe or attribute their bariatric surgery 
journey to complexities about their socio-emotional status or the emotional ‘feelings’ that many 
of the focus group participants described. For example, one person said that: 
   ‘had a lap-band about six years ago and ah prior to that I had diabetes; type 2 I 
developed um high blood pressure. I had tried lots of weight things and got my weight 
down. I was sitting at 130-odd kilo’. (male, post-surgery private system) 
After bariatric surgery most participants described their increased self-esteem, self-worth 
and/or confidence by having ‘more energy’ and being ‘social enough’ to socially engage, or to 
now ‘participate’ in community volunteering or paid employment. Some participants said they 
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‘wanted to look good’ and that they were ‘being treated with more respect’. For example, one 
participant said she was trying not to be ‘vain’ about the fact that she could now ‘see her 
cheekbones and chin’ when she looked in the mirror and that she ‘avoided looking in the 
mirror’ before she underwent bariatric surgery. Table IV provides examples of relevant 
verbatim quotes from participants after they underwent bariatric surgery. Collectively, these 
verbatim quotes reveal increased self-esteem and confidence, participation and social 
engagement, and productivity. For example, one participant contrasted their before surgery 
experience of being on an invalid pension to their after surgery experience of wanting to seek 
part-time paid employment. 
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Table 4: Examples of verbatim quotes that support the theme of emotional capital after 
bariatric surgery. 
 
Focus 
group 
 
Full quotation 
Females 
post-
surgery 
private 
system less 
than three 
years 
It’s given me all the confidence back in the world. I’ve had a few little issues with it to begin with, and had to 
go in and have a little bit more surgery. But just, I’m in – I’m back. That’s really all I can say. So I would 
recommend it to absolutely everyone. 
 
 Well I’m actually looking now at the prospect of actually being able to go back and participate – contribute. 
You know and even the possibility of taking on some part-time work. So from becoming an invalid pension 
who could hardly shower myself, and all those things. 
 
 But yeah health-wise, um I’ve got much more energy now than when I had my children. I can run around after 
my granddaughters now whereas I couldn’t run around after my kids- 
That was the basis behind me too. I thought, “Sooner or later I’m going to become a grandmother and I’ve got 
to be able to chase them” 
 
Females 
post-
surgery 
public 
system 
Well one thing I have noticed is that when I was bigger, I’d just put on my big, floppy clothes and I – I’ve always 
worn make-up um because that’s how I was brought up – that when you go out of the house you put make-up 
on.  But I’d put my make-up on and that was the only time I’d look at myself in the mirror because I didn’t like 
looking at myself. Um but as started losing weight I sort of – I tried not to be vain about it, but I’d keep looking 
at think, “Oh my God. I’ve got cheekbones. I have a chin.’ 
 
Males 
waitlisted 
and then 
post-
surgery. 
The change in my depression changing as well, ‘cause it has helped quite a bit with my depression losing the 
weight. So it’s got to the stage where you know my family have seen that change and they can see it’s helped 
me quite a bit with my self-esteem um and even in my work um – I’m not working at the moment but when I was 
working up ‘til June this year um my work colleagues even noticed the change. Um I mean they could see the 
weight coming off. They were going, “Oh I can’t believe how quickly you’re losing that weight,” you know, and 
then they were saying, “You’ve become more alive, become more active,” um you know, “and more interested 
in things compared to when you first started.’ 
 
Males 
post-
surgery 
public and 
private 
I had the operation two and a bit years ago now; um July 2012, I think it was. Um I – at the eighteenth month 
mark I reached my goal which was about 50 kilos down. Um and now I’m actually doing a personal trainer’s 
thing so that I can help other people um start losing – losing and putting muscle mass on. So yeah. That’s pretty 
much where I am at the moment.   
Females 
post-
surgery 
private 
greater 
than three 
years 
‘Definitely people treat you with more respect if you’ve got less weight. I wouldn’t have been able to get things 
that I’ve got through – you know if I hadn’t got it done. So in some ways it’s been a really good thing for me. 
You know I met – I basically wouldn’t have been social enough to meet anyone and get married. I was you know 
in my late-thirties before I met anyone because I just was like thinking, “Well, you know I didn’t want to go 
out.” I had this perception’ 
 
 ‘It’s all how you feel. That’s what it comes down to- 
 
 
(ii) Out-of-pocket costs 
The potential range of out-of-pocket costs and the consequences of financial burden and 
distress (individually or within the household budget) are an important consideration for people 
who are undergoing bariatric surgery. Some people discussed partially or fully self-funding the 
primary surgical procedure by ‘paying cold hard cash for the whole thing’. A couple of 
participants from lower-socio economic groups accessed the private system by either 
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purchasing private insurance specifically for the primary surgical procedure where there were 
also substantial co-payments, or fully funding the procedure by accessing their superannuation: 
‘so I took the money out of my super to have it done because I just felt so strongly about it’. 
To illustrate, one participant described herself as ‘poor’ and she highlighted the considerable 
financial burden of the private health insurance co-payment: 
   ‘Well I had a three-and-a-half thousand dollar … gap that I had to pay and being on a 
pension I just paid it off. We had a few battles over that but ah, “You can’t get blood 
from the stone,” as I told them so they just had to wait. And they did, I think it was 
about 18 months it took me to pay it off. but on a pension there’s not much you can do. 
Poor’s poor and that’s it.’ (female, post-surgery private system). 
Additionally, a couple of participants described the financial burden of fully self-funding the 
primary procedure: 
  ‘I’d say eight [thousand dollars]…And it’s amazing how many do. 
  [New Speaker] Eleven thousand. 
  Yeah, and that hurts’ (female, post-surgery private system) 
Some participants described their frustration about enduring multiyear waiting times on the 
public healthcare system waiting list. Consequently, a few participants decided to pay for 
private healthcare by either using their own funds for the primary surgical procedure and 
follow-up healthcare costs or taking up relatively expensive private health insurance (with 
concomitant ‘gap’ payments) to pay for the primary surgical procedure.  
Participants also described the burden of small but relatively regular unexpected out-of-pocket 
costs. Some participants discussed the unexpected frequency of band adjustments (one 
participant mentioned six weekly adjustments) and concomitant out-of-pocket co-payments:  
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‘The adjustment I think is 10 dollars; just the adjustment. And that’s to cover – I think 
that’s to cover the equipment that they use because I think most of its just thrown away’ 
(male, post-surgery private system).  
‘I’m out-of-pocket like 60 bucks [dollars] when I go- …I have to pay like 170 and I get 
one-hundred-and-something back, but I’m out-of-pocket 50, 60 dollars when I go.’ 
(female, post-surgery private system). 
Our study also found that body-contouring surgery to remove excess skin was acknowledged 
as a potentially important follow-up procedure for focus group participants. After rapid and 
continued weight loss, bariatric surgery patients are often left with heavy skin folds of 
redundant skin and contour irregularities and the resultant functional problems have raised 
concerns about effects on quality-of-life (Soldin et al., 2016). Several participants expressed a 
desire for body-contouring surgery in the future to remove excess skin, sometimes even years 
after the initial surgical procedure. Some participants indicated that they desired body-
contouring procedures but that they could not ‘afford’ the procedure. One participant said that 
they paid for the cost of the body-contouring procedure(s) out-of-pocket: 
It was almost as much as I originally paid for the – the first lap-band. So I’d be looking 
at around 10 grand [10 thousand dollars].’ (female, post-surgery private system) 
(iii) Implications for improvement in practice 
Bridging the gap between our qualitative results and the current economic evaluation 
framework for bariatric surgery could be achieved by creating a specific ‘emotional capital’ 
bolt-on item for the internationally prevalent multi-attribute utility instrument the EQ-5D and 
testing this against the AQoL-8D multi-attribute utility instrument that is preferentially 
sensitive for the bariatric surgery study population, or by developing a separate survey 
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instrument for emotional capital. Additionally, the conceptualisation and construction phase of 
an individual health economic evaluation model could take into account the patient-relevant 
findings of emotional capital and out-of-pocket costs.  
The operationalization of our key findings within the current economic evaluation framework 
for bariatric surgery are discussed in detail below. 
6.4  Discussion 
Our study is important because qualitative research methods enabled us to identify health 
economic impacts of bariatric surgery that typically have been excluded from existing health 
economic evaluations. Through a dialogue between the qualitative patient-relevant data and 
pre-existing economic theory, we identified and prioritised the concept of emotional capital as 
a ‘booster’ for human capital where participants described fundamental life-changing outcomes 
and desires to be productive and participate in their communities postoperatively. We also 
found that of the two-thirds of the focus group participants that accessed the private healthcare 
system for their surgery, some experienced substantial economic burden to do so. Another 
important finding was the identification of body-contouring surgery as an integral to the 
treatment journey, nonetheless prohibitively costly. 
6.4.1 Emotional capital leading to participation and productivity 
By listening to patients we found that emotional capital is paramount for the study population. 
Many participants described the way that they ‘felt’ and their ‘emotions’ about themselves as 
the most important drivers supporting the desire to undergo surgery, and/or the success of their 
bariatric surgery. Focus group participants described and put into context an overall positive 
outlook and coupled with their increased physical function enabled many participants to ‘leave 
the house’ and engage with society in a participatory, productive and meaningful way. Some 
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people described a desire to participate or their participation in paid employment, others 
described wanting to volunteer in their communities and socially engage. These are important 
productive and participatory variables, whereby emotional capital is in fact boosting human 
capital: they should not be ignored or devalued by health economists in the health economic 
evaluation and reporting of bariatric surgery. 
Recent evidence suggests that patient-centred care is increasingly important and relevant for 
informed healthcare decision-making (Basch et al., 2015). As the missing stakeholder group in 
the development of health economic models, patients have said that health care calculations 
are too narrow (van Voorn et al., 2016). Our qualitative health economic study revealed that 
bariatric surgery patients inherently embody multifaceted physical and psychosocial lived 
complexities that can only be fully captured, evaluated and explained by adopting the unique 
advantages of qualitative research methods. More specifically, our study showed that 
qualitative techniques enabled the innate complexity of these people’s lives to emerge, to 
identify areas of difficulty and success in regard to their bariatric surgery both pre- and 
postoperatively that ultimately translated to health economic ramifications. For example, by 
exploring bariatric surgery patients’ stories we showed that participation and productivity are 
key to the surgery’s success and they are also key to the publicly waitlisted patients’ frustration 
and plight. Our study’s examination of emotional capital provided a deeper, nuanced and 
contextual understanding of the socio-emotional status of our study population. The 
participants’ individual stories coupled with the exchange of their lived experiences provided 
new and highly relevant information about the ‘how’ and ‘why’ of psychosocial health status. 
This important information should be considered with sufficient priority in health economic 
evaluation and subsequent resource allocation decisions. 
The following sections explore examples of how we could operationalise the study’s key 
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findings to improve the economic evaluation of bariatric surgery. 
(i) The EQ-5D: an emotional capital bolt-on item? 
Psychosocial health status has been increasingly identified as an important health-related 
quality-of-life outcome measure for morbidly obese patients who receive bariatric surgery 
(Herpertz et al., 2015, Campbell et al., 2017, Campbell et al., 2016b) ). Most cost-utility 
analyses of bariatric surgery adopt the internationally prevalent EQ-5D multi-attribute utility 
instrument to assess the health-related quality-of-life impacts of the intervention however four 
of the five items of the EQ-5D focus on physical health (Campbell et al. 2016a). Our recent 
suite of studies revealed that the EQ-5D-5L, compared to the AQoL-8D, does not preferentially 
capture or assess the psychosocial health status for people who are waiting for or who have 
undergone bariatric surgery. The AQoL-8D multi-attribute utility instrument has instead been 
recommended due to the instrument’s substantially broader descriptive/classification system 
concerning psychosocial health status (Campbell et al., 2016b, Campbell et al., 2017, 
Richardson et al., 2014). At the individual question level for the AQoL-8D (e.g. social 
isolation), our qualitative research provided an even deeper and contextual understanding of 
the socio-emotional drivers for many participants’ inability to participate and socially engage, 
their social isolation before bariatric surgery. 
Our qualitative study’s interpretative analyses of participants’ socio-emotional experiences 
further highlighted the fundamental inadequacy of the EQ-5D for the study population. 
Emergent published literature has explored the concept of ‘bolt-on’ items to augment the EQ-
5D’s existing classification system that focuses on physical health (Devlin and Brooks, 2017, 
Yang et al., 2015). Some of this literature has cautioned against the development of bolt-on 
items because it could detract from ‘the advantages of using a generic instrument’ (Yang et al., 
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2015). A study that discussed the past present and future of the EQ-5D and the EuroQol group 
also stated that this approach could raise issues as follows: 
‘the EuroQol Group is also undertaking experiments on another approach to 
enhancing instrument performance in certain population sub-groups i.e. through the 
use of ‘bolt-on’ dimensions. In its simplest form this retains the core five dimensions, 
but adds one or more dimensions to capture aspects of health which may not be 
adequately captured by these dimensions. Some initial experiments with bolt-ons have 
been undertaken for vision, hearing, tiredness, psoriasis and sleep. At a descriptive 
level, the introduction of bolt-on dimensions can add to the richness of respondent 
profile data. However, this approach raises non-trivial issues, especially in connection 
with the consequences for health state valuations in the expanded instruments.’ 
Our suite of published studies established that the EQ-5D-5L’s descriptive system is inadequate 
for different subgroups of the bariatric surgery study population. (Campbell et al., 2016b, 
Campbell JA, 2017, Campbell et al., 2017). One of our studies also acknowledged that the use 
of bolt-on items may result in consequences for health state utility values including non-
interchangeablity (Campbell et al., 2016b). We also established that, as a single multi-attribute 
utility instrument, the AQoL-8D captures the vast majority of domains considered crucial in 
the bariatric surgery study population (Campbell et al., 2016b). 
Notwithstanding the caveats outlined above, we suggest that a bolt-on item for the concept of 
emotional capital could be explored for the EQ-5D-5L. It is vital that development of an 
emotional capital bolt-on item be tested against the AQoL-8D multi-attribute utility instrument 
that preferentially captures the complex physical and psychosocial health-related quality of life 
for the bariatric surgery patients when compared to the EQ-5D-5L. 
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We also make the vital point that our qualitative results provide a deeper and nuanced 
understanding of psychosocial health for the study population and the concept of meotional 
capital could also be reported separately in its qualitative form. 
(ii) Qualitative methods to supplement quantitative methods: health economic 
modelling 
Patients are key stakeholders in health economic modelling, yet their involvement is sparse at 
best (van Voorn et al., 2016). Arguments in favour of patient involvement in model 
development (and therefore model credibility) include the identification of relevant factors 
such as costs - patients have said that ‘health care calculations are too narrow, excluding various 
second-order costs and benefits from treatments of chronic diseases simultaneously, and for 
whom cost-effectiveness analyses could be positive that are otherwise negative’ (van Voorn et 
al., 2016). We recommend that the concept of emotional capital should be explored in the health 
economic model conceptualisation and construction phase of the health economic evaluation 
of bariatric surgery. In particular, participation and productivity could be explored – for 
example, does emotional capital lead to labour market productivity? Additionally, our 
qualitative findings could be reported separately in their qualitative form to supplement the 
quantitative results of an economic evaluation. 
In summary, if emotional capital is understood within the current economic evaluation 
framework, emotional capital could be prioritised by healthcare policymakers and planners. 
The concept of emotional capital provides further context concerning the socio-emotional or 
psychosocial drivers for patients seeking bariatric surgery (including what drives patients to 
endure waitlist times and what happens during that time, the purchasing private insurance and 
self-funding), and the subsequent success of the bariatric surgery (ultimately translating into 
productivity). In other words, the success of bariatric surgery is not just about losing weight, it 
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is about the complex psychosocial needs of these patients before and after their bariatric 
surgery.  
6.4.2 Financial hardship and a broader perspective 
Our study established that some participants who accessed the private healthcare system 
through self-funding the primary procedure experienced substantial financial burden to do so, 
and that regular unexpected (albeit small) out-of-pocket payments were prevalent. 
The consequences of financial burden due to out-of-pocket expenditures for people who 
undergo bariatric surgery (and indeed other disease categories across different healthcare 
systems) are poorly understood (Timmons et al., 2013, Ubel  et al., 2013, Gott et al., 2015, Wu 
et al., 2014, Aji et al., 2014, Campbell et al., 2016a). A recent study has found that financial 
distress is a key determinant of health (Meyer, 2017). 
Previous work has found that there is much scope for augmenting the essential elements of 
economic evaluation with additional qualitative data to inform the context of the study (Kelly 
et al., 2005, Husbands et al., 2017, van Voorn et al., 2016). Additionally, from an individual 
study perspective, patient narratives have been used to inform a recent UK Health Technology 
Assessment about the emotional, social and material environments that informed the ‘push and 
pull’ of financial incentives to modify participants’ (pregnant and breastfeeding women that 
smoke) smoking behaviour (Hoddinott et al., 2014). 
The conceptualisation and construction phase of a health economic model could, for example, 
take into consideration that patients who are experiencing financial distress are at a higher risk 
of seeking ongoing bariatric surgical care (such as complications and reoperations) in the public 
healthcare system. In regard to potential complications and reoperations, recent evidence has 
found that complications and/or reoperations can cost as much as the primary procedure itself, 
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and that the estimated rates (particularly after secondary bariatric surgery) are higher than the 
usually reported risks (Campbell et al., 2016a, Kuzminov et al., 2016). In turn, some of these 
participants may allow their private health insurance to lapse if they experience even more 
financial hardship, increasing likelihood of future presentations for complications and 
reoperations through the public sector. Financial hardship could also be linked with emotional 
capital and this could be explored further in relation to financial distress as a key determinant 
of health. 
Our study also found there was a general acknowledgement that body-contouring procedures 
(as an ongoing procedure) are an integral part of the patient’s journey and these procedures are 
a consideration even for people publicly waitlisted for surgery. Our study established that out-
of-pocket costs of body-contouring were considered to be prohibitive and comparable to the 
cost of the primary bariatric procedure.  
Overall, our qualitative health economic study revealed some complex choices for policy-
makers and funders. We showed that some patients experienced economic burden to fully or 
partially self-fund their primary surgery in the private healthcare system. Importantly, there are 
a range of additional or ongoing procedures and costs related to bariatric surgery after the 
primary procedure - not providing adequately for these costs through public coverage (or, 
indeed, in private health insurance benefit schedules) may simply push significant costs onto 
patients – who may quickly turn to the public sector by default if they are unable to finance 
them.  
6.4.3 Qualitative research methods: improving health economics practice 
Our study highlighted clear pathways regarding the practical implications of our key findings 
to improve our health economics practice in the economic evaluation of bariatric surgery from 
model conceptualisation and construction through to the separate reporting of qualitative 
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findings. Qualitative research methods revealed the importance of emotional capital and out-
of-pockets costs for bariatric surgery patients: qualitative methods should supplement 
quantitative methods to elicit nuanced and detailed analysis of the health economic impact of 
waiting for and/or undergoing bariatric surgery. 
It has been suggested that the application of qualitative methods to the development of health 
economic models for bariatric surgery will enhance the credibility of the model. A focus group-
style approach for model conceptualisation has been advocated within modelling guidelines, 
particularly for patient involvement as a key stakeholder group (Roberts et al., 2012). 
Our qualitative study also highlighted the importance of a key finding of our previously 
published systematic review that recommended a broader societal perspective in the health 
economic evaluation and reporting of bariatric surgery, and the appropriate consideration of 
out-of-pocket costs, complications and reoperations and productivity gains or losses (Campbell 
et al., 2016a). Fully accounting for all such costs may impact not only on the affordability of 
bariatric surgery, but potentially on its cost-effectiveness. The important point here is that 
standard health economic evaluation should factor all of these known knowledge gaps/costs 
into their economic evaluation through the identification process at a minimum. Putting this 
into perspective, in practice – they do not. This paper has revealed and highlighted key costs 
and consequences that should be afforded sufficient priority and included in health economic 
reporting. More importantly, this paper has highlighted the consequences of not prioritising the 
inclusion of these costs and consequences in health economic reporting of bariatric surgery. 
Overall, we suggest that the unique advantages of qualitative research methods in a mixed-
methods setting can provide health economists with important information about key costs and 
benefits that would otherwise be overlooked, not fully understood and not afforded sufficient 
priority in the health economic evaluation of bariatric surgery. Furthermore, key questions of 
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“sufficiency” versus “gold standard” care are visible here – for example, is body-contouring 
surgery really necessary, and if it is not, should it be provided at all in publicly-funded systems? 
The dissemination of qualitative health policy research is the subject of concentrated debate in 
the contemporary scholarly literature (Daniels et al., 2016, Greenhalgh et al., 2016). Supporters 
of qualitative research argue that this research explores and explains the complex relations 
between the healthcare system and the outside world, such as the socio-political context in 
which healthcare is regulated, funded, and provided, and the ways in which clinicians and 
regulators interact with industry (Greenhalgh et al., 2016). Supporters also contend that the 
marginalisation of qualitative research in ‘special interest journals’ devalues the work relevant 
to health services, weakens understanding of the interface between qualitative and quantitative 
research and undermines the breadth and the quality of the analysis (Daniels et al., 2016).  
We have provided our government partner with a contextualised understanding of the 
psychosocial health impacts of bariatric surgery. Our previously published quantitative 
analyses revealed that psychosocial health status is a crucial to the success of the surgery 
(Campbell et al., 2017). Importantly, our qualitative results provided a deeper understanding 
of the how and why psychosocial health status is important. In turn, our research has informed 
some of the future direction of our ongoing research program, and highlighted important policy 
gaps to our government partners. 
We also acknowledge challenges must be overcome to enable the operationalisation of our key 
findings within the current economic evaluation framework for bariatric surgery. These 
challenges could include the lack of appropriate knowledge and skills in qualitative research, 
and the entrenched ‘quantitative culture’ within the health economics community. 
Nevertheless, there has been a growing advocacy for mixed-methods research in health 
economics, including Health Technology Assessment programs and Cochrane Collaborations 
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(Coast, 1999; Coast et al., 2004; Obermann et al., 2013; Husbands et al 2017 (Greenhalgh et 
al., 2016)), and our research has attempted to address this evidence gap for bariatric surgery. 
Additionally, recent evidence of partnership arrangements between academics and policy-
makers, that is knowledge-users and researchers, can be a powerful mechanism for improving 
the policy relevance of research (Jose et al., 2016). This study is part of a broader collaborative 
partnership arrangement between key government policy-makers and researchers. It is also a 
good example of the generation of policy-relevant qualitative research in health economics 
where interpretivist qualitative methodologies have been adopted to complement and enhance 
the quantitative component. We identified important and complex policy issues for the 
consideration of healthcare decision makers regarding the supply of bariatric surgery to meet 
ever increasing demand on the Australian healthcare system. We have revealed the how and 
why to complement the how much. 
6.4.4 Strengths and Limitations 
The key limitation of our study was that the scope of our investigation was restricted to focus 
group data. Follow-up in-depth interviews of key participants could further enrich our 
understanding of the key themes identified in our study. 
There were several strengths to our study. First, the use of qualitative research methods to 
identify key knowledge gaps in regard to the health economic impacts of bariatric surgery. 
Second, the economic component of the focus group discussions were embedded and thus 
identified during discussions of the broader ‘lived’ experiences of participants. Third, we had 
a large sample size (n=49) for qualitative research, with diversity of participants’ treatment 
modality (i.e. public/private/waitlisted), and socio-demographic characteristics. Finally the 
research team embodied a combination of knowledge and skills of experienced qualitative 
researchers and health economists from research and policy-making backgrounds to enable a 
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multi-disciplinary investigation of the predominantly quantitative health economic research of 
bariatric surgery.  
6.5  Conclusions 
Qualitative methods can inform improved practice in the health economic analyses of bariatric 
surgery by eliciting health economic impacts of an intervention that would typically be 
excluded or not provided with sufficient priority in reporting to the healthcare decision maker. 
Emotional capital is a key health economic consideration for people who are waiting for and/or 
undergo bariatric surgery and should be considered with sufficient priority by healthcare 
decision makers. The disproportionate level of financial burden endured by some individuals 
who undergo primary bariatric surgery privately should be investigated as a reason or in the 
light of their potential subsequent access of publicly funded healthcare.  
To provide further supporting eviednece regarding the allocation of additional healthcare 
resources to bariatric surgery as a treatment for the increasing prevalence of severe and resistant 
obesity our key findings could be included in the conceptualisation and construction of a health 
economic model or reported as supplementary information to economic evaluation.  
We suggest that the benefits derived from mixed-methods health economic research regarding 
bariatric surgery far outweigh the costs of including robust qualitative research methods within 
study design and subsequent reporting. Key policy decision-makers and ultimately patients and 
their carers would derive substantial benefits from health economic analyses and reporting that 
harnesses the unique advantages of qualitative techniques. 
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for obesity surgery: diversity of patient experiences in the 
information age and demand-induced supply. 
Preface 
Chapter 7 presents the second health economics study of this thesis that implemented 
qualitative research methods to investigate the experiences of people waiting for, or who had 
received bariatric surgery.  
The inspiration for the method of this qualitative study was partly generated from a conceptual 
synthesis of my PhD research’s earlier studies and partly from a broader review of the 
published literature (particularly health economic methodology) during my PhD research. In 
regard to the earlier studies of this thesis, Chapter 2’s published systematic review identified 
the limited scope of costs and consequences for most health economic reporting of bariatric 
surgery and called for a more comprehensive investigation and reporting of health economic 
outcomes of bariatric surgery to identify aspects of the bariatric surgery patient’s journey that 
reached well beyond the primary surgery’s direct medical costs. Published Chapters 3, 4 and 5 
established that psychosocial health is a vital consideration for people who are waiting for and 
who then undergo bariatric surgery; and Chapter 6 revealed that the concept of emotional 
capital is a key driver for the success of bariatric surgery.  
In regard to my broader review of the published literature during my PhD research, Chapter 7 
investigated the emergence of the concept of demand-induced supply in the information-age 
for people waiting for or who undergo bariatric surgery. Does demand-induce supply exist in 
the marketplace of bariatric surgery? Are bariatric surgery patients more information-savvy in 
the information-age? Chapter 7 is also consistent with a call for health economists to effectively 
integrate combinations of qualitative and quantitative methods into their research toolkit to 
enrich their research methodologies. 
In the information age, patients may be more empowered in their negotiated relationship with 
healthcare providers, and information asymmetries may occur that place patients in a superior 
information position to healthcare professionals. Therefore, the main objective of this study 
was to employ qualitative research methods to investigate the concept of information 
asymmetry for bariatric surgery patients in the information age. The study achieved the 
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objective by frequent comparison of emergent thematic categories of the qualitative data (focus 
groups n=10; n=49 participants) with the pre-existing economic theories of information 
asymmetry, the principal-agent relationship and demand-induced supply.  
This study established that psychosocial or socio-emotional drivers informed the sources and 
types of information that were important to participants preoperatively. The study also found 
that information sources relevant to participants preoperatively (e.g. family and friends, and 
the Internet) were different postoperatively (surgeon, allied-health professionals e.g. 
psychologist). This study identified important information ‘drivers’, sources and types 
(including the quality and consistency of information), and the divergence of what information 
is ‘important’ to bariatric surgery patients in the pre- and postoperative periods.  
This qualitative study revealed key considerations for the healthcare decision maker about 
bariatric surgery patients’ information gathering and use. This qualitative health economics 
study recommended that high-quality and consistent information sources be targeted towards 
the psychosocial domains of health for bariatric surgery patients preoperatively and ongoing 
postoperatively. The study also recommended that appropriate healthcare information be 
provided to enable a smoother transition for the management of physical health impacts such 
as postoperative dehydration and electrolyte imbalance which can result in unexpected 
hospitalisation: smoother postoperative transition would likely translate to less burden on the 
healthcare dollar. 
Please note that the Reference and Abstract style of this paper reflects the submitted 
journal’s style. This chapter has been submitted to PharmacoEconomics. 
Impact factor: 3.99 
Campbell JA, Ezzy D, Hensher M, Neil A, Venn A, Sharman MJ, Wilkinson S and Palmer 
AJ. A qualitative investigation of information asymmetry for obesity surgery: diversity of 
patient experiences in the information age and demand-induced supply. 
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Summary 
A key market failure in healthcare is information asymmetry between the consumer and 
supplier where the level of knowledge and expertise is weighted to the supply-side 
(physician/surgeon). In the information-age, bariatric surgery patients may be more 
empowered in their negotiated relationship with healthcare providers. Importantly, information 
that empowers the consumer potentially enables ‘demand-induced-supply’ (patients 
demanding and receiving care that their clinician would not otherwise have offered) and has 
implications for healthcare resource allocation to bariatric surgery. Our study used the pre-
existing health economics theory of information asymmetry to inform qualitative inductive and 
deductive theory building about information drivers, sources and needs for bariatric surgery 
patients pre- and postoperatively. Ten semi-structured focus groups of people who were 
waitlisted or had undergone bariatric surgery were conducted (n=49). Thematic analyses were 
employed to analyse verbatim transcripts. We found a divergence between the pre- and 
postoperative information drivers. Psychosocial or socio-emotional drivers informed the 
sources and types of information that were important to participants preoperatively. We also 
found that information sources relevant to participants preoperatively (e.g. family and friends, 
and the Internet) were different postoperatively (surgeon, allied-health professionals e.g. 
psychologist). We recommend that high-quality and consistent patient information be more 
targeted towards the psychosocial domains of health preoperatively and ongoing 
postoperatively. 
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7.1  Introduction 
7.1.1 Qualitative research in health economics 
Our study adopted qualitative research methods to investigate information asymmetry in the 
market for obesity surgery, consistent with a call for health economists to effectively integrate 
combinations of qualitative and quantitative methods into their research toolkit to enrich their 
research methodologies (Coast et al., 2004, Coast, 1999, Obermann et al., 2013, Campbell JA, 
2018). Importantly, it has been suggested that qualitative research methods could particularly 
identify nuanced and policy-relevant arguments in health economics and that major sources of 
relevant information in health economics’ research goes untapped including the meaningful 
participation of patients in health economic model conceptualisation and development 
(Obermann et al., 2013, Campbell JA, 2018).  
7.1.2 Obesity (bariatric) surgery 
Obesity is a public health and economic problem (Cawley, 2011, Cawley, 2015, Cawley and 
Meyerhoefer, 2012, Gortmaker et al., 2011, Campbell et al., 2018, Campbell et al., 2016a). 
Obesity surgery (clinically described as bariatric or metabolic surgery) as a treatment 
intervention for obesity and related comorbidity has been increasing across developed and 
developing countries (Angrisani et al., 2015, Buchwald and Oien, 2013). Bariatric surgery is 
generally recommended for those with intractable class 2 obesity [body mass index (BMI) 35–
39.9 kg/m²] and obesity-related comorbidity (e.g. type 2 diabetes mellitus, cardiovascular 
disease or joint pain) or class 3 obesity (BMI ≥ 40 kg/ m²) with or without obesity-related 
comorbidity (NHMRC, 2013). 
Recent evidence has found that psychosocial health-related quality-of-life (HRQoL), including 
the concept of emotional capital, is a fundamental consideration for people awaiting or who 
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have undergone bariatric surgery, and that weight status is only one factor contributing to these 
complex HRQoL outcomes for this study population (Burgmer et al., 2014, Herpertz et al., 
2015, Campbell et al., 2016b, Sharman et al., 2016a, Campbell JA, 2018). 
7.1.3 The information age: from Kenneth Arrow 1963 to Google Trends 
It has long been recognised that healthcare markets display a number of significant and special 
characteristics that differentiate them from a perfectly competitive market, including pervasive 
uncertainty, unavoidable information asymmetries and the need for principal-agent 
relationships (Hensher, 2017). The patient-physician relationship is a classic example of the 
principal-agent relationship in health economics (Shih and Tai‐Seale, 2012).  
The insight that health information is a valuable commodity to patients dates back to Arrow’s 
work (Arrow, 1963, Schmid, 2015). Arrow’s ground-breaking paper on Uncertainty and 
Welfare Economics of Medical Care explored and described the concept of product uncertainty 
and consumer information in the ‘medical-care market’ (Arrow, 1963). The seminal paper 
notably outlined the concept of asymmetry of information by introducing the following 
concepts:  
‘Because medical knowledge is so complicated, the information possessed by the physician 
as to the consequences and possibilities of treatment is necessarily very much greater than 
that of the patient, or at least so it is believed by both parties. Further, both parties are 
aware of this informational inequality, and their relation is coloured by this knowledge.’ 
In turn, the information asymmetry between patients and physicians sometimes raises concerns 
that a physician may exert a strong influence over the patient’s demand for medical care and 
may provide services that offer more financial benefits to the physician than clinical benefits 
to the patient (Shih and Tai‐Seale, 2012). This theory, known as supplier-induced demand, is 
well recognised by economists and policy-makers (Shigeoka and Fushimi, 2014, Johnson and 
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Rehavi, 2016, Cromwell and Mitchell, 1986, Labelle et al., 1994).  
Fast-forward from Arrow’s 1963 seminal paper to the 2000s: the information age (Shapiro and 
Varian, 2013), the emergence of the ‘economics of information’ (Stiglitz, 2000), and the 
proliferation of analyses of Google trends including for bariatric surgery (Linkov et al., 2014). 
In the information age, patients may be more empowered in their negotiated relationship with 
healthcare providers, and information asymmetries may occur that place patients in a superior 
information position to professionals (Shih and Tai‐Seale, 2012, Schmid, 2015). Recent 
evidence has also suggested that patients’ requirements for information consistently outstrip 
the expectations of clinicians (Owen-Smith et al., 2010). In turn, the increasing availability of 
interactive information that is accessible to healthcare consumers, most notably through the 
Internet and related technologies such as digital television and web television, coincides with 
the desire of most healthcare consumers to assume more responsibility for their health (Flaherty 
et al., 2015). However, other evidence suggests that information has a negative effect on health 
care utilisation, contradicting previous findings (Schmid, 2015). 
7.1.4 Supplier-induced demand versus demand-induced supply: are bariatric surgery 
patients empowered in the information age? 
 
In the information age, information asymmetries for bariatric surgery may emerge on the 
producer (physician) or consumer (patient) side. Under supplier-induced demand, a physician 
takes an action to shift the patient’s demand curve in the direction of the physician’s own 
interests. Physicians can effect such a shift, because they have more information regarding the 
patient’s condition and treatment options than the patient (Culyer, 2014). 
In contrast, under demand-induced supply the unprecedented amount of information made 
available through, for example, the media and Internet may reduce the information gap between 
physicians and more information-savvy patients (Shih and Tai‐Seale, 2012). Such easy access 
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to medical information could allow some patients to know more than their physicians on 
particular issues in which they have a personal interest, or to have confidence (founded or 
otherwise) in their own choices about these issues. This emerging phenomenon of demand-
induced supply may arise due to patient empowerment through the availability of medical 
information through online sources and social networks. Thus patients (instead of physicians) 
shift the demand curve out due to a change in their knowledge or taste (Shih and Tai‐Seale, 
2012) (Figure 1). Additionally, this outward shift of the demand curve causes a movement up 
the supply curve by physicians, even though the move may be inconsistent with the physician’s 
professional judgement (Figure 1). Quantitatively, demand-induced supply is the additional 
amount of healthcare services provided by the physicians at the request of patients (which could 
include bariatric surgery patients seeking bariatric surgery as a treatment option for obesity 
informed by their preoperative information gathering) that would not have otherwise been 
offered (Shih and Tai‐Seale, 2012). The impact of the patient’s request for services could 
coalesce with the physician’s response to financial incentives (McGuire, 2000, Shih and Tai‐
Seale, 2012). 
The consequent ‘empowerment’ of the healthcare consumer (including the bariatric surgery 
consumer) in healthcare decision-making is now fundamental to the patient-physician 
relationship, and the ‘patient-healthcare organisation’ relationship (Graffigna et al., 2014). 
Several patient-centred models have subsequently emerged to drive efficiencies in the 
resource-constrained healthcare environments. These models include the exchange of 
information between healthcare professionals and patient through consumer informatics, 
shared decision making, patient-centredness and patient health engagement models (Graffigna 
et al., 2014). It has also been suggested that patients should be given a meaningful seat at the 
table of health economic model conceptualisation and development (e.g. cost-effectiveness and 
cost-utility modelling) through a qualitative approach to elicit health economic impacts of an 
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intervention that would typically be excluded or not provided with sufficient priority in 
reporting to the healthcare decision maker (Campbell JA, 2018) 
Nevertheless, emerging trends in behavioural economics have suggested that the traditional 
neo-classical model is deficient in understanding over-eating and obesity (Ruhm, 2012, Cawley 
and Ruhm, 2011). Behavioural economics debunks the neo-classical tenet of the ‘rational 
consumer’ and instead provides practical insights into the provision of information in health 
policy settings under the tenet of ‘bounded rationality (Matjasko et al., 2016). 
7.1.5 Qualitative research methods: are bariatric surgery patients information-savvy? 
The main objective of our study was to employ qualitative research methods to investigate the 
concept of information asymmetry for bariatric surgery patients in the information age. We 
aimed to achieve our objective by frequent comparison of emergent thematic categories with 
the pre-existing economic theories of information asymmetry, the principal-agent relationship 
and demand-induced supply. Through our qualitative analysis we sought to identify important 
information ‘drivers’, sources and types (including the quality and consistency of information), 
and the divergence of what information is ‘important’ to bariatric surgery patients in the pre- 
and postoperative periods.  
Figure I In the information age bariatric surgery patients shift the demand curve from D1 to D2 
and are at the equilibrium point p2 and q2 when they seek bariatric surgery from their physician. 
This outward shift of the demand curve causes a movement up the supply curve by physicians. 
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7.2 Materials and Methods 
7.2.1 Quality reporting 
The development of a formalised qualitative research methods checklist for focus groups and 
in-depth interviews (the Consolidated Criteria for Reporting Qualitative Research (COREQ) 
checklist) acknowledged that qualitative research explores complex phenomena encountered 
by clinicians, healthcare providers, policy-makers and consumers in healthcare (Tong et al., 
2007). The preparation of our study’s report was guided by the individual items of the COREQ 
checklist (Tong et al., 2007)). 
7.2.2 Recruitment, study design and focus group structure 
This qualitative study was conducted in Tasmania, an island state of Australia, which has a 
population of approximately 500,000 people with approximately 35,000 adults classified as 
Class 2 obesity (body mass index (BMI)  35 kg/m²) (ABS, 2012). The recruitment 
methodology, study design and procedures for the focus groups are comprehensively outlined 
in previous published work (Sharman et al., 2016b, Sharman et al., 2016a, Campbell JA, 2018).  
In summary, ten focus groups (n=49) were conducted in the north and south of the state of 
Tasmania and there was a purposeful sampling of males and females, private versus public 
surgery, and people who were waitlisted for their surgery in the public healthcare system. Each 
focus group was no longer than 1.5 hours in duration, all were audio-recorded, transcribed 
verbatim and names were de-identified. 
7.2.3 Economic data collection 
The pre-existing theory of information asymmetry, the principal-agent relationship and 
demand-induced supply in the information age supported the initial development of health 
economics questions and prompts. A focus group discussion schedule was developed in liaison 
with the broader research team and revised during the focus group program (three month 
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timeframe). The questions and prompts contained in the discussion schedule guided the semi-
structured focus group discussions to elicit the health economics data for thematic analysis. 
7.2.4 Qualitative research methods employed for data analysis 
Thematic analysis underpinned by grounded theory (Strauss and Corbin, 1990, Strauss and 
Corbin, 1998, Liamputtong and Ezzy, 2005, Ezzy, 2013) informed the development of this 
study’s sub and central themes through the process of open, axial and selective coding of the 
focus group transcripts (Campbell JA, 2018). This thematic analysis was descriptive and 
interpretive and facilitated by use of software (QSRInternational, 2010). Table 1 provides an 
outline of the process of coding in thematic analysis (Campbell JA, 2018, Ezzy, 2013).  
We mixed inductive and deductive qualitative research methods. By adopting inductive and 
deductive theory building themes do not emerge from the data uninfluenced by the pre-existing 
theory (in this study asymmetry of information, the principal-agent relationship, and the 
subsequent concepts of supplier-induced demand and demand-induced supply). Additionally, 
the process of theory building involves an ongoing dialogue between data and theory in which 
emerging theories are repeatedly tested against the data (Figure 1, (Ezzy, 2013) (Campbell JA, 
2018).  
During the coding development for this study, the first author discussed the emergent sub- and 
central themes with the other qualitative and health economics investigators. An audit trail was 
kept for the project that comprised of a journal of question development, focus group sessions 
and refinement of questions, all coding sessions, memos, reflective notes, emails, group 
meetings, and individual meetings with the first author. Focus group participants’ experiences 
are highlighted with quotations and longer verbatim quotes are italicised and indented. 
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Table 1: Coding in grounded theory and thematic analysis* 
Open coding: 
• Explore the data. 
• Identify the units of analysis. 
• Code for meanings, feelings, actions. 
• Make metaphors for data. 
• Experiment with codes. 
• Compare and contrast events, actions and feelings. 
• Break codes into subcategories. 
• Integrate codes into more inclusive codes. 
• Identify the properties of codes. 
Axial coding: 
• Explore the codes. 
• Examine the relationships between codes. 
• Specify the conditions associated with a code. 
• Review data to confirm associations and new codes. 
• Compare codes with pre-existing theory. 
Selective coding: 
• Identify the core code or central story in the analysis. 
• Examine the relationship between the core code and 
other codes. 
• Compare coding scheme with pre-existing theory. 
Source: Adopted from Qualitative Analysis: Practice and Innovation (Douglas Ezzy 2013)*. 
 
7.2.5 Participant characteristics 
Baseline socio-demographic and clinical data are presented descriptively as mean (standard 
deviation (SD)) for continuous variables and frequency (%) for categorical variables. 
Participants’ height and (current) weight data were measured and recorded before the focus 
group sessions. Body mass index (BMI) was calculated as weight (kg)/[height (m)]². 
Percentage total weight lost (%TWL) was calculated as (lost weight / initial weight) *100 and 
percentage excess weight lost (%EWL) was calculated as (lost weight) / (initial weight – [25 * 
height (m)²]) *100. 
7.3 Results 
7.3.1 Participant characteristics 
Table 2 provides participants’ sociodemographic characteristics. Participants were middle-
aged, predominantly female and their education levels were evenly dispersed. Clinically, for 
participants who underwent bariatric surgery (n=41), Mean (SD) % total weight lost (TWL) 
and % excess weight lost (EWL) was 25.7% (12.5) and 60.6% (28.8) respectively. Ninety-eight 
percent of participants were severely obese before surgery (BMI 35 kg/m²) and this was 
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reduced to 26% of participants after surgery. All participants who were waitlisted for bariatric 
surgery were severely obese. 
Table 2: Participants’ socio-demographic characteristics 
Characteristics 
(n=49) 
 
Participants who had 
undergone bariatric surgery 
(n=41) 
Participants waitlisted for 
bariatric surgery 
(n=8) 
Age years 
Mean (SD) 
 
55 (11) 
 
54 (8) 
Sex 
(Female, n=x, %) 
 
(n=26, %) 
 
(n=6, 75%) 
Highest level of education* 
Category 1 
Category 2 
Category 3 
Category 4 
 
 
(11, 27%) 
(6, 15%) 
(13, 32%) 
(11, 27%) * 
 
 
(2, 25%) 
0 
(6, 75%) 
0 
LAGB (n=x, %) 
 
(n=40, 98%) NA 
Secondary Procedure (n=x, %) (n=6, 15%) NA 
Notes: 
SD = standard deviation; LAGB = Laparoscopic adjustable gastric band. 
*Highest level of education: category 1 = year 10 or less; category 2 = year 11 and/or 12; category 3 = 
certificate, diploma or trade; category 4 = university.  
 
 
7.3.2 Thematic analysis 
The core finding that emerged from our interpretive analysis was that irrespective of the 
sources and types of information that the participants used to inform their decision to undergo 
bariatric surgery, most participants’ decision to undergo surgery would be unlikely to change. 
We found that both publicly and privately treated participants identified similar information 
types and sources before and after surgery. We also found that psychosocial ‘drivers’ for 
information gathering and interpretation were fundamentally important before surgery and that 
the quality and consistency of validated, objective healthcare information became more 
important to participants after their bariatric surgery. 
Key themes that emerged from our thematic analysis are outlined below. 
(i) Divergence of information sources before and after bariatric surgery 
In the information age, bariatric surgery patients access and interpret a wide-range of 
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information sources before and after their bariatric surgery. Importantly, our study found that 
the drivers to seeking out particular information sources about bariatric surgery pre- and 
postoperatively were substantially different. Our study also found that information sources 
diverged pre- and postoperatively. 
Before surgery, many participants discussed accessing information more informally through 
social networks such as family and friends, the Internet or medical television programs. For 
example, participants stated ‘I had looked up the Internet’, ‘I did a bit of research on the 
Internet’, ‘the girlfriend had it done’ and ‘any medical show on TV I watch’. For example, one 
participant suggested that these more informal information sources were important in their 
decision-making to undergo bariatric surgery: 
 I know a couple of my friends – well my wife’s friends had, had it and it worked for them. 
Um I didn’t know much about it. I did a bit of research on the internet um thought, “Yeah 
it’s a good idea (male, public system) 
Some participants described the importance of social networks for gathering their information 
about bariatric surgery before they decided to have bariatric surgery. These included 
participants’ partners, close family and friends, or speaking to acquaintances who had 
undergone bariatric surgery. For example, one participant outlined the benefit of speaking to 
‘lots of people’ to gain information about their personal experiences before making the decision 
have bariatric surgery: 
 I’ve just spoken to – I’ve just spoken to lots of people that have had the lap-band surgery 
you know what their experiences of it were. Some people have said it’s the best thing 
they’ve ever done. There’s been other people that said it’s not the answer to everything, 
it’s not been easy at all (female, public system) 
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Nevertheless, some participants described situations where the physician (including at public 
information sessions) explained the lap-band procedure and expectations regarding dietary and 
lifestyle changes, coupled with the provision of a ‘lap-band’ information booklet. Some people 
described using an ‘information booklet’ or flyer with accompanying Internet searching for 
information. To illustrate, one participant said: 
Well when I first made the initial appointment to see the specialist, I was given a 
booklet…had to take that home and read it. So basically a lot of the information came from 
there, also doing internet research. Mainly a lot studies I sort of looked at came from 
America, where it had been done – trialled over there quite a bit; not here in Australia. 
Yeah so that was the main areas where I got mine (male, public system) 
After surgery, many participants acknowledged that the information sources they accessed 
before surgery were insufficient to appropriately inform them about their postoperative 
experiences and complex physical and psychological HRQoL needs. These participants 
suggested that more targeted, high-quality healthcare information and support (particularly 
psychological) should be an important consideration before surgery. To illustrate, Table 3 
provides verbatim quotes that highlight participants’ acknowledgement of key information 
gaps regarding their psychosocial HRQoL impacts or needs after their bariatric surgery. 
(ii) Weight status is only one factor influencing HRQoL: psychosocial HRQoL as a key 
‘driver’ for gathering information 
In the information age, high-quality, validated, consistent and targeted information about 
bariatric surgery is important to bariatric surgery patients. Our study found that the 
complexities of many focus group participants’ psychosocial HRQoL before bariatric surgery 
and their subsequent shift in perceptions about relevant psychological information needs after 
undergoing bariatric surgery informed many participants’ understanding about their 
preoperative healthcare. 
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Before surgery, we found that focus group participants discussed a tremendously complex 
interweaving of psychosocial drivers for seeking information about bariatric surgery and their 
perceived healthcare literacy and empowerment before they underwent bariatric surgery. Many 
participants discussed these psychosocial or emotional drivers for seeking surgery that included 
the way they felt about themselves and their emotions. These complex socio-emotional drivers 
were linked to discussions about ‘seesawing weight’. One participant discussed the ‘seesawing 
weight’ as an illness: 
 It became an illness – or it did become an illness for me trying to go up and down. I did go 
down very quickly but I’d go up twice as much, and twice as fast. And that seesawing for 
me was a mental illness. It was not a nice place to be, and I’m never going back there, ever 
in my life. That’s why I say I came to a place of acceptance (female, private). 
Importantly, our study found that it was only after bariatric surgery that many participants fully 
acknowledged the complexity of their psychosocial HRQoL. Many participants discussed the 
psychosocial and socio-emotional drivers that motivated them to undergo bariatric surgery. For 
example, a couple of participants used language like ‘magic-bullet effect’ and ‘mindset’, others 
talked about their ‘comfort eating’, nevertheless these participants appeared to have only 
acknowledged these psychosocial drivers after they had their surgery. Most of these 
participants also discussed the need for high-quality and validated healthcare psychological 
information and support before their surgery to address their mindset. 
For example, one participant suggested that despite gathering information about lifestyle and 
eating practices, psychological information was important after surgery: 
  We’ve done some research, we know what it’s about, we know what happens, we know that 
it’s going to really severely affect the way that you eat, and all that kind of thing. But I 
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guess no one really prepares you for the psychological stuff. The, “Yes, you might not be 
hungry anymore but the habits are still there.” (female, private system). 
(iii) Information regarding the management of physical health impacts after bariatric 
surgery 
Physical health impacts that are not directly associated with weight loss (for example, improved 
HbA1c as an indicator of diabetes status, blood pressure as an indicator of cardio-vascular 
health or joint pain) are important postoperative considerations for people who undergo 
bariatric surgery. Nevertheless, many participants did not particularly seek information 
regarding these types of physical health impacts, nor did they know about or understand ways 
to manage other potentially debilitating physical impacts that would enable a smoother 
transition after their bariatric surgery. To illustrate, many participants discussed physical health 
concerns such as ‘dehydration’, ‘not being able to get enough fluids’, ‘anaemia’, ‘vomiting’, 
and regurgitation of food. Some participants described unexpected emergency department 
visits or hospital admissions due to fluid and electrolyte deficiency (e.g iron deficiency and 
dehydration) or food bolus obstruction. In regard to dehydration and food intake one participant 
said: 
 I can’t seem to find the right balance. I’m either like you [another focus group participant] 
for days on end and end up in the LGH [Launceston General Hospital] hooked up to a drip 
because I’m so dehydrated, or I’m able to eat more than what I should. (female, private 
system). 
In regard to maintaining a clinically acceptable fluid balance another participant said: 
 Liquids were one of the hardest things for me; still are. That’s why everywhere I go, I take 
my drink bottle with me, because that’s how I drink my liquids. I have to keep slowly 
[drinking] all day, and I’m sure others are the same, otherwise I can’t – don’t get enough 
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fluids. And it’s just something you learn to do; something – you learn to manage it. (female, 
private system). 
Some participants described unexpected physical symptoms that occurred in the first few days 
(and meals) after their gastric band adjustment that were both physically and psychologically 
distressing. For example, one participant described a food blockage situation when she was out 
at a restaurant the evening of the band adjustment and she said: 
 Yeah, that’s what it feels like. You’re just so shocked [Previous speaker: Oh it is. It’s like 
this pain in your chest; you can’t breathe], and I think I almost lost it the first time that 
happened, I remember turning gray and thinking, “How – what on earth’s going on?” I 
mean, now I know how to cope with that.” But at the time there’s no feedback on what to 
do when that happens. (female private system). 
(iv) Divergence of information types and sources: would patients still undergo bariatric 
surgery? 
The bariatric surgery patient’s decision to undergo bariatric surgery is generally preceded by 
sustained periods of psychosocial experiences related to ‘years of dieting’, ‘seesawing weight’, 
‘ballooning’ weight, ‘hitting three digits’ (in kilograms) on the scales, and stigmatisation and 
discrimination. Despite most participants’ transitional period after surgery that was marked by 
health illiteracy about some of the postoperative psychosocial considerations and physical 
health impacts (as outlined in the key themes above), most participants said that they would 
still undergo the surgical procedure: ‘I’m pleased I’ve had it done; I just wish there was more 
education, more help to get me through to being okay’. One participant articulated that: 
I’m not sorry I had it done, because at the time I was ballooning and it stopped that and I 
lost 30 kilos – which I still have masses to lose – but it stopped that progression of going 
towards death at a rate of knots, I suppose. So I’m not sorry I had it done. (female, private 
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system). 
Another participant said that: 
 I am really happy that I’ve had it done. And I would never want it to come out either. 
Because I don’t think I trust myself. Because of that mental thing that’s never been 
addressed or whatever, if I had it out I reckon I’d just put all the weight back on again. 
That’s what scares me. So, I wouldn’t – even – and this is what I’ve been this way now. 
(female, private system). 
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Table 3: Examples of verbatim quotes that highlight the acknowledgement of psychosocial 
support needs after bariatric surgery that were not identified before bariatric surgery. 
 
 
Full quotation 
How psychologically it works. And how much of a trauma it is that you’ve actually got to 
really retrain yourself in thinking, “I’m not hungry,” because most of us have been binge 
eaters, and comfort eaters, and whatever. (female, private system) 
 
Yeah that’s what I found too. In the first 12 months the psychology of the whole things is the 
biggest battle [New speaker: Good point]. It’s ah let’s – you know the truth’s the truth, let’s 
face it – every big person ah loves food, eats fast, and eats plenty of it you know. You know 
so we’ve had lap-band surgery and ah we’ve adjusted it up so now the ah psychology of it 
where we can’t eat fast, we can’t eat a lot of it and ah – yeah that’s probably the most 
difficult part over the 12 months…And it does probably take 12 months wouldn’t you say, to 
get that psychology right? Where that’s – forget about somebody eating a big baked meal 
over there, might smell nice, but you know darn well that you can’t eat and ah [New speaker: 
That’s right]. (male, public and private system) 
 
Yeah it stopped you eating too much, and that’s what I’m now right into working – I’m still 
battling – my mindset never went away with the operation [New speaker: No, no], and that’s 
what I’m returning to. It’s still there – that’s what I found – the same psychology’s still in 
my head. I don’t have that thing that makes me – I can’t be feeling ill because I literally – it 
doesn’t do anything for me anymore. I’ve still got a little bit of obviously tightness there, 
and I can’t go crazy. But I can still – it’s not working for me, and I’m thinking, “Geez, that 
whole mindset is still there and it never went away. (female, private system) 
 
My family told me that I should go and get my head sorted. So I’ve just been doing it. (female, 
private system) 
 
So it isn’t a curable. You’ve got to do head work for it to be successful as well. (female, 
private system) 
 
It really is a psychological issue and there is really no help for that basically. Nobody tells 
you or it’s really hard to get knowledge, that’s what I found. (male, public and private 
system) 
 
You know, you’ve still got – even though you’ve had surgery and you’ve lost weight, there 
is so much more mind stuff, which in my experience, isn’t really addressed. You know your 
body’s changed, you’re a different shape, you’re a different person – I certainly feel like 
I’m a different person than I was then – but there’s still a lot of mind stuff happening in 
there. There really – unless you want to go and get it privately addressed – isn’t addressed 
it just goes, “Okay, you know I’m smaller now, I can – you know I can walk better, I can 
do this” – but there’s still all that stuff going in your head (female, private system) 
 
It’s also the psychology of your eating patterns before your lap-band. If you’re a comfort 
eater – or you know, I eat when I’m happier, I eat when I’m sad, I eat when I’m disappointed. 
I eat when it’s Monday, I eat when it’s Tuesday. So if the – if your eating patterns and your 
psychology are like that, as the other lady alluded to, nothing is done to address those issues. 
(female, private system) 
Chapter 7: A qualitative investigation of information asymmetry for obesity surgery: diversity 
of patient experiences in the information age and demand-induced supply. 
 
393 | P a g e  
 
7.4 Discussion 
Our study is the first health economics study to use qualitative research methods to investigate 
bariatric patient’s lived experiences with the pre-existing theory of information asymmetry in 
the marketplace for bariatric surgery. Importantly, through sophisticated grounded theory we 
adopted the process of frequent comparison of emergent thematic categories from our 
qualitative data with the pre-existing economic theories of asymmetry of information and the 
principal-agent relationship (particularly demand-induced supply) for bariatric surgery patients 
in the information age. By exploring bariatric surgery patients’ experiences we found that there 
were substantial inconsistencies in preoperative and postoperative information drivers, sources 
and types for the study population. Importantly, we found that consumers of bariatric surgery 
perceived that they were informed by the information sources they accessed and used in their 
decision-making to seek or undergo bariatric surgery. We also found that psychosocial ‘drivers’ 
for information gathering and interpretation were fundamentally important before surgery and 
that the quality and consistency of validated, objective healthcare information became more 
important to participants after their bariatric surgery. 
7.4.1 Bariatric surgery in the information age: demand-induced supply and postoperative 
transition 
Our study endeavoured to understand the potential consequences of the emerging concept of 
demand-induced supply in the information age (in contrast to supplier-induced demand) in 
today’s marketplace for bariatric surgery where demand-induced supply has been defined as 
the phenomenon that patients move the demand curve out due to a change in their knowledge 
or taste. Importantly, our study’s findings revealed that most focus group participants’ decision 
to undergo bariatric surgery would not change regardless of their postoperative health literacy. 
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We suggest that preoperative information gathering by the population of bariatric surgery 
patients is likely to have resulted in the outward shift of the demand curve as illustrated in 
Figure 1 preoperatively, and that despite the identification of inadequate health literacy 
postoperatively, most bariatric patients would still undergo their surgery. The important point 
here is that in the information age bariatric surgery patients perceive that they are empowered 
by information and perhaps seek surgery that they may not have otherwise sought. 
One of few studies (and the first study) to investigate the concept of demand-induced supply 
(described as physician-enabled demand) found the variable with the strongest impact on 
physician-enabled demand was a variable that measured the proportion of patients who 
provided medical information at the physician’s practice (Fang and Rizzo, 2009). This study 
also concluded that the recent movement towards consumerism in healthcare will arm the 
consumer with more information and should be the subject of future research directions. 
Our qualitative health economics study found that in the information age, most focus group 
participants would still undergo their bariatric surgery notwithstanding unexpected 
postoperative physical and psychological health impacts. Despite the forces of demand-
induced supply that could have caused the outward shift of the demand curve, the key point is 
that high-quality, targeted and endorsed healthcare information preoperatively may adjust 
individual choices regarding bariatric surgery, and there could be a smoother postoperative 
transition after surgery. More specifically, our results suggest that appropriate pre-and 
postoperative information sources and types would enable these patients to better manage their 
psychosocial and physical health related quality of life transition after surgery. Additionally, 
there was a substantial divergence between information sources, types and drivers before and 
after bariatric surgery. We found that many participants accessed preoperative information 
through online sources or their family and friends (i.e. social networks). We also found that 
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psychosocial drivers were fundamentally important before surgery and that the quality of 
healthcare information became more important to bariatric surgery patients after their surgery. 
Recent evidence has found that the Internet is an important source of information for morbidly 
obese patients who are potential candidates for bariatric procedures (Corcelles et al., 2014). 
Their study found that bariatric surgery candidates viewed poor quality and content of 
information on the Internet. They concluded that while the Internet is a vast resource, to realise 
its full potential it is necessary to direct consumers to high quality information and to teach 
them how to assess the quality of information (Corcelles et al., 2014).  
We found that participants recognised the value of targeted, high-quality and consistent 
information from healthcare professionals after they had their bariatric surgery. Nevertheless, 
the challenge is to motivate bariatric surgery patients to access and understand the intrinsic 
value of high-quality, validated, relevant information preoperatively. We suggest that poor 
health literacy for bariatric surgery patients preoperatively will translate to poorer HRQoL and 
health economics outcomes. For example, unexpected emergency department presentations 
and hospitalisations due to poor management of fluid and electrolyte imbalance that could be 
avoided with improved knowledge from the outset of surgery. In turn, we suggest that a 
smoother postoperative transition would also translate to decreased burden on healthcare 
resources. 
Our broader qualitative program of work also identified that providers of bariatric surgery 
should discuss support needs and accessibility regularly with patients especially in the first year 
postoperatively and following significant change in a patient’s life (Sharman et al., 2016a). 
7.4.2 The economics of risky behaviour: bounded rationality 
Emerging literature in behavioural economics postulates that mainstream neoclassical theory 
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is deficient in describing the complex nature of the economics of the obesity epidemic. A recent 
study regarding the application of behavioural economics to public health policy suggests that 
under the behavioural economic theory of ‘bounded rationality’, rationality in decision making 
is curtailed by a lack of information, cognitive limitations, and a finite amount of time to make 
a decision (Matjasko et al., 2016). The study also found that people may also have finite 
amounts of willpower and experience decision fatigue, and that all public health policy makers 
and providers should simplify how information is presented in order to make it easy for people 
to use (Matjasko et al., 2016).  
Our study has identified that validated and targeted preoperative information is essential to 
rational in decision-making of bariatric surgery patients. High-quality, consistent and 
accessible information should be provided to enable a smoother postoperative transition for 
bariatric surgery participants. Our study also suggests that the challenge could be in motivating 
these patients to access and understand the value of this validated information. 
7.4.3 The economics of emotional capital 
Our broader program of qualitative work regarding people who have been waiting for or 
undergone bariatric surgery has also taken the concept of psychosocial health-related quality 
of life a step further and identified ‘emotional capital’ as a fundamental driver for participants 
seeking bariatric surgery and for the short- and long-term success of their bariatric surgery 
(Campbell JA, 2018).  
In regard to information sources and needs, coupled with rational (or bounded rationality) 
decision making within the constraints of recently identified emotional capital drivers, we also 
suggest that it is important to recognise that emotional capital drivers may dominate negatively 
preoperatively (when people don’t want to leave their own homes before they have their 
surgery because of their obesity), and perhaps positively after surgery (where clinical and 
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physical concerns that should be addressed may in fact be overridden by emotional capital 
factors of feeling ‘respected’ and ‘good’ because of their weight loss) (Campbell JA, 2018). 
7.4.4  Qualitative research in health economics 
It has been argued that health policy development, research, and management could benefit 
from more in-depth, textured descriptions of what actually happens in practice settings, 
healthcare markets, and patients’ lives (Weiner et al., 2011, Greenhalgh et al., 2016, Campbell 
JA, 2018). In regard to the market for bariatric surgery, our qualitative study has particularly 
identified the psychological drivers that influenced the participants’ preoperative information 
gathering. It has also identified the acknowledgement of pre- and postoperative health illiteracy 
postoperatively. 
This qualitative study has highlighted the strengths that qualitative research methods can bring 
to health economics study design. By listening to the ‘other’; by listening to our participants’ 
stories and then considering and analysing the spoken word through verbatim transcripts, we 
have provided health economic and policy decision-makers with a deeper contextual 
understanding about information in the bariatric surgery marketplace. From a research 
translation perspective, this means that we have identified important health economics findings 
that can be provided to decision-makers not be identifiable through traditional quantitative 
approaches. 
7.4.5 Limitations 
The key limitation to our study was that the study was based on people who had been exposed 
to information regarding bariatric surgery who had subsequently decided to opt for the surgery 
including those people on the waitlist who have had their bariatric surgery. It is suggested that 
a sample of partcipants that was exposed to information regarding bariatric surgery and then 
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decided not to have the bariatric surgery should be the subject of future research. Another key 
limitation to our study was that the scope of our investigation was restricted to focus group 
data. Another limitation was that we did not include a qualitative investigation of physician 
behaviour. 
The strengths of our study included the use of qualitative research methods to identify key 
knowledge gaps in regard to the information asymmetries for bariatric surgery patients where 
the economic component of the focus group discussions were embedded and thus identified 
during discussions of the broader ‘lived’ experiences of participants. Our study was informed 
by a relatively large sample size for qualitative research (n=49), with diversity of participants’ 
treatment modality (i.e. public/private/waitlisted), and socio-demographic characteristics. 
Finally, our research team embodied a combination of knowledge and skills of experienced 
qualitative researchers and health economists from research and policy-making backgrounds 
to enable a multi-disciplinary investigation of the predominantly quantitative health economics 
research of bariatric surgery.  
7.5 Conclusions 
This study found that in the information age, there was a divergence of information sources 
and needs pre- and postoperatively for bariatric surgery patients. We recommend that high-
quality and consistent information sources be targeted towards the psychosocial domains and 
even the emotional capital of pre- and postoperative health. We also recommend that 
appropriate healthcare information be provided to enable a smoother transition for the 
management of physical health impacts such as postoperative dehydration and electrolyte 
imbalance which can result in unexpected hospitalisation. A smoother postoperative transition 
would likely translate to less burden on the healthcare doll
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Chapter 8: A cost-outcome study: A real-world investigation of long-
term inpatient hospital utilisation and costs for a retrospective cohort 
of bariatric surgery patients in an Australian public hospital system 
based on Australia’s Activity Based Funding model. 
Preface 
Chapter 8 presents the final study of this mixed-methods PhD research regarding the health economics 
of obesity and bariatric surgery. Chapter 8’s applied quantitative costing study is the first study within 
the Australian public hospital setting to report on individual episodes-of-care and costed patient-level 
pathways for primary, and secondary/tertiary bariatric surgery informed by Australia’s Independent 
Hospital Pricing Authority’s Activity Based Funding model.  
The NHMRC partnership project between the Tasmanian State Government and the University of 
Tasmania was, in part, developed to investigate and identify direct medical costs for a retrospective 
cohort of bariatric surgery patients in Tasmania, based on the Activity Based Funding model. Prior to 
this study, accurate individual patient-level resource use and costs of bariatric surgery for people with 
severe obesity waitlisted for, and who then undergo bariatric surgery in the Tasmanian public hospital 
system were not known. The findings of the systematic review in Chapter 2 particularly guided the 
study’s investigation of the patient-level unit costs, the costs of waiting for bariatric surgery, subgroup 
analyses, and the accurate cost of complications and reoperations over a long time horizon. The study’s 
strategic research alliance exploited the economic concepts of heterogeneity of human capital, division 
of labour and comparative advantage to drive a clinical costing team for bariatric surgery in the 
Tasmanian public hospital system. Data were extracted on an individual patient basis to track the 
primary Activity Based Funding episodes-of-care and associated length-of-stay and costs attributed to 
each patient pathway before and after primary bariatric surgery. The study found that the cost of 
providing the primary laparoscopic adjustable gastric band (LAGB) bariatric procedure compared with 
the sleeve gastrectomy procedure is similar. The study also suggested that prevalent LAGB device-
related costs could be mitigated with alternative surgical methods such as sleeve gastrectomy (rather 
than the prevalent LAGB) within the Tasmanian public hospital system. Another interesting finding 
from subgroup analysis was that the average cost for an episode-of-care reduced from the first year after 
surgery for people with diabetes. 
Overall this study’s findings suggest that bariatric surgery in the Tasmanian public hospital system may 
be an attractive value-based option in the longer term: bariatric surgery realised health benefits (reduced 
inpatient episodes-of-care) and reduced costs at year 3 postoperatively. Costs could be mitigated by 
substituting LABG with SG when clinically appropriate, taking into account our small SG sample size. 
Three years postoperatively, episodes-of-care and costs reduced substantially versus preoperatively, 
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particularly for people with diabetes/cardiovascular disease. One year preoperatively, the study 
population recorded the highest number of inpatient episodes-of-care and costs. We also found that the 
cost of secondary and tertiary surgery maximised at year 2. 
This study was presented at the Australian Health Economics Society Doctoral Workshop on 20 
September 2017. The workshop Discussant and participants provided valuable and positive feedback 
that has been incorporated into the draft. The positive observations included comments regarding the 
applied nature of the project and the identification of each patient pathway, resource use and cost from 
the primary surgical procedure through to the secondary and tertiary procedures.  
Our project partner has stated that the findings from this study are of policy-changing interest, 
particularly when the findings of this study are pooled with the findings and recommendations of my 
PhD research’s investigation regarding the health economic evaluation of bariatric surgery (Chapter 2), 
the assessment of health-related quality of life for people waiting for or who had received bariatric 
surgery in the public and private healthcare systems (Chapters 3, 4 and 5) and the qualitative research 
regarding bariatric surgery patients’ lived experiences (Chapters 6 and 7).  
The holistic summary of this PhD’s body of work on the health economics of obesity and bariatric 
surgery internationally, nationally and locally within Tasmania is provided in Chapter 9 of this thesis. 
Please note that the Reference and Abstract style of this paper reflects the submitted journal’s 
style. This chapter is under review at PharmacoEconomics Open. 
Impact factor: New journal. 
Campbell JA, Hensher M, Davies D, Green M, Hagan B, Jordan I, Venn A, Kuzminov A, Neil A, 
Palmer AJ. A cost-outcome study: A real-world investigation of long-term inpatient hospital utilisation 
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Abstract 
Background: Within the Australian public hospital setting, no studies have previously reported total 
hospital utilisation and costs (pre/postoperatively), and costed patient-level pathways for primary 
bariatric surgery and surgical sequelae (including secondary surgery) informed by Australia’s 
Independent Hospital Pricing Authority’s Activity Based Funding (ABF) model. We aimed to provide 
our Tasmanian State Government partner with information regarding key evidence gaps about the total 
costs of bariatric surgery (including before and after surgery, types of surgery, and comorbidities) and 
the costs of surgical sequelae. We also aimed to provide some direction regarding the types of bariatric 
surgery offered within the Tasmanian public hospital system. 
Methods: Data were extracted from administrative sources routinely collected, clinically-coded/costed 
according to ABF. Aggregated ABF (2015 Australian dollars) inpatient episodes-of-care for the surgical 
procedure and before and after surgery associated length-of-stay and costs (including micro-unit costs 
of operating theatre, pharmacy, ward and salary costs) were investigated for the fiscal-years 2007/08 to 
2015/16. Sensitivity (cost outliers) and subgroup analyses (people with diabetes, cardiovascular disease 
and BMI cut-points) were also conducted. 
Results: N=105 publicly-waitlisted severely-obese patients with multi-morbidity underwent primary 
bariatric surgery (laparoscopic adjustable gastric band (LAGB) n=89; sleeve gastrectomy (SG) n=16) 
in Tasmanian public hospitals. Annual total costs (TC) 1 year preoperatively were $434,710 and 3 years 
postoperatively were $122,820. TC and episodes-of-care decreased at 3 years postoperatively for the 
entire cohort. The average cost/episode-of-care decreased in the first year postoperatively for people 
with diabetes, from $6,984 to $5,610/episode-of-care. TC (pre/postoperative over 8 years) for all 
inpatient episodes-of-care (n=779 episodes-of-care) were $5,791,530. When the ten identified cost 
outliers were omitted from the total cost, this cost reduced to $4,570,275. Mean costs for primary LAGB 
and SG bariatric surgery were $14,071 and $14,448, respectively. Twenty-seven LAGB patients (30%) 
required surgery due to surgical sequelae (including revisional/secondary surgery) (n=58 episodes-of-
care), and 56% of these episodes-of-care were secondary LAGB device-related (mostly port/reservoir-
related) with mean costs of $6,031. 
Conclusions: Our patient-level analyses provided much needed information regarding the costs of 
bariatric surgery to the Tasmanian public hospital system. Three years postoperatively, episodes-of-
care and costs reduced substantially versus preoperatively, particularly for people with 
diabetes/cardiovascular disease. Costs could be mitigated by substituting LABG with SG when 
clinically appropriate, taking into account our small SG sample size. We recommend that a larger 
confirmatory study regarding SG versus LAGB be undertaken at a more granular level of ABF costing.  
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8.1 Introduction 
8.1.1 Obesity and bariatric surgery: the Australian context 
The obesity epidemic is a complex public health, economic and strategic policy problem [1-4]. 
In Australia, over 60% of adults are overweight or obese, and in line with global trends, the 
rate of severe obesity (body mass index (BMI) 35 kg/m²) is increasing more rapidly than 
overweight and obesity (overweight BMI 25–29.9 kg/m²; obesity BMI 30–34.9 kg/m²) [5-7]. 
Given this increasing trend of severe obesity, recent clinical literature also describes a fourth 
class of obesity known as ‘super-obesity’ defined as a BMI of 50 kg/m² [8].  
The most recent estimate contained in the published literature of the total annual direct cost of 
overweight and obesity in Australia in 2005 was 21 billion Australian dollars: this estimate was 
substantially higher than previous estimates [9]. An international study has established that 
costs rise rapidly in the range of severe obesity [10].  
The Australian National Health and Medical Research Council’s clinical guidelines 
recommend bariatric (obesity, weight-loss, metabolic [11]) surgery as a treatment option for 
severe and resistant obesity [12]. In 2014–15, there were more than 22,700 weight loss 
surgery separations in Australia, most of which involved a primary procedure (79.4%) 
[5]. The majority of these bariatric surgery separations (88.0%, or 20,000 separations) 
occurred in private hospitals [5]. 
A recent Australian study determined that the potential demand for publicly- and privately-
funded bariatric surgery in Australia was 882,441 adults aged between 18-65 years [13]. 
Importantly, 45.8% of these potential bariatric surgery candidates had no private health 
insurance [13]. 
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Importantly, another recent qualitative health economics study found that of the people who 
partially or fully self-funded their bariatric surgery experienced economic burden to do so [14]. 
This qualitative health economics study also found that some people were accessing their 
superannuation to fund their surgery because they either had no private health insurance, or 
they had to pay the concomitant health insurance gap [14]. 
The Australian healthcare system presents a complex and fragmented set of arrangements 
between the public (two tiers of government) and private sectors [15]. The Commonwealth 
government holds the major revenue raising power. The state governments operate public 
hospitals which account for about two-thirds of all hospitalisations and provide emergency 
department visits without charge. Australia’s National Health Reform Agreement established 
the new basis for the Commonwealth’s contribution to public hospital funding based on a 
hospital’s casemix and defined as Activity Based Funding (ABF) [16, 17]. Constrained public 
sector budgets contribute to the incapacity of the Australian public health system to address the 
problems of severe obesity increasing more rapidly than obesity [1, 18]. This problem is 
reflected internationally [15, 19-21] 
8.1.2 Real-world data to inform health economic decision making 
Health decision-makers involved with coverage and payment policies are increasingly seeking 
information on real-world outcomes on which to base their decisions recognising the 
importance of evidence that goes beyond information collected in randomised control trials 
[22].  
A recent Australian Institute of Health and Welfare (AIHW) report regarding weight loss 
surgery in Australia that used Medicare data to analyse the costs of bariatric surgery, suggested 
further research could report on ‘typical patient journeys’ incorporating a broad range of direct 
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medical costs (rather than just analysing Medicare linked data). The report stated that the ability 
to track and analyse patient journeys from primary through to surgical sequelae (including 
secondary surgery) would greatly assist in understanding the broader relationships between 
primary surgical procedures and subsequent adjustments and revisions and their associated 
costs [5]. Notably this AIHW report only provides aggregate figures for the number of bariatric 
surgery separations for some Australian jurisdictions, including Tasmania, suggesting a key 
evidence gap [5]. 
8.1.3 Objectives of this study 
Our comprehensive systematic review of the health economic evaluations of bariatric surgery 
found that bariatric surgery is cost-effective or potentially cost-saving for severely obese 
patients (body mass index (BMI)  35 kg/m²) with concomitant diabetes [1]. However, the 
review also found that costs due to complications and reoperations of bariatric surgery were 
only incorporated in one-third of the included studies [1]. Additionally, when these costs were 
included, a conservative estimate of the costs of complications or re-operations, or low 
probabilities of these events were assumed [1]. Another recent systematic review regarding 
reoperations after secondary bariatric surgery found that despite being poorly reported, risks of 
reoperations and long-term complications and tertiary bariatric surgery are higher than usually 
reported risks of short-term complications [23]. The most recently published Australian cost-
utility study of bariatric surgery took rates of complications and reoperations from the 
literature, rather than from the administrative hospital database that was used for the costs of 
the initial bariatric surgery therefore suggesting another conservative estimate [24]. 
Furthermore, the base case for the cost-utility study assumed a severely-obese female cohort 
of 30 years of age with no co-morbidity at the time of the operation [24]. 
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While previous attempts have been made to quantify the costs of bariatric surgery in an 
Australian setting [24], they did not use the Independent Hospital Pricing Authority’s ABF 
model. An Australian National Health and Medical Research Council partnership project 
between the Tasmanian State Government and the University of Tasmania was, in part, 
developed to investigate and identify direct medical costs for a retrospective cohort of bariatric 
surgery patients in Tasmania, based on the Australian Independent Hospital Pricing Authority’s 
ABF model.  
Prior to our current study regarding bariatric surgery in the Tasmanian public hospital system, 
accurate resource use and costs of bariatric surgery for people with severe obesity waitlisted 
for, and who then undergo bariatric surgery in the Tasmanian public hospital system have not 
been known. More specifically, our State Government project partner does not know the 
hospital utilisation and costs for people with severe obesity (predominantly with concomitant 
comorbidity) who receive bariatric surgery in the Tasmanian public hospital system, informed 
by the Australian Independent Hospital Pricing Authority’s Activity Based Funding Model. 
Nor does our project partner know the relative costs of the two types of bariatric surgery offered 
in the Tasmanian public hospital system. Therefore, our research aimed to address a key 
evidence gap by providing our State Government partner’s key decision-makers with hospital 
utilisation and cost analyses to inform policy decisions about prioritisation and access to public 
hospital resources for bariatric surgery in the Tasmanian public hospital system.  
More specifically, we aimed to provide evidence regarding the total costs (over a long time 
horizon) of providing public healthcare resources to people waiting for, and who then receive, 
bariatric surgery in Tasmania. We also aimed to provide evidence regarding hospital utilisation 
and costs for LAGB and SG, both primary and surgical sequelae of bariatric surgery (including 
secondary and tertiary surgery) in Tasmania. 
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8.2 Methods 
8.2.1 Study design 
(i) Validated guidelines 
This study has been conducted in accordance with validated guidelines including the 
Consolidated Health Economic Evaluation Standards (CHEERS checklist) (Appendix 1) [25], 
the Independent Hospital Pricing Authority Patient Costing Standards version 3.1. [17], the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement 
[26], and the Tasmanian Department of Health and Human Services (DHHS) Patient Level 
Costing Policy and Manual (October 2016) [27]. We also reported in accordance with the 
International Society for PharmacoEconomics Outcomes Research Real-World Data Taskforce 
Report [22], which states that real-world data are essential for sound coverage and 
reimbursement decisions: context matters greatly in determining the value of a particular type 
of intervention in any circumstance [22]. 
(ii) Study setting, the strategic research alliance, information sources and economic 
perspective 
This retrospective health economics study was part of a much broader mixed-methods 
partnership project between the Tasmanian State Government and the University of Tasmania. 
The study’s strategic research alliance exploited the economic concepts of heterogeneity of 
human capital [28], division of labour [29] and comparative advantage [30] to drive a clinical 
costing research team for bariatric surgery in the Tasmanian public hospital system between 
the university researchers and the departmental officers. The team comprised of: state 
government officials who were experts in the department’s administrative databases, clinical 
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coding and costing (under the auspices of the Australian Independent Hospital Pricing 
Authority’s ABF model that informed the costs extracted for analyses), database construction 
and raw cost data extraction; university researchers expert in clinical research, health 
economics and epidemiology; and a state government official who was a health economist, 
policy-leader and decision-maker within the DHHS.  
Patient sociodemographic, clinical, resource use and cost data were extracted from the DHHS’s 
Patient Management System and Clinical Cost databases. 
The costing was performed primarily from the Tasmanian Government’s perspective and to a 
lesser extent the Commonwealth Government’s perspective (under the National Health Reform 
Agreement [16]). Relevant ethics approvals were obtained from the University of Tasmania’s 
Health and Medical Human Research Ethics Committee. 
(iii) Study population 
From the patients who were enrolled on the waiting list for bariatric surgery from 1 January 
2008 to 31 December 2013 the study population was defined as all patients who had received 
primary bariatric surgery in a Tasmanian public hospital (i.e. not contracted-out into the private 
hospital sector for their surgery, nor treated elsewhere privately), and subsequently ABF costed 
for the fiscal years 2007/08 to 2015/16. 
Patients who were then identified from the waiting list (1 January 2008 to 31 December 2013) 
as having received primary bariatric surgery in the Tasmanian public hospital system over this 
time horizon were then classified by surgery type: primary laparoscopic adjustable gastric band 
(LAGB) and primary sleeve gastrectomy (SG). Importantly, these were the only forms of 
bariatric surgery performed in Tasmania during this period. 
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(iv) Activity based funding model 
A bottom-up costing methodology (in relation to the DHHS predefined ABF cost buckets) for 
resource use and costing was used [27]. Within the ABF model, the DHHS focused on costs at 
the patient level. The DHHS states that a consistent approach to identifying how individual 
patient costs are built-up can help organisations understand where variations arise within a 
patient pathway, for example, in theatres, wards or diagnostics [27]. The DHHS’s development 
of patient-level costs builds costs from the bottom-up, identifying where possible the resources 
used in treating individual patients – for example, prosthetic devices (such as LAGB-
appliance), the intensity of nursing resources and indirect or overhead costs such as the costs 
of the payroll or finance team through appropriate allocation and apportionment methods [27]. 
More specifically, the DHHS costing methodology [27] adheres to 6 steps for ABF patient-
level costing [17]: (1) ‘define the patient care to be costed’ - the first step is to identify the 
elements of patient care that need to be costed. Figure 1 provides an outline of the DHHS 
process to identify the patient care to be costed; (2) ‘identify the activities’ - to assign costs 
accurately to a defined element of patient care, the activities associated with delivering that 
care need to be accurately identified; (3) ‘identify the relevant costs’ – once the element of 
patient care to be costed has been defined, and associated activities and resources identified, 
the next step is to determine the relevant costs incurred in delivering the patient care; (4) 
‘classify costs’ – after identifying costs for an element of patient care, the next step is to analyse 
and classify these costs. Under ABF, the Independent Hospital Pricing Authority’s costing 
standards classify costs based on direct and overhead costs and fixed, semi-fixed and variable 
costs; (5) ‘assign costs’ – once the resource costs and activities underpinning the element of 
patient care to be costed have been fully analysed and understood, the next step is to assign the 
resource costs to the respective elements of patient care [costs can be attributed using the 
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following methodologies (Actual use, Weighted costs, Apportionment based on relevant 
statistics such as floor area)]; and (6) ‘validate the outputs’ – basis checks are undertaken to 
ensure the costing is accurate [27]. This study investigated the aggregated ABF costs. 
An episode-of-care is defined by the Australian Independent Hospital Pricing Authority as ‘A 
phase of treatment from admission to separation. An admission may be 'statistical' in that the 
patient changed from one type of admitted patient category to another (between any two of 
acute, rehabilitation, palliation, or non–acute) without being separated from the hospital. It 
follows that there must be a 'statistical separation' before every statistical admission’ [17]. Our 
study population’s primary bariatric surgery inpatient hospital admissions and all their 
preoperative and postoperative inpatient hospital admissions (for the pre-defined time horizon 
of 2007-8 to 2015-16) were extracted to generate a unique episode-of-care number that was 
costed according to ABF[17, 31]. 
Table 1 provides examples of ICD-10-CM, AR-DRG, and procedure codes of interest for the 
primary LAGB surgery [32, 33]. 
Figure 1: The Tasmanian Department of Health and Human Services patient level costing process 
mapping (Source: Patient Level Costing Guidance Manual October 2016). 
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Table 1: Examples of ICD-10-CM, Australian Refined Diagnostic Related Group (AR-DRG) codes, 
and procedure codes of interest for primary bariatric surgery. 
 
 
 
 
 
 
 
 
 
 
8.2.2 Key outcomes of interest and data analysis 
Key outcomes estimated from the patient-level resource utilisation and aggregated cost data 
were: the length-of-stay and direct medical costs of the inpatient episodes-of-care for primary 
bariatric surgery in Tasmanian public hospitals for the pre-defined study population; the 
number and costs of all inpatient episodes-of-care before and after primary bariatric surgery 
for the pre-defined study population from 2007/08 to 2015/16 (also expressed as mean cost per 
patient and mean cost per episode-of-care); the number and costs of all episodes-of-care for 3 
years before primary LAGB bariatric surgery and 3 years after primary LAGB bariatric surgery 
(on a year by year basis and totals), and calculated from the date of the primary surgical 
procedure, the pre- and postoperative total costs for both LAGB and SG; and the relative costs 
of the primary surgical procedure for LAGB versus SG in the Tasmanian public hospital 
system. 
 
Principal diagnosis  
 
 
Description 
ICD-10-CM codes  
E65 Localised adiposity 
E66.8 Other obesity 
E66.9 Obesity, unspecified 
E10 Type 1 diabetes mellitus 
E11 Type 2 diabetes mellitus 
AR-DRG codes  
G02A Major Small and Large Bowel Procedures, Major Complexity 
G02B Major Small and Large Bowel Procedures, Intermediate 
Complexity 
G05C Minor Small and Large Bowel Procedures 
K04A Major procedures for obesity 
K04B Major procedures for obesity 
K04Z Major procedures for obesity 
K12Z 
K60 
K60A 
K60B 
Other Bariatric Procedures 
Diabetes 
Diabetes Minor Complexity 
Diabetes Major Complexity 
Procedure codes  
30511-02  Laparoscopic adjustable gastric banding 
30511-04 Adjustable gastric banding 
30511-09 Laparoscopic sleeve gastrectomy 
30511-10 Sleeve gastrectomy 
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Subgroup and sensitivity analyses of the total inpatient costs for all surgical procedures for the 
study population included the investigation of cost outliers (defined as an episode-of-care > 
$50,000). Subgroup analyses were conducted for patients with a reported history of diabetes or 
cardiovascular disease (including hypertensive diagnosis included in the admitted episode of 
care) sourced from patient diagnoses tables contained within the Patient Management System. 
Subgroup analyses were also conducted for patients with a BMI  and < the median cut-point 
of the sample. 
Surgical sequelae procedures’ key outcomes of interest included the inpatient episode-of-care’s 
length of stay and direct medical costs for surgical sequelae. Secondary surgical sequelae for 
the pre-defined study population included any LAGB device/implant-related procedures such 
as LAGB revisions or reversals, and LAGB port/reservoir-related procedures (e.g. port 
revision, port re-suturing, change of port, infection and/or wound or sinus debridement). Other 
surgical sequelae (i.e. directly related to the primary surgery) that generated an inpatient 
episode-of-care included hernia repair, cholecystectomy, complex gastro-intestinal procedures 
that were LAGB-related (e.g. leaks, bleeding and subsequent corrective surgery), any body-
contouring surgery or body-lifting procedures [34] (e.g abdominoplasty or paniculectomy), and 
colonoscopy and gastroscopy. Length of stay and cost outliers for secondary surgical sequelae 
were identified and assumed as a length of stay of > 6 days per episode-of-care and a cost of  
$25,000 per episode-of-care. 
For surgical sequelae, individual patients could be represented more than once and this was 
included in the socio-demographic, clinical and cost analyses of the surgical sequelae and 
secondary procedures. 
Summary data of socioeconomic characteristics were described as mean (standard deviation 
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(SD)) and median (inter-quartile range (IQR)) for continuous variables and frequencies for 
categorical variables. BMI was calculated as weight (kg)/height (m²).  
Costs were expressed in constant Australian dollars with 2014-15 as the reference year=100 
(Appendix 2). There are a wide variety of price indexes (deflators) for the Australian health 
sector and these may be distinguished by the scope of the index or the technical manner in 
which the indexes are constructed and our studies costs were adjusted for inflation using the 
price index for Government Final Consumption Expenditure (GFCE) on hospitals and nursing 
homes index ([35]; Appendix 2). The GFCE on hospitals and nursing homes index is the index 
that most appropriately reflects the scope of the health servies being analysed in this study. 
Statistical analyses were conducted with ‘R’ version 3.0.2. 
$50,000, guided by this study’s average cost per patient for an episode-of-care. For the analyses 
of primary and secondary bariatric surgery costs and length of stay, cost outliers were defined 
as > $25,000 for the primary and secondary bariatric surgical procedure and secondary surgical 
sequelae, based on the cost of primary bariatric surgery in the most recent Australian cost-
utility study [36]. 
8.3 Results 
8.3.1 Patient eligibility and characteristics 
Figure 2 provides an outline of the flow of patients into the study.  
One-hundred and five patients were included in the study. These patients underwent primary 
LAGB (n=89 patients) or SG (n=16 patients) bariatric surgery in the Tasmanian public hospital 
system. Detailed patient-level cost data were available for this study group of Tasmanian public 
hospital treated patients, but not for those contracted to private hospitals, nor patients treated 
Chapter 8: A cost-outcome study: A real world investigation of long-term inpatient hospital 
utilisation and costs for a retrospective cohort of bariatric surgery patients in an Australian 
public hospital system based on Australia’s Activity Based Funding model. 
 
417 | P a g e  
elsewhere. 
Clinical socio-demographic characteristics of the 105 included patients are reported in Table 
2. For the LAGB bariatric surgery patient group, the mean (SD) age at the time of surgery was 
47.9 (11.3) years and the SG bariatric surgery patient group was a decade older. Females 
represented almost three-quarters (74%) of the LAGB patient group and just over half (56%) 
of the SG patient group. The LAGB patient group’s obesity classification and concomitant co-
morbidity load revealed severe obesity (in the super obesity classification [37] BMI recorded 
for n=52 patients, mean (SD) BMI 50.2 (10.5) kg/m²)) with multi-comorbidity (51% (diabetes), 
53% (cardiovascular disease) and 61% (smoking)). Only one BMI reading was available for 
the SG patient group. The co-morbidity load for the SG patient group was higher with 69% of 
patients reporting a history of diabetes, 94% cardiovascular disease, and 88% reporting a 
history of smoking. Most of the primary bariatric surgery patients were retired, on a 
government pension, or unemployed (Table 2).  
Twenty-seven of the 89 primary LAGB bariatric surgery patients (30%) underwent surgical 
sequelae LAGB-related surgery. Compared to the primary surgical group, this patient group 
had a higher mean age at the time of surgery sequelae (including secondary/revisional surgery) 
and an increased prevalence of cardiovascular disease. Diabetes prevalence was similar. The 
general trend of mean (SD) BMI was marginally higher 52.2 (9.2) kg/m² (Table 2). Only one 
of the 16 SG patients recorded a surgical sequelae event (outlined below).  
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Figure 2: Flow of patients into the study 
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Table 2: Participant characteristics for patients who had primary laparoscopic adjustable gastric band 
(LAGB) surgery (n=89) and sleeve gastrectomy (SG) (n=16) surgery, and patients who had secondary 
LAGB-related surgery (n=27). 
 
Patient characteristics 
(n=105) 
 
Primary surgery Secondary surgery 
 
LAGB 
(n=89) 
Sleeve gastrectomy 
(n=16) 
LAGB only 
(n=27) 
Number of inpatient  
episodes of care 
 
 
89 
 
16 
 
58 
Age years (at surgery)* 
Mean (SD) 
 
Median (IQR) 
 
47.9 (11.3) 
 
47 (40 - 57) 
(at surgery) 
 
57.2 (8.1) 
 
59 (50 – 62.3) 
(at surgery) 
 
51.5 (10.7)** 
 
48.5 (44.0 – 60.5) 
(at surgery) 
Sex 
(n = x, %) 
Male 
Female 
 
 
(n = 23, 26%) 
(n = 66, 74%) 
 
 
(n = 7, 44 %) 
(n = 9, 56 %) 
 
 
(n= 7, 26%) 
(n = 20, 74%),  
Co-morbidity status 
(n=, %) 
Diabetes 
Cardiovascular disease 
Smoker (reported history) 
 
 
 
(n = 45, 51 %) 
(n = 47, 53%) 
(n = 54, 61 %) 
 
 
(n = 11, 69 %) 
(n = 15, 94 %) 
(n = 14, 88 %) 
 
 
 
(n = 12, 44%) 
(n = 19, %) 
(n = 14, 52%) 
Occupation status† 
(n=, %) 
Employed 
Home Duties 
Retired 
Pensioner 
Student 
Unemployed 
 
 
 
 
(11, 12%)† 
(21, 24%) 
(17, 19%) 
(18, 20%) 
(0, 0%) 
(5, 6%) 
 
 
(1, 6%) ^ 
(3, 19%) 
(3, 19%) 
(7, 44%) 
(0, 0%) 
(0, 0%) 
 
 
(3, 11%) † 
(7, 26%) 
(6, 22%) 
(7, 26%) 
(1, 4%) 
(1, 4%) 
BMI  
Before surgery 
 
Mean (SD) 
 
Median (IQR) 
 
(Min, Max) 
 
 
 
50.2 (10.5) †† 
 
48.6 (45.8 – 54.1) 
 
(32.4, 97.9) 
 
 
 
 
NA 
 
 
 
52.2 (9.2) 
 
52.7(48.8 – 58.1) 
 
(32.4, 66.4) 
 
 
 
  
* Age in years at surgery identified at the inpatient episode for the primary surgical procedure; 
** Age in years at surgery identified at the secondary surgical procedure (note that the same patient may be 
a different age for a different episode); 
† Available data for occupational status reflected in the n=x; and 
†† n = 52. 
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8.3.2 Public hospital utilisation and cost analyses 
 
(i) Total episodes-of-care and costs for the study population 
Table 3 describes the total costs of all inpatient episodes-of-care for the study population 
(n=105 patients) from the fiscal years 2007-08 to 2015-16 expressed in 2015 Australian dollars. 
The total number of episodes-of-care for the study population over the 8 year time horizon was 
n=779 at a total cost to the Tasmanian (and to some extent Australian) healthcare system of 
$5,791,530. This total cost included the cost of the primary bariatric surgery and the surgical 
sequelae (including secondary and tertiary revisional surgery). 
For the entire study population, (and excluding the episodes-of-care for the surgical 
procedures), the total number of inpatient episodes-of-care before surgery was n=278 at a cost 
of $1,529,211. After surgery (including the inpatient admissions costs for surgical sequelae, 
and excluding the costed inpatient episodes of care for the primary bariatric surgery (Table 3)) 
the number of episodes of care was n=397 at a cost of $2,792,670 (Table 3). The relative costs 
per episode of care for SG patients were lower than LAGB both before and after surgery 
(Table3). Additionally, for the LAGB group (n=89 patients) total costs for the n=692 episodes-
of-care for the study population both pre- and postoperatively was $5,256,413. For the SG 
patient group (n=16 patients) total costs for the n=87 episodes-of-care both pre- and 
postoperatively was $535,117.  
Regarding the the total costs for the bariatric surgical procedures themselves, the total cost for 
primary LAGB (n=89 patients) was $1,252,322 and for surgical sequelae (including secondary 
revisional surgery) $484,286, or an additional 39% of the cost of the primary procedure. The 
total cost for primary SG bariatric surgery was $217,327 (n=16 patients) (Table 3). 
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The relative costs per episode-of-care were $7,595 (LAGB) and $6,012 (SG), and the costs per 
patient were $59,069 (LAGB) and $33,444 (SG). Therefore, the LAGB patient’s total episodes-
of-care pre- and postoperative costs were almost twice the costs of SG patients (Table 3). One 
patient of the n=105 patients (LAGB) recorded a catastrophic event (major gastro-intestinal 
secondary surgery) with a 291 day stay at a cost of $362,724. A further nine cost outliers were 
identified and their costs ranged from $55,364 to $171,353 for an episode-of-care (Table 3). 
When all cost outliers were removed from the total cost’s estimate, total costs reduced from 
$5,256,413 to $4,570,275 (Table 3). Sensitivity analyses also revelaed that the relative total 
costs for an episode-of-care reuced by almost $1,500 to $6,019 for LAGB patients and by over 
$500 to 5,407 for SG (Table 3). 
Appendices 3A and 3B also provide the ICD-10-CM and AR-DRG coding for the total 
episodes-of-care identified from the administrative databases for the study cohort of n=105 
people who received bariatric surgery. 
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Table 3: Total costs of all inpatient episodes of care for patients who were waitlisted (1 January 2008 
to 31 December 2013), and then underwent primary bariatric surgery in the Tasmanian public hospital 
system over 8 years for the fiscal years 2007-08 to 2015-16 expressed in constant dollars (Reference 
case 2014-15=100), and sensitivity analyses (cost outliers removed). 
 Totals Totals 
(cost outliers 
removed) 
Totals 
Before 
surgery†† 
Totals 
After 
surgery†† 
Global (n=105 patients)     
Number of episodes of Care 779† 768 278†† 397†† 
Total costs ($) 5,791,530†* 4,570,275 1,529,211 2,792,670 
  Cost per episode 7,434 5,951 5,501 7,034 
  Costs per patient 55,157 43,526 14,563 26,597 
     
LAGB (n=89)     
Episodes of Care (n=x) 692† 682 219†† 384†† 
Total Costs ($) 5,256,413†* 4,105,239** 1,279,753 2,724,338 
  Cost per episode 7,595 6,019 5,843 7,094 
  Cost per patient 59,069 46,126 NA NA 
Total cost of primary 
surgery  
1,252,322*    
Total cost of secondary 
surgery  
484,268    
     
Sleeve gastrectomy (n=16)     
Episodes of Care (n=x) 87^ 86** 59†† 13†† 
Total Costs ($) 535,117^ 465,036 249,458 †† 68,332 †† 
  Cost per episode 6,012 5,407 4,228 5,256 
  Cost per patient 33,444 29,064 15,591 4,271 
Total cost of primary sleeve 
gastrectomy surgery 
(n=15)† 
217,327 NA   
 
 
 
 
 
(ii) Year-on-year public hospital utilisation and costs 
Table 4 provides analyses of all inpatient episodes-of-care and costs pre- and postoperatively 
for the LAGB surgical group (n=89 patients) 3 years before (defined as -3 years from the date 
of the primary procedure, -2 years, -1 year) and for the 3 years after surgery (described as +1 
year from the date of the primary procedure, +2 years and +3 years).  
Table 4 particularly highlights that the number of episodes-of-care and costs increased from -
Notes: 
Primary sleeve gastrectomy recorded from 2013-14. 
LAGB=laparoscopic adjustable gastric band; LOS=length of stay (days); SG=sleeve gastrectomy includes all costs 
(including the cost of primary bariatric surgery). 
* one major LAGB cost outlier of $362,724 included i.e. a multiple morbidity admission LOS 291 days; 
**ten cost outliers removed for LAGB >$50,000 (namely, $ $50,761 primary LAGB surgery; $55,952 orthopaedic 
admission; $55,364 congestive cardiac failure admission LOS 44 days; $60,454 neurology admission LOS 7 days; 
$60,620 primary LAGB surgery; $91,593 multiple morbidity admission LOS 16 days; $110,548 brain tumour admission 
LOS 42 days; $131,805 surgical sequelae from primary LAGB surgery; $171,353 multiple morbidity LOS 43 days; and 
362,724 multiple morbidity admission LOS 291 days); 
† costs available for n=15 sleeve gastrectomy (not available for one primary surgery in 2016-2017) 
†† totals before and after surgery do not include the cost of the primary surgical procedure, however, do include the cost 
of the secondary and tertiary surgical sequelae procedures after surgery. Note that SG (n=15) for costed primary surgery. 
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3 years to -1 year before surgery and for the 2 years after surgery, and then recorded a decrease 
at year +3 after surgery. More specifically, episodes-of-care: -3 year, 30 episodes-of-care; -2 
year, 60 episodes-of-care; -1 year, 82 episodes-of-care; +1 year, 72 episodes-of-care; +2 year, 
88 episodes-of-care; +3 year, 34 episodes-of-care; and costs per episode-of-care: -3 year 
$5,431, -2 year $4,697, -1 year $5,301 and +1 year $7,431; +2 year, $12,587 and +3 year 
$3,612. Interestingly, this result revealed that the number of inpatient episodes-of-care reduced 
from 82 in the -1 year before surgery to 34 episodes-of-care +3 years after surgery, at an 
average cost of $5,301 and $3,612 respectively. The table also revealed that the number of 
episodes-of-care and total and average costs maximised at +2 year after surgery. 
The subgroup analyses presented in Table 4 revealed that the general trend of a decrease of 
costs per episode-of-care at year +3 after surgery was lower than for the entire study population. 
To illustrate, for patients with cardiovascular disease and diabetes, the difference from year -1 
before surgery to year +3 after surgery was $3,350 and $2,752 respectively, compared to 
$1,689 for the entire study population. The total cost and episodes-of-care maximised at year 
+2 after surgery for the entire cohort and people with cardiovascular disease. Interestingly, for 
people with diabetes average costs maximised before surgery and a decrease in average costs 
was revealed from the +1 year after surgery (compared to year +3 for the entire cohort and for 
people with cardiovascular disease). 
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Table 4:Total costs and inpatient episodes of care for patients who were waitlisted (1 January 2008 to 31 December 2013), and then underwent primary bariatric 
surgery in the Tasmanian public hospital system expressed in constant dollars (Reference case 2014-15=100) for the 3 years before and after surgery, and 
sensitivity (cost outliers omitted) and subgroup analyses (patients with diabetes and cardiovascular disease). 
Laparoscopic adjustable 
gastric band 
(n=89) 
Before Surgery 
 
   After Surgery    
 - 3 years -2 years 
 
-1 years Total/average 
(before surgery) 
+1 year +2 years +3 years Total/average 
(after surgery) 
Episodes of Care 38 60 82 180 72 88 34 194 
Total Costs 206,369 281,796 434,710 922,875 535,296 1,107,691 122,820 1,765,807 
Average cost per EoC 5,431 4,697 5,301 5,143 (average) 7,435 12,587 3,612 7,878 (average) 
Sensitivity analyses 
Cost outliers removed 
        
Episodes of Care 
Total costs 
Average costs per EoC 
Total cost outliers 
removed 
37 
145,915 
3,944 
60,454* 
60 
281,796 
4,697 
No cost outliers 
81 
343,117 
4,236 
91,593** 
178 
770,828 
4,292 
152,047 
72 
535,296 
7,435 
No cost outliers 
85 
502,614 
5,913 
605,077*** 
34 
122,820 
3,612 
No cost outliers 
191 
1,160,730 
5,653 
605,077 
Subgroup analysis 
Patients with diabetes 
(n=45) 
        
Episodes of Care 15 19 26 60 36 49 20 105 
Total Costs 49,453 125,651 181,580 356,684 201,969 251,220 84,641 537,830 
Average cost per EoC 
Cost outliers removed 
3,297 
No cost outliers 
6,613 
No cost outliers 
6,984 
No cost outliers 
5,631 5,610 
No cost outliers 
5,127 
No cost outliers 
4,232 
No cost outliers 
4,990 
Subgroup analysis 
Patients with CVD 
(n=47) 
        
Episodes of Care 23 45 55 123 56 57 23 136 
Total Costs 155,545 237,860 375,062 768,467 447,234 475,654 79,794 1,002,682 
Average cost per EoC 
Cost outliers removed 
6,762 
1* 
5,286 
No cost outliers 
6,819 
1** 
6,289 
2 
7,986 
No cost outliers 
8,344 
1 
3,469 
No cost outliers 
6,600 
1 
Episodes of care 22 45 54 121 56 56 23 135 
Total costs 95,091 237,860 283,469 616,420 447,234 343,805 79,794 870,833 
Average cost per EoC 4,322 5,286 5,249 4,952 7,986 6,140 3,469 5,865 
*cost outlier >$50,000 namely, $60,454 neurology 
** cost outlier >$50,000 namely $91,593 multiple medical issues not surgical sequelae 
*** cost outlier >$50,000 namely $362,724 multiple issues LOS 291 days; 110,548 brain tumour LOS 42 days; $131,805 bariatric surgery cost outlier surgical sequelae. 
EoC=episode-of-care 
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(iii) Primary bariatric surgery 
Table 5 describes total hospital utilisation and summary inpatient episode-of-care costs and 
subgroup analyses (diabetes and BMI) for primary LAGB and primary SG bariatric surgery. 
Figures 3A and 3B provide the frequency distributions for inpatient LAGB episode-of-care 
costs, and episode-of-care costs per day. 
The mean (SD) length of stay for SG was 1.6 days longer than LAGB (LAGB: 2.4 (3.6) days). 
When length of stay outliers were omitted for LAGB sensitivity analyses (n=6; range 6 to 30 
days) this reduced to 1.7 (0.9) days per episode-of-care for primary LAGB bariatric surgery 
(Table 5). 
Mean (SD) costs for an inpatient episode-of-care for primary LAGB and SG surgeries were 
$14,071 (8,797) and $14,448 (5,678), respectively. The mean costs per day for SG were half 
the cost for LAGB (Table 5). When cost outliers were omitted for the LAGB primary surgery 
sensitivity analyses (i.e. n=6; range $26,758 to $60,620), the inpatient cost per episode-of-care 
for primary surgery reduced to $12,120 (4,022). There were no reported cost outliers for SG 
primary bariatric surgery (Table 5, Table 3, Figure 2A). The base case costs per day for an 
episode-of-care revealed that the mean (SD) costs per day for SG were half the cost for LAGB 
(Table 5). 
Subgroup analyses for the LAGB primary surgery group revealed that most cost outliers were 
people with a reported history of diabetes (n=45) (Tables 3, 5, Figures 3C and 3D). 
Overall, LAGB subgroup analyses for patients with or without diabetes revealed that the mean 
cost per inpatient episode-of-care for surgically-treating people with diabetes was $3,660 
higher (p=0.02) than for people without diabetes. When cost outliers were omitted from both 
samples (study participants with a history of diabetes n=5 and study participants without a 
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history of diabetes n=1) this difference reduced to only $1,660 (p=0.06) (Table 5). Inpatient 
length of stay analyses revealed similar trends. Table 4 also revealed that the average cost per 
episode-of-care for people with diabetes decreased substantially from 1 year before surgery to 
3 years after surgery, and that the total cost was reduced by almost half. 
The SG subgroup with a reported history of diabetes (n=11) revealed similar costs to the LAGB 
subgroup with diabetes (SG mean (SD); $15,300 ($6,246)) (Table 5). Nevertheless, Table 4 
showed that costs and episodes-of-care for people with diabetes decreased from +1 year after 
surgery (compared to year +3 for the entire cohort and for people with cardiovascular disease). 
Subgroup analyses of people with a BMI classified above and below the median cut-point of 
48.6 kg/m for LAGB primary bariatric surgery, revealed that the mean cost per inpatient 
episode-of-care for the primary surgical procedure for people with a BMI > 48.6 kg/m² (n=26) 
was $4,770 higher than for people with a BMI  48.6 kg/m² (n=26). This result was not 
statistically significant. Similar trends were revealed for length of stay (Table 5).  
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Table 5: Inpatient episode-of-care length of stay (days) and public hospital activity based funding costs expressed in constant dollars (Reference case: 2014-15 = 100) for patients who underwent 
primary laparoscopic adjustable gastric band (LAGB) (n=89) and sleeve gastrectomy (SG) (n=16) bariatric surgery in the Tasmanian public hospital system, and subgroup analyses. 
 
Primary Surgery 
 
(n=105) 
 
Episode-of-
care for 
primary 
surgery 
(n=x) 
Length of stay 
 
 
 
Mean (SD) 
Length of stay 
(sensitivity 
analyses) 
 
Mean (SD) 
Cost of episode-of-care 
 
Mean (SD) 
Median (IQR) 
Min, Max 
Cost of episode-of-care 
(sensitivity analysis) 
Mean (SD) 
Median (IQR) 
Min, Max 
Cost of episode-of-care 
per day 
Mean (SD) 
Median (IQR) 
Min, Max 
LAGB (n=89)       
 
Entire cohort 
 
 
89 
 
(n=89) 
2.4 (3.6) 
 
(n=83) 
1.7 (0.9)ꝉ 
 
(n = 89) 
14,071 (8,797) 
11,830 (9,814 – 14,870) 
(5,142, 60,620) 
 
(n=83)* 
12,120 (4,022) 
11,630 (9,595 – 14,040) 
(5,142; 22,940) 
 
(n=89) 
8,709 (6,093) 
7,408 (5,333 – 10,700) 
(1,065; 50,760) 
Subgroup analyses     
 
Diabetes 
 
 
45 
 
3.1 (4.8) 
 
(n=40)** 
1.8 (0.8) 
(n = 45) 
15,880 (10,100) 
12,580 (10,380 – 18,050) 
(5,467; 60,620) 
(n=40) 
12,980 (4,431) 
12,180 (9,991 – 15,020) 
 
NA 
 
ToS WR  p = 0.01 
 
p = 0.06 p = 0.02 p = 0.07  
No diabetes 
 
44 1.7 (1.3) (n=43)*** 
1.6 (0.9) 
(n=44) 
12,220 (6,860) 
10,800 (9,516 – 12,530) 
(5142; 50,760) 
(n=43) 
11,320 (3,463) 
10,700 (9,514 – 12,390) 
(5,142; 21,670) 
 
NA 
BMI (high) 
 48.6 
 
26 3.7 (6.1) 
 
 
NA 
 
 
16,620 (13,552) 
12,300 (10,400 – 15,250) 
(5142; 60,620) 
NA NA 
ToS WR 
 
BMI (low) 
< 48.6 
 
 
26 
p = 0.24 
 
1.9 (1.3) 
NA 
 
 
p = 0.15 
 
11,960 (6,227) 
10,920 (8,774 – 11,980) 
(5,323; 37,430) 
NA  
Sleeve Gastrectomy (n=16)      
Entire cohort 
 
16 4.0 (1.1) 3.8 (1.1) 14, 448 (5,678)‡ 
12, 789 (10,581 - 18,040) 
(6,312; 25,172) 
NA 3,878 (6,124) 
3,197 (2,969 – 4,410) 
(2,104; 7,737) 
    p = 0.80   
Diabetes 
 
11 NA 3.9 (1.3)ꝉꝉꝉ 15,300 (6,246) 
14,010 (8,749 – 20,670) 
(8,684; 25,170) 
NA NA 
LAGB = laparoscopic adjustable gastric band; SG = sleeve gastrectomy; LoS = length of stay; ToS WR = test of significance Wilkoxon rank sum test; *Reference case 2014-15 = 100; ‡ cost data for primary sleeve gastrectomy available 
for (n=15) patients (also see Table 3). Cost outliers removed > $25,000. ** n=5 LOS outliers removed in diabetes subgroup (range 6 to 30 days); *** n=1 outlier removed in not diabetes subgroup 8 days; ꝉꝉꝉ (n=10). 
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Figure 3A and 3B: Frequency distribution of an episode-of-care of inpatient costs expressed in constant 
dollars (Reference 2014-15=100) for all patients (n=89) who received laparoscopic adjustable gastric 
band surgery (2A) and cost/day for an episode-of-care (2B). 
 
 
Figure 3C and 3D: Frequency distribution of inpatient episode-of-care costs expressed in constant 
dollar (Reference 2014-15=100) for all patients with diabetes (n=46) and without diabetes (n=45) who 
underwent laparoscopic adjustable gastric band surgery in the Tasmanian public hospital system. 
 
(iv) Surgical sequelae: LAGB and SG 
Table 6 describes the inpatient hospital utilisation and direct medical costs of LAGB-related 
surgical sequelae and secondary LAGB surgery. The classifications of secondary/tertiary 
LAGB surgery for analyses included LAGB device/implant-related procedures (e.g. revision 
or reversals of the LAGB-system, change of tubing, re-suturing of port, flipped port, change of 
port, wound or sinus debridement related to an infected port), and surgical sequelae of 
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colonoscopy/gastroscopy, hernia repair, cholecystectomy, and body-contouring surgery. 
Twenty-seven patients (30%) recorded a LAGB surgical sequelae (including secondary/tertiary 
revisional surgery) and (n=58) associated inpatient episodes-of-care. Of these (n=27) patients, 
8 patients required  3 secondary surgical procedures and an associated inpatient episode-of-
care. Over half of the surgical sequelae procedures were secondary surgery LAGB-
device/implant related (n=33 of the n=58 episodes-of-care; 57%), and most of these procedures 
were LAGB port/reservoir-related surgical procedures (Table 6).  
Sixteen patients required n=33 episodes-of-care for LAGB device-related procedures, and 12 
patients required 27 episodes-of-care for LAGB port-related procedures. The remaining 
device-related procedures were LAGB revisions or reversals (n=6). Colonoscopy and 
gastroscopy accounted for 10 of the (n=58) episodes-of-care of the surgical sequelae 
procedures. There were only two major LAGB-related secondary gastro-intestinal surgical 
procedures, related to two patients. Only 1 of these procedures could be classified as a post-
operative catastrophic event and was a major cost outlier of the cohort (Table 6). 
The mean (SD) inpatient length of stay and costs for the total episodes-of-care for LAGB-
related surgical sequelae were 3.5 (6.6) days and $9,495 (18,585) respectively. Removal of 
length of stay and cost outliers for sensitivity analyses revealed a substantial reduction in both 
length of stay and costs to 1.8 (1.5) days and $6,158 (4,693) per inpatient episode-of-care 
(Table 6).  
Mean (SD) LAGB port/reservoir-related costs per inpatient episode-of-care was $5,096 
(3,711). Revisions or reversals of the LAGB device (not specifically described or classified as 
a device/port-related procedure) accounted for 12% of the total episodes-of-care, and the mean 
(SD) costs were $11,310 (6,181). Colonoscopy and gastroscopy accounted for 17% of the 
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episodes-of-care and mean (SD) costs were $2,430 (1,062) (Table 6). Body-contouring surgery 
(abdominoplasty and paniculectomy) was provided to one patient at a length of stay of 4 days 
(cost data not available as procedure undertaken in current fiscal year) (Table 6). 
Of the 16 primary SG procedures, 14 procedures were performed in 2015 and 2016. There were 
13 episodes-of-care recorded after the primary SG procedures and one of these procedures 
could be attributed as surgical sequelae of the primary sleeve gastrectomy procedure. This 
inpatient episode-of-care was a laparoscopic cholecystectomy performed 10 months after the 
SG procedure at a cost of $7,467. 
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Table 6: Length of stay and costs for secondary and tertiary surgery for medical sequelae after 
laparoscopic adjustable gastric band (LAGB) surgery, and sensitivity and subgroup analyses. 
 
LAGB 
secondary surgery 
(n=27) 
 
 
Episodes-of-
care 
(n=x) 
 
Patients 
 
(n=x) 
 
Length of stay 
(days) 
 
Mean (SD) 
Median (IQR) 
 
 
Costs 
 
 
Mean (SD) 
Median (IQR) 
(Min, Max) 
 
Total 
 
 
 
Sensitivity analysis 1* 
(cost and LoS outliers 
removed) 
 
Sensitivity analysis 2** 
(cost and LoS outliers 
removed) 
 
 
51 (cost)† 
58(LoS) 
 
 
50 (cost) 
57 (LoS) 
 
 
48 (cost) 
51 (LoS) 
 
 
27 
 
 
 
27 
 
 
 
27 
 
 
3.5 (6.6) 
1 (1 – 3.8) 
(1; 46) 
 
2.7 (3.3) 
1 (1 – 3) 
(1; 20) 
 
1.8 (1.5) 
1 (1 – 2) 
(1; 6) 
 
9,495 (18,585) †† 
4791(3201 – 10,600) 
(149; 131,800) 
 
7,049 (6,408) 
4,756 (3,195 – 10,190) 
(149; 31,870) 
 
6,158 (4,693) 
4,618 (2,976 – 9,318) 
(149; 18,260) 
 
Subgroup analyses 
 
    
Device-related (including 
port-related) 
 
33 16 2.2 (2.4) 
1 (1 – 2) 
(1; 11) 
6,031 (4,533) 
4,721 (3,260 – 9,046) 
(149; 15,660) 
Costs 29 
 
Port-related 
 
 
27 
 
12 
 
1.8 (2.3) 
1 (1 – 1) 
(1; 11) 
 
5,096 (3,711) 
4,444 (3,248 – 6,061) 
(149; 14,960) 
Costs 25 
 
Revision or reversal 
 
 
6 
 
 
 
3.5 (2.1) 
3.5 (2 – 5) 
(1 – 6) 
 
11,310 (6181) 
13,560 (11,850 – 14,920) 
(560; 15,660) 
 
 
Colonoscopy/ 
Gastroscopy 
 
 
 
10 
 
9 
 
1 day 
 
2,430 (1,062) 
2,199 (1,664 – 2,976) 
(1,326; 4,133) 
 
Cholecystectomy 
 
 
 
4 
 
4 
 
3 (1.2) 
 
9,609 (4,076)* 
10,210 (7,738 – 11,780) 
(5,264; 13,350) 
 
Hernia repair 
 
 
4 
 
4 
 
3.3 (3.9) 
1.5 (1 – 3.8) 
(1, 9) 
 
9,928 (8,537) 
6,522 (5,136 – 11,310) 
(4,111; 22,650) 
 
Body contouring surgery 
 
 
1 
 
1 
 
4 
 
NA 
  LoS, length of stay 
  † n=51 costs i.e. n=7 costs not available 
  †† note that totals costs for the n = 51 episodes-of-care were $484,268 ((Reference case: 2014-15 = 100) 
  * Sensitivity analyses 1: one major cost and length of stay outlier for major and complicated gastro-intestinal  
  surgery length of stay 46 days (including an ICU admission of 3,199 minutes) and cost $131,805;  
  ** Sensitivity analyses 2: length of stay outliers > 6 days (n = 6) and cost outliers  $25,000 (n = 2; $131,805 and $31,871); 
  *** (n=3) costs 
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8.4 Discussion 
8.4.1 The costs of obesity and bariatric surgery in Tasmania 
Our study provided much needed information regarding the inpatient episodes-of-care, 
resource use and costs of obesity and bariatric surgery in the Tasmanian public hospital system. 
We extracted data on an individual patient basis to track the primary Activity Based Funding 
episodes-of-care and the costs attributed to each patient pathway before and after primary 
bariatric surgery. 
We found that total costs of public hospital inpatient care to the Tasmanian public healthcare 
system for the 105 patients waitlisted for, and who subsequently received bariatric surgery in 
the Tasmanian public healthcare system over an 8 year time horizon was almost $5.8 million 
dollars, of which $1.7 million dollars was for primary bariatric surgery procedures. 
Another key finding was that the average cost of providing primary bariatric surgery in the 
Tasmanian public hospital system is lower than the most recent Australian estimate, which was 
derived from a sample of Queensland data and then extrapolated in a cost-effectiveness model 
The base case scenario of a severely obese 30 year old female with no co-morbidity was 
estimated to cost $24,167 for a primary AGB and $52,440 for a SG [24]. We also found that 
our average cost of providing primary bariatric surgery in the Tasmanian public hospital system 
is lower than recent comparable international estimates [1]. For example, recent Canadian 
estimates for bariatric surgery are $15,000 to $20,000 Canadian dollars for the primary surgery 
[1].  
Other findings included that cost outliers are mostly patients with a reported history of diabetes, 
and that for LAGB primary surgery device/implant-related medical sequelae accounted for half 
of the secondary and tertiary surgery. From a patient journey/pathway perspective, we also 
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found that device-related procedures were concentrated to a subgroup of patients. 
Importantly, we also found that for people with diabetes the costs for inpatient public hospital 
care from a total cost and cost per episode-of-care perspective, that costs were substantially 
reduced 3 years after surgery compared to 1 year before surgery.  
Another interesting finding from our subgroup analysis was that the average cost for an 
episode-of-care decreased for people with diabetes from the first year after surgery.  
A recent AIHW study estimated the cost of primary bariatric surgery by adopting a narrower 
cost-base (Australian Medicare-linked data) than our study or the recent Australian cost-utility 
study [5]. The AIHW report reported that the costs of primary bariatric surgery were marginally 
lower than our base case analyses. Nevertheless, this report does not include the broader costs 
captured in our study using ABF data linked with patient records.  
Overall, our findings suggest that bariatric surgery in the Tasmanian public hospital system 
may be an attractive value-based option in the longer term: bariatric surgery realised health 
benefits (reduced inpatient episodes-of-care) and reduced costs at year 3 postoperatively. One 
year preoperatively the study population recorded the highest number of inpatient episodes-of-
care and costs suggesting that the severely obese study population with multi-morbidity was 
experiencing substantially reduced health 1 year before surgery. We also found that the cost of 
bariatric surgical sequelae (including secondary and tertiary revisional surgery) maximised at 
year 2. The maximisation of inpatient-episodes-of-care and costs at year 2 suggests that 
postoperative care should be ongoing during this critical time horizon and could potentially 
mitigate some of these inpatient costs. 
8.4.2 Surgical sequelae (including secondary/tertiary surgery) 
Our investigation of patient-level data regarding surgical sequelae after primary LAGB surgery 
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is novel. We tracked each publicly-treated LAGB and SG patient’s individual inpatient 
episode-of-care and cost pathway to provide our project partners with a comprehensive 
understanding of the patient pathway, and prevalence of surgical sequelae, and secondary and 
tertiary surgery resource use and costs. 
Importantly, our study found that over half of the costs of complications and reoperations for 
publicly-treated LAGB patients were device-related and that these episodes-of-care and costs 
were mostly LAGB port/reservoir-related and concentrated to a further subgroup of patients. 
Nevertheless, the overall costs of bariatric surgery (including the total costs of reoperations and 
complications) for our older and sicker cohort of bariatric surgery patients were less than the 
direct medical costs reported in the most recent Australian cost-utility study. 
We also found that for sleeve gastrectomy, only 1 of 16 inpatient episodes-of-care could be 
attributed to surgical sequelae.  
A recent comprehensive systematic review regarding the health economic evaluation of 
bariatric surgery, found that one-third of the 77 included studies either ignored the costs and/or 
consequences of complications and reoperations, or for the studies that accounted for 
reoperations and complications commonly only assumed short-term events, considered an 
incomplete list of complications or assumed relatively low probabilities of adverse events 
occurring. The review also found that the longer-term costs of bariatric surgery have therefore 
probably been underestimated, and the value for money for bariatric surgery subsequently 
overestimated. Additionally, the most recent Australian cost-utility study estimated the 
prevalence of surgical sequelae and secondary surgery from the literature (notwithstanding 
estimating the surgical costs from an administrative database).  
In direct comparison, our study suggests that the most recent health economics studies have 
underestimated the prevalence and real costs of surgical sequelae and secondary/tertiary 
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bariatric surgery.  
8.4.3 Resource allocation: type of surgery and patient prioritisation 
Contemporary debate regarding the provision of bariatric surgery has, to a certain degree, 
shifted beyond the cost per QALY health economic metric to the economic barriers-to-entry in 
public healthcare systems, and the associated issue of supply not meeting ever-increasing 
demand for publicly-provided bariatric surgery [13, 38].  
Other authors have called for a reconsideration of the use and role of adjustable gastric band 
surgery (compared to other procedures such as SG), particularly for Medicare beneficiaries in 
the United States [39-41]. A recent key epidemiological study that investigated reoperations 
and Medicare (United States) expenditures after LAGB surgery found that device-related 
reoperation was common, costly and varied widely across hospital referral regions [42]. On the 
other hand, it has been suggested that no single bariatric procedure is appropriate for all 
patients, and that the regional variation in outcomes observed is important [40].  
Given our study’s reported rates (and costs) of secondary/tertiary LAGB device-related 
surgery, policy-makers should reconsider the type of surgery provided to certain patient groups 
to mitigate LAGB device-related issues. 
A common theme that has emerged from a review of the health economics reporting of bariatric 
surgery is that it is highly cost-effective (and even cost-saving) for severely obese patients with 
type 2 diabetes [1]. Our subgroup analyses revealed that half of our severely obese cohort had 
a history of diabetes, and that the cost of providing them with primary surgical procedure was 
only marginally higher than for people without diabetes. More importantly, our subgroup 
analyses for people with diabetes also found that total costs of publicly-funded inpatient care 
were substantially reduced 3 years after bariatric surgery.  
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Our previously published work has also found that long-waiting public hospital system 
bariatric surgery patients should not be ‘written-off’ by healthcare planners – they can still 
realise significant improvements in health-related quality-of-life outcomes when ultimately 
treated, and this should be factored into patient prioritisation decisions [43]. Our previously 
published work also suggested that addressing this issue given the large gap between the 
demand for and supply of publicly funded bariatric surgery in many countries, would require 
significant commitment and investment [43]. 
8.4.4 Strategic research alliance in an applied health economics study 
Our study harnessed the comparative advantages of a self-assembled strategic alliance that 
comprised heterogeneous human capital. The team identified key gaps for the state government 
partner regarding the resource use and costs of publicly-provided bariatric surgery including a 
comparison between LAGB and SG surgery. Additionally, this study has enabled university 
researchers to build on a collaborative and productive relationship with our health partner. 
8.4.5 Limitations and Strengths 
The main limitation of our study was the sample size for SG. Nevertheless, our Tasmanian 
State Government partner indicated that this subgroup was important and that we should track 
each patient journey for this group. We recommend that a larger conformatory study of 
disaggregated costs for later years (that is from 2013-14 onwards) be conducted given that SG 
as a treatment option in the Tasmanian public hospital system from 2013 may have increased. 
A further limitation was that it focused on the inpatient hospitalisation and direct medical costs 
(compared to, for example, primary care). On the other hand, this focus was also a key strength 
of our paper because we provided our policy decision-makers with important information about 
the study population that was previously unknown. The large sample size of bariatric surgery 
patients and their associated before and after surgery episodes-of-care that were individually 
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tracked for a long time horizon was a strength. Sufficient data to enable robust sensitivity and 
subgroup analyses over a long timeframe was also a strength. A final limitation is about our 
assumption that secondary surgical sequelae includes colonoscopies. On the other hand, there 
were only a few colonoscopies identified in the sample (combined gastroscopy and 
colonoscopy 10 episodes-of-care) and a proportion of this small sample would be directly 
related to LAGB surgery. We also suggest that a larger confirmatory study investigate the rate 
of colonoscopy and gastroscopy for the Tasmanian public hospital system. 
8.5 Conclusions 
The costs of providing bariatric surgery in Tasmania are lower than comparable national and 
international published estimates, even after Tasmanian costs for surgical sequelae and 
secondary/tertiary surgery are included. A robust cost-effectiveness study could be the subject 
of further research for the retrospective cohort and our planned prospective cohort. 
Targeting appropriately prioritised patients with SG in preference to LAGB surgery in 
Tasmania would mitigate LAGB implant-related costs. 
Patients with diabetes and cardiovascular disease incur lower costs in the longer term after 
bariatric surgery. 
This study and our earlier health-related quality of life work provides the building blocks for 
our project team to conduct a robust and real world cost-effectiveness analysis for our DHHS 
project partner. We also recommend that a larger confirmatory ABF cost study (that 
investigates disaggregated costs) about SG versus LAGB (and other forms of bariatric surgery 
that could now be offered) in the Tasmanian public hospital system from 2013 onwards be 
conducted. 
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Appendix 8.1: Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 24 item checklist 
Section/Item Item Recommendation 
Title and Abstract   
Title 1 Identify the study as an economic evaluation or use more specific terms such as “cost-
effectiveness analysis”, and describe the interventions compared. 
Abstract 2 Provide a structured summary of objectives, perspective, setting, methods (including study 
design and inputs), results (including base case and uncertainty analyses), and conclusions. 
Introduction   
Background and objectives 3 Provide an explicit statement of the broader context for the study. 
Present the study question and its relevance for health policy or practice decisions. 
Methods   
Target population and 
subgroups 
4 Describe characteristics of the base case population and subgroups analysed, including why 
they were chosen. 
Setting and locations 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be made. 
Study perspective 6 Describe the perspective of the study and relate this to the costs being evaluated. 
Comparators 7 Describe the interventions or strategies being compared and state why they were chosen. 
Time horizon 8 State the time horizon(s) over which costs and consequences are being evaluated and say why 
appropriate. 
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say why appropriate. 
Choice of health outcomes 10 Describe what outcomes were used as the measure(s) of benefit in the evaluation and their 
relevance for the type of analysis performed. 
Measurement of 
effectiveness 
11a Single study-based estimates: Describe fully the design features of the single effectiveness 
study and why the single study was a sufficient source of clinical effectiveness data. 
 11b Synthesis-based estimates: Describe fully the methods used for identification of included 
studies and synthesis of clinical effectiveness data. 
Measurement and valuation 
of preference based 
outcomes 
12 If applicable, describe the population and methods used to elicit preferences for outcomes. 
Estimating resources and 
costs 
13a Single study-based economic evaluation: Describe approaches used to estimate resource use 
associated with the alternative interventions. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit cost. Describe any adjustments 
made to approximate to opportunity costs. 
 13b Model-based economic evaluation: Describe approaches and data sources used to estimate 
resource use associated with model health states. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit cost. Describe any adjustments 
made to approximate to opportunity costs. 
Currency, price date, and 
conversion 
14 Report the dates of the estimated resource quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for 
converting costs into a common currency base and the exchange rate. 
Choice of model 15 Describe and give reasons for the specific type of decision-analytical model used. Providing a 
figure to show model structure is strongly recommended. 
Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model 
Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include methods for 
dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling 
data; approaches to validate or make adjustments (such as half cycle corrections) to a model; 
and methods for handling population heterogeneity and uncertainty. 
Results   
Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. 
Report reasons or sources for distributions used to represent uncertainty where appropriate. 
Providing a table to show the input values is strongly recommended. 
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the main categories of estimated costs and 
outcomes of interest, as well as mean differences between the comparator groups. If 
applicable, report incremental cost-effectiveness ratios. 
Characterising uncertainty 20a Single study-based economic evaluation: Describe the effects of sampling uncertainty for the 
estimated incremental cost and incremental effectiveness parameters, together with the 
impact of methodological assumptions (such as discount rate, study perspective). 
 20b Model-based economic evaluation: Describe the effects on the results of uncertainty for all 
input parameters, and uncertainty related to the structure of the model and assumptions. 
Characterising heterogeneity 21 If applicable, report differences in costs, outcomes, or cost-effectiveness that can be 
explained by variations between subgroups of patients with different baseline characteristics 
or other observed variability in effects that are not reducible by more information. 
Discussion   
Study findings, limitations, 
generalisability, and current 
knowledge 
22 Summarise key study findings and describe how they support the conclusions reached. 
Discuss limitations and the generalisability of the findings and how the findings fit with 
current knowledge. 
Other   
Source of funding 23 Describe how the study was funded and the role of the funder in the identification, design, 
conduct, and reporting of the analysis. Describe other nonmonetary sources of support. 
Conflict of interest 24 Describe any potential for conflict of interest of study contributors in accordance with journal 
policy. In the absence of a journal policy, we recommend authors comply with International 
Committee of Medical Journal Editors recommendations. 
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Appendix 8.2A: The principal and additional diagnoses for ICD-10-CM codes for our study population (n=105) 
of people who received primary and secondary laparoscopic adjustable gastric band surgery in the Tasmanian 
public hospital system. 
Principal and secondary diagnosis ICD-10-CM  Description 
B95.6 Staphylococcus aureus 
D64.9 Anaemia unspecified 
E65 Localized adiposity 
E66.8 Other obesity 
E66.9 Obesity, unspecified 
E10.61 Type 1 diabetes mellitus 
E10.64 Type 1 diabetes mellitus 
E10.74 Type 1 diabetes mellitus 
E11.21 Type 2 diabetes mellitus 
E11.22 Type 2 diabetes mellitus 
E11.31 Type 2 diabetes mellitus 
E11.4 Type 2 diabetes mellitus 
E11.65 Type 2 diabetes mellitus 
E11.71 Type 2 diabetes mellitus 
E11.72 Type 2 diabetes mellitus 
E87.6 Hypokalaemia 
G47.32 High altitude periodic breathing 
G62.9 Polyneuropathy, unspecified 
H35.0 Background retinopathy 
K31.88 Diseases of the oesophagus, duodenum and stomach 
K42.9 Umbilical hernia without obstruction or gangrene 
K43.2 Incisional hernia 
K43.9 Ventral hernia 
K44.9 Diaphragmatic hernia 
K55.8 Other vascular disorders of intestine 
K56.5 Internal adhesions with obstruction 
K66.0 Peritoneal adhesions 
K80.1 Calculus of gallbladder with other cholycystitis 
K92.2 Gastrointestinal haemorrhage, unspecified 
I10.0 Essential (primary) hypertension 
I20.0 Incisional hernia without obstruction or gangrene 
I95.5 Hypotension 
I97.8 Other intraoperative and post procedural complications and disorders 
I99.59 Chronic embolism and thrombosis of other specified deep vein of lower extremity 
M79.58 Residual foreign body in soft tissue, other site 
M79.61 Achilles tendonitis, right leg 
M79.62 Pain in upper arm 
N18.2 Chronic kidney disease 
N18.9 Chronic kidney disease 
N99.0 Post procedural (acute)(chronic) kidney failure. 
R00.0 Tachycardia, unspecified 
R00.1 Bradycardia unspecified 
R07.4 Chest pain, unspecified 
R10.4 Other and unspecified abdominal pain 
R19.5 Other faecal abnormalities 
R51.0 Headache 
R52.2 Headache 
S35.2 Injury of celiac or mesenteric artery and branches 
S36.52 Contusion of colon 
T43.0 Poisoning by, adverse effect of and under dosing of tricyclic and tetracyclic antidepressants 
T81.0 Haemorrhage or haematoma complicating a procedure, not elsewhere classified  
T81.1 Post procedural shock 
T81.2 Accidental puncture and laceration during a procedure, not elsewhere classified 
T81.2 Post-procedural shock 
T81.4 Infection following a procedure 
T85.5 Complications of foreign body accidentally left in body following procedure 
T85.6 Mechanical complication of other specified internal and external prosthetic devices 
T85.78 Infection and inflammatory reaction to other internal prosthetic devices, implants and grafts 
U79.3 Depression 
U82.3 Hypertension 
U86.2 Arthritis and osteoarthritis 
Y60.0 Unintentional cut, puncture, perforation or haemorrhage during surgical and medical care 
Y60.8 Unintentional cut, puncture, perforation or haemorrhage  
Y83.1 Surgical operation with implant of artificial internal device as the cause of abnormal reaction of 
the patient, or of later complication, without mention of misadventure at the time of the procedure 
Y83.8 Other surgical procedures as the cause of abnormal reaction of the patient, or of later 
complication, without mention of misadventure at the time of the procedure 
Y92.22 Religious institution as the place of occurrence of the external cause 
Z41.1 Encounter for cosmetic surgery 
Z72.0 Tobacco use 
Z80.0 Family history of  
Z86.43 Personal history of benign neoplasm 
Z92.21 Personal history of antineoplastic chemotherapy 
Z92.22 Personal history of monoclonal drug therapy 
Z95.5 Presence of coronary angioplasty and graft 
Z96.8 Presence of other specified functional implants 
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Appendix 8.2B: Australian Refined Diagnostic Related Groups for people who received primary and 
secondary laparoscopic adjustable gastric band primary and secondary surgery in the Tasmanian public 
hospital system (n=105). 
 
 
 
 
 
 
 
 
 
 
 
 
   Source: Independent Hospital Pricing Authority, Australian Refined Diagnosis Related Groups Version (6.0-9.0) 
 
  
AR-DRG Description 
 
F21B Other Circulatory System GIs, Intermediate Complexity*  
G02A Major Small and Large Bowel Procedures, Major Complexity* 
G02B Major Small and Large Bowel Procedures, Intermediate Complexity* 
G04C Peritoneal Adhesiolysis, Minor Complexity* 
G05C Minor Small and Large Bowel Procedures 
G10B Hernia Procedures, Minor Complexity* 
G11Z Anal and Stomal Procedures 
G47C Gastroscopy, Minor Complexity** 
G48A Colonoscopy, Major Complexity* 
G48B Colonoscopy, Minor Complexity*  
G48C Colonoscopy, same day 
H07A Open Cholecystectomy, Major Complexity* 
H08A Laparoscopic Cholecystectomy, Major Complexity* 
H06B Other Hepatobiliary and Pancreas GIs, Intermediate Complexity* 
H08B Laparoscopic Cholecystectomy, Minor Complexity* 
K04A Major procedures for obesity 
K04B Major procedures for obesity 
K04Z Major procedures for obesity 
K10A Revisional and Open Bariatric Procedures, Major Complexity** 
K12Z Other Bariatric Procedures* 
T01C Infectious and Parasitic Diseases W GIs, Minor Complexity* 
X06B Other Procedures for Other Injuries, Intermediate Complexity* 
X63B Sequelae of Treatment, Minor Complexity* 
Z01B Other Contacts W Health Services W GIs, Minor Complexity* 
Z40Z Other Contacts W Health Services W Endoscopy* 
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Appendix 8.3: Health indices - General final consumption expenditure (GFCE) on hospitals and 
nursing homes (reference year 2014-15 = 100) †. 
 
 2006-07 2007-08 2008-09 2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 
GFCE on 
hospitals 
and 
nursing 
homes 
80.7 83.0 85.7 89.0 90.1 92.3 95.0 97.7 100.0* 
 
†Sourced from Australian Institute of Health and Welfare Health Expenditure Australia Report 2014-15  
*assume fiscal year 2015-16 at reference year =100. 
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Chapter 9: Summary and future directions. 
Preface 
As the health economics component of the National Health and Medical Research Council 
partnership project regarding bariatric surgery, this thesis presented an overview of the obesity 
epidemic, the increasing health and economic burden of obesity, and health economic impact 
of bariatric surgery as a treatment option for obesity locally in Tasmania, nationally, and 
internationally. 
To achieve the research objectives of my PhD project, this thesis adopted a mixed-methods 
approach using quantitative and qualitative research methods, consistent with a call for health 
economists to implement mixed-methods policy-relevant research that is embedded in and 
derived from real-world policy settings [1, 2]. This thesis addressed key evidence gaps and 
provided much needed information regarding the health economics of obesity and bariatric 
surgery for people with obesity waiting for, and/or who had received bariatric surgery, the 
project partner, the health economics community, the healthcare systems and society by: 
• Conducting a comprehensive systematic review and quality appraisal to provide 
critical baseline evidence of the key evidence gaps and common themes regarding 
the health economic evaluation and reporting of bariatric surgery nationally and 
internationally; 
• Investigating the complex health-related quality of life needs of people waiting for 
and who had received bariatric surgery using a preferentially sensitive multi-
attribute utility instrument to capture and assess psychosocial health; 
• Using qualitative research methods to elicit crucial health economic impacts that 
would typically be omitted from current economic evaluation frameworks, or not 
fully understood with traditional quantitative research methods; and 
• Investigating Australian Activity Based Funding resource use and costs of bariatric 
surgery pre- and postoperatively in the Tasmanian public hospital system. 
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9.1 Chapter summary of this thesis 
Overall, this thesis identified and addressed key knowledge gaps in the health economics 
reporting of bariatric surgery including the under-reporting of complications and reoperations 
following primary bariatric surgery and the identification of crucial psychosocial health-related 
quality of life impacts of bariatric surgery. The section below provides a chapter-by-chapter 
summary of this thesis. Section 9.2 then provides an integrated summary of this thesis and the 
key contributions to the science including recommendations (section 9.2.1) to our project 
partners and the health economics community. 
Chapter 1 provided an overview of the health economics of obesity and bariatric surgery, and 
health economics as an important and separate discipline. Health economics guides scarce 
healthcare resource allocation from one treatment modality to another in the complex and 
competitive rationing process of healthcare budgets. 
Chapter 1 stated that against a multifactorial background of a worldwide epidemic, obesity is 
a profoundly complex economic problem [3]. Demand far outstrips supply for bariatric surgery 
locally, national and internationally and decision makers who allocate resource-constrained 
healthcare budgets are forced to consider competing alternatives of treatments for obesity, 
including bariatric surgery [4, 5]. Within this epidemiological and economic climate of demand 
already far outstripping supply for bariatric surgery, severe obesity is increasing rapidly and 
the economic burden of Class 2 and Class 3 obesity is significantly higher than obesity [6]. 
Additionally, a greater prevalence of obesity is observed in more disadvantaged groups and 
these groups are generally not privately insured for their healthcare [7, 8]. These important 
health economic characteristics suggest that future patient prioritisation of bariatric surgery in 
public healthcare systems will become even more challenging within resource-constrained 
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healthcare systems. 
The societal economic impacts of obesity are a fundamental health economic consideration 
including work productivity [9-13], and personal and family impacts arising from 
discrimination and stigmatisation of the overweight and obese both individually and 
collectively, poorer relationships and social engagement [14, 15], however, most health 
economic studies regarding bariatric surgery ignore crucial societal considerations [4]. 
The nationally and internationally prevalent bariatric surgical procedure is laparoscopic sleeve 
gastrectomy [16], however, in Tasmania the most common procedure is laparoscopic 
adjustable gastric banding [7]. There is much current debate about the device-related 
complication and reoperation rates for laparoscopic adjustable gastric band surgery [17, 18]. 
Bariatric surgery is an efficacious and cost-effective treatment for severe and resistant obesity, 
nevertheless, this thesis’ comprehensive systematic review (Chapter 2) established that most 
health economic evaluations of bariatric surgery are based on the narrow payer perspective 
(rather than a broader societal perspective), narrowly defined direct medical costs, if included 
(only 30%) the costs of complications and reoperations adopt a short timeframe or assumed a 
probability of the event occurring as low, short time horizons for analyses are prevalent, and 
administrative data sources inform most studies [19]. Psychosocial health status is a vital 
consideration for people with obesity who are waiting for and who undergo bariatric surgery 
[20, 21, 19]. This thesis’ systematic review established that the EQ-5D is the most prevalent 
instrument in cost-utility analyses of bariatric surgery, however, only one of the instrument’s 
five items assesses psychosocial health [4, 22].  
Departures from mainstream neoclassical theory by health economists turns out to have been 
the territory in which some of the most innovative ideas of health economics have been 
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generated [23]. Nevertheless, the concepts and tools of health economic evaluation are 
fundamental to many key health economic resource allocation decisions worldwide [24]. The 
basic tasks of any economic evaluation are to identify, measure, value and compare the costs 
and consequences of the alternatives being considered [24, 25]. Health economic evaluation of 
bariatric surgery mostly employ a narrow spectrum of costs and consequences for analyses [4]. 
There is a paucity of qualitative research in health economics, where qualitative research 
methods could enrich health economics research methodology and improve health economics 
practice [1]. Additionally, reporting in numbers and not words is encouraged within the 
mainstream neoclassical paradigm that considers sophisticated mathematical technique as the 
work of the scientific inquiry [1, 26]. 
In summary, Chapter 1’s general overview highlighted that the prevalence of severe obesity is 
increasing and the obesity epidemic is costing more both directly and indirectly. Chapter 1 also 
revealed health economic evaluations that employ a wider scope of costs and consequences 
that reach well-beyond direct medical costs and administrative databases for their data inputs 
are needed. Additional allocation of scarce healthcare resources to bariatric surgery 
(particularly publicly-funded bariatric surgery) could be further motivated by health economic 
evaluations that employ a wider range of costs and consequences of bariatric surgery. 
Holistically, this thesis has substantially extended the scope of the costs and consequences that 
are considered in the health economic evaluation of bariatric surgery. 
A published comprehensive systematic review of the global health economic literature 
pertaining to the economic evaluation of bariatric surgery was provided in Chapter 2 [4]. This 
review identified 77 published papers containing health economic data from partial and full 
economic evaluations of bariatric surgery. As an important alternative to previously published 
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systematic reviews regarding bariatric surgery, this study did not seek to capture homogenous 
studies for meta-analysis to inform a further cost-effectiveness study: as an important and much 
needed alternative, this study aimed to adopt a broader approach with a view to identifying 
common themes and key evidence gaps across the depth and breadth of the health economic 
evaluation of bariatric surgery.  
Importantly, this systematic review established that most studies employed a narrow payer 
perspective and were based on a limited spectrum of data input (mostly direct medical costs, 
and cost-utility studies were dominated by the EQ-5D multi-attribute utility instrument). A 
common theme was that bariatric surgery for severely obese people with type 2 diabetes is 
cost-effective (and even cost-saving). Only one study investigated the health economic impact 
of waiting for surgery. Chapter 2 called for a more comprehensive investigation and reporting 
of health economic outcomes of bariatric surgery to identify aspects of the bariatric surgery 
patient’s journey that reached well beyond the primary surgery’s direct medical costs. The 
review recommended that there is a need for studies that assume a broader societal perspective 
(including out-of-pocket costs, costs to family and productivity losses) and longer-term costs 
(capture reoperations/complications, waiting for surgery, body contouring), and consequences 
(health-related quality-of-life). The important evidence gaps identified in Chapter 2’s 
systematic review regarding current knowledge and understanding of health economic 
evaluation of bariatric surgery informed the direction of the subsequent PhD projects of this 
thesis, part of the work program for the NHMRC partnership project, and future directions for 
research beyond this thesis.  
Published Chapters 3, 4 and 5 of this thesis investigated the health-related quality of life for 
people waiting for (public system, longitudinal [19, 21]) and who then received bariatric 
surgery, and people who had received bariatric surgery many years previously (private system, 
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cross-sectional [20]). This integrated suite of health-related quality of life studies were the first 
studies to systematically select two vastly different multi-attribute utility instruments (namely 
the EQ-5D-5L an internationally prevalent instrument that is dominant in the cost-utility 
analyses of bariatric surgery [4], and the AQoL-8D that is underpinned by psychometric 
principles and testing [27, 28]). The studies systematically compared the two instruments and 
identified robust health state utility valuations (both instruments), and individual and super 
dimension scores (AQoL-8D only) for the bariatric surgery study population.  
Chapter 3 of this thesis was the first study to reveal that people who had received bariatric 
surgery many years previously (in the private sector) whom reported perfect health on the EQ-
5D-5L (health state utility valuation of 1.0) rated themselves on the AQoL-8D as having a 
health state utility valuation of mean (standard deviation) 0.87 (0.08) [20]. This alternate 
valuation reported by the same participants for the AQoL-8D was driven by the instrument’s 
individual domains of psychosocial health. These participants recorded a low score of 0.52 
(0.13) for the Psychosocial super dimension (a composite measure of Happiness, Coping, Self-
worth, Relationships and Mental Health) [20].  
Chapter 2 of this thesis identified that only one health economic study investigated the impact 
of waiting for surgery [4]. Chapters 4 and 5 of this thesis were the first studies to use the EQ-
5D-5L and AQoL-8D for a unique cohort of long-term publicly waitlisted patients who then 
received bariatric surgery due to a public policy decision to reduce waiting lists. One of the 
main findings of these studies was that the preoperative AQoL-8D health state utility valuation 
for this subgroup of bariatric surgery patients was less than those of people with cancer or heart 
disease. Even three months, and then 12 months after bariatric surgery, long-term publicly 
waitlisted patients recorded significant and clinically meaningful health-related quality of life 
improvements. This crucial result suggested that long-waiting patients should not be ‘written-
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off’ by healthcare decision makers: they can still realise significant improvements in health-
related quality of life outcomes when ultimately treated, and this should be factored into patient 
prioritisation decisions.  
In summary, the AQoL-8D’s health state utility valuations reported in this integrated and 
published health-related quality of life suite of studies were the most robust reported to date 
because they have captured and assessed psychosocial health for the bariatric surgery study 
population. These health state utility valuations can be used to populate future health economic 
models for bariatric surgery. Additionally, there is an emerging literature regarding the use of 
patient-reported outcomes in the clinical setting and the health state utility valuations and 
individual and super dimension scores derived in Chapters 3, 4 and 5 could be employed for 
comparisons. 
Chapter 6 presented one of two studies that used qualitative research methods to investigate 
the experiences of people waiting for, or who had received bariatric surgery. Over the past 
decade there has been a call for health economists to effectively integrate combinations of 
qualitative and quantitative methods into their research toolkit to enrich their research 
methodologies and therefore improve their practice in health economic study design, data 
gathering and analysis, reporting and ultimately research translation. Chapter 2’s published 
systematic review identified the limited scope of costs and consequences for most health 
economic evaluation and subsequent reporting of bariatric surgery [4]. The review 
recommended a more comprehensive investigation and reporting of health economic outcomes 
of bariatric surgery to identify aspects of the bariatric surgery patient’s journey that reached 
well beyond the primary surgery’s direct medical costs [4]. Additionally, Chapters 3, 4 and 5 
established that psychosocial health is a vital consideration for people who are waiting for and 
then undergo bariatric surgery [20, 19, 21]. Chapter 6 of this thesis employed qualitative 
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research methods to listen to patients. By listening to patients’ experiences this thesis identified 
the new concept of emotional capital where patients described life-changing desires to be 
productive and participate in their communities postoperatively. This thesis also established 
that after self-funding bariatric surgery, some patients experienced financial distress.  
The new concept of emotional capital identified in Chapter 6 as a key consideration for health 
economic evaluation of bariatric surgery particularly consolidates the findings of Chapters 3, 
4 and 5 of this thesis that identified psychosocial health as a vital consideration for people 
waiting for or who undergo bariatric surgery. To improve health economics practice, this thesis 
recommended a mixed-methods approach to the economic evaluation of bariatric surgery from 
model conceptualisation through to the separate reporting of qualitative findings to supplement 
the quantitative findings. 
Chapter 7 also adopted the qualitative method and investigated the emergence of the concept 
of demand-induced supply in the information-age for people waiting for or who undergo 
bariatric surgery. Does demand-induce supply exist in the marketplace of bariatric surgery? 
Are bariatric surgery patients more information-savvy in the information-age? Chapter 7’s 
study established that psychosocial or socio-emotional drivers informed the sources and types 
of information that were important to patients preoperatively. The study also found that 
information sources relevant to patients preoperatively (e.g. family and friends, and the 
Internet) were different postoperatively (surgeon, allied-health professionals e.g. psychologist).  
Chapter 7 recommended that high-quality and consistent information sources be targeted 
towards the psychosocial domains of health for bariatric surgery patients preoperatively and 
ongoing postoperatively. The study also recommended that appropriate healthcare information 
be provided to enable a smoother transition for the management of physical health impacts 
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such as postoperative dehydration and electrolyte imbalance which can result in unexpected 
hospitalisation: smoother postoperative transition would likely translate to a reduced burden 
on the healthcare dollar. 
Chapter 8 is the final study of this mixed methods thesis. This quantitative health economics 
study has provided our project partner with accurate episode-of-care changes, resource use and 
cost analyses regarding the provision of bariatric surgery in the Tasmanian public hospital 
system that were not known. Chapter 8’s inpatient patient-level outcomes, resource use costing 
study is the first study within the Australian public hospital setting to report on individual 
episodes-of-care and costed patient-level pathways for primary bariatric surgery, and 
subsequent surgical sequelae including secondary/tertiary surgery informed by Australia’s 
Independent Hospital Pricing Authority’s Activity Based Funding model. Chapter 2 of this 
thesis particularly guided the study’s investigation of the patient-level unit costs, the costs of 
waiting for bariatric surgery, subgroup analyses (patients with diabetes and cardiovascular 
disease), and the accurate cost of complications and reoperations over a long time horizon. 
Chapter 8 found that the cost of providing the primary laparoscopic adjustable gastric band 
bariatric procedure compared with the sleeve gastrectomy procedure is similar. The study also 
suggested that prevalent laparoscopic adjustable gastric band device-related costs could be 
mitigated with alternative surgical methods such as sleeve gastrectomy (rather than the 
prevalent laparoscopic adjustable gastric band) within the Tasmanian public hospital system. 
Subgroup analyses revealed that for people with diabetes, the average cost for an episode-of-
care reduced from the first year after surgery. The accurate and broad scope of patient-level 
and real-world cost data reported in this study can be used to populate future health economic 
models for bariatric surgery. 
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9.2 Integrated conclusions of this thesis 
At the commencement of the NHMRC partnership project regarding bariatric surgery, our 
Tasmanian State Government partner stated that ‘the burden of morbid obesity on individuals, 
government and society is unclear and the allocation of public resources to bariatric surgery 
lacks a strong evidence base’. Therefore, the key objective of this PhD research was to address 
these pressing health economic knowledge and policy gaps for people with obesity waiting for, 
and/or who had received bariatric surgery, our project partners, the health economics 
community, the healthcare systems and society.  
In response to the key evidence gaps and principal research aims of this thesis outlined in 
Chapter 1 sections 1.7 and 1.8, as the health economist within the NHMRC partnership project 
this research found that the health economics reporting of costs and quality of life for bariatric 
surgery were deficient and this PhD research has addressed both key information gaps. This 
PhD thesis employed the AQoL-8D multi-attribute utility instrument and adopted qualitative 
research methods to elicit the psychosocial and emotional health needs of the study population. 
Psychosocial and emotional health are paramount considerations for people seeking bariatric 
surgery and for the success of their surgery. Through the development of a strategic alliance 
with our project partner, this PhD research provided much needed information to our project 
partner regarding the costs of bariatric surgery in Tasmania, the complication and reoperation 
rate and cost, the benefits for people with diabetes and cardiovascular disease, and preliminary 
information regarding the benefits of sleeve gastrectomy versus laparoscopic adjustable gastric 
banding. This research suggests that bariatric surgery is an attractive value-based option for 
people with severe and morbid obesity in Tasmania, and particularly for subgroups of patients 
such as people with T2DM. Preliminary evidence from this research also suggested that sleeve 
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gastrectomy could be a cost-saving option, compared to laparoscopic adjustable gastric band 
surgery and that a larger confirmatory study of disaggregated costs should be conducted.More 
specifically, the principal conclusions of this thesis regarding the health economics of obesity 
and bariatric surgery were: 
• There is disparate health economic evaluation and reporting of bariatric surgery of 
inconsistent quality. Partial and full health economic evaluations of bariatric surgery 
generally populate their models with a narrow spectrum of short-term direct medical 
cost data regarding the primary surgery only from administrative databases; 
• Overall, this thesis provided a broader economic perspective regarding bariatric surgery 
as a treatment option for obesity; 
• Health economic evaluation of bariatric surgery generally finds that bariatric surgery is 
cost-effective, and even cost-saving for people with type 2 diabetes who are severely 
obese; 
• As an important emerging subgroup of bariatric surgery patients, there is a paucity of 
health economic analyses of costs and consequences for long-term publicly waitlisted 
patients in an environment of multiyear wait times where severe obesity is increasing 
rapidly for people in areas of lower socioeconomic disadvantage who do not have 
private health insurance; 
• Why does the health economics community use the EQ-5D for the bariatric surgery 
study population? The AQoL-8D is preferentially sensitive regarding psychosocial 
health for the study population and this crucial finding has implications for downstream 
cost-utility analyses of bariatric surgery; 
• Psychosocial health status is crucial for people waiting for and who then undergo 
bariatric surgery; 
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• Long-term waitlisted patients preoperative health state utility valuations are 
substantially diminished and comparable to patients undergoing cancer treatment or 
patients with severe cardiovascular disease; 
• Long-term waitlisted patients realise significant health state utility valuation 
improvements (and individual and super dimension scores for the AQoL-8D) even three 
months after bariatric surgery suggesting that these patients should not be ‘written-off’ 
by healthcare planners if significant health benefits can be realised when they are 
ultimately treated; 
• Qualitative research methods revealed the importance of emotional capital and out-of-
pocket costs, and the sources and types of information before and after bariatric surgery.  
• Qualitative research methods should supplement quantitative methods to elicit nuanced 
and detailed analysis of the health economic impact regarding bariatric surgery; 
• Health economists should employ a mixed-methods approach to the economic 
evaluation of bariatric surgery from model conceptualisation through to the separate 
reporting of qualitative findings to supplement the quantitative findings; and 
• Patient-level Tasmanian public hospital inpatient episodes-of-care, resource use and 
cost analyses provided much needed information regarding the resource use costs of 
bariatric surgery to the Tasmanian public hospital system. Bariatric surgery in the 
Tasmanian public hospital system may be an attractive value-based option in the longer 
term: bariatric surgery realised health benefits (reduced inpatient episodes-of-care) and 
reduced costs at year 3 postoperatively. The costs for publicly-waitlisted severely obese 
patients waiting for bariatric surgery who are then treated patients in Tasmania’s public 
hospital system start decreasing at year three. Laparoscopic adjustable gastric band 
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device-related costs could be mitigated if replaced with sleeve gastrectomy bariatric 
surgery where clinically appropriate.  
Holistically, this thesis has substantially extended the scope of the costs and consequences that 
have been considered in the health economic evaluation of bariatric surgery. The evidence gaps 
identified in Chapter 2’s systematic review regarding current knowledge and understanding of 
health economic evaluation of bariatric surgery informed the direction of the subsequent PhD 
projects of this thesis. Chapter 2 called for a more comprehensive investigation and reporting 
of health economic outcomes of bariatric surgery to identify aspects of the bariatric surgery 
patient’s journey that reached well beyond the primary surgery’s direct medical costs. Chapter 
2 recommended that there is a need for studies that assume a broader societal perspective 
(including out-of-pocket costs, costs to family and productivity losses) and longer-term costs 
(capture reoperations/complications, waiting for surgery, body contouring), and consequences 
(health-related quality-of-life). Chapters 3 to 8 of this thesis have addressed all of these key 
evidence gaps. 
Severe obesity is increasing rapidly particularly in areas of socioeconomic disadvantage where 
people do not purchase private health insurance. Public places for bariatric surgery compete 
with life-saving cancer treatment, sick children, multiple trauma accidents, dementia care, end-
of-life care, and the list goes on. Unfortunately, for our society health economic choices need 
to be made: the healthcare budget is finite. Moreover, public (and to some extent private) 
healthcare budgets are also allocated on political grounds – politics and policy are inextricably 
linked and the political allocation of scarce healthcare resources on a particular day may favour 
one alternative over another due to many competing interests including news’ coverage – not 
the cost/QALY or any other health economics metric. Nevertheless, in this challenging and 
constantly evolving environment where there is a ‘pragmatic tension’ between the best-practice 
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evidence-based health economics research and the realities of the policy and political 
environments, it is incumbent upon the health economist to convince the decision-maker that 
their research addresses the key evidence gaps in a relevant, accessible, and timely way: that 
the research is useful.  
Our project partner has stated that the findings from this PhD thesis are of policy-changing 
interest, particularly when the findings of Chapter 8 are pooled with the findings and 
recommendations of my PhD research’s investigation regarding the health economic 
evaluation of bariatric surgery (Chapter 2), the assessment of health-related quality of life for 
people waiting for or who had received bariatric surgery in the public and private healthcare 
systems (Chapters 3, 4 and 5) and the qualitative research regarding bariatric surgery patients’ 
lived experiences (Chapters 6 and 7).  
9.2.1 Key recommendations 
This thesis’ key recommendations align with the objectives of this thesis outlined in Chapter 
1. This research recommends that: 
• Given the evidence gaps identified by the thesis regarding the health economic 
reporting of bariatric surgery, this thesis recommends that studies assume a broader cost 
base, longer time horizon and societal perspective. Additionally, studies regarding 
people with diabetes and Class I Obesity should investigate the cost-effectiveness or 
even cost-saving of bariatric surgery; 
• Appropriate choice of a multi-attribute utility instrument (e.g. AQoL-8D) to capture 
and assess the complex physical and psychosocial needs for people waiting for and who 
have received bariatric surgery; 
• Prioritisation decisions regarding long term and severely obese long-term waitlisted 
  
Chapter 9: Summary and future directions 
 
460 | P a g e  
bariatric surgery patients should factor the psychosocial and emotional health-related 
quality of life impacts of the surgery into patient prioritisation decisions; 
• Wherever possible, use qualitative research methods in the health economic reporting 
of bariatric surgery to identify important costs and consequences to validate and 
supplement quantitative results; and 
• From a Tasmanian, perspective, bariatric surgery is an attractive value-based 
proposition for people waiting for bariatric surgery in the Tasmanian public hospital 
system. Sleeve gastrectomy should be considered as a treatment alternative where 
clinically indicated. 
The next section of this thesis highlights the most promising key areas for future directions that 
have emerged from this PhD research and thesis. 
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9.3 Key areas for future directions and research translation 
Chapters 2 to 8 of this PhD thesis have separately described promising opportunities for future 
directions. Further detail regarding some of these key opportunities for future directions are 
outlined in detail below. 
9.3.1 Health economic evaluation 
(i) Use the findings of this thesis to conduct a larger confirmatory study regarding 
sleeve gastrectomy as the preferred type of bariatric surgery when clinically 
appropriate. 
Chapter 8 of this thesis revealed some promising evidence regarding sleeve gastrectomy as an 
attractive value-based proposition for the Tasmanian public health system. A larger 
confirmatory study is indicated that compares the costs and episodes-of-care for sleeve 
gastrectomy versus laparoscopic adjustable gastric banding, particularly the costs of 
complications and reoperations. 
 
(ii) Use the findings of this thesis to populate a cost-utility model for bariatric surgery 
that adopts a broader perspective 
Chapter 2 of this thesis highlighted the need for health economic evaluations of bariatric 
surgery that employ a wider scope of cost data, and that most cost-utility studies adopt health 
state utility valuations derived from the EQ-5D. Holistically, Chapters 3 to 8 of this thesis 
provided both quantitative and qualitative health economic analyses that explored a wider 
range of costs and consequence of bariatric surgery as a treatment option for obesity. These 
new results provide much needed data for a cost-utility analyses of bariatric surgery that adopts 
a broader societal perspective and beyond with the supplementary qualitative findings. 
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Chapter 8 provided real-world patient-level cost data (including subgroup analyses of people 
with diabetes and cardiovascular disease) before (for waitlisted patients) and after laparoscopic 
adjustable gastric band and sleeve gastrectomy bariatric surgery. These costs are informed by 
Australia’s Activity Based Funding model and include accurate patient-level rates and costs of 
complications and reoperations of bariatric surgery. Chapters 3, 4 and 5 derived robust health 
state utility valuations that captured and assessed the complex physical and psychosocial 
health-related quality of life needs for severely obese patients who are waiting for and then 
undergo bariatric surgery. Chapters 6 and 7 derived qualitative results regarding out-of-pocket 
costs and emotional capital that led to productivity and participation. 
This thesis is the first tranche of health economics analyses for the NHMRC partnership project 
regarding obesity and bariatric surgery. A new health economics PhD candidate will commence 
on the NHMRC partnership project in December 2017. This mixed-methods thesis provides 
robust quantitative data to populate a real-world cost-utility model for the broader NHMRC 
project and our project partner. This mixed-methods thesis also provides much needed 
qualitative data generated from listening to patients. The qualitative data will provide crucial 
information for the conceptualisation and construction of the model. The qualitative data will 
also supplement the cost-utility results. 
(iii) Advocate for mixed-methods research in health economics to improve practice in 
economic evaluation of bariatric surgery 
Reviewer comments to Chapter 6 of this thesis stated: 
‘I completely agree with, and commend the author’s on their research seeking to advance 
the use of mixed methods research, and particularly their efforts to advance the use of 
qualitative input into economic evaluation. It is crucially important that economic 
evaluation output is patient relevant, and the current study seeks to address an important 
gap in the literature. As the authors quite correctly acknowledge the use of mixed methods 
research is too often ignored in the economic evaluation literature, and this is particularly 
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true in bariatric surgery.’ 
This thesis advocated for mixed-methods research in health economics for both health 
economic evaluation model conceptualisation and construction, and for qualitative results to 
be reported to the policy decision-maker as supplementary information – in words and not 
numbers.  
I will continue to advocate for mixed-methods research in health economics.  
9.3.2 Health-related quality of life 
 (i) Scoring the EQ-5D-5L with an Australian algorithm 
An important area for future research is scoring the EQ-5D-5L with an Australian algorithm. 
This will enable further work to be done to compare this instrument with the AQoL-8D. 
(ii) Explore a revised EQ-5D-5L with a bolt-on item/s for emotional capital and test against 
the AQoL-8D 
Chapters 3, 4 and 5 of this thesis identified that, compared to the EQ-5D-5L, the AQoL-8D 
preferentially captured and assessed the complex psychosocial health for bariatric surgery 
patients who had received their bariatric surgery many years previously in the private system 
(Chapter 3) and for long-term publicly waitlisted patients who then received bariatric surgery 
(Chapters 4 and 5). 
Chapter 6 identified a new concept of emotional capital for people who were waiting for or had 
received bariatric surgery. One of the reviewers stated that the concept of emotional capital 
was ‘enticing and convincing’ and suggested that the entire manuscript should explore the 
concept of emotional capital ‘that would hold true for many patient groups’ not just for bariatric 
surgery but for other disease processes such as diagnosis of a life-threatening condition, or for 
people with a seriously sick child. This reviewer also asked for concrete suggestions where 
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emotional capital could or should become part of some revised form of the EQ-5D. 
Chapter 6 included the requested revisions and also explored the recent literature that raised 
concerns regarding these bolt-on items to the EQ-5D (including the concerns that were raised 
in Chapter 3). Notwithstanding these qualifications and in accordance with the revised 
manuscript contained in Chapter 6, my PhD thesis recommends that a promising area for future 
research is the development of an ‘emotional capital’ bolt-on item/s for the EQ-5D-5L.  
A bolt-on item should also be tested against the AQoL-8D multi-attribute utility instrument 
and follow the methods that I have developed in my two published head-to-head comparison 
papers [20, 21]. 
(iii) Explore emotional capital for other disease processes 
As mentioned in point 9.3.2 (i), the concept of emotional capital would hold true for many 
disease processes and a promising area for future directions would be to explore this crucial 
new concept, particularly for other chronic diseases. One of the reviewers for Chapter 6 made 
the point that emotional capital could apply to many disease processes for patients and their 
carers including ‘parents with a seriously sick child and people waiting for an organ transplant’. 
(iv) Explore the predictive capabilities of the AQoL-8D 
As an independent measure of health-related quality of life, there is emerging literature that 
suggests health state utility valuations could be independent predictors of health outcomes. 
Prediction is more likely to be accurate when the instrument used for prediction takes account 
of the full range of the complex physical and psychosocial health domains associated with the 
problem. This thesis found that the AQoL-8D is more likely to provide correct prediction than 
the EQ-5D-5L for the bariatric surgery study population.  
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Therefore, the area of clinical prediction using the AQoL-8D for the bariatric surgery study 
population is a promising area for future research.  
(v) Compare the AQoL-8D with the SF-6D for bariatric surgery 
An important area for future research suggested in Chapter 4 of this thesis was that the AQL-
8D could be compared against the SF-6D. Comparison for long-term waitlisted patients who 
then receive bariatric surgery would be useful, given that this thesis found that the health state 
utility valuations for these patients preoperatively are comparable to people with cancer or 
heart disease. 
(vi) Advocate for the inclusion of the AQoL-8D in the International Society for 
Pharmacoeconomics Outcomes Research (ISPOR) teaching materials 
International workshops regarding patient-reported outcomes are convened by ISPOR. 
Interestingly, these workshops (including the Asia-Pacific workshop) do not include any 
materials regarding the AQoL-8D and instead advocate the use of the EQ-5D-5L and other 
prevalent instruments such as the SF-6D. These materials could be more balanced by providing 
health economists with the opportunity to explore the multi-attribute utility instrument that is 
informed by psychometric principles and testing. 
(vii) Advocate for qualitative research methods to improve health economics practice 
Overall, there is a critical need for health economists to enrich their research methodologies 
with qualitative methods. This is an important area for future directions – the publication of 
Chapter 6 in the world leading journal Health Economics will enable the author of this thesis 
to facilitate this message. 
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9.3.3 The provision of bariatric surgery in Tasmania 
Overall, the findings of this thesis suggest that providing bariatric surgery in Tasmania is 
efficient and that severely obese waitlisted patients should not be written off by healthcare 
planners because they can still realise significant health benefits when ultimately treated.  
Our project partner has stated that the findings from this PhD thesis are of policy-changing 
interest. The costs of providing bariatric surgery in Tasmania are lower than comparable 
national and international published estimates; even after Tasmanian costs for secondary 
surgery are included. As outlined above, a robust cost-utility study will be the subject of future 
directions for our project partner. 
Our project partner has also suggested that the comparison of sleeve gastrectomy and 
laparoscopic adjustable gastric band surgery is of policy-changing interest because it would 
mitigate the cost of device-related costs for banding. 
The strategic research alliance created in Chapter 8 for the real-world costing study will be the 
subject of a further policy study. Lessons learnt from the alliance will inform some of the future 
directions for more collaborative work with the critical health partner. 
  
  
Chapter 9: Summary and future directions 
 
467 | P a g e  
Postscript 
During my PhD research I have been tremendously fortunate to be provided with the 
opportunity to collaborate with and learn from such a dedicated and scholarly team that 
comprises academic researchers from wide-ranging disciplines, clinicians, government policy 
decision makers and allied-health practitioners.  
I would encourage health economics PhD candidates to explore the opportunities that an 
applied partnership project within a multi-disciplinary team could bring to their learnings and 
research, and ultimately their research translation. Collectively, our multi-disciplinary team has 
worked hard to help people with severe obesity who are waiting for or who undergo bariatric 
surgery, to provide much needed information to healthcare planners about patient pathways 
and the costs and consequences of those pathways. 
Ultimately, I hope that my research will help people with severe obesity who are waiting for 
or who undergo bariatric surgery, locally, nationally and internationally.  
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